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3ABSTRACT
Biophotonics is an emerging area of scientific research that uses light of photons 
to probe biological specimens, such as tissues, cells and molecules. The field of 
biophotonics is broad and considerably multidisciplinary. Therefore the prerequisite 
for understanding biophotonics is the capability to integrate the fundamental 
knowledge of the physics of light with perspectives of engineering of devices and 
instruments used to generate, modify, and manipulate light. Also, the fundamentals 
of biology and medicine are essential – particularly comprehension of the 
biochemical and cellular phenomena that occur in living systems, and how such 
phenomena can be scaled up to concern the physiology of organisms, for example 
humans. Biological pathways and processes differ in the healthy and diseased state, 
and that is why it is essential to develop understanding of pathophysiology and 
various states of disease such as cancer, neurodegenerative disease or infectious 
states. Consequently, solid insights into the functions of medical treatments, 
including biopharmaceutics, are needed. Raman and surface plasmon resonance 
(SPR) are both light-based technologies enabling label-free measurements with high 
sensitivity. The primary aim of this Thesis was to tackle the emerging hardships 
encountered in the fundamental biopharmaceutical research, clinical settings, or in 
the pharmaceutical industry by introducing applications and data analysis methods 
based on the cutting edge Raman and SPR technologies. These techniques represent 
the biophotonic cornerstones as tools for biopharmaceutical applications throughout 
this Thesis. 
The scope of this Thesis was essentially broad. First, small drug molecules 
were investigated with state-of-the-art time-gated Raman technology, showing 
that the interfering photoluminescent backgrounds can be effectively suppressed 
thus improving the acquired Raman data significantly. Additionally, EVs were 
studied with laser tweezers Raman spectroscopy (LTRS) as larger scale analytes 
and representatives of a highly interesting topic in the current nanomedical field. 
When Raman data from several different types of single EVs was examined 
using sophisticated data analysis, distinct subpopulations were observed, and 
the differences could be related to the biochemical compositions of the vesicle 
membranes. For the first time, the study showed the importance of measuring 
single EVs instead of a pool of vesicles. 
Multi-parametric SPR (MP-SPR) technology was harnessed to develop 
applications and data analysis methods for small and larger scale analytes. Hence, 
a new small drug molecule, spin-labeled fluorene (SLF), was investigated in the 
context of Alzheimer’s disease (AD) – particularly its potential to interfere with the 
detrimental amyloid peptide aggregation processes. The developed bio-functional 
4in vitro platform in combination with rigorous data analysis and computational 
simulations demonstrated the capabilities of SLF when it was employed in various 
biomimetic aggregation schemes. Moreover, liposomes were examined with 
the MP-SPR as larger scale nanomedical particles for the purposes of safe and 
effective nanocarrier development. The administration of a liposomal nanocarrier 
into the blood circulation was mimicked in the designed bionanophotonic in vitro 
schemes. Undiluted serum was made to interact with immobilized model liposomes 
in dynamic flow conditions. The findings revealed that the variation in surface 
chemistries of the liposomes plays a role when serum – essentially immune system 
– components are interacting with the liposomes. In particular, distinct “soft” and 
“hard” protein coronas were observed and characterized during the interactions.
Collectively, the results and findings in this Thesis underline the broad potential 
of biophotonics for biopharmaceutical applications. The technical improvements in 
instrumentation, and creativity in the application and data analysis development 
make the future of biophotonics bright.
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1 INTRODUCTION
Light is a convenient tool for studying and resolving various questions in life sciences 
and biopharmaceutical research. In essence, photonics as a field encompasses the 
technologies and applications whereby light interactions with matter are exploited 
to find out the chemical structures of compounds or to initiate light-sensitive 
reactions. Biophotonics concerns light interactions with biological matter – which 
can be expanded to cover biopharmaceutical compounds and different types of 
formulations, like small drug molecules, liposomes, and extracellular vesicles 
(EVs), respectively. Photonics and essentially biophotonics offer a wide variety of 
opportunities to tackle the emerging hardships encountered in life sciences. The 
evolution of lasers and sensitive detectors has paved the way for affordable, effective 
and compact instrumentation to counter these challenges. Regardless these technical 
advancements, the tedious and costly drug discovery process, further optimization 
tasks to improve drug formulations already in market, and the need for new in vitro 
testing methods continuously trouble researchers in the multidisciplinary field of 
biopharmaceutical research. Furthermore, the advent of nanomedicine has brought 
us to a new era. In the context of nanomedicine, there is a growing need for sensitive 
and robust preclinical platforms to detect various nano-sized cell organelles, 
extracellular vesicles (EVs), in order to better understand their complex biochemical 
pathways in the biological environment – particularly in cancer pathogenesis. Also, 
recent findings indicate that EVs could act as biomimetic targeted drug delivery 
carriers (DDCs) against tumor cells. A plethora of problems exist in the EV research; 
they cannot be observed by conventional diffraction-limited microscopy, the EV 
isolation and purification steps are labor intensive, their cumbersome biochemical 
composition plagues researchers worldwide, and there is a multitude of biological 
functions the EVs can perform in the body. Another important aspect relates to 
nanomedicine as well; namely, in the event of administering e.g. liposomal drug 
nanocarriers into the blood circulation, various biophysical phenomena occur at 
the nano-bio interfaces [1]. The rational design of such nanocarriers is in need of 
methods to fulfil the demanding requirements in different phases of the process 
and to better understand the functions of these interfaces. Such phenomena must 
be rigorously scrutinized to accomplish rational nanocarrier development, and to 
increase the in vivo relevance of in vitro studies.
From a diagnostic standpoint, biophotonics encompasses developing new 
technologies and applications for detecting and diagnosing biological states of 
health and disease, and observing for changes in these states. Early stage disease 
detection is seen as one of the important aims in diagnostic biophotonics since the 
probabilities of successfully treating and curing the disease are highest at its earliest 
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phase. New optical technologies are constantly needed to monitor and analyze 
these interactions and thus the development of such techniques is one of the key 
areas in biophotonics. The use of light and optics provides a number of advantages 
because the obtained and analyzed data is typically multi-dimensional, imaging and 
sensing performed at the scale of individual cells or molecules. Therefore in order to 
effectively implement these technical advantages in biophotonics, the applications 
and data analysis methods must be aligned to formulate biologically relevant assays. 
The therapeutic perspective of biophotonics covers the application of light for treating 
disease or altering biological processes. It can involve exploiting the higher energies 
of optical radiation that can alter the chemical or mechanical properties of cells and 
tissues, for instance resulting in the ablation of a tumor. Additionally, light can be 
utilized to change cellular and molecular functions via photochemical treatment, 
or photothermally or photomechanically manipulate tissues. Importantly, in 
therapeutic biophotonics an essential goal is to predict felicitously how the drug 
formulations interact with the living surroundings when administered into the body. 
All of the above taken into consideration, this is how new biophotonic technology is 
created and new biophotonic science – including applications and innovative data 
analysis methods – are discovered. Although advancement happens constantly, 
the current situation can be improved by harnessing the potential of biophotonics 
in previously unseen ways. Three distinct aspects can be emphasized in order to 
elucidate the main shortcomings of the present state – essentially why biophotonic 
methods in biopharmaceutics are in demand of novel approaches.
Firstly, the biophotonic technologies themselves are in need of innovative 
solutions; Raman spectroscopy is a scattering-based technique that provides a 
highly specific chemical fingerprint of the molecule of interest. However, thus far 
the major obstacle for its broader use outside the laboratory settings has been the 
strong photoluminescent background signals swamping the weak Raman responses, 
non-user-friendly equipment and data analysis, and high prized instrumentation. 
The aforementioned drawbacks can be overcome by the compact time-gated 
Raman system that utilizes the time difference between Raman scattering and 
photoluminescence phenomena. Additionally, Raman tweezers is a somewhat 
underused spectroscopic technique for acquiring Raman data from single particles 
trapped in the force field of a firmly focused laser. Such tweezers are particularly 
useful to investigate small drug molecules and nano-carriers with biochemical 
contents like EVs. Furthermore, surface plasmon resonance (SPR) is a well-
established label-free technique for studying molecular interactions in real time. The 
multi-parametric SPR (MP-SPR) has been recently introduced as a next-generation 
SPR technique that essentially preserves the benefits of traditional SPR concurrently 
adding the possibility for thorough molecular surface characterization. 
Secondly, there is a lack of innovative methodologies and applications based 
on biophotonics. For instance, the technical advantages of MP-SPR allow for the 
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development of creative in vitro biophotonic platforms for a diverse set of problems; 
in its traditional sense, it can be utilized for detecting interaction kinetics as with any 
other SPR system. However, the features of MP-SPR also yield valuable information 
on the properties of the surface after the analytes of interest have been adsorbed 
onto the sensor surface. Such pertinent properties include the layer thickness (d) and 
refractive index (n). In addition, by harnessing the benefits of Raman spectroscopy 
– such as its capability to give detailed structural information on the molecules and 
insensitivity to aqueous background signals of biological samples – it can be used 
in a considerably broader array of applications than it is used today. Hence, by 
developing new in vitro applications, prospective small drugs can be characterized 
and monitored from multiple standpoints; their kinetic properties can be evaluated 
while their functions can be demonstrated in biomimetic environments. In this 
Thesis, these assays are exploited as bio-functional assays. Moreover, larger scale 
analytes, such as liposomes and extracellular vesicles can be studied in biologically 
relevant in vitro environments that resemble the natural milieu they encounter 
when either administered in blood circulation as drug delivery carriers or when 
found as partners of intracellular communication.
Thirdly, in addition to novel technologies and applications, the statistical analysis 
of the raw data must be designed and refined in a way that it yields interpretable 
and explicit results. For example the surface characterization is based on the 
modeling and fitting of the measured MP-SPR spectral data with sophisticated 
algorithms. Multivariate analysis, on the other hand, are needed to interpret Raman 
data for which the visual inspection is not an option to distinguish the nuances 
between different spectra. From the standpoint of biopharmaceutics, the introduced 
innovations can be used to study small drugs as well as larger scale analytes and 
nanocarriers without a priori labeling. It is to be noted that – instead of replacing 
the existing well established methods, for instance fluorescence-based assays – 
biophotonic methods can provide valuable complementary information. Thus, 
the new viewpoints enable better understanding of the mechanisms underlying 
the phenomena of interest. In conclusion, revolutionary approaches are needed 
in the field of biopharmaceutics to resolve existing tenacious challenges as well as 
completely new ones. Biophotonic methods can offer feasible solutions for those 
demands.
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2 BIOPHOTONICS
Biophotonics is an established term to cover the broad range of light-based 
technologies applied to the life sciences, for example pharmaceutical research 
and development, medicine, and biochemistry. Even though existing for decades, 
biophotonics has emerged during the 21st century as a very rapidly evolving field, 
primarily owing to the significantly improved laser technology; semi-conductor 
lasers allowing for developing compact-sized equipment with remarkably reduced 
cost of manufacturing while maintain the required power for given applications. 
Furthermore, the overall knowledge on the light-matter and -materials interactions, 
and increased computing capacity have been important advancements. In general, 
“photonics” is a technology-based term to encompass all the methods and techniques 
using light over the whole spectrum, and its interaction with any matter. In this 
context, biophotonics represents a novel extension to photonics. The roots of 
the word “biophotonics” extend back to the Greek language – “bios” being the 
expression for life and “phos” for light. Thus, biophotonics is a fusion of photonics 
and biology, dealing with the interactions between light and biological matter, and 
seeking answers to the mechanisms of fundamental life processes from micro to 
macro level, as well as the early detection, prevention, and therapy of diseases. In 
some cases “biomedical optics” is understood to cover the clinical applications of 
light in diagnostics and therapy while biophotonics represents a complementary 
term to biomedical optics [2]. In that context, biophotonics mostly deals with the 
fundamental research aspects, for example the investigation of cellular processes. 
However, being an all-encompassing, coherent and beautiful term, biophotonics is 
used throughout this Thesis to cover all the interactions between biological matter, 
biopharmaceutical compounds and structures, and light, from the very fundamental 
research level all the way to the highly sophisticated technologies used for clinical 
purposes and diagnostics.
Biophotonics is an excessively cross-disciplinary field of science that integrates 
four major technologies: lasers, photonics, nanotechnology and biotechnology. 
These technologies have been estimated to collectively generate several billions of 
dollars in the global marketplace [3]. Biophotonics has impact on a wide range of 
industries from biotechnology companies and health care organizations through 
medical instrument suppliers to pharmaceutical manufacturers, information 
technology and optical telecommunication. Table 1 summarizes some of the many 
ongoing and future prospects dealing with biophotonics.
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Table 1. Biophotonics is a pervasive field that integrates multidisciplinary expertise. Sorted by discipline, 
the table displays areas of development in biotechnology, biomedicine, and fundamental research 
where biophotonics is employed.
Discipline Area of development and reference
Chemists
Development of fluorescent tags [4]
Development and identification of chemical probes for analyte detection 
and high-throughput (HTS) assays [5, 6] 
Nanoscale chemistry for designing probe materials [7]
Fundamental knowledge on the optical activation phenomena [8]
Physicists
Understanding the photochemical processes in biomolecules and 
bioassemblies [9, 10] 
Discerning the physical principles for imaging and biosensing [11, 12]
Single molecule biophysics [13, 14]
Nonlinear optical processes for research, therapy and diagnostics [15]
Engineers
Integration of new generation lasers, delivery systems and detectors [16]
Device miniaturization, automation and robotics [17]
Noninvasive or minimally invasive light activation [18]
Development of in vivo optical spectroscopic techniques [19, 20]
Optical micro-electro-mechanical systems (BioMEMS) and their 
nanoscale analogues [21]
Biomedical 
researchers
Early detection of infectious diseases and cancers [22, 23]
Dynamic imaging of physiological responses to therapy and drug 
delivery [24, 25]
Cellular mechanisms of drug activation [26]
Toxicity of light-activated nanomaterials [27]
Biocompatibility of biomaterials and implants [28]
Clinicians
In vivo human patient imaging [29-32]
Tissue welding, contouring and regeneration [33]
Laboratory tests (e.g. analysis of body fluids) and point of care (POC) 
diagnostics [34, 35]
Biopharmacists
Drug discovery and drug development [36-40]
Pharmacokinetics and pharmacodynamics [41-45]
High-throughput screening (HTS) and process analytical technologies 
(PAT) [46, 47]
An intuitive question would be, what is so special about light that makes it an ideal 
tool for life sciences? There exists a wealth of favorable features that make light 
an excellent probe to work with. Firstly, light offers a spatial scale of six orders of 
magnitude. Observations and object manipulation can be performed on a scale from 
several nanometers up to centimeters. This allows for detection and manipulation 
of macromolecules to subcellular manipulation and macroscopic diagnosis and 
tissue surgery. For instance, findings and applications on a single cell level can 
be adapted to the inspection of cellular networks and tissues. Another advantage 
in light-based research and development is the vast time scale for monitoring of 
events; from femtoseconds (10-15 s) to even days (105 s). Extremely fast processes 
can be monitored or manipulated using pulsed femtosecond lasers. On the other 
hand, the stability of light sources enables long-term monitoring of structures 
and bioprocesses. In essence, photonics is the only available technology offering 
this formidable time scale. Moreover, optical technologies make it possible to 
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determine the different features of molecules, cells and tissue [48]. Examples 
include morphological features (e.g. measuring reflection, transmission/absorption, 
scattering), chemical features and their changes (e.g. utilizing Raman spectroscopy 
or fluorescence), mechanical features (e.g. using optical trapping) or movement 
(e.g. using dynamic light scattering measurements). The wide compatibility of 
light-based methods is beneficial in life sciences where cross-disciplinary work 
is always needed; optical methods can be combined easily with one another and 
measurements can be performed in the spatial and temporal domain. Furthermore, 
optical methods can also be combined with non-optical methods, and with other 
advanced technologies such as nanotechnology (nanoparticles, optically triggered 
nanocapsules, and optical nanostructures) and microsystems (microfluidics, lab-
on-a-chip applications). Lastly, optical technologies are practical – which, in turn, 
is important especially when moving from bench to bedside, i.e. when transforming 
the technologies and applications achieved in fundamental research towards real 
life science methodologies. Contactless, non-invasive application, easy transmission 
of energy and signals, and minimal side effects to patient are some of the benefits 
facilitating this transformation. Additionally, opto-electric components have become 
compact and inexpensive, for example laser diodes, which allows the development 
of affordable systems [48]. In summary, the properties and advantages of photonics 
over the other biomedical tools, for example ultrasound, X-ray, or magnetic and 
nuclear medical technologies, are undisputable and offer cross-sectional methods 
to overcome a broad array of challenges in modern life sciences. In order to 
demonstrate the vast field of biophotonics, Table 2 summarizes some important 
methods and technologies.
22
Table 2. Summary of essential methods and technologies in biophotonics.
Technology Examples Reference
Spectroscopy
Absorption (THz, microwaves, IR, UV-Vis)
Emission (fluorescence methods in general; one-photon/
multi-photon fluorescence, FRET, FRAP, FLIM, FLIP)
Elastic and inelastic light scattering (for example Rayleigh, 
Raman, CARS, SRS, SERS, TERS, Mie, LIDAR)
Surface-sensitive technologies (SPR, label-enhanced SPR, 
MP-SPR)
[49-52]
Light microscopy
Fluorescence microscopy (autofluorescence or fluorescence 
labels, e.g. proteins), sub-diffraction techniques (optical 
nanoscopy, e.g. STED, NSOM, PALM/STORM, structured 
illumination) and 3D imaging techniques (e.g. confocal and 
multi-photon excitation microscopy)
Raman microscopy (CARS, SRS, TERS)
Contrast methods (e.g. phase contrast microscopy, digital 
holographic microscopy (DHM))
[53-56]
Chip-based 
analysis
Biochips and biosensors for POC diagnostics (“lab-on-a-
chip”) [57]
Therapeutic 
methods
Photodynamic therapy (PDT), controlled release of bioactive 
agents, Laser-in-situ Keratomileusis (LASIK), low-level laser 
therapy (LLLT), laser-induced thermotherapy (LITT)
[58-60]
Optical 
micromanipulation
Optical tweezers, optical stretcher, laser catapulting, cell 
sorting and cell positioning [61, 62]
Optical 
components
Light sources, detectors, and other optical components, e.g. 
ultrafast lasers, adaptive optics, fiber endoscopes [63, 64]
Other technologies
Micro- and nanofluidics, biochemistry (evaluation of targets, 
development of marker molecules), data modeling (image 
analysis, chemometrics), data management (user-oriented 
GUI, Big Data handling, bioinformatics), system integration 
and automation
[65-68]
2.1 SPECTROSCOPY AND SURFACE-SENSITIVE TECHNIQUES IN  
 BIOPHOTONICS
Today, the wide range of sophisticated spectroscopic methods enable detailed 
examination of (bio) chemical structures as well as physiological and biological 
processes. The evolution of spectroscopy has paved the way for molecular research 
in chemistry, biophysics, physical chemistry and biopharmaceutics. Prominent 
measurement technologies are label-free, and non- or minimally invasive, and 
observations can be performed in real time. The applicability of these technologies in 
life sciences is extremely broad. For instance, during the drug discovery process the 
chemical structures and solid state behavior of the potential drug molecules have to 
be evaluated, and their safety and efficacy tested in vitro according to the guidelines 
of the regulatory agencies in Europe, USA and Japan (FDA, EMA, and PMDA, 
respectively). Furthermore, an immense amount of various interactions can be 
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observed by spectroscopic methods – especially using surface-sensitive techniques 
that utilize photonics and biosensor technologies. Examples of interactions that can 
be detected on or at the close proximity of functionalized sensor surfaces include 
drug-protein affinities [69], protein-protein interactions [36], liposome interactions 
with various analytes [70], or various interaction schemes of biomimetic structures 
resembling cell lipid bilayers [71]. In general, interaction of light with (bulk) matter 
such as molecular aggregates having a size equal to or larger than the wavelength 
can result to reflection, refraction, scattering and absorption processes. These 
processes are depicted in Figure 1. In essence, the refractive index n at frequencies 
corresponding to the gap between the two different states of a medium (near the 
resonance, e.g. air and metal) is defined as a complex quantity given as , where the 
real part,  describes the refraction and scattering, the imaginary part, , describes the 
absorption of light in a medium. Moreover, the dielectric properties of materials 
and evanescent field phenomena construct the bedrock for surface-sensitive 
techniques [72]. Particularly, scattering-based Raman spectroscopy and surface-
sensitive surface plasmon resonance (SPR) as biophotonic methods, their current 
state and modern applications for the biopharmaceutical field are represented in 
detail throughout this Thesis.
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Figure 1. A beam of light is propagating from medium 1 (air) to a medium 2 (e.g. biological tissue 
or metal). 
2.2 Biosensors and optical biosensors 
Biosensor, by the definition of the International Union of Pure and Applied Chemistry (IUPAC), is 
“a self-contained integrated device which is capable of providing specific quantitative or semi-
quantitative information using a biological recognition element which is in direct spatial contact with 
a transducer element” [73]. This definition has been challenged as unnecessarily stringent [74] but 
nevertheless the basic concept is in the use of a device that can measure biologically-derived signals. 
Originally biosensors were used to describe enzymatic interactions. The first biosensor was a glucose 
sensor. Soon it turned out that the possibilities offered by the biosensor technology could be utilized 
to investigate biological systems, receptors, nucleic acids, lipids, and a wide range of small molecule 
and bigger particle interactions with various ligands. Despite the signals are occasionally hardly 
recognizable, the biosensor technologies have established a strong position in the field of life sciences 
[75-82].  
Optical biosensors, for one, are components that are used with optical techniques to detect and 
identify chemical or biological species. There are numerous advantages in using optical biosensing 
such as remote sensing with high selectivity and specificity and the opportunity to use highly 
modifiable biorecognition schemes. In addition, electromagnetic interference can typically be isolated 
during the measurements, which essentially means that the instrument-related noise can be minimized 
with minor effort. It is also useful that multiple channels and multi-parameter approaches can be used 
for detection, and the instruments are compact and affordable. Furthermore, detailed chemical 
information on analytes is provided by optical biosensors. The main aspects related to optical 
biosensing are (i) a choice of appropriate bio-recognition scheme and parameters to detect chemical 
Figure 1. A beam of light is propagating from medium 1 (air) to a medium 2 (e.g. biological tissue 
or metal).
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2.2 BIOSENSORS AND OPTICAL BIOSENSORS
Biosensor, by the definition of the International Union of Pure and Applied 
Chemistry (IUPAC), is “a self-contained integrated device which is capable of 
providing specific quantitative or semi-quantitative information using a biological 
recognition element which is in direct spatial contact with a transducer element” 
[73]. This definition has been challenged as unnecessarily stringent [74] but 
nevertheless the basic concept is in the use of a device that can measure biologically-
derived signals. Originally biosensors were used to describe enzymatic interactions. 
The first biosensor was a glucose sensor. Soon it turned out that the possibilities 
offered by the biosensor technology could be utilized to investigate biological 
systems, receptors, nucleic acids, lipids, and a wide range of small molecule and 
bigger particle interactions with various ligands. Despite the signals are occasionally 
hardly recognizable, the biosensor technologies have established a strong position 
in the field of life sciences [75-82]. 
Optical biosensors, for one, are components that are used with optical techniques 
to detect and identify chemical or biological species. There are numerous advantages 
in using optical biosensing such as remote sensing with high selectivity and specificity 
and the opportunity to use highly modifiable biorecognition schemes. In addition, 
electromagnetic interference can typically be isolated during the measurements, 
which essentially means that the instrument-related noise can be minimized 
with minor effort. It is also useful that multiple channels and multi-parameter 
approaches can be used for detection, and the instruments are compact and 
affordable. Furthermore, detailed chemical information on analytes is provided 
by optical biosensors. The main aspects related to optical biosensing are (i) a 
choice of appropriate bio-recognition scheme and parameters to detect chemical or 
biological species, (ii) a transduction mechanism to convert the physical or chemical 
response of bio-recognition into a measurable signal, and (iii) selection of correct 
data analysis techniques to process and interpret reliably the acquired data. Being 
a part of biophotonic methods, optical biosensors can be found very useful in a 
vast number of applications, for instance, clinical diagnostics, drug development, 
environmental monitoring (air, water, soil) and food quality control. These features 
make optical biosensors an intriguing option for multiple purposes in life sciences, 
for example in biopharmaceutics. 
An overview, examples and a chronological insight into the evolution of biosensors 
are provided for example in references [50, 83-88]. Ideally a biosensor-based assay 
is label-free and the measurements can be performed in real time. This, in turn, 
offers many advantages over the other techniques and methods in which complex 
sample preparation, sophisticated laboratory equipment or trained personnel may 
be needed. Additionally, instead of measuring solely the start and end phase of the 
phenomenon of interest in static conditions, biosensor assays enable monitoring 
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events constantly over the time and dynamic conditions are easily implemented e.g. 
by the use of microfluidics [38]. The aforementioned features serve as good starting 
points for various in vitro analysis and biomimetic assays in biopharmaceutics where 
fast, cost-effective, robust and highly modifiable methodology is needed in order 
to discover novel venues for studying pharmacodynamics and pharmacokinetic 
phenomena in biologically relevant environments.
2.2.1 Biosensor development
The main components of an optical biosensor system are (i) a light source, (ii) an 
optical transmission medium (e.g. fiber, waveguide), (iii) immobilized biological 
recognition element (e.g. enzymes, peptides, antibodies, lipid bilayers, liposomes, 
or cells), (iv) optical probes (e.g. fluorescent marker in labeled settings or surface 
plasmon propagation in label-free settings) for transduction, and (v) an optical 
detection system. In the case of evanescent wave sensing, such as surface plasmon 
resonance, a metal acts as a solid support for the bio-recognition elements. The bio-
recognition elements are typically immobilized on the surface, either by physical (for 
example adsorption) or by chemical attachment. Since the first reports of enzyme-
based biosensors for glucose by Clark et al. in 1962 [89], there has been an extensive 
evolution in the biosensor development [69]. Unless otherwise stated, throughout 
this Thesis, the bio-recognition material attached to the sensor surface is referred 
to as the receptor ligand or simply ligand. The detected material, for one, is called 
the analyte. Below, various immobilization techniques are briefly discussed.
Physical adsorption. Relatively straight-forward physical methods include 
bio-recognition containment within semipermeable membranes or adsorption on a 
solid support. Ionic, hydrophobic, or Van der Waals forces can be used for selective 
adsorption. The advantage of physical adsorption is simplicity, but it may suffer from 
the non-specific nature of the method or variation in the density of attachments, 
orientation and desorption of bio-recognition elements. A bio-recognition element 
can be immobilized on a solid support by electrostatic interactions between them. 
The polarity or charge of the bio-recognition element can be adjusted with varying 
pH conditions, and thus, by selecting suitable polymer (e.g. containing negatively 
charged sulfonic groups -SO3
-, or positively charged ammonium groups –NH4
+) 
carrying opposite charge, the bio-recognition element can be adsorbed onto the 
surface.
Physical entrapment. In this method the bio-recognition element is entrapped 
within a polymer of biomimetic matrices, for example polyacrylamide, polyvinyl 
alcohol, polyvinyl chloride, sol-gel processed glass or Langmuir-Blodgett film. The 
advantage is that the leaching (desorption) of the bio-recognition element and bio-
fouling effect (adherence of non-specific biologics) can be minimized. However, 
the immobilized biomolecule has to retain its affinity, activity and stability in the 
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entrapped form, and it also has to be accessible to the analyte. In addition, the 
entrapment matrix has to be optically transparent.
Chemical immobilization. A formation of a covalent bond between the solid 
support or the sensor surface and the bio-recognition element is the basis of chemical 
immobilization techniques. Control of the surface density of bio-recognition element 
is crucial for achieving high efficiency. Of importance, the support surface is typically 
modified in order to introduce coupling groups such as –OH, –NH2, –COOH, and 
–SH. Another covalent attachment scheme involves a –COOH reaction with an 
amine group to form an amide linkage. Furthermore, a frequently used covalent 
bio-recognition element association method is the immobilization on a gold surface 
– this is a common method especially in the case of SPR sensors. For this purpose, 
a self-assembling phenomenon of a molecular monolayer composing of long-chain 
molecules with an –SH group at one end and another functional group such as 
–NH2 or –COOH at the other end is used. In principle, the –SH group binds to 
the gold surface whereas the –NH2 or –COOH group at the other end is used to 
couple e.g. to an enzyme or an antibody at multiple sites. Moreover, cellulose, 
polyacrylamide, carboxymethyl-modified dextran (CMD), carboxylic-acid-modified 
polyvinyl chloride (PVC) or polystyrenes can be used as functionalized surfaces 
for binding with proteins. An important method for the chemical immobilization 
of biotinylated ligands/analytes is the avidin-biotin coupling technique [90]. The 
avidin-biotin coupling is illustrated in Figure 2. 
In general, covalent attachment protocols yield more stable and reproducible 
activities than the physical methods, but the downside can be occasional complexity 
in the immobilization procedure. It is noteworthy that the covalent chemical 
immobilization techniques are most commonly used when preparing SPR sensors; 
glass slides are typically coated with a thin noble metal layer with good plasmonic 
properties such as gold, platinum or silver. Gold as the coating material is favored 
since it is relatively inert and affordable, and its plasmonic behavior with different 
excitation wavelengths is well established [91].
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Figure 2. An artistic impression of the biotin-avidin coupling events.  
2.2.2 Label-free detection 
The cornerstones of life sciences research, pharmaceutical industry and medical diagnostics are the 
capabilities to investigate interactions among biomolecules, to observe activity and response of cells 
in the presence of different stimuli (e.g. drug molecules), and to detect analytes from bodily fluids, 
cell supernatants or at various stages of manufacturing processes. These tasks are enabled by the 
ability to perform biopharmaceutical, biochemical and cell-based assays in order to find out whether 
an analyte interacts with another, and if so, how strong the binding affinity is between the bio-
molecular species. Furthermore, relevant questions are, for instance, what is the concentration of a 
biomarker for cancer within a patient’s blood sample, what the chemical fingerprint of a certain 
biomarker is or how the physicochemical properties of the biomimetic or living environment are 
affected when drug molecules or drug carrier vehicles are introduced to the system. During the drug 
discovery and development process in the pharmaceutical industry, it is important to perform rigorous 
chemical characterization of the drug candidates in solid state as well as in dissolved state. 
The development of technologies to meet the requirements mentioned above is ever-challenging, 
because the analytes in question can include small molecular drug compounds with molecular weights 
below 500 Da, DNA oligomers, peptides, enzymes, antibodies, and viral particles – in other words, 
the analytes can be exceedingly small and the measured concentrations in the range of fg/ml to pg/ml 
[90, 92]. Simultaneously, the samples can contain thousands of other molecules at concentrations 
orders of magnitude greater or there are other distracting signals that hamper the detection of analytes, 
for example strong fluorescence background or non-specific binding events. Larger biochemical 
analytes such as bacteria, spores, cells, EVs or nano-sized drug carrier molecules are less difficult to 
observe – especially if they can be fluorescently labeled.  
Overall, due to the difficulty in detecting biological and biopharmaceutical analytes using their 
intrinsic properties (e.g. mass, size, electrical impedance, dielectric permittivity), the methodology 
has relied upon attachment of a label to one or more of the molecules/viruses/cells/nanoparticles being 
studied. In general, the label is detected by its color or its ability to generate photons at a particular 
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2.2.2 Label-free detection
The corners ones of life sciences research, pharmaceutical industry and medical 
diagnostics are the capabilities to investigate interaction  among biomolecules, 
to observe activity and esponse of cells in the presence of different stimuli (e.g. 
drug molec les), and to detect analytes from bodily fluids, cell supernatants or at 
various stages of manufacturing pr cesses. These tasks are enabled by the ability 
to perform biopharmaceutical, biochemical and cell-based assays in order to find 
out whether an analyte interacts with another, and if so, how strong the binding 
affinity is between the bio-molecular species. Furthermore, relevant questions are, 
for instance, what is the concentration of a biomarker for cancer within a patient’s 
blood sample, what the chemical fingerprint of a certain biomarker is or how the 
physicochemical properties of the biomimetic or living environment are affected 
when drug molecules or drug carrier vehicles are introduced to the system. During 
the drug discovery and development process in the pharmaceutical industry, it is 
important to perform rigorous chemical characterization of the drug candidates in 
solid state as well as in dissolved state.
The development of technologies to meet the requirements mentioned above 
is ever-challenging, because the analytes in question can include small molecular 
drug compounds with molecular weights below 500 Da, DNA oligomers, peptides, 
enzymes, antibodies, and viral particles – in other words, the analytes can be 
exceedingly small and the measured concentrations in the range of fg/ml to pg/
ml [90, 92]. Simultaneously, the samples can contain thousands of other molecules 
28
at concentrations orders of magnitude greater or there are other distracting signals 
that hamper the detection of analytes, for example strong fluorescence background 
or non-specific binding events. Larger biochemical analytes such as bacteria, 
spores, cells, EVs or nano-sized drug carrier molecules are less difficult to observe 
– especially if they can be fluorescently labeled. 
Overall, due to the difficulty in detecting biological and biopharmaceutical 
analytes using their intrinsic properties (e.g. mass, size, electrical impedance, 
dielectric permittivity), the methodology has relied upon attachment of a label to one 
or more of the molecules/viruses/cells/nanoparticles being studied. In general, the 
label is detected by its color or its ability to generate photons at a particular excitation 
wavelength and act as an indirect marker to indicate the presence of the analyte to 
which it has been attached. However, such treatments generally result in the death 
of the specimen or significant biological or chemical changes in the structures of the 
analytes [93]. In essence, label-based assays require a high degree of development 
to assure that the label itself does not block an important active site on the tagged 
molecule or modify the physicochemical properties of the molecules or particles. 
Particularly for sandwich-type assays, the washing conditions, blocking conditions, 
and exposure protocols for a range of reagents are needed. Moreover, labware for 
fluorescent assays must be constructed from non-auto-fluorescent materials, as 
unintentional background fluorescence can swamp the signals being measured. 
Another challenge included in the use of labeling arises from the need to perform 
several thousands of individual measurements as in the biopharmaceutical discovery, 
for example, there is a need to perform a great number of assays in parallel in order to 
understand how molecular permutations affect the efficacy or safety of the potential 
drug candidate [94]. Thus, the cost of performing such assays regarding disposable 
labware, reagents, and personnel time must be considered with particular care. 
Lastly, the measured data must be translated into biologically relevant information 
efficiently, and thus the selection of a particular assay technology plays a significant 
role. Even though the range of technologies available is immense, it also brings 
about complexities; the choice of suitable reagents and instruments may require 
fundamental knowledge of the analytes beforehand. Hence, multiple trial-and-error 
efforts might be needed before the assay even starts functioning in an expected 
manner. Taking into account all the considerations above, there exists a notable need 
for the continuous research and development of label-free techniques and methods 
in the field of life sciences, for instance, biopharmaceutics and pharmaceutical 
industry. In particular, biophotonic methods allow for reducing the assay costs 
and complexity while providing more quantitative information with moderate high 
throughput capabilities [92].
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2.2.3 Biophotonic label-free techniques in biomedicine
As the biosensor technology in general, biophotonic label-free detection generally 
involves a transducer capable of directly measuring certain physical property of 
the chemical compound, DNA, molecule, peptide, protein, virus, EV, cell, or drug 
carrier particle. For example, all biochemical molecules and cells have finite mass, 
volume, viscoelasticity, dielectric permittivity, and conductivity; these can be utilized 
to indicate their presence or absence using an appropriate technique and sensor. 
The sensor acts as a transducer that is capable of converting one or more of these 
physical properties into a quantifiable signal that can be collected by an appropriate 
instrument (e.g. current of voltage proportional to the surface-deposited mass or 
a photon diode detector). However, the question is not all about biosensors; label-
free detection can also be performed using biophotonic spectroscopy techniques 
that allow for detection of absorbed or scattered light. Examples of such label-
free techniques are infrared (IR) and Raman spectroscopy. These techniques are 
particularly practical when the measurement must be carried out without sensors 
or the amount of analyte is very low.
Overall, the experimental uncertainty generated by the effects of the label 
on molecular conformation, blocking of active binding sites, steric hindrance or 
inaccessibility of the labeled site itself can be overcome with label-free detection [93, 
94]. Additionally, the complexity related to finding appropriate labels that function 
equivalently for all the molecules in a given experiment, can also be omitted. The 
time and effort required for the development of a robust assay are reduced and 
simplified, and the amount of experimental artefacts are decreased. At present, there 
are considerably many methods that allow direct detection of biological structures 
and biopharmaceutical compounds without a priori labeling. However, there are 
still limitations and cavities related to the current methodology; the instrumentation 
is considered non-user-friendly and costly, and data analysis steps are occasionally 
seen complicated. Furthermore, “thinking outside the box” has been lacking, and 
thus relying on the traditional formulas in the development of assays has been 
hampering the evolution of the field. In this context, Raman and SPR as biophotonic 
methods offer a wide array of opportunities in both directions; in the development 
of new instrumentation and revolutionary assays. It is also noteworthy that in the 
field of biopharmaceutics, the focus of development has to reside simultaneously 
in small and large analytes since such compounds and structures are practically 
always present in living systems. Thus, in this Thesis, small molecular drugs act as 
a conventional example of small-scale analytes under investigation, and liposomes 
and EVs as large-scale analytes of interest.
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2.2.4 General theoretical overview of label-free optical biosensing
A biopharmaceutical small drug or a biological EV as an analyte – which are referred 
to as analyte in this text unless otherwise stated – have certain mass, a natural 
intrinsic property for label-free detection. Additionally, all molecules have the 
capability to interact with electromagnetic fields that pass through them because 
there are atoms with nuclei and a variety of electrons in different orbital states. 
Light is known to consist of an oscillating magnetic and electric fields perpendicular 
to each other. In essence, the electrons within molecules experience a force when 
exposed to the oscillating electromagnetic field associated with the propagation 
of light. Consequently, light’s electromagnetic field will result in the polarization 
of the molecules with abundance of free electrons. This means that one side of 
the molecule will become temporarily more positively charged than the opposite 
side, and thus an electric dipole is formed. The extent of polarization may differ 
depending on the molecule; the size, shape and orientation with respect to the electric 
field determine the magnitude of polarization. A constant, electric susceptibility, 
Χe, quantifies the magnitude of a molecule’s polarizability. Molecules with larger 
Χe are readily polarizable. Of importance, the Raman scattering phenomenon is 
fundamentally based on the concept of molecule’s polarizability, which is more 
profoundly described in chapter “5.1 Physical principles of Raman spectroscopy”. 
A polarizable molecule set in an external electric field undergoes the described 
polarization, and the resulting dipole produces a secondary field. Finally, the 
resulting electric field (= the sum of the originally applied field and the secondary 
field) is of lower magnitude than that of the applied field. Furthermore, as the 
electromagnetic field related to light is varying with respect to time, the electrons 
within the molecule placed in that particular field experience a force that varies with 
respect to time. Thus, the electrons will oscillate within the molecule. By definition, 
moving electrons produce an electrical current. Hence, the molecule experiences a 
polarization current because of this motion of electrons. Subsequently, light travels 
more slowly through the molecule than it would through free space. Free space has 
a permittivity defined by the constant ε0 = 8.85 x 10
-12 F/m, and the permittivity of 
a dielectric material containing molecules is specified as ε = εr ε0, where εr is known 
as the relative permittivity of the dielectric constant of the molecule. εr is related to 
the polarizability of the molecule since it is defined as εr = 1 + Χe. 
The term refractive index (n), for one, is a more common physical quantity to 
describe a dielectric material. Generally, in an ordinary dielectric material at optical 
wavelengths, n is defined as n = ; the refractive index is directly related to the 
polarizability of the molecules within a dielectric material. It is worth pointing out 
that the refractive index is a quantity defined for a bulk material whereas the electric 
susceptibility and dielectric permittivity generally refer to individual molecules such 
as those adsorbed to optical biosensor surfaces. All the biological analytes (proteins, 
lipids, carbohydrates, cells, nucleic acids etc.) possess dielectric permittivity that is 
31
larger than the dielectric permittivity of air and water. Such analytes are capable of 
hindering the propagation velocity of electromagnetic fields passing through them. 
The development of optical label-free biosensors relies on that physical principle; 
the biosensor simply must translate the change in propagation speed of the applied 
electromagnetic field, i.e. light, into a signal that is quantifiable and proportional 
to the amount of analyte deposited onto the sensor surface. 
Notably, a common erroneous interpretation prevails in terms of what is 
actually measured by optical biosensors. Namely, typically the biosensor surface 
is covered with water molecules, and in the case of biological analytes associating 
to surfaces, some of the water molecules are superseded and substituted by the 
surface-associating analyte molecules. The analyte molecules, for one, are often 
easily polarized by the oscillating electromagnetic field of light. Consequently, 
the biosensor development must aim to find a suitable transducer element 
that possesses a measurable property that is altered by transitions in dielectric 
permittivity of the sensor surface. Thus, stringently taken, optical biosensors do 
not directly measure the mass of surface-deposited analytes but the changes in 
dielectric permittivity – however, such change is typically converted to change in 
surface concentration (or mass) of the adsorbed analytes. The changes in refractive 
properties of analytes at the biosensor surface and at the vicinity of the biosensor 
surface constitute the physical cornerstones of SPR, covered in more detail in 
chapter “6.1 Physical principles of SPR”.
Whether the incident light source is a laser, light-emitting diode or an 
incandescent light bulb, all of the introduced physical principles can be exploited in 
different spectroscopic and optical biosensing techniques. The mutual principle is to 
detect reflection, refraction, transmission and scattering phenomena as the samples 
are irradiated with light. In general, optical biosensors are affordable in terms of 
production since they can be engineered on glass or plastic surface instead of using 
e.g. etching or lithographic techniques that are often more complex and expensive. 
In addition, the optical biosensors are regarded as passive optical components; the 
alterations in properties of reflected/transmitted light are measured and the incident 
excitation light is delivered from external sources. The benefit is that the sensor 
does not deplete power, and measurable responses are achieved using relatively low 
irradiation. Lastly, the detection can be performed without making direct physical 
contact with the sensor or without prerequisites for electrical contacts – these 
features are definitely favorable for optical label-free biosensing. 
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3 BIOPHARMACEUTICAL RESEARCH WITH ITS  
 NEW CHALLENGES
As of today, a number of varying definitions for “biopharmaceutical” exist [95]. 
Within the scope of this Thesis, the term “biopharmaceutical” includes, but is not 
restricted to biologics; it also covers the chemically synthetized pharmaceuticals, 
i.e. small drug molecules. “Biopharmaceutics”, in this respect, refers to the scientific 
discipline concerned with the physicochemical properties of pharmaceuticals 
in relation to their bioavailability and pharmacokinetics. Furthermore, in this 
regard the liposomes and EVs are prominent biopharmaceutical particles for drug 
administration and diagnostics – representing larger scale of analytes in comparison 
to the conventional small molecular drugs in the field of biopharmaceutical research. 
The physical and chemical characterization, interaction studies [96-99], 
and for instance, monitoring the morphological changes of drug compounds 
during the manufacturing process i.e. PAT are some of the important phases 
of biopharmaceutical drug research. Moreover, the number of Food and Drug 
Administration (FDA) approved nanoparticle-based drug preparations is relatively 
low; liposome-based formulations of drugs (Doxil, Ortho Biotech, Bridgewater, NJ, 
USA; DaunoXome, Gilead, Foster City, CA, USA), albumin-bound nanoparticles 
of paclitaxel (Abraxane, Abraxis BioScience, Schaumburg IL, USA), and products 
using nanocrystal technology (sirolimus (Rapamune), Wyeth Pharmaceuticals, 
Collegeville, PA, USA; Emend, Merck, Whitehouse Station, NJ, USA) [100, 101] 
are some of the few approved preparations. Recently, the bioequivalence guideline 
for liposome drug products was approved. In addition, the European Medicines 
Agency (EMA) is on the verge of adopting updated regulations in regards of novel 
nanotechnology-based formulations [102]. Thus, for instance extracellular vesicles 
provoke great interest as prospective “natural” drug carriers or diagnostic tools in 
the early-stage cancer detection [103, 104]. Spectroscopic techniques relying on 
the foundations of biophotonics have shown great potential in the aforementioned 
stages of biopharmaceutical drug discovery, development, industry processes, 
and diagnostics. Even though many of these techniques and methods are well 
established, the current pharmaceutical space is lacking novel approaches by 
which those techniques are implemented. The biopharmaceutical research and 
development has essentially stuck into two elements; there has not been a substantial 
driving force to develop (i) novel technology nor (ii) methodology (i.e. protocols 
relying on biophotonic technology) or (iii) data analysis techniques in order to 
pioneer uncharted venues. For example, Raman spectroscopy is still seen as an 
unnecessarily complex technique for real-life applications, and the versatile surface 
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plasmon resonance technique [105], traditionally considered highly applicable for 
analyte-ligand interaction with occasional issues with sensitivity [106], is not seen 
to offer much outside the interaction studies. However, there is much more to the 
picture than meets the eye. 
3.1 SMALL DRUGS IN BIOPHARMACEUTICAL RESEARCH
Rational and successful drug discovery, development and further optimization is 
an extremely demanding process initiating from the potential candidate molecule 
screening, and further proceeding through in vitro testing phase to clinical trials 
[107-109]. Moreover, the journey does not end when the final drug preparation is 
released for the markets; the industry processes for large-scale drug production 
are constantly in need of optimization and better understanding of control over 
the various process parameters [110]. From the pharmaceutical perspective, 
small molecular drugs are conventional, orally administered drugs, e.g. as tablets 
or capsules. Christopher Lipinski’s “rule of five” is one of the most well-known 
definitions for small molecular drugs [111-113]. It describes pharmaceutically 
relevant features for evaluating the potential and suitability of a molecule to act 
as an orally administered, therapeutically active compound. In brief, the molecule 
has to adhere at least three of the following properties: (i) it should not have more 
than 5 hydrogen bond donors, (ii) no more than 10 hydrogen bond acceptors, (iii) 
the upper limit of molecular mass is 500 Da, (iv) octanol-water partition coefficient 
log P not greater than 5. In fact, the physicochemical features described by the 
Lipinski’s rule of five cover ~90% of the orally administered drugs in the market 
[112]. There also exists certain additions and specifications to the rule of five in 
order to enhance the applicability of the rule [114]. Importantly, the rule does not 
prefigure whether the molecule is pharmacologically active, but instead, it focuses 
on the pharmacokinetic properties of the molecule. Such properties affect greatly on 
the administration, distribution, metabolism and excretion (ADME) characteristics 
of the drug. 
The pharmaceutical industry is on the verge of new era as personalized 
medicament and biological medicinal products (e.g. protein drugs that are copies 
or optimized relatives of endogenous human proteins [115]) are seen as the state-
of-the-art preparations and attract special interest from the viewpoints of both, 
fundamental research and high-tech industry. However, conventional small 
molecular drugs are still the cornerstones of the pharmaceutical market. Regardless 
the increased proportion of biologics, for instance in 2015 33 new molecular entity 
(NME) approvals out of total 45 NME approvals were granted to small-molecule 
therapeutics by the FDA [116]. It is worth emphasizing that the trend of the FDA 
approvals in 2015 followed the tendencies observed during previous years [117]. 
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The opportunities of biophotonic instruments and methods, in particular Raman 
spectroscopy and SPR for investigating small drugs are introduced in chapters “5 
Raman spectroscopy” and “6 Surface plasmon resonance”, respectively.
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4 NANOMEDICINE AND BIOPHOTONICS
In addition to conventional small drugs, researchers have increasingly been 
interested in the applications of nanomedicine. Nanomedicine is essentially a part 
of biomedicine, sometimes referred to as medical biology that implements biology 
and other natural sciences to clinical practice. The first research publications to 
use the term nanomedicine date back to the year 2000 [100]. Nanomedicine has 
been defined as a technology that utilizes molecular tools and knowledge of the 
human body for the purposes of medical diagnosis and treatment [118]. Another 
distinct and scientifically subtle definition emphasizes the physical effects taking 
place at the interface between molecular and macroscopic scale whereby quantum 
mechanics are of importance occurring in objects of nanoscale [119]. However, 
within the scope of this Thesis, nanomedicine is defined as the use of nanoscale 
or nanostructured materials in biomedicine. Their physicochemical structures 
have unparalleled medical effects, and as such are different from conventional 
small-molecule drugs. They may, for instance, have capability to cross biological 
barriers or are specifically targeted to certain types of cells or tissues. In essence, 
such medical effects are not constrained to size scale under 100 nm; although the 
strict physical definition of nanotechnology suggests to restrict the observations 
to particles within the range of 1-100 nm in diameter, the scale can be stretched 
up to 1000 nm. The justification for the size scale of 1-1000 nm is convenient 
since the better understanding of medical effects occurring in nanoscales requires 
new approaches from the viewpoint of manufacturing techniques, chemistry and 
physics. If the scale was stringently defined, essential features could be missed in 
the research and development of nanomedicines. However, a clear difference to 
small-molecule drugs is made; they are not specifically developed on the nanoscale 
to accomplish therapeutic effects that are in relation to their nanosize dimensions. 
Nanotechnology has become a prominent tool in various disciplines – including 
biomedical science. For instance, targeted drug delivery carriers (DDC), for example 
liposomes, are intensively studied in order to gain comprehensive understanding of 
their safety and efficacy in biological surroundings [120] or to optimize and enhance 
their performance [121]. Furthermore, the nature and behavior of EVs hold promise 
for them to act as DDCs or diagnostic tools in nanomedical applications [104]. 
However, a prerequisite is rigorous knowledge of the chemistry, physics and biology 
involved in the interactions at the interfaces of nanoparticles (artificial or inherent) 
and living systems [1, 122]. It is to be noted that one of the fundamental problems in 
nanomedicine and –medication arise from the requirement for controllability and 
reproducibility of chemical reactions and interactions in the nanometer scale. The 
challenging goals of rational DDC design and other nanomedical needs can be met 
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by the strongly evolving field at the crossroad of nanoscience, biomedical research 
and optical science. The combination is also referred to as bionanophotonics [123]. 
In bionanophotonics, one of the challenges is the complex interaction of light and 
biological media, typically introducing a cascade of events. The interactions can 
evoke physical, chemical, thermal, and mechanical effects – or combinations of 
them. The development of label-free versatile instruments, probes and sensors 
can augment their applicability, and minimize the unwanted interferences with 
the native state of the analytes during the measurement or manipulation. In the 
following two chapters, liposomes and EVs, respectively, are introduced as important 
species from the perspective of nanomedicine. Consequently, from the standpoint of 
bionanophotonics, their investigation with Raman and SPR is dealt with in chapters 
“5 Raman spectroscopy” and “6 Surface plasmon resonance”. 
4.1 LIPOSOMES IN THE BIOPHARMACEUTICAL FIELD
Biophysicochemical laws apply to drug delivery carriers (DDCs) as well as essentially 
every foreign particle entering into the body. The transitions, exchange and excretion 
of external materials is effectively controlled by distinct physiological barriers. For 
instance, the endothelial cells of blood vessels are capable of halting the migration of 
potentially harmful compounds and particles [124]. Systemically administered drugs 
and nanocarriers are instantly recognized by the efficient barrier mechanism in blood 
circulation; the foreign compounds are marked with proteins via an opsonisation 
process [125], and consequently excreted from the systemic circulation by the 
mononuclear phagocyte system (MPS) [126]. The foreign nanoparticles are treated 
by a specific process whereby bloodstream proteins attach onto the surface of the 
particle before the phagocytes of the MPS system can recognize the invaders. The 
process is appreciated as the complement activation [127] or opsonisation [128]. 
Thus, the requirements for effective and safe DDCs are somewhat rigorous; first, 
upon administration, they must pass the endothelial vascular barrier, then evade 
the clearance processes of the immune system, and lastly, accumulate at the desired 
tissue in quantities that are adequate for the expected pharmacological efficacy. 
Notably, to some extent, the nanocarriers for controlled drug administration mimic 
the biophysicochemical properties of pathogenic particles; such particles strive to 
resolve exactly the same barriers that the DDCs encounter upon administration. 
Moreover, as denoted previously, EVs can act as model structures for the biomimetic, 
synthetic DDCs since they are constantly migrating throughout the aforementioned 
barriers.  
The wide array of various DDCs consists of liposomes [129], dendrimers [130], 
carbon nanotubes [131], inorganic nanoparticles [132, 133], and polymer-based 
nanoparticles [134], for instance. One of the most pertinent nanotechnological tools 
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used in nanomedicine are liposomes [135, 136]. In fact, more than ten approved 
liposome-based drug formulations exist currently, and the research, development 
and clinical trials are continuously ongoing for new preparations to be launched 
[129]. In short, liposomes are membrane-delimited vesicles that are typically 
produced on hydration of dried phospholipids above their transition temperature 
[129, 137]. Three categories for liposome classification exist based on their size 
and the amount and type of lipid bilayers. Hence, the multilamellar vesicles are 
comprised of multiple lipid bilayers separated from each other by aqueous space. 
The multilamellar vesicles are relatively heterogeneous in size, typically ranging from 
few hundreds to thousands of nanometers in diameter. Furthermore, small (< 100 
nm) unilamellar vesicles (SUVs) and large (> 100 nm) unilamellar vesicles (LUVs) 
compose of a single lipid bilayer constraining the inner, aqueous compartment of 
the liposome. When acting as DDCs, the drug molecules can be entrapped into the 
aqueous inner compartment of the vesicles or included into the lipid bilayers; this 
depends on the chemical and physical properties of the drug. Both hydrophobic and 
hydrophilic molecules can be incorporated. Of importance, the surface of liposomes 
is highly modifiable with various ligands and polymers for different purposes, which 
will be elucidated in the next chapter.
4.1.1 Conventional methods for studying liposomes
Biophysicochemical characteristics of liposome-based DDC determine their success 
in achieving the desired effects in the biological environment – simultaneously the 
safety of the nanocarrier must be ensured. Thus, relevant features in the rational 
liposome development are size, shape, deformability, surface charge, stability, and 
chemical composition [138]. Such properties affect the nanocarrier’s capability 
to evade phagocytosis, determine the interactions with vasculature and traverse 
through cell membranes, and survive from endosomes before the drug degradation. 
Therefore, various experimental and computational methods are often needed 
for prosperous liposome design. Three distinguishable aims prevail in liposome 
engineering; to create a stealth shield against the MPS system, enable liposome 
targeting (passive [139] or active [140]), and in some instances, strive to optimize 
their performance (e.g. stability [141] or surface charge [142]). In brief, the purpose 
of stealth sheath is, in an optimal situation, to prevent unspecific protein binding 
and to block the complement activation cascade that may alter the biodistribution, 
decrease cellular uptake, and result in unwanted and rapid nanocarrier clearance 
from the systemic circulation in the body. By camouflaging the nanocarrier’s foreign 
nature, its circulation time in the bloodstream can be increased. The prolonged 
circulation time, for one, can enhance the overall bioavailability, decrease the dose 
and dosing frequency, resulting to fewer side and adverse effects. The current gold 
standard for shielding the nanocarriers is the usage of polyethylene glycol (PEG) for 
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nanoparticle PEGylation [143, 144]. However, drawbacks of PEGylation have been 
demonstrated as it may induce immunological responses [145]. Additionally, trials 
to bioconjugate PEGylated nanocarriers with targeting ligands have shown that 
the overall controllability and reproducibility of the process may be difficult [146]. 
Since the use of PEG is not always unproblematic, substituting approaches are being 
charted [147, 148]. By using PEG alternatives, amended pharmacokinetic properties, 
enhanced stability and degradability can be accomplished. Biodegradable choices 
include polysialic acid (PSA), hydroxyethyl starch (HES), and polyglutamic acid 
(PGA). Examples of non-biodegradable alternatives are poly(carboxybetaine) (PCB), 
poly(N-hydroxypropyl)methacrylamide (pHPMA), and poly(vinylpyrrolidone) 
(PVP). Branched and comb-like alternatives for PEG could be poly(glycerol) (PG) 
or poly(poly(ethyleneglycol) p(PEGMA). 
Of importance, several physicochemical components can be modified in the 
liposome design process [70]. Namely, (i) the liposome size and lamellarity can 
be tuned via the extrusion process, (ii) the phospholipid or synthetic phospholipid 
components for the liposome membrane bilayer can be chosen for optimal 
performance, (iii) surfactants or amphiphilic molecules (for instance cholesterol 
or ethanol) can be included, (iv) to produce the stealth sheath a subset of head 
groups of molecules in the membrane of the liposome can be functionalized, and 
(v) ligands for targeting purposes can be used. It is to be remembered that, all of 
the depicted nanocarrier properties can also be applied to rational development of 
EV-based targeted drug delivery carriers as well. In fact, the ongoing research within 
the field of DDCs constantly widens our knowledge of the nano-bio interfaces, and 
pioneers towards novel DDS applications. Table 3 highlights the currently used 
methods and techniques that are used in liposome characterization and analysis. It is 
worth noticing, however, that the present toolbox for nanocarrier, and in particular, 
liposome characterization and modification still lacks complementary methods. 
Since labeling can induce considerable alterations to the biophysicochemical 
structures of the liposomes, particularly their lipid membranes, the properties of 
liposomes of interest may undergo significant changes. Consequently, such changes 
may bias the in vitro results, which often leads to problems during in vivo phase. In 
order to better bridge the gap between the significant amounts of papers published, 
and on the other hand, quite few actual breakthroughs in the form of actual approved 
drug formulations, especially novel label-free biological assays are needed. In this 
Thesis, such assays are appreciated as bio-functional assays where for example a 
new small drug candidate is tested in a biologically relevant in vitro environment 
– or interactions of DDCs and drugs with the living cell surfaces are investigated. 
In addition, the bio-functional assays can be complemented with computational 
simulations.
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Table 3. Currently used methods and techniques for liposome characterization and analysis.
Method or Technique Measured quantity or property Reference
Fluorescence recovery after 
photobleaching Characterizing membranes [149]
Fluorescence resonant 
energy transfer (FRET) Characterizing membranes [150]
Dynamic light scattering 
(DLS) Size and aggregation [151]
Nanoparticle tracking 
analysis (NTA) Size [152]
ζ-potential measurements 
Net electrical charge at the boundary between 
the hydrodynamic surface of the liposome and the 
dispersion media
[153]
Cryo-transmission electron 
microscopy (cryo-TEM) Size, shape, dispersity, surface morphology [154]
Nuclear magnetic 
resonance (NMR) 
The arrangement of hydrocarbon chains in the 
liposome lipid bilayer. Lamellarity of liposomes. [155]
Differential scanning 
calorimetry (DSC) 
Phase transitions, partitioning and interactions of 
drugs, biomolecules, polymers and surfactants with 
liposomes
[156]
Isothermal titration 
calorimetry (ITC) 
Phase transitions, partitioning and interactions of 
drugs, biomolecules, polymers and surfactants with 
liposomes
[157]
Langmuir film balance (LB) Phase behavior, surface potential, and viscoelastic properties of lipid layers on an air-water interface [158]
Brewster angle microscopy 
& imaging ellipsometry 
Phase transitions in lipid layers on an air-water 
interface [159, 160]
Quartz-crystal microbalance 
(QCM) 
Phospholipid membranes and membrane 
interactions [161, 162]
Surface plasmon resonance 
(SPR) 
Phospholipid membranes and membrane 
interactions [163]
Dual polarization 
interferometry (DPI) 
Phospholipid membranes and membrane 
interactions [164]
Attenuated total reflection 
Fourier transform infra-red 
spectroscopy (ATR-FTIR) 
Bond vibrations; observing the structures of surface-
adsorbed lipid bilayers and biomolecules in the 
presence of liposomes
[165]
Sum-frequency generation 
spectroscopy (SFG) 
Revealing structural correlations between liposome 
lipid layer constituents and molecular dynamics in 
lipid layers
[166, 167]
Synchrotron small-angle 
X-ray scattering Structural transitions [168, 169]
X-ray & neutron 
reflectometry 
Distribution of perpendicularly oriented molecules in 
lipid layers [170, 171]
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4.2 EXTRACELLULAR VESICLES: TERMS AND STRUCTURES
EVs are a group of membrane-bound, cell-derived biological nanoparticles. 
Varying definitions and nomenclature are abundant in the literature concerning 
the size characterization of these vesicles [104]. A common consensus prevails that 
exosomes are in the range of ~ 30-100 nm and microvesicles ~ 0.1-1 µm in diameter 
[172]. A single cell type can release both, exosomes and microvesicles [173, 174], 
and the circulating vesicle populations are evidently composed of exosomes and 
microvesicles. Still, one of the fundamental difficulties in the field of EV research is 
that the current isolation and purification methods do not fully guarantee that the 
exosomes and microvesicles can be discriminated, and their analysis is relatively 
laborious [175]. For instance, differences in size, morphology, buoyant density, and 
protein composition remains insufficient for legitimate distinction [176]. Unless 
otherwise stated, the term EVs is used herein to cover both of those subtypes to 
avoid confusion. In this respect, the focus is in introducing the extracellular vesicles 
as potential nanotechnological, bi-functional particles for the (i) diagnostic purposes 
as disease biomarkers and (ii) therapeutic purposes as drug delivery carriers. 
Consequently, as for the nanotechnological applications in general, biophotonics 
offers prospective tools for research in both of the abovementioned areas. A 
wealth of novel tools can be developed to meet the demands of physicochemical 
characterization of EVs, and their various interaction events with the surroundings 
– which can be highly modifiable biomimetic in vitro schemes.
Microvesicles are considered to originate by direct shedding from the plasma 
membrane whereas the exosomes stem from the inner compartments of the cells, 
released from the cells by multivesicular endosome (MVE) excretion processes by 
fusion of the MVEs with the plasma membrane [177]. Practically every cell type 
secretes EVs and thus, they can be found in a range of human body fluids; saliva 
[178], breast milk [179], plasma [180], urine [181], bile [182], and in cerebrospinal 
fluid [183]. In essence, EVs consist of a membrane evidently separating the inner 
compartment of the vesicles from the surrounding media. The membrane of EVs 
is similar to plasma membrane to some extent, in particular that of MVs, which 
are produced by direct shedding. However, since an important pathway of the 
biogenesis of EVs passes via an endosomal secretion, their membrane contents can 
be rather different from the plasma membrane [184]. The protein contents of EVs 
originating from a range of different sources have been analyzed for example using 
SDS-PAGE in combination with protein staining, immunoblotting, or proteomic 
analysis. It is important to note that in an optimal situation the EV samples are 
devoid of pollutants distracting the analysis; such pollutants can be serum proteins 
and protein components of intracellular compartments (e.g. endoplasmic reticulum 
or mitochondria). Due to the endosomal pathway of genesis, they carry membrane 
and transmembrane proteins such as tetraspanins (CD63, CD81, CD9) [185], heat 
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shock proteins (Hsp70 and Hsp90), and membrane fusion proteins (Annexins 
and Rabs) [186]. In addition, they are enriched in proteins associated with lipid 
rafts, including glycosylphospatidylinositol-anchored proteins and flotillins [187]. 
Contrary to plasma membrane, membranes of EVs originating from a variety of 
cells are abundant in cholesterol, sphingomyelin, and hexosylceramides whereas 
the proportion of phosphatidylcholine and phosphatidylethanolamine is lower [188, 
189]. A natural corona structure is also found in the membranes of EVs, mainly 
consisting of various proteins [190]. Different cell types generate various types of 
EVs, and the discrepancies in their biochemical membrane contents may be related 
to their biological functions [104]. The interior of the vesicles is known to carry at 
least nucleic acids (DNA, RNA, siRNA, miRNA, noncoding RNAs) [191, 192] as 
well as various peptides, proteins and uptake/fusion machineries [190]. Figure 3 
illustrates the main structural components of an EV.
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Figure 3. Visualization of an extracellular vesicle and the associated fundamental structures. The 
illustration also depicts a hypothesized role of the extracellular vesicles to act as targeted drug 
delivery vehicles when loaded with various drug molecules. 
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[195]. In brief, the protocol for reticulocyte exosome purification from tissue culture-conditioned 
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4.2.1 EV isolation and characterization techniques
The most common method for isolating EVs is to establish a cell line of interest in 
the cell culture, and recover the corresponding EVs from cell culture-conditioned 
media [175, 193, 194]. Witwer et al. introduced a detailed and rigorous overview 
on the isolation and characterization of EVs in 2013 [195]. In brief, the protocol 
for reticulocyte exosome purification from tissue culture-conditioned medium was 
developed by Johnstone et al. in 1987 [196], followed almost a decade  later by 
the works of Raposo et al. and Zitvogel et al. [197, 198], and thoroughly described 
by Théry et al. in 2006 [175]. The protocol is based on differential centrifugation 
whereby the vesicles are sedimented by ultracentrifugation at 100 000 x g. It is 
noteworthy that the smallest vesicles – including exosomes, can be sedimented 
at this velocity. Instead of performing direct ultracentrifugation at 100 000 x g, 
larger vesicles are collected by consequently centrifuging at increasing velocities. 
There are also variants of this protocol that use e.g. higher speeds at 140 000 x 
g [199] or filtration steps in order to eliminate debris and larger vesicles [175]. 
Size-exclusion chromatography can be used to recover entities that are larger than 
50 000 kDa, and thus discard soluble proteins [200]. Additionally, a number of 
protocols exist to isolate larger EVs, and are based on variants of centrifugation 
techniques, in general from lower speeds at 10 000 x g to 50 000 x g [201, 202]. 
However, caution is to be taken at any event since ultracentrifugation is not a 
“proper” purification; different EVs of similar size as well as protein aggregates can 
co-sediment at 100 000 x g. A method to separate membrane-enclosed vesicles 
from aggregated proteins is the exploitation of a sucrose gradient [197, 203]; the 
protein aggregates sediment through sucrose whereas the lipid-enriched EVs float 
upward to reach a position of equilibrium buoyant density. This method has also 
been tuned to purify EVs of clinical grade for therapeutic use [204]. The protocol 
defines a combination of filtration/concentration through a 500 kDa membrane 
and ultracentrifugation through a D20/sucrose cushion in order to recover vesicles. 
Moreover, an immunoadsorption technique has been proposed and used for 
additional purification [187]. Recently, a variety of commercially available EV 
isolation kits have been introduced. The rationale for such kits is the opportunity to 
avoid somewhat arduous ultracentrifugation procedures, simultaneously providing 
easy and fast EV recovery. Heretofore the chemicals and reagents used in the kits 
are confidential but the presumed function lies on the foundations of polymer-based 
precipitation or immunocapture by antibody-coated beads. The use of polymers 
should precipitate a wider range of vesicles and the latter a more restricted scale 
of vesicles. However, the researchers working in the EV field are susceptive in 
relying on the isolation kits; first, up to this date, there are no thorough comparative 
studies addressing whether these novel tools are adequate or valid over the existing 
protocols and what types of vesicles they exactly precipitate. Secondly, such isolation 
approaches may fail to discriminate between EVs of different sizes and membrane-
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free aggregates in the range of macromolecules. Thirdly, the reagents used in the 
isolation kits may contribute to the physicochemical nature of the vesicles, e.g. 
by coating the vesicles with synthetic chemical species of non-natural origin, and 
thus distorting the actual analysis. Overall, it is of utmost importance to take into 
account the described nuances between the different EV isolation methods in order 
to perform reproducible and rational EV assays. This minimizes the potential error 
sources arising from the isolation and purification steps. 
Further characterization of EVs is typically performed using complementary 
biochemical methods, for example immunoblotting [205]. In addition, studies 
have been implemented to analyze the lipid [189, 206] and nucleic acid [191, 207] 
compositions of EVs. Mass spectrometry [208] and imaging techniques (e.g. confocal 
microscopy and electron microscopy (EM) [209]) are also widely applied techniques. 
In general, larger EVs are analyzed by conventional microscopy, and smaller sized 
EVs are deposited on electron microscopy grids as whole mount samples [197]. It is 
to be noted that the latter approach may result in EVs collapsing during drying, and 
consequently leading to cup-shaped vesicles. Thus, misinterpretations in terms of 
EV morphology are occasionally made. The cryo-electron microscopy performed for 
rapidly frozen and vitrified vesicles clearly shows the rounded shape of EVs [210]. 
Furthermore, atomic force microscopy (AFM) has been demonstrated as a feasible 
technique for EV size and morphology studies [211]. The advent of super resolution 
microscopy (SRM) has been introduced as a novel technique for imaging EVs beyond 
the diffraction limited threshold posed by conventional optical microscopes [212]. 
However, it has not yet been adopted as a standard EV characterization technique 
and more rigorous work is warranted for the widespread use of SRM. Up to this 
date, it remains to be demonstrated that single EVs can be detected by SRM.
The various microscopic techniques can be complemented with e.g. nanoparticle 
tracking analysis (NTA), which enables determination of the size distribution of 
EVs in the sample. NTA is based on the Brownian motion of EVs in suspension 
[213]. The drawback of NTA for determining the EV size distribution is that it is 
not capable of distinguishing a vesicle from a protein aggregate of similar size and 
the reproducibility of this technique is somewhat vague. A comprehensive guideline 
of using NTA instrument for EV analysis was published in 2013 by Gardiner et al. 
as an attempt to shape a framework for more reliable EV quantification and size-
distribution analysis [214]. Flow cytometers can be used but the “resolution” (i.e. 
resolving between noise and vesicles) of the conventional setups is comparably low; 
EVs under the diameter of 300 nm cannot be distinguished. Therefore, a high-
resolution method based on flow cytometry has been developed. In essence, the 
method can perform high-throughput analysis of single nanosized immunolabeled 
vesicles [215, 216]. However, the drawback is the use of fluorescent labeling of vesicles 
by lipid dyes; label-free methodology is in demand also for the EV characterization. 
Heretofore it is evident that EV analysis is not limited to a specific technique – 
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instead, multiple methods are typically needed. Raman [217, 218] and SPR [219] 
have been successfully implemented for EV characterization. However, they are 
still somewhat underused methods. Raman spectroscopy can offer fundamental 
information on the chemical contents of EVs, especially when used with rigorous 
spectral data analysis methods. SPR, for one, may provide opportunities to assess 
for example kinetic properties of given types of EVs, or to characterize the biolayers 
that are formed during EV adsorption onto a functionalized sensor surface. Table 
4 shows a summary of the abovementioned methods and techniques for studying 
and characterizing EVs.
Table 4. Currently used methods and techniques for studying and characterizing EVs.
Method or Technique Measured quantity or property Reference
Immunoblotting Characterizing protein contents [205]
Liquid chromatography with tandem mass 
spectrometry (LC-MS) Proteomic analysis
[208, 
209]
Confocal microscopy Size and morphology, cellular uptake [209]
Electron microscopy (e.g. TEM, cryo-TEM) Size and morphology [197, 210]
Atomic force microscopy (AFM) Size and morphology [211]
Nanoparticle tracking analysis (NTA) Quantification and size distribution [213, 214]
Flow cytometry, “high-resolution” 
cytometry Quantification and size distribution [215, 216]
Lipid analysis; hydrophilic interaction 
liquid chromatography (HILIC), 
mass spectrometry, reverse phase 
chromatography
Characterizing lipid contents [189]
Sequencing techniques, e.g. PCR Characterizing nucleic acid contents [191, 207]
Raman spectroscopy Analysis of the chemical composition [217, 218]
Surface plasmon resonance Immunoassay for protein profiling [219]
Today, the EV research is still in urgent need of reliable and reproducible protocols 
in order to isolate and characterize EVs. In general, each new technique must be 
validated for any cell type or biological fluid of interest as a source of EVs to confirm 
the identity of purified EVs. Furthermore, several methods and often laborious steps 
are needed to resolve their physical, biochemical and morphological characteristics.
4.2.2 Extracellular vesicles in nanomedicine
EVs have an ever-increasing significance to act as potential diagnostic biomarkers, 
nano-sized drug delivery carriers (DDC), and mediators in intercellular 
communication [104]. In the broad sense the true biomedical relevance of EVs 
45
has been unrevealed during the recent two decades. In general, almost every cell 
type – malignant and healthy, releases nanosized EVs in the extracellular space and 
thereafter to blood circulation. Migration of EVs between different compartments 
of the biological system is typically a continuous, dynamic movement affected by 
complex biochemical and biophysical pathways. Hence, EVs take part in various 
biological phenomena, for example intercellular communication related to the 
immune system, inflammation events and regeneration of tissues. 
In addition to mediating targeted intercellular communication under 
physiological [220] conditions, EVs also play a significant role in pathophysiological 
circumstances; they have been observed to have functions in various types of cancers 
[221], asthma and allergic conditions [222], as well as neurodegenerative diseases 
[223]. It is worthwhile pointing out that although EVs are present in the bodily 
fluids of healthy and diseased individuals, e.g. the concentration and biomolecular 
compositions of EVs have been detected to undergone alterations in the state of 
disease [224]. Detection of such alterations with enhanced specificity, sensitivity 
and reproducibility warrants for development of novel techniques and data analysis 
methods. Furthermore, according to their biophysical characteristics, EVs hold 
potential to act as therapeutic agents in immune therapy, vaccines, drug-delivery 
carriers (DDCs) and regenerative medicine [172, 225]. Examples of EVs as disease 
biomarkers and therapeutic agents are provided within the next two chapters. Of 
importance, whichever of the two mentioned purposes is pursued, there is a clear 
need to better understand the complex structures and biological pathways of EVs 
in living systems since the already existing methodology has several limitations in 
terms of quantification accuracy, for instance [214].
4.2.3 EVs as disease biomarkers
The disease biomarkers represent an unmet clinical challenge, not only for 
different types of cancer but other human diseases as well. As EVs are found in 
every bodily fluid, they offer unequaled opportunities for early detection of cancers, 
neurodegenerative diseases, infectious diseases, autoimmune diseases, and other 
malignant states [104]. The cancerous tumor cells have been observed to produce 
EVs that carry a tumor-specific molecular fingerprint [103]. The EVs can carry a 
certain biomarker in their chemical composition, e.g. levels of plasmatic caveolin-1 
and CD63-positive EVs were increased in the samples of melanoma patients [226] 
and glypican-1 –positive EVs were distinguishable in the serum of pancreatic cancer 
[227]. In general, even the elevated levels of EV concentration might have clinical 
relevance as indicating the status of the patient; as the gastro-intestinal stromal 
tumor was treated with imatinib, the concentration of EVs before the treatment 
was higher compared to the control [228]. Interestingly, EV-associated heat 
shock protein (HSP60) levels were decreased among colon cancer patients as the 
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tumor was surgically removed [229]. EVs have also acted as tumor biomarkers in 
glioblastoma (diagnosis; cancer biomarkers mRNA, miRNA, angiogenic proteins 
/ early diagnosis; cancer biomarkers RNU6-1, miR-320, miR-574-3p) [230, 231], 
gastric cancer (prognosis; cancer biomarkers miR-21, miR1225-5p) [232], ovarian 
cancer (prognosis/therapy follow up; cancer biomarkers TGFB1 and MAGE3/6) 
[233], and bladder cancer (diagnosis; cancer biomarker TACSTD2) [234]. In 
addition to plasma and serum as sources for EVs, other body biofluids such as 
gastric juice, may be exploited for noninvasive (an example of liquid biopsy) and 
information-rich sources for cancer diagnosis or monitoring patient’s status [232]. 
Furthermore, bronchoalveolar lavage, nasal lavage fluid and urinary EVs can be 
used as sources of biomarkers [235-237]. Notably, the EVs isolated from urine 
are considered as stable as the EVs from other body fluids, and the molecular 
composition of urinary EVs may reflect the pathophysiological status of the system 
– which extends the usability of urinary EVs to diagnosis of kidney injury or diabetic 
neuropathy [220].
Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s, and 
amyotrophic lateral sclerosis have all been connected with various neurological 
diseases [238]. This is not particularly surprising since the central nervous system 
(CNS) neural and non-neural cells produce EVs, and consequently release them to 
biological fluids, blood and cerebrospinal fluid (CSF), among the others. Thereby 
the EVs originating from CNS hold extensive potential for carrying notable amount 
of biochemical information, and thus reporting of various disorders in the CNS. 
In particular, according to current knowledge, the complex pathogenesis of AD is 
characterized by the release and presence of neurotoxic protein species, amyloid 
peptides (Aβ) [239]. Aβ peptides are intrinsically disordered and have tendency to 
undergo a dynamic aggregation pattern [240]. Such pattern can ultimately result 
in deposited Aβ plaques in the brain. Interestingly, the researchers have observed 
that the Aβ peptides are released in association with EVs, and demonstrated that 
such EVs contain Aβ peptides. This, in turn, can facilitate the deposition of peptides 
into detrimental amyloid plaques or participate in the long-range transport of Aβ 
peptides [241]. However, the neuroprotective role of EVs has also been suggested 
in the form of clearance of amyloids [242, 243]. 
As the knowledge of EVs in parasitic diseases evolves, they can be used as 
biomarkers for infectious diseases [172]. Viruses, bacteria, fungi, protozoa, and 
helminths all generate EVs, and prions have been perceived in EVs [244, 245]. 
The roles of EVs in infectious diseases are many-faced; for instance HIV-1 and 
hepatitis C and A viruses can exploit EVs for altering the host cell or for transporting 
themselves into the host cells. Furthermore, infectious species may use EVs in order 
to spread infection by aiding the movement of infectious materials, and by escaping 
the host’s immune system response [246]. Lastly, EVs have been recognized to 
contribute to several autoimmune diseases, for example Behcet’s disease (BD), 
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a complex multiorgan inflammatory condition [247] and autosomal dominant 
polycystic kidney disease (ADPPKD) whereby the changes of surface glycosylation 
of urinary EVs were detected [248].
4.2.4 EVs as therapeutic agents
An intriguing question whether EVs could be used as therapeutic agents, has 
arisen. The answer is definitely affirmative; in fact, EVs have abundantly favorable 
physicochemical features to overcome the prevailing difficulties related to synthetic 
nanoparticles, e.g. unwanted provoking of the immune system [144]. In addition, 
EVs could be used as a biomimetic model system for the synthetic particles, i.e. 
their biochemical composition could be mimicked in order to achieve less adverse 
effects when administered to blood circulation as targeted drug delivery carriers, 
for instance [249-251]. However, further studies are warranted in order to show 
whether the “biomimetic synthetic EVs” could provide similar efficacy and safety 
as purified EVs from naturally secreted sources. 
Initially the EVs isolated from B-cells were observed to convey MHC-peptide 
complexes on the surfaces of their membranes, thereby capable of exerting T-cell 
stimulatory functions [197]. Consequently, EVs originating from dendritic cells 
(DCs) were pulsed with tumor antigens, and they were seen to intercede antitumor 
responses [198]. Thus, EVs as vaccines for antitumor therapy have been introduced 
[252]. Furthermore, a similar approach has later been adopted to develop infectious 
disease vaccination by using EVs from DCs pulsed with infectious pathogens such as 
fungi, bacteria or parasitic protozoa [253]. EV therapies have also been considered 
as potential for treating various autoimmune, chronic, and acute inflammatory 
disorders, for example rheumatoid arthritis, inflammation of connective and 
vascular tissues, intestinal chronic inflammatory diseases, Crohn’s disease, type 
I diabetes, and multiple sclerosis [225]. Moreover, regenerative therapies could 
benefit from the use of EV-mediated therapies; for instance myocardial infarction, 
ischemic stroke, acute and chronic kidney failure, drug-induced liver injury, and 
perinatal asphyxia. 
EVs offer a potential alternative – or complement, to existing nanocarriers used in 
targeted delivery of drugs [254, 255]. Namely, the most used drug-delivery platforms 
to date are the liposomes or lipid-based nanoparticles (LNPs) [256]. Although 
effective, demonstrated to hold feasibility and safety, cavities in using LNPs still exist 
to a wide extent. For instance, their potential toxicity and immunogenicity can be 
troublesome. Their constrained ability to penetrate into organs and tissues may pose 
a problem in terms of their bioavailability. Therefore, there exists an undisputable 
need for new drug delivery carriers. EVs have been used for instance to dispense 
exogenous drugs (small molecules, miRNAs, and siRNAs) [257] and catalase, an 
exogenous protein to concede neuroprotection Parkinson’s disease models [258]. 
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A recently introduced approach dealt with the concept of developing biomimetic 
nanoparticles by functionalizing EV-sized PLGA (poly (lactic-co-glycolic acid) gold 
or silicon nanoparticles with cellular plasma membranes derived from cancer 
cell membranes. Profitable immune responses for vaccination [259], enhanced 
circulation times to avoid immune uptake, and increasing cancer cell specificity were 
observed [260]. In conclusion, the experts in the EV field are constantly searching 
for novel techniques and methods to reveal the multi-dimensional opportunities 
that EVs possess for the purposes of modern biomarker diagnostics and therapeutic 
use as DDCs. Creative development of biophotonic methods for the EV research 
can open up new venues to meet these demands.
Thus far small molecular drugs have been introduced as small-scale analytes 
whereas liposomes and EVs have been represented as larger, nanomedical analytes. 
Intriguing questions that merit for further studies are for example related to the 
development of bio-functional assays to improve the mechanistic understanding 
of small drug behavior in real biological environment, or to better predict the 
nanocarrier interactions with its surroundings in a living system. Biophotonics 
offers a wide variety of choices and technical advantages to counter the still unmet 
diagnostic and therapeutic challenges in the fields of small drug and nanocarrier 
research for biopharmaceutical applications. Thereby, biophotonic techniques and 
methods based on Raman and SPR are discussed next in more detail, and their 
current application to the analytes of small and larger scale is represented – as well as 
the cavities existing in present research. Figure 4 summarizes the above discussed 
DDC and EV routes and interactions in biological environment. Of importance, the 
displayed events are also relevant from the viewpoint of bionanophotonics – and in 
particular, the illustrated phenomena are examples where biophotonic methods can 
be efficiently applied. The drug release from the DDC [261, 262] or EV interactions 
with living cells can be measured, for instance.
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Figure 4. Events and pathways of DDCs and EVs in 
living system. (1) The DDC is administered into the 
blood circulation. (2) Vital phase in the DDC 
development is the stability of the drug-carrier system; 
if it is not stable, unwanted events, e.g. accidental drug 
release can occur before the DDC reaches its target. The 
possible interactions of DDC with (3) other 
biomolecules or (4) ions in blood circulation have to be 
investigated in vitro during the DDC development and 
optimization; in this regard the surface functionalization 
of DDC plays a major role. Another crucial step in the 
DDC surface modification concerns the DDC entrance 
into the extracellular space (5). Hence, the carrier has to 
be capable of penetrating between (or through) the 
capillary membranes at certain expedition 
simultaneously retaining the physicochemical stability of the carrier despite the changes of e.g. pH. 
The interactions at the interface of the target cell membrane and DDC determines whether the DDC 
can be taken up into the cell; two major pathways are (6) penetration through the cell lipid bilayer 
membrane via endocytosis or (7) directly through the plasma membrane. If the DDC internalizes via 
endocytosis, the nanocarrier has to be discharged from the endosome (8). In order to function in 
cytoplasm or nucleus, the active drug compound must be released from the nanocarrier (9); this can 
also be regulated by the biomolecules present in the intracellular space (10). (11) EVs are released 
from both; malignant and healthy cells. Dynamic migration of EVs from cells to blood circulation 
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living system. (1) The DDC is administered into the blood 
circulation. (2) Vital phase in the DDC development is 
the stability of the drug-carrier system; if it is not stable, 
unwanted events, e.g. accidental drug release can occur 
before the DDC reaches its target. The possible interactio s 
of DDC with (3) other biomolecules or (4) ions in blood 
circulation have to be investigated in vitro during the DDC 
development and optimization; in this regard the surface 
functionalization of DDC plays a major role. Another crucial 
step in the DDC surface modification concerns the DDC 
entrance into the extracellular space (5). Hence, the carrier 
has to be capable of penetrating between (or through) the 
capillary membranes at certain expedition simultaneously 
retaining the physicochemical stability of the carrier despite 
the changes of e.g. pH. The interactions at the interface of 
the target cell membrane and DDC determines whether th  
DDC can be taken up into the cell; two major pathways are 
(6) penetration through the cell lipid bilayer membrane via 
endocytosis or (7) directly through the plasma membrane. If 
the DDC internalizes via endocytosis, the nanocarrier has to 
be discharged from the endosome (8). In order to function 
in cytoplasm or nucleus, the active drug compound must be 
released from the nanocarrier (9); this can also be regulated 
by the biomolecules present in the intracellular space (10). 
(11) EVs are released from both; malignant and healthy cells. 
Dynamic migration of EVs from cells to blood circulation 
and vice versa is continually ongoing. It is n tew rthy that 
the biochemical features in the embrane structures of EVs 
possess characteristics that form the basis of the relevance 
to act as disease biomarkers. (12) EV-mediated intercellular 
communication between the cells (healthy-healthy and 
malignant-healthy) have been observed as well.
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5 RAMAN SPECTROSCOPY
All analytes, whether small molecular drugs or larger scale biological specimen, 
behave like any bulk medium in which light propagation induces absorption, 
scattering, refraction and reflection. These processes are depicted in Figure 1. 
However, probably the most emphasized effect is scattering. In biophotonics 
and spectroscopy the high scattering of samples of interest are exploited vastly. 
For instance, a biological sample typically consists of a turbid medium, and the 
solid-state samples have various solid-state forms, e.g. crystalline, amorphous, 
polymorphic forms. Therefore, the turbidity or apparent non-transparency of 
samples causes multiple scattering processes from excessively heterogeneous 
structures. Furthermore, the scattering results in spreading of a collimated light 
beam, e.g. laser beam, leading to a loss of its initial direction and defocusing of 
the light beam spot. Figure 5 represents the important scattering processes; Mie, 
Rayleigh, Brillouin and Raman scattering.
Raman spectroscopy belongs to the group of vibrational spectroscopy techniques; 
other common techniques in the same group are mid-infrared (IR) and near-IR 
spectroscopy. Essentially, mid-IR and Raman are utilized to provide information 
of molecule’s characteristic fundamental vibrations. Those vibrational states, for 
one, are highly specific for a given molecule and its chemical structures. Vibrational 
spectroscopy can be employed to investigate thin films and nanostructures as well 
as samples in bulk quantities. Furthermore, the types of measurable samples can 
vary over a wide array of possibilities, and assays can be carried out from fast and 
straightforward identification to rigorous full-spectrum analysis. In addition, Raman 
spectroscopy is easily applicable for both qualitative and quantitative studies. Raman 
and mid-IR are complementary techniques with one physically profound difference 
related to the way in which the incident photon energy changes the vibrational states 
of the analyzed molecule. Namely, in mid-IR spectroscopy radiation is absorbed 
into the sample changing the molecular vibrational energy states. Importantly, in IR 
spectroscopy one observes a resonance condition where an electric dipole moment 
mediated transition takes place between vibrational energy levels while Raman is 
a two-photon inelastic scattering phenomenon. Raman spectroscopy, in general, 
elucidates excellently symmetric vibrations of non-polar groups whereas IR is best 
at showing the asymmetric vibrations of polar groups.
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Figure 5. An illustration of the different scattering processes induced by the incident irradiation, for 
example laser light. 
5.1 General theoretical overview of Raman spectroscopy 
Raman scattering was first hypothesized by Smekai in 1923. The first experimental observations were 
made in 1928 by Raman and Krishnan [263]. In essence, Raman scattering is seen as the change in 
frequency for a small percentage of the intensity in a monochromatic light beam as the result of 
coupling between the incident radiation and vibrational energy levels of molecules. A vibrational 
mode of the molecule will be Raman active only if the polarizability of the molecule undergoes a 
change. 
When monochromatic radiation with a wavenumber ν��  is incident on systems, most of it is 
transmitted without change. However, scattering of the radiation occurs as well. When the frequency 
content of the scattered radiation is analyzed, there will be the wavenumber  ν�� �associated with the 
incident radiation. In addition, pairs of new wavenumbers of the type ν�� � � � ν�� � �� �̅M are observed. 
Particularly the wavenumbers �̅M are found in molecular systems to reside typically in the ranges 
associated with transitions between rotational, vibrational, and electronic levels; this scattering of 
radiation is the cornerstone of the Raman scattering phenomenon. Essentially, the normal modes of 
vibration can be explained by using vibrating mechanical models [264]. Today, Raman spectroscopy 
is a widely exploited technique in order to investigate the vibrational structures of molecules of 
interest – and as such, highly applicable to biophotonics and biopharmaceutical studies. Infrared (IR) 
spectroscopy is occasionally used as a complementary technique for Raman [265]. 
The rigorous mathematical treatment of the theory of Raman scattering is profoundly described 
elsewhere [265-267]. In brief, the Raman scattering can be described using classical theory or 
Figure 5. An illustration of the different scattering processes induced by the incident irradiation, for 
example laser light.
5.1 GENERAL THEORETICAL OVERVIEW OF RAMAN    
 SPECTROSCOPY
Raman scattering was first hypothesized by Smekai in 1923. The first experimental 
observations were made in 1928 by Raman and Krishnan [263]. In essence, Raman 
scattering is seen as the change in frequency for a small percentage of the intensity in 
a monochromatic light beam as the result of coupling between the incident radiation 
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be Raman active only if the polarizability of the mol cule undergoes a change.
When monochromatic radiation with a wavenumber    is incident on systems, 
most of it is transmitted without change. However, scattering of the radiation occurs 
as well. When the frequency content of the scattered radiation is analyzed, there 
will be the wavenumber    associated with the incident radiation. In addition, 
pairs of new wavenumbers of the type =   ±  M are observed. Particularly 
the wavenumbers M are found in molecular systems to reside typically in the 
ranges associated with transitions between rotational, vibrational, and electronic 
levels; this scattering of radiation is the cornerstone of the Raman scattering 
phenomenon. Essentially, the normal modes of vibration can be explained by using 
vibrating mechanical models [264]. Today, Raman spectroscopy is a widely exploited 
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technique in order to investigate the vibrational structures of molecules of interest 
– and as such, highly applicable to biophotonics and biopharmaceutical studies. 
Infrared (IR) spectroscopy is occasionally used as a complementary technique for 
Raman [265].
The rigorous mathematical treatment of the theory of Raman scattering is 
profoundly described elsewhere [265-267]. In brief, the Raman scattering can be 
described using classical theory or quantum mechanical treatment. The origin of 
the modified frequencies found in Raman scattering is explained by the energy 
transfer, which occurs between the scattering system and the incident radiation 
(sometimes referred to as excitation radiation). When a system interacts with 
radiation of wavenumber    it makes an upward transition from a lower energy 
level E1 to an upper energy level E2. It must then acquire the necessary energy, ΔE 
= E2-E1, from the incident radiation. Hence, the energy ΔE can be expressed with 
regards to a wavenumber  M  connected with the two mentioned energy levels:
  (1) M
The above stated energy consists of the absorption of one photon of the incident 
radiation energy  0  and the simultaneous emission of a photon of smaller energy 
hc( M), thus the scattering of radiation of lower wavenumber, M, 
takes place. Alternatively, interaction of radiation with the molecule may cause a 
transition from higher energy level E2 to a lower level E1, in which case the emission 
of a photon of higher energy can be expressed as hc( M), and the scattering at 
higher wavenumber  M, occurs. Rayleigh scattering, for one, has no resultant 
change in the energy state of the system; a photon of the same energy as the incident 
one is simultaneously emitted. Therefore, in the Rayleigh scattering the unchanged 
wavenumber, , is observed.
On a conceptual level, a Raman band in the Raman spectrum is not characterized 
by its absolute wavenumber (i.e. =   ±  M). Instead, it is characterized by the 
magnitude of the shift of its wavenumber  M  from the incident wavenumber. The 
corresponding  M  are typically referred to as Raman wavenumbers. In general,  M 
is positive for Stokes and negative for anti-Stokes scattering. The different scattering 
processes and infrared absorption phenomenon are displayed in Figure 6.
In the classical theory of electromagnetic radiation, electric and magnetic fields 
oscillating at a given frequency are capable of giving out electromagnetic radiation 
that is of the same frequency. The electromagnetic radiation theory can be utilized 
in order to explain the light scattering phenomena. In short, for the majority of 
systems of interest, only the induced electric dipole moment μ is taken into account. 
A power series can be used to express a dipole moment induced by an electric field E:
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  (2) μ = μ(1) + μ(2) + μ(3) + …
where
  (3) μ(1) = α * E
  (4) μ(2) =  β * EE
  (5) μ(3) =  γ * EEE
In essence, α is called the polarizability tensor; it is a second-rank tensor having 
all the components in the unit of CV-1m2. Typically, for components α, β, and γ the 
orders of magnitude are α ~ 10-40 CV-1m2, β ~ 10-50 CV-2m3, and γ ~ 10-61 CV-3m4. 
Thus, the contributions of μ(2) and μ(3) can be recognized as negligible unless the 
electric field is extremely high. Furthermore, since Rayleigh and Raman scattering 
are observed with very much lower electric field intensities, those can be explained 
in terms of μ(1). When the interaction of a molecular system is considered to occur 
with the harmonically oscillating electric field in the frequency ω0, and for simplicity, 
only the vibrational part is taken into account, the variation of components in 
polarizability tensor with vibrational coordinates can be expressed using Taylor 
series. The fundamental mathematical treatment is omitted as being out of the 
scope of this Thesis. The rigorous explanation is provided for example in [265-267]. 
However, the outcome of these mathematical calculations yield a very practical 
qualitative description for the Rayleigh and Raman scattering in terms of classical 
radiation theories. The Rayleigh scattering emerges from the dipole oscillating at 
ω0 induced by the electric field of the incident radiation at frequency ω0. Raman 
scattering stems from the dipole moment oscillating at ω0 ± ωk, which is produced 
by the modulation of the dipole oscillating at ω0 with molecular vibration ωk. In 
practice this means that the observed frequencies in Raman scattering are beat 
frequencies of the radiation frequency ω0 and the molecular vibration frequency ωk. 
The quantum mechanical approach for Raman scattering is based on the 
radiation, which is emitted or absorbed as a result of a system making an upward 
or downward transition between two discrete energy levels; the energy levels are 
considered quantized. Thus, a quantum mechanical treatment of spectroscopic 
processes treat the radiation and molecule together as an entity or system, and 
investigate how energy is transferred between the incident radiation and the 
molecule as a result of their interaction. A transition between energy levels of 
a molecular system occurs with the emission or absorption of radiation, given 
that, a transition moment associated with the initial and final molecular states is 
different from zero. The vibrational transition polarizability components used in 
the quantum mechanical treatment of Raman scattering establish better basis for 
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defining selection rules for vibrational transitions in Raman effect compared to the 
derived polarizability tensor components used in the classical treatment – which is 
considered as the overall benefit of relying on the quantum mechanical treatment, 
especially within the context of profound theoretical approaches.
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Figure 6. An energy level schematic for (i) Infrared absorption, (ii) Rayleigh scattering, (iii) Stokes 
Raman scattering, and (iv) Anti-Stokes Raman scattering. 
5.1.1 Raman instrumentation 
In Raman spectroscopy the emitted light from the sample is collected and focused onto a device 
capable of separating the light into distinct wavelengths. Two most commonly used such devices are 
monochromators in dispersive instruments and interferometers used in Fourier transform (FT) 
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5.1.1 Raman instrumentat on
In Raman spectroscopy the emitted light from the sample is collected and focused 
onto a device capable of separating the light into distinct wavelengths. Two most 
commonly used such devices are monochromators in dispersive instruments and 
interferometers used in Fourier transform (FT) instruments [268]. Currently 
Raman instruments mainly consist of both grating-based systems using multi-
channel detectors and interferometer-based (FT-Raman) spectrometers. A couple 
of decades passed after the first observations of Raman phenomenon before 
powerful enough excitation lasers and sensitive detectors (photo multipliers) were 
introduced. Still, hindrances were caused by bulky, non-practical instruments, and 
the range of analyzable samples was rather limited. A technique that was almost 
deemed inadequate, however, underwent a complete resurgence in the ‘90s. The 
most significant technical outreaches were multilayered dielectric filters that were 
manufactured using dichroic glass and extremely sensitive charge coupled device 
(CCD) detectors. Simultaneously affordable low-power irradiation lasers (~ 1-10 
mW) became more common and also hardware speed and performance were 
increasing almost exponentially. Finally, the opportunity to couple for example 
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scanning electron microscopies (SEM) or confocal microscopies to Raman 
instruments accelerated the popularity of Raman systems.
Optical micromanipulation of biological specimens by laser light provides an 
intriguing concept for utilizing Raman spectroscopy. Such techniques are known 
as optical tweezers or optical traps [61]. Essentially, it means that an accurately 
focused continuous-wave (CW) laser beam is used to trap noninvasively single 
biological particles, and acquiring Raman spectra of the trapped particles. The 
working principle is based on the gradient force that is derived from the change 
in the momentum of light. Typically, the laser beam wavelength (usually 1064 nm 
from NdYaG) is chosen from the optical transparency region of the particle to avoid 
absorption of light. The trapped samples can vary from DNA molecules through 
subcellular organelles to whole cells. Another motives for laser micromanipulation 
may be for example to measure almost negligible forces present in biological systems 
[269] (i.e. in the order of piconewtons) or mechanically unzip DNA strands by 
trapping and stretching them [270].
5.1.2 Data analysis techniques in Raman spectroscopy
The vibrational energy levels are unique to each molecule, and thus Raman (and 
mid-IR, if used as a complementary technique) spectrum provides a fingerprint 
of the molecule. In Raman spectrum the vibrational bands are discriminated and 
characterized by three main components; their (i) frequency (i.e. energy), (ii) 
intensity (polar character of the molecule or simply polarizability), and (iii) band 
shape (the physical environment of chemical bonds). Importantly, the frequencies 
of molecular vibrations depend on the masses of the atoms that form the molecule, 
geometric arrangement of the atoms, and strength of the chemical bonds. All in all, 
the spectra can be appreciated as a window to the molecular structure, dynamics, and 
molecule’s environment. Typically two distinct approaches are used in the spectra 
interpretation and subsequently, determination of molecular structures. Group 
theory in combination with mathematical calculations is used to interpret the forms 
and frequencies of molecular vibrations whereas empirical characteristic frequencies 
are used for determining the presence (or sometimes absence) of chemical functional 
groups. It is worthwhile pointing out that many empirically found group frequencies 
have been explained and elaborated using the mathematical theoretical approach 
– thus, the two mentioned principles are often used together. 
Another important part of Raman spectroscopy is the raw data processing. 
After the Raman spectra have been experimentally acquired, the collected spectral 
data has to be processed in a way that relevant Raman spectral signatures can be 
revealed. Sometimes simple means are enough but occasionally somewhat rigorous 
algorithms and effort are needed to carry out further analysis. Some of the commonly 
used methods are described next.
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In order to compare different spectra, generally the first step in the data 
processing is the background subtraction and Raman signal normalization. The 
background can be due to photoluminescent phenomena occurring simultaneously 
with Raman scattering or noise in the measurement instrumentation. Often 
the photoluminescent background spectrum – which typically is generated by 
fluorescence, is laborious to measure separately since the fluorescent components 
in the sample can be very difficult to separate physically. Thus, a straightforward 
subtraction is out of the question. The background subtraction can be accomplished 
by assuming that the whole spectrum is a combination of Raman bands and a 
slowly varying background that can be represented by a 3rd or 4th order polynomial. 
Subsequently, the background shape for the subtraction can be defined by choosing 
e.g. 4-5 reproducible anchor points in the “valleys” of the whole spectrum where 
the Raman contribution is minimal and the background dominates. Lastly, the 
determined background is subtracted from the whole spectrum. However, variation 
and arbitrariness can be manifested by the described “manual” background 
subtraction, mainly due to the choice of anchor points. Therefore more robust and 
reproducible automated methods have been introduced [271]. The benefit of using 
such algorithms is not only the robustness but also the high modifiability by e.g. 
MATLAB programming language. Moreover, possibly a more accurate background 
subtraction method at the expense of increased experimental complexity is known 
as shifted Raman spectroscopy [272]. The method is based on the physical fact 
that the Raman spectra peaks are prone to shifting due to small changes in the 
excitation wavelength. On the other hand, the fluorescent background is left 
practically unchanged because fluorescence emission spectra generally consist of 
broad spectral features, and they are not sensitive to subtle changes in the incident 
wavelength. 
Once the spectra have been background subtracted and normalized, a meaningful 
approach has to be employed for finding out spectral variation between the collected 
spectra, and thus identify the physical and chemical components that may contribute 
to those variations. In general it may be useful to determine first, how much spectral 
variation exists between the samples of the same type. Such an estimate can be 
performed by recording e.g. 10 spectra from one single sample (e.g. sample type 
I) and consequently measuring 10 spectra from that same sample type I by picking 
randomly the samples for the latter measurement. Next, the relative variation of 
both measurements can be calculated by dividing the standard deviation (SD) by 
the mean, and finally, determining the ratio of the relative variations. This approach 
will roughly outline whether the sample types (e.g. type I, type II, type III, type IV) 
are inherently homogeneous and it would thus be realistic to discriminate between 
different samples; essentially if the described ratio resides approximately between 
1-1.5 throughout the spectrum. For clarity, the calculation is displayed below:
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In order to compare different sample types against each other, a relatively 
straightforward method is to subtract the means of two sets of spectra (e.g. sample 
type I and type II), and subsequently calculate the SD for that difference (it should 
be noted that it is the SD for the difference of means, i.e. not the SD of different 
sample types). Regions where the differences in the means are considerably bigger 
than ± 1 SD are feasible to have real biochemical differences. 
The measured spectra can also be analyzed by a method called component 
decomposition. Such approach is based on the assumption that the original recorded 
spectrum is a linear superposition of component spectra (or basis spectra). Hence, 
each component spectra represents a certain biochemical constituent of the analyzed 
sample (e.g. protein, lipid, carbohydrate, DNA/RNA). The mathematical treatment 
is carried out using least-squares optimization to determine the linear coefficients 
that multiply each component spectrum thus producing a match to the originally 
measured spectrum. The disadvantages of the component decomposition are that it 
can be difficult to obtain the component spectra and often the measured spectrum is 
not a simple superposition of the components. Furthermore, it can be occasionally 
difficult to differentiate subtle spectral signatures by visual inspection. Principal 
component analysis (PCA), is a multivariate analysis method developed for that 
purpose. In essence, the aim is to reduce the number of variables in complex data 
sets potentially consisting of thousands of variables, and enable intuitive, easily 
interpretable representation in two or three dimensions [273]. 
In short, the PCA is a transformation method in which the original multi-
dimensional coordinate system is rotated in such a way that the resulting new 
coordinate system directions are essentially linear combinations of the original 
(multi-dimensional) directions. Initially, each spectrum from the original data set 
is depicted in multi-dimensional space as a single dot whereby each wavenumber 
represents one coordinate direction, and respectively, the recorded intensity 
represents the magnitude of contribution of that particular wavenumber to the 
spectrum (i.e. those are the coordinates of the dot in a multi-dimensional space). As 
a result of the coordinate system rotation, the dimensions are reduced significantly. 
That, in turn, means that only the dimensions that are responsible for the largest 
variation between spectra, are left. As the spectra are depicted as dots in the new 
coordinate system, much clearer differentiation and grouping is usually observed. 
With regard to Raman spectra, typically 2-4 coordinates can explain most of the 
variations in the data. Finally, the observed groups can be further sorted and 
analyzed e.g. using clustering analysis.
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In general, the spectral peak and band assignments are performed by using 
published literature references or by the mathematical calculations, or as a 
combination of both. The mathematical assignment of vibrational Raman 
frequencies is usually executed by means of computational methods, essentially 
the quantum mechanical methods, Hartree-Fock (HF) or density function theories 
(DFT), described in more detail e.g. in references [274, 275]. Moreover, various 
chemometric methods have been developed and introduced for quantitative Raman 
spectral analysis [276].
5.2 RAMAN IN BIOMEDICAL APPLICATIONS
Raman spectroscopy as a biophotonic method is feasible for a wide scale of biomedical 
applications; the measurements can be performed label-free, vibrational spectra 
can be obtained in aqueous medium since water has weak Raman scattering, and 
does not interfere with the relevant Raman bands of interest. In addition, samples 
can be measured in their natural states (e.g. liquid, solid, gel), no excessive sample 
preparation is needed, and the measurements can also be performed through the 
container walls or e.g. blister packages in the case of pharmaceuticals. Furthermore, 
the visible wavelength laser excitation source can be focused to a micron-sized 
spot. This, in turn, allows for acquiring Raman spectra of micro-size dimensions 
such as single cells. A specific chemical segment or subcellular component can be 
probed by resonantly enhancing the Raman scattering. One of the disadvantages of 
Raman spectroscopy is the very weak Raman signal; approximately every 106 to 107 
photon is Raman scattered. Probably the most utilized technique for enhancing the 
weak Raman scattering phenomenon is surface enhanced Raman scattering (SERS), 
where the signal enhancement is achieved by using nano-plasmonic properties of 
noble metals. Another hindrance for the effective utilization of Raman spectroscopy 
can be a strong photoluminescent background produced by the various chemical 
structures (for example conjugated double bonds) in the investigated compounds. 
Such a background can overwhelm the already weak Raman spectra features 
completely and it has prevailed as one of the fundamental drawbacks in exploiting 
Raman spectroscopy to its full potential. Thus, a demand for new approaches has 
arisen.
5.2.1 Raman spectroscopy for the analysis of small drugs
Raman spectroscopy is a useful tool for characterizing small drugs. It has 
been used in a wide range of various applications in life sciences where small 
drugs are concerned. From the viewpoint of pharmaceutical research and 
development and PAT, pivotal assays are dosage form manufacturing, storage, 
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and administration [277]. Furthermore, material characterization, incoming (raw) 
material identification, end product quality control, and polymorph recognition 
are of relevance in the pharmaceutical industry setting [278]. Despite the earlier 
described benefits of Raman spectroscopy, the major limitations are the weak Raman 
signal, photoluminescence masking the already weak Raman scattering signals, 
and inadequately sensitive detectors [279]. Some of these hindrances have been 
resolved by improved hardware [280] and various spectral manipulation methods 
[281, 282]. However, drawbacks still exist; the instrumentations are often large, 
expensive and best suited only for laboratory setting, the analysis suffer from 
complexity, and the strong photoluminescent backgrounds can still perseveringly 
swamp important Raman spectral signatures leading to useless data. Essentially 
that poses a major problem in biopharmaceutical and several other life science 
settings where the overwhelming photoluminescent backgrounds are present due 
to the chemical nature of biological samples. An unmet need exists in order to 
develop affordable and user-friendly, label-free Raman spectroscopy technologies 
for characterizing highly fluorescent small drugs or for monitoring phase transitions, 
for instance [283].
5.2.2 Laser tweezers Raman spectroscopy for EV analysis
Initial proteomic studies have shown that EVs, in particular exosomes, contain a 
unique subset of cellular proteins. Some of the proteins are dependent on the cell 
type that secrets those exosomes, and on the other hand, some of the proteins 
can be found in most exosomes regardless the cell from which the exosomes are 
derived. Heretofore, relatively straightforward propositions have been made to 
explain these perceptions in exosome studies [284-288]. However, the overlap 
of protein expression between various subtypes of exosomes and existence of 
other biomolecules in the membranes and interior parts of exosomes has led to a 
junction of multiple paths. A common consensus prevails that cells actively control 
the packaging of various biochemical specimens, for example RNA, proteins and 
lipids, into exosomes. However, it remains ambiguous whether the biochemically 
distinct subpopulations emerge from varying packaging pathways during exosome 
biogenesis or alterations after the synthesis and release [289-291]. Thus, a clear 
need for complementary – and clarifying, methods and techniques exists in order to 
better understand the multiple roles of EVs in homeostasis as well as pathogenesis.
Raman spectroscopy, and particularly laser tweezers Raman spectroscopy 
(LTRS), allows for recording the unique biochemical Raman spectral fingerprint 
of samples. As a brief revision from chapter “5.1.1 Raman instruments”, it is based 
on a tightly focused laser beam that traps and holds small objects at the light’s focal 
point. The trapping laser simultaneously excites Raman scattering from the trapped 
particle, and the backscattered light can be collected through an objective. Figure 7 
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illustrates the working principle of a LTRS system. When equipped with a confocal 
photon collection and detection systems, the capabilities are further increased, and 
Raman scattering is acquired from a very precise focal volume. Therefore, cellular 
and sub-cellular particles, such as exosomes, can be studied on an individual basis. 
LTRS has already been successfully applied to study individual cancerous and 
non-cancerous cells [292, 293], activation responses of individual immune cells 
[294], bacteria [295] and spores [296]. Moreover, nano-sized particles such as lipid 
droplets in milk [297] and subcellular organelles [298] have been investigated. It is 
worth stressing that the prior studies show the capabilities of Raman spectroscopy 
to assess the biochemical fingerprints from individual nano- and micron sized 
particles. Such particles are conventionally below the limit of detection (LOD) for 
traditional methods whereby large amounts of starting material is typically required. 
Surprisingly, even though a relatively well-established technique, not until recently 
the potential of Raman tweezers for EV studies have raised common awareness 
[299]. A study in 2014 explored exosomes in clusters that were trapped in the laser 
tweezer focus [300]. However, the drawback was that the information gained was 
averaged over an exosome population in the focal spot rather than from single 
vesicles. To date, no studies have been performed to investigate single EVs from 
healthy and cancerous origins to potentially highlight their distinctive biochemical 
contents, and thus their functions in living systems.
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6 SURFACE PLASMON RESONANCE 
Surface plasmon resonance (SPR) is an evanescent wave sensing technique and thus 
the SPR biosensors belong to the group of evanescent wave biosensors. Such sensors 
are based on total internal reflection (TIR) of light at the interface of the sensor 
surface and analyte solution. The TIR generates a surface-sensitive evanescent wave 
that extends a short distance into the solution. Already by 2003, over 3000 scientific 
papers had been published using optical biosensors based on surface plasmon 
resonance, planar waveguides and/or resonant mirrors [94], and the popularity 
of these techniques is constantly increasing. In SPR, a metal-dielectric interface 
is the pertinent milieu in terms of surface plasmon excitation and sensing events. 
Metals, in general, contain abundantly mobile free electrons, forming a “floating 
ocean of electrons” on the surface. Surface plasmons, in turn, are electromagnetic 
waves that are generated by external excitation energy, for instance light. Surface 
plasmons can propagate along the surface, and the most typical method to create 
them is attenuated total reflection (ATR). Further theoretical aspects of SPR are 
being discussed in the next chapter, below.
6.1 GENERAL OVERVIEW OF SPR
In the late 1960’s Kretschmann, Raether and Ritchie made fundamental observations 
and experiments demonstrating that electrons at the interface of a dielectric 
and conductive metal surface can be excited by polarized light [301, 302]. The 
investigations gave rise to SPR, and since then the field has evolved significantly. 
In brief, plasmons are quasi-particles (and/or waves) connected with the collective 
oscillations of the free electron gas in a metal. A polarized light beam can excite 
plasmons via interacting with the metal surface at a physically defined incident angle 
at a certain wavelength, thus resulting in formation of surface plasmons. When the 
resonance condition is met, exact matching of photons and plasmons takes place 
[303]. However, optical excitation of plasmons by directly impinging light onto the 
metal surface is not possible. The phenomenon can be clearly seen in Figure 8 that 
illustrates the situation when excitation light (Ii) is directed onto the metal surface 
at incident angle θ, and it reflects from the surface (Ir). The dielectric constants 
of air, metal, media on the other side of the metal are ε0, ε1, and ε2, respectively. 
The wave vector of the incident light is given as kph and the wave vector of the 
surface plasmons as ksp. Excitation of the surface plasmons is not possible due to 
the condition |kph, x | < |ksp|; the resonance condition is not matched.
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collective oscillations of the free electron gas in a metal. A polarized light beam can excite plasmons 
via interacting with he metal surface at a physically defi e  incident angle at a certain wav length, 
thus resulting in formation of surface plasmons. When the resonance condition is met, exact matching 
of photons and plasmons takes place [303]. However, optical excitation of plasmons by directly 
impinging light onto the metal surface is not possible. The phenomenon can be clearly seen in Figure 
8 that illustrates the situation when excitation light (Ii) is directed onto the metal surface at incident 
angle , and it reflects from the surface (Ir). The di lectric constants of air, metal, media on the other 
side of the metal are 0, 1, and 2, respectively. The wave vector of the incident light is given as kph 
and the wave vect r of the surface plasmons as ksp. Excitation of the surface plasmons is not possible 
due to the condition |kph,	x| � 	 |ksp|; the resonance condition is not matched. 
(7)       ksp = 	�� �
ε�		ε�
ε��	ε�	     and    kph = 
�
� �ε�     and     |kph,	x| � 	 |ksp|	���	���	�	��	��������� 
 
Figure 8. An illustration of the fundamentals of the surface plasmon resonance phenomenon. 
Figure 8. An illustration of the fundamentals of the surface plasmon resonance phenomenon.
Typically an optical arrangement called the Kretschmann-configuration is utilized to 
pass a parallel polarized (p-polarized) collimated light beam through a glass prism 
to the glass-metal-dielectric interface, ε0, ε1 and ε2 being the dielectric constants of 
the prism (glass), the metal, and the medium in contact with it, respectively. Figure 
9 illustrates the effect of a prism coupling. 
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Thus, energy is transferred from photons to plasmons, and the plasmon resonance condition is 
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light beam, and ε0, ε1, ε2 are the dielectric constants of the prism, the metal, and the medium in contact 
with it, respectively. In general, the dielectric constant ε and refractive index n for a given material 
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majority of materials are non-magnetic at optical frequencies,	� can be approximated very close to 1.  
Similarly, �̂, ε and  �� are the complex dielectric constant, real- and imaginary parts of the complex 
refractive index. As a sum of the definitions made here, the refractive index and dielectric constant 
are related as � � √�̂	. Furthermore, the detected reflectance (or transmittance), angle of incidence 
(θ), used laser wavelength (λ), layer thicknesses (di), refractive indices (ni) and ki-values (attenuation 
index of ith layer) are physically related. They form the mathematical background for converting the 
measured SPR-signals to meaningful qualitative and quantitative observations in a broad range of 
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Thus, energy is transferred from photons to plasmons, and the plasmon resonance 
condition is observable as a sharp minimum of the reflectance when the incident 
angle is varied. The fundamental mathematical depiction of surface plasmon 
resonance is derived from the Maxwell’s equations, and has been described 
extensively elsewhere [72, 91, 303, 304]. In brief, when the wave vectors of the 
incident light photons (kph) and the plasmons (ksp) match, the resonance condition 
is accomplished:
(8) 
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where c s the speed of ligh  in vacuum, ω is the light frequ ncy, θ0 is the angle of 
incidence of the light beam, and ε0, ε1, ε2 are the dielectric constants of the prism, 
the metal, and the medium in contact with it, respectively. In general, the dielectric 
constant ε and refractive index n for a given material can be expressed in their 
complex forms as , and , where , n and k are 
the complex refractive index, real- and imaginary parts of the complex refractive 
i dex, resp ctiv ly. The qu ntity μ denotes permeability, occurring in Maxwell’s 
equations. Since the majority of materials are non-magnetic at optical frequencies, 
μ can be approximated very close to 1. Similarly, , ε and   are the complex 
dielectric constant, real- and imaginary parts of the complex refractive index. As 
a sum of the definitions made here, the refractive index and dielectric constant 
are related as . Furthermore, the detected reflectance (or transmittance), 
angle of incidence (θ), used laser wavelength (λ), layer thicknesses (di), refractive 
indices (ni) and ki-values (attenuation index of i
th layer) are physically related. They 
form the mathematic l b ckgrou  for converting the me sured SPR-sign ls to 
meaningful qualitative and quantitative observations in a broad range of different 
life and materials science applications [50]. SPR offers a robust and sensitive tool 
for label-free real-time interaction analysis, biosensing and thin film characterization 
[91].  
6.1.1 Instrumentation and biosensors in SPR
A typical SPR system consists of a light source, prism, detector, flow channel and 
the sensor surface. Based on the previously discussed physical facts, the sensor 
surface comprises a conducting metal surface such as gold or silver in order to enable 
plasmon coupling. After immobilizing one of the interacting partners (ligand) onto 
the surface of the sensor, the other partner (analyte) is injected over the surface at 
a given flow rate through a microfluidic channel system. It is worth emphasizing, 
however, that halted state analysis can also be performed. In comparison to other 
surface-sensitive – and complementary techniques, for instance quartz crystal 
microbalance (QCM), SPR reveals the “dry mass” of the surface-deposited analyte, 
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even though measured in liquid environment [305], because SPR detects only 
the events occurring at the close proximity of the surface via refractive index and 
thickness changes. The most widely used SPR technology for biochemical interaction 
and drug interaction studies is the Biacore platform. It uses a fixed-angle, focused 
beam light-emitting diode (LED) to simultaneously excite a narrow range of incident 
angles (typically a few degrees), including the angular position of SPR peak minimum 
(θSPR), at which the resonance condition is met and minimal reflection is observed 
[306]. There is no scanning of incident angles involved.
From the viewpoint of biosensor design, the key of SPR is the traveling 
evanescent field that extends from the sensor surface into the test sample. The 
evanescent field is dependent on the used excitation wavelength and the refractive 
indices of the prevalent conditions and the field intensity decays exponentially with 
respect to distance from the sensor surface [307]. The penetration depth dp is defined 
in terms of the used wavelength (λ), incident angle (θ), and dielectric constants of 
the prism (εp) and dielectric substrate in contact with the prism ( ) (Eq. 9).
 (9) 
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Typically the wavelength range for optical biosensors used in SPR is in the range of 600-900 nm, and 
thus the evanescent field can be considered to extend ~ 100-150 nm into the test sample. Such a short 
distance allows for analyte detection at the very close proximity of the sensor surface while the 
unbound material in the solution does not affect the measurement. On the other hand, to circumvent 
this limitation, the characteristics of the evanescent field can be modified so that it can extend deeper 
or is constrained tightly to the sensor surface; the crucial aim in designing a high sensitivity SPR 
sensor is to match the highest chemical binding region to the regions with the highest evanescent field 
intensity. 
However, the short reach of the evanescent field still poses a constraint in the SPR experiments [90], 
and the traditional instruments are capable of measuring the analyte-ligand interactions and acquiring 
kinetic data but not much else. In order to overcome these limitations, a next-generation SPR system 
has been developed [308, 309]. The multi-parametric SPR (MP-SPR) expands on the conventional 
SPR allowing for recording the full SPR angular spectrum over a wide angular range (~40 degrees) 
instead of monitoring only the narrow angular area near the θSPR. The angular position of the TIR is 
also recorded. In addition, the MP-SPR measurements can be performed using multiple excitation 
wavelengths. These technical features widen the applicability of SPR from kinetic assays also to 
Typically the wavelength range for optical biosensors used in SPR is in the range 
of 600-900 nm, and thus the evanescent field can be considered to extend ~ 100-
150 nm into the test sample. Such a short distance allows for analyte detection at 
the very close proximity of the sensor surface while the unbound material in the 
solution does not affect the measurement. On the other hand, to circumvent this 
limitation, the characteristics of the evanescent field can be modified so that it can 
extend deeper or is constrained ightly to the ensor surface; the crucial aim in 
designing a high sensitivity SPR sensor is to match the highest chemical binding 
region to the regions with the highest evanescent field intensity.
How er, the short reach of the vanescent field still poses a constraint i  the 
SPR experiments [90], and the traditional instruments are capable of me suring the 
analyte-ligand interactions and acquiring kinetic data but not much else. In order 
to overcome these limitations, a next-generation SPR system has been developed 
[308, 309]. The multi-parametric SPR (MP-SPR) expands on the conventional SPR 
allowing for recording the full SPR angular spectrum over a wide angular range 
(~40 degrees) instead of monitoring only the narrow angular area near the θSPR. The 
angular position of the TIR is also recorded. In addition, the MP-SPR measurements 
can be performed using multiple excitation wavelengths. These technical features 
widen the applicability of SPR from kinetic assays also to optical characterization of 
surface-associated molecular layers in terms of their refractive index and thickness 
up to micrometer scale. The full SPR angular spectra recorded at two or more 
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independent wavelengths contain all the needed physical information to solve for 
the thin film thickness and refractive index [309, 310].
With the traditional SPR techniques it can be arduous to determine the 
proportion of bulk effect in the change of θSPR [90]. If the refractive indices between 
the running bulk liquid and the injected sample liquid are different – which is often 
the case – the θSPR is a combined signal stemming from real binding events at the 
surface and from changes in the running bulk flow during the sample injection. 
With the traditional SPR instruments that bulk effect cannot be subtracted from the 
signal without using a reference channel and bulk correction calibration methods. 
However, by scanning over the wide angular range in MP-SPR, the bulk effect can 
be subtracted directly without the need to use reference channel and bulk correction 
calibrations. Since the main contribution of the bulk effect can be observed as a 
shift in the position of TIR, that information can be used to deduct the bulk effect 
contribution. In practice, a weighted subtraction algorithm is implemented using the 
recorded angular position of TIR. The bulk effect correction for the obtained raw 
data facilitates the subsequent data analysis steps, and enhances the accuracy of the 
analysis. In comparison with the traditional SPR techniques where the interaction 
kinetics have been in the focal point, the MP-SPR has shown potential for utilizing 
SPR in previously unseen ways in various applications of life and materials sciences. 
Three essential data analysis methods used in SPR are introduced within the 
next “Data analysis” sections; the first chapter dealing with interaction kinetics 
calculations, the second covering the thin film thickness and refractive index 
evaluations, and the third describing the mathematical principles of relating the 
recorded change of θSPR with the change of mass on the sensor surface. Notably, the 
described methods are based on both the features of traditional SPR instruments, 
and the new capabilities of the MP-SPR.
6.1.2 Data analysis: Interaction kinetics
In the SPR data analysis phase, information from two distinct graphs is typically 
used. The non-scanning and scanning instruments record sensorgrams where the 
relative shift of the angular position of θSPR is shown as a function of time (Figure 
10). Thus, the analyte injections can typically be seen as shifts in the position of 
θSPR. When the injected analyte concentrations are known, the affinities and kinetic 
parameters (association and dissociation rate constants) can be calculated using 
mathematical formulae as described later in this section. The SPR curve is another 
essential graph. It demonstrates the angular position of the incident light on the 
x-axis, and the intensity of reflected light or reflectivity on the y-axis (Figure 11). 
Notably, the scanning property is needed.in the instrumentation in order to acquire 
the reflectivity data as a function of incident angle.
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The recorded sensorgrams can be pre-processed using baseline correction 
algorithms. The interaction kinetics are evaluated using established mathematical 
models [91, 311]. Figure 10 illustrates an idealized sensorgram of the interaction 
between pre-immobilized ligand and analyte. Experimental sensorgrams are fitted to 
the chosen model, and typically the residuals are calculated in order to estimate, how 
the measured sensorgrams agree with the model. Parameters such as rate constants 
(ka, kd, KD) and maximum binding capacity (for instance Bmax) can be derived from 
the fits using numerical integration. Two frequently utilized models are described 
and shown in Table 5. It is noteworthy to mention that there exists a plethora of 
more complex models for various interaction schemes. In short, the one-to-one 
binding system is a common curve fitting algorithm based on 1:1 analyte-to-ligand 
binding. Despite its simplicity, in most cases it generates reasonably good fittings. 
The algorithm and the yielded quantities are shown in Table 5. Respectively, the 
one-to-two binding model is suitable for interactions where the analyte in solution 
binds to two independent targets (i.e. ligand binding sites) on a solid support. The 
algorithm and the resulting quantities for one-to-two model are also shown in 
Table 5.
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Figure 10. A typical sensorgram depicting the interaction events between the pre-immobilized ligand 
and analyte.  After a stable baseline is observed at the beginning, the analyte is injected over the 
sensor surface. In the association phase the SPR undergoes a shift that can be perceived as a relative 
shift in the sensorgram. In the dissociation phase the adsorbed analytes detach from the surface. 
Depending on the ligand-analyte interaction, the dissociation can take place partially, completely or 
it can be chemically forced with various regeneration methods. At the end, a stable baseline is 
observed. 
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Table 5. Two commonly used interaction models; One-to-One and One-to-Two binding kinetics.
Model Equations Conditions Result
One-to-
One
               ka
A + B  AB = Y
               kd
 = ka × cA × 
(Ymax – Y) – kd × Y
Y, t=0 = 0
A: Analyte
B: Ligand
Y: Concentration of the formed 
molecular complex (AB)
Ymax: Total concentration of the 
immobilized ligand
ka: Association rate constant
kd: Dissociation rate constant
cA: Concentration of the 
(injected) analyte A
Bmax [Signal units]: 
Maximum signal obtained 
(dependent e.g. on the 
number of receptors)
ka = 
 
] ] 
kd = 
 
] ] 
 
BI [Signal units]: Bulk effect 
(if present)
One-to-
Two
ka1
A + B  AB = Y1
kd1
ka2
A + C  AC = Y2
kd2
 = ka1 × cA ×
(Ymax – Y1 – Y2) – kd1 × 
Y1 – ka2 × Y1 + kd2 × Y2
 = ka2 × Y1 – kd2 
× Y2
Y1, t=0 = 0
Y2, t=0 = 0
A: Analyte
B: Ligand/binding site 1
C: Ligand/binding site 2
Y1: Concentration of the formed 
molecular complex (AB)
Y2: Concentration of the formed 
molecular complex (AC)
ka1: Association rate constant 1
kd1: Dissociation rate constant 1
cA: Concentration of the 
(injected) analyte A
ka2: Association rate constant 2
kd2: Dissociation rate constant 2
Bmax1 [Signal units]: 
Maximum signal from target 
1 (dependent e.g. on the 
number of receptors)
ka1 = 
 
] ] 
kd1 = 
 
] ] 
 
Bmax2 [Signal units]: 
Maximum signal from target 
2 (dependent e.g. on the 
number of receptors)
ka2 = 
 
] ] 
kd2 = 
 
] ] 
 
BI [Signal units]: Bulk effect 
(if present)
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6.1.3 Data analysis: Modeling for layer thickness and refractive index
For the layer thickness and refractive index modeling, the shape and quantities 
(θSPR, depth of minimum, width of minimum) associated with the SPR curve are 
utilized [307]. The Fresnel equations can be used to calculate the fraction of light 
wave reflected and transmitted by a flat interface between two media with different 
refractive indices. The Fresnel equations for p-polarized light can be expressed as:
 (10) 
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6.1.3 Data analysis: Modeling for layer thickness and refractive index 
For the layer thickness and refractive index modeling, the shape and quantities (SPR, depth of 
minimum, width of minimum) associated with the SPR curve are utilized [307]. The Fresnel 
equations can be used to calculate the fraction of light wave reflected and transmitted by a flat 
interface between two media with different fractive indices. The Fresnel equations for p-polarized 
light can be expressed as: 
  (10) �ǁ � � ������ � �
��� ��������� �������
��� ��������� �������  
  (11) �ǁ � � ������ � �
��� �������
��� ��������� ������� 
 
 (11) 
where (Eq. 10) denotes the reflection coefficient, rǁ, E0r and E0i are the electric 
fields for reflected and incident light, respectively. The refractive indices for incident 
medium and transmitting medium are  and , respectively. And θi is the angle 
of incidence for the light, θt is the angle of the transmitted light. Analogously, 
(Eq. 11) describes the transmission coefficient, tǁ for the incident light; E0t  is the 
electric field for transmitted light. It is noteworthy that under ATR conditions, the 
transmittance coefficient tǁ equals zero. Moreover, R= │rǁ│2 for calculating the 
theoretical full SPR curve as a function of the incident light angle.
More exactly, the SPR curve can be described with Fresnel’s equations as the 
reflectivity of a multilayered system for p-polarized light [307]. In principle, the 
layers are assumed linear, homogenous, and isotropic. The calculation is based 
on a 2 × 2 scattering matrix derived from Fresnel’s complex-amplitude reflection 
and transmission coefficients; the matrix representing the summarized optical 
properties and expressed as a product of the interface and layer matrices of the 
entire structure. The intermediate zones between different layers are introduced 
into Fresnel’s equations as new layers. Thus, the thickness of the intermediate 
layer describes the average roughness of the surface, its complex refractive index, 
for one, corresponds to the light losses via scattering and plasmon decoupling into 
radiative modes (especially the imaginary part). The overall benefit of this approach 
is that only Fresnel equations can be used in the model with no need to apply 
scattering theories. Figure 11 depicts an example of this multilayer scheme. The 
whole procedure can be modeled step-wise by performing the curve fitting in each 
phase. However, the downside of this fitting procedure using data recorded with 
single incident wavelength is that at least either the d or n of the new layer should 
be known from the existing literature or otherwise estimated accurately.
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refractive indices of various layers. First, the gold sensor surface is measured in buffer solution 
Figure 11. An example of the multilayer approach typically used for evaluating thicknesses and refractive 
indices of various layers. First, the gold sensor surface is measured in buffer solution (uppermost 
row). Second, the adsorbates in buffer solution are associating onto the surface (middle row). In this 
phase, the measured SPR curve undergoes a shift from the background (black) to the situation after 
the adsorption (green). Notably, the effect of adsorbate solution can be seen as a shift in the TIR 
angle (i.e. Δnbulk). The angular position of θSPR is affected by the adsorbate solution and the adsorbing 
film (i.e. Δnbulk & Δnadsorbate film). Lastly, the surface is rinsed with the buffer solution (bottom row). The 
SPR curve (purple) can shift back slightly, the shift in TIR angle recovers, and the position of θSPR 
corresponds to the contribution of adsorbate film on the surface (Δnadsorbate film).
Information produced by multiple independent incident wavelengths can be used 
to resolve for the layers more explicitly. The general solution for a multilayered, 
optically active system connected with measurable and controllable quantities, can 
be derived using the transfer matrix formalism of 2 × 2 matrices. In the complex 
refractive index  , the real part n corresponds to the refraction of light, 
and the complex coefficient k to the extinction or absorption of light by the material. 
Furthermore, the relationship    connects the refractive index and dielectric 
constant. Finally, the surface plasmon wave vector (ksp) is considered to contain 
all the information and constants that affect the measured SPR spectra, and lead 
to differences in SPR spectra measured at multiple wavelengths. Therefore, the 
continuum solution for the surface plasmon wave vector (ksp) in one set of conditions 
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can be described by the mathematical relationship between (ksp), the material layer 
thickness d, and the refractive index n:
 (12) 
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(uppermost row). Second, the adsorbates in buffer solution are associating onto the surface (middle 
row). In this phase, the measured SPR curve undergoes a shift from the background (black) to the 
situation after the adsorption (green). Notably, the effect of adsorbate solution can be seen as a shift 
in the TIR angle (i.e. Δnbulk). The angular position of SPR is affected by the adsorbate solution and 
the adsorbing film (i.e. Δnbulk & Δnadsorbate film). Lastly, the surface is rinsed with the buffer solution 
(bottom row). The SPR curve (purple) can shift back slightly, the shift in TIR angle recovers, and the 
position of SPR corresponds to the contribution of adsorbate film on the surface (Δnadsorbate film). 
Information produced by multiple independent incident wavelengths can be used to resolve for the 
layers more explicitly. The general solution for a multilayered, optically active system connected with 
measurable and controllable quantities, can be derived using the transfer matrix formalism of 2  2 
matrices. In the complex refractive index � � � � ��, the real part n corresponds to the refraction of 
light, and the complex coefficient k to the extinction or absorption of light by the material. 
Furthermore, the relationship � � √�̂ connects the refractive index and dielectric constant. Finally, 
the surface plasmon wave vector (ksp) is considered to contain all the information and constants that 
affect the measured SPR spectra, and lead to differences in SPR spectra measured at multiple 
wavelengths. Therefore, the continuum solution for the surface plasmon wave vector (ksp) in one set 
of conditions can be described by the mathematical relationship between (ksp), the material layer 
thickness d, and the refractive index n: 
  (12) k�� � � ∗ � 
However, the definition above describes only the continuum solution for the (ksp). The unique solution 
for the apparently interconnected thickness d and refractive index n of the layer can be found from 
the intersection of two continuum solutions from two different measurements in two different media 
or multiple wavelengths [308, 309]. In the mathematical treatment with the two-wavelengths, the 
refractive index n has a wavelength dependency, dn/dλ. Noteworthy, if a third wavelength is used, 
the dispersion coefficient dn/dλ can be accurately quantified [309]. For relatively similar materials 
and molecules this dependency can be assumed as linear, resulting in good approximations. 
Furthermore, by using the established dispersion coefficient values in combination with the two-
wavelength technique results to significant improvement in accuracy compared to modeling where 
the value for either n or d is estimated or adopted from the literature for bulk materials [309]. The 
unique solution for layer thickness d and refractive index n can be found by solving for the equations: 
  (13) ���1 � ��� ∗ � 
  (14) ���2 � ��� ∗ � 
where ���1 denotes the surface plasmon vector for wavelength 1, ��� the refractive index for 
wavelength 1, ���2  the surface plasmon vector for wavelength 2, and ��� the refractive index for 
wavelength 2, and: 
  (15) ��� � ���� � ���� ∗ ��� ����� 
and: 
  (16) ���1 � ��� ∗ � 
However, the definition above describes only the continuum solution for the (ksp). 
The unique solution for the apparently interconnected thickness d and refractive 
index n of the layer can be found from the intersection of two continuum solutions 
from two different measurements in two different media or multiple wavelengths 
[308, 309]. In the mathematical treatment ith e two-wavelengths, th  refractive 
in ex n has a wavelength dependency, dn/dλ. Noteworthy, if a third wavelength 
is used, the dispersion coefficient dn/dλ can be accurately quantified [309]. For 
relatively similar materials and molecules this dependency can be assumed as 
linear, resulting in good approximations. Furthermore, by using the established 
dispersion coefficient values in combination with the two-wavelength technique 
results to significant improvement in accuracy compared to modeling where the 
value for either n or d is estimated or adopted from the literature for bulk materials 
[309]. The unique solution for layer thickness d and refractive index n can be found 
by solving for the equations:
 (13) 
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(uppermost row). Second, the adsorbates in buffer solution are associating onto the surface (middle 
row). In this phase, the measured SPR curve undergoes a shift from the background (black) to the 
situation after the adsorption (green). Notably, the effect of adsorbate solution can be seen as a shift 
in the TIR angle (i.e. Δnbulk). The angular position of SPR is affected by the adsorbate solution and 
the adsorbing film (i.e. Δnbulk & Δnadsorbate film). Lastly, the surface is rinsed with the buffer solution 
(bottom row). The SPR curve (purple) can shift back slightly, the shift in TIR angle recovers, and the 
position of SPR corresponds to the contribution of adsorbate film on the surface (Δnadsorbate film). 
Information produced by multiple independent incident wavelengths can be used to resolve for the 
layers more explicitly. The general solution for a multilayered, optically active system connected with 
measurable and controllable quantities, can be derived using the transfer matrix formalism of 2  2 
matrices. In the complex refractive index � � � � ��, the real part n corresponds to the refraction of 
light, and the complex co fficient k to the xtinction or absorption of light by the material. 
Furthermore, the relationship � � √�̂ connects the refractive index and dielectric constant. Finally, 
the surface plasmon wave vector (ksp) is considered to ontain all the information and constants that 
affect the measured SPR spectra, and l ad to differ nces in SPR spectra measured at multiple 
wavelengths. Therefore, the continuum solution for the surface plasmon wave vector (ksp) in one set 
of conditions can be described by the mathematical relationship between (ksp), the material layer 
thickness d, and the refractive index n: 
  (12) k�� � � ∗ � 
However, the definition above describes only the co tinuum solution f r the (ksp). The nique s lution 
for the apparently interconnected thick ess d and refractive ind x n of the layer can be found from 
the intersection of two continuum solutions from two different measurements in two different media 
or multiple wavelengths [308, 309]. In the mathematical treatment with the two-wavelengths, the 
refractive index n has a wavelength dependency, dn/dλ. Noteworthy, if a third wavelength is used, 
the dispersion coefficient dn/dλ can be accurately quantified [309]. For relatively similar materials 
and molecules this dependency can be assumed as linear, resulting in good approximations. 
Furthermore, by using th  established dispersi n coefficient values in combinatio  with the two-
wavelength technique results to s gnificant improvement in accuracy compared to modeling where 
the value for either n or d is estimated or adopted from the literature for bulk materials [309]. The 
unique solution for layer thickness d and refractive index n can be found by solving for the equations: 
  (13) ���1 � ��� ∗ � 
  (14) ���2 � ��� ∗ � 
here ���1 denotes the surface plasmon vector for wavelength 1, ��� the refractive index for 
wavelength 1, ���2  the surface plasmon vector for wavelength 2, and ��� the refractive index for 
wavelength 2, and: 
  (15) ��� � ���� � ���� ∗ ��� ����� 
and: 
  (16) ���1 � ��� ∗ � 
 (14)
where  ksp1 denotes the surface plasmon vector for wavelength 1, λ1  the refractive 
index for wavelength 1,  ksp2  the surface plasmon vector for wavelength 2, and  
λ2 the refractive index for wavelength 2, and:
 (15) 
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(uppermost row). Second, the adsorbates in buffer solution are associating onto the surface (middle 
row). In this phase, the measured SPR curve undergoes a shift from the background (black) to the 
situation after the adsorption (green). Notably, the effect of adsorbate solution can be seen as a shift 
in the TIR angle (i.e. Δnbulk). The angular position of SPR is affected by the adsorbate solution and 
the adsorbing film (i.e. Δnbulk & Δnadsorbate film). Lastly, the surface is rinsed with the buffer solution 
(bottom row). The SPR curve (purple) can shift back slightly, the shift in TIR angle recovers, and the 
position of SPR corresponds to the contribution of adsorbate film on the surface (Δnadsorbate film). 
Information produced by multiple independent incident wavelengths can be used to resolve for the 
layers more explicitly. The general solution for a multilayered, optically active system connected with 
easurable and controllable quantities, can be derived using the transfer matrix formalism of 2  2 
matrices. In the co plex refractive index � � � � ��, the real part n corresponds to the refraction of 
light, and the complex coefficient k to the extinction or absorption of light by the material. 
Furthermore, the relationship � � √�̂ connects the refractive index and dielectric constant. Finally, 
the surface plasmon wave vector (ksp) is considered to contain all the information and constants that 
affect the measured SPR spectra, and lead to differences in SPR spectra measured at multiple 
wavelengths. Therefore, the continuum solution for the surface plasmon wave vector (ksp) in one set 
of conditions can be described by the mathematical relationship between (ksp), the material layer 
thickness d, and the refractive index n: 
  (12) k�� � � ∗ � 
However, the definition above describes only the continuum solution for the (ksp). The unique solution 
for the apparently interconnected thickness d and refractive index n of the layer can be found from 
the intersection of two continuum solutions from two different measurements in two different media 
or multiple wavelengths [308, 309]. In the mathematical treatment with the two-wavelengths, the 
refractive index n has a wavelength dependency, dn/ λ. Noteworthy, if a third wavelength is used, 
the dispersion coefficient dn/dλ can be accurat ly quantified [309]. For r atively similar materials 
and molecules this dependency can be assumed as linear, resulting in good approximations. 
Furthermore, by using the established dispersion coefficient values in combination with the two-
wavelength technique results to significant improvement in accuracy compared to modeling where 
the value for either n or d is estimated or adopted from the literature for bulk materials [309]. The 
unique solution for layer thickness d and refractive index n can be found by solving for the equations: 
  (13) ���1 � ��� ∗ � 
  (14) ���2 ��� ∗ � 
where ���1 denotes the surface plasmon vector for wavelength 1, ��� the refractive index for 
wavelength 1, ���2  the surface plasmon vector for wavelength 2, and ��� the refractive index for 
wavelength 2, and: 
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and: 
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  (17) ���2 �� ���� � ���� ∗ ��� ������ ∗ � 
The statements above hold true for sample layers that do not absorb light at the wavelengths used in 
the SPR spectrum measurement. In practice, it means that the imaginary component k for the 
refractive index = 0, which is the case for the majority of organic sample layers. However, if the layer 
absorbs light, �� � �, then there is a unique solution for the sample layer in the ��� � �� � ��� ∗ � 
space. 
For instance, one can utilize laser wavelengths 670 nm and 785 nm that are aligned to irradiate 
simultaneously the same spot on the measured surface. Hence, the layer thickness can expected to be 
the same for both wavelengths. The complex refractive index can be input as an independent variable 
for the background (pure metal layer) modeling, or as a linearly dependent variable between the two 
used wavelengths for reasons described above. Overall, the two-wavelength method combined with 
the angular scanning has been demonstrated efficient for characterizing adsorbed (organic) thin and 
thick layers on surfaces [71, 310, 312, 313]. 
6.1.4 Data analysis: Surface mass density calculations 
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface [91, 314]. The 
surface mass densities can be calculated by using the de Feijter equation [305] derived from the 
definition of refractive index increment of adsorbed biomolecules �� ��� : 
  (18) ���� � �
�����
��  
where n� is the refractive index of a solution of biomolecule p with concentration ��, n� is the 
refractive index of medium and �� ���  represents the concentration (mass) dependency of refractive 
index. Thus the surface density ��� is defined as the Gibbs surface excess: 
  (19) �� � ���� 
where �� is the thickness of the adsorbed layer. By combining the two equations above, and 
eliminating ��, the de Feijter equation relating the surface density to the refractive index increment 
and the layer thickness becomes: 
  (20) �� � � ����������� ���   
Since the instrument signal is an important factor to take into account, the latter equation is derived 
further to include the instrument signal: 
  (21) �� � �� � ��� � ������  
and thus: 
  (22) �� � � ����������� ���     
where the constant k is the instrument (sensor, wavelength) dependent coefficient for sensitivity, and 
Θ is the θSPR shift obtained from the sensorgram where the θSPR is observed as a function of time. For 
Th  stateme ts above hold tru  for sample layers that do not absorb light at the 
wavelengths used in the SPR spectrum measurement. In practice, it means that 
the imaginary component k for the refractive index = 0, which is the case for the 
majority of organic sample layers. However, if the layer absorbs light, k  0, then 
there is a unique solution for the sample layer in the ksp = (n + ik) * d space.
71
For instance, one can utilize laser wavelengths 670 nm and 785 nm that are 
aligned to irradiate simultaneously the same spot on the measured surface. Hence, 
the layer thickness can expected to be the same for both wavelengths. The complex 
refractive index can be input as an independent variable for the background 
(pure metal layer) modeling, or as a linearly dependent variable between the 
two used wavelengths for reasons described above. Overall, the two-wavelength 
method combined with the angular scanning has been demonstrated efficient for 
characterizing adsorbed (organic) thin and thick layers on surfaces [71, 310, 312, 313].
6.1.4 Data analysis: Surface mass density calculations
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface 
[91, 314]. The surface mass densities can be calculated by using the de Feijter 
equation [305] derived from the definition of refractive index increment of adsorbed 
biomolecules :
 (18) 
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  (17) ���2 �� ���� � ���� ∗ ��� ������ ∗ � 
The statements above hold true for sample layers that do not absorb light at the wavelengths used in 
the SPR spectrum measurement. In practice, it means that the imaginary component k for the 
refractive index = 0, which is the case for the majority of organic sample layers. However, if the layer 
absorbs light, �� � �, then there is a unique solution for the sample layer in the ��� � �� � ��� ∗ � 
space. 
For instance, one can utilize laser wavelengths 670 nm and 785 nm that are aligned to irradiate 
simultaneously the same spot on the measured surface. Hence, the layer thickness can expected to be 
the same for both wavelengths. The complex refractive index can be input as an independent variable 
for the background (pure metal layer) modeling, or as a linearly dependent variable betwe  the two 
used wavelengths for reasons described a ove. Overall, the two-wavele gth method combined with 
the angular scanning has been demonstrated efficient for characterizing adsorbed (organic) thin and 
thick layers on surfaces [71, 310, 312, 313]. 
6.1.4 Data analysis: Surface mas density calcula ions 
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface [91, 314]. The 
surface mass densities can be calculated by using the de Feijter equation [305] derived from the 
definition of refractive index increment of adsorbed biomolecules �� ��� : 
  (18) ���� � �
�����
��  
where n� is the refractive index of a solution of biomolecule p with concentration ��, n� is the 
refractive index of medium and �� ���  represents the concentration (mass) dependency of refractive 
index. Thus the surface density ��� is defined as the Gibbs surface excess: 
  (19) �� � ���� 
where �� is the thickness of the adsorbed layer. By combining the two equations above, and 
eliminating ��, the de Feijter equation relating the surface density to the refractive index increment 
and the layer thickness becomes: 
  (20) �� � � ����������� ���   
Since the instrument signal is an important factor to take into account, the latter equation is derived 
further to include the instrument signal: 
  (21) �� � �� � ��� � ������  
and thus: 
  (22) �� � � ����������� ���     
where the constant k is the instrument (sensor, wavelength) dependent coefficient for sensitivity, and 
Θ is the θSPR shift obtained from the sensorgram where the θSPR is observed as a function of time. For 
where np is the refractive index of a solution of biomolecule p with 
concentration Cp,  nm  is the refractive index of medium and    represents 
the concentration (mass) dependency of refractive index. Thus the surface 
density (Γ ) is defined as the Gibbs surface excess:
 (19) 
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  (17) ���2 �� ���� � ���� ∗ ��� ������ ∗ � 
The statements above hold true for sample layers that do not absorb light at the wavelengths used in 
the SPR spectrum measurement. In practice, it means that the imaginary component k for the 
refractive index = 0, which is the case for the majority of organic sample layers. However, if the layer 
absorbs light, �� � �, then there is  unique soluti n for the sample lay r in the ��� � �� � ��� ∗ � 
space. 
For instance, one can utiliz laser wavelengths 670 nm and 785 nm that are align d to irradiate 
simultaneously the same spot on the m asured surface. Hence, the layer thickness can exp cted to be 
the same for both wavelengths. The complex refractive index can be input as an independent variable 
for the background (pure metal layer) modeling, or as a linearly dependent variable between the two 
used wavelengths for reasons described above. Overall, the two-wavelength method combined with 
the angular scanning has been demo strated ef i ient for characterizing adsorbed (organic) thin and 
thick layers on surfaces [71, 310, 312, 313]. 
6.1.4 Data n lysis: Surface mass den ity calculations 
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface [91, 314]. The 
surface mass densities can be alculated by using the de Feijter equation [305] derived from the 
definition of refractive index increment of adsorbed biomolecules �� ��� : 
  (18) ���� � �
�����
��  
where n� is the refract ve index of a solution of biomolecule p with conc ntration ��, n� is th
refractive index of medium and �� ���  repr sents the concent ation (ma ) dependency of refractive 
index. Thus the surface density ��� is defined as the Gibbs surface excess: 
  (19) �� � ���� 
where �� is the thickness of the adsorbed layer. By combining the two equations above, and 
eliminating ��, the de Feijter equation relating the surface density to the refractive index increment 
and the layer thickness becomes: 
  (20) �� � � ����������� ���   
Since the instrument signal is an important factor to take into account, the latter equation is derived 
further to include the instrument signal: 
  (21) �� � �� � ��� � ������  
and thus: 
  (22) �� � � ����������� ���     
where the constant k is the instrument (sensor, wavelength) dependent coefficient for sensitivity, and 
Θ is the θSPR shift obtained from the sensorgram where the θSPR is observed as a function of time. For 
where dp is the thickness of the adsorbed layer. By combining the two equations 
above, and eliminating Cp, the de Feijter equation relating the surface density 
to the refractive index increment and the layer thickness becomes:
 (20) 
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  (17) ���2 �� ���� � ���� ∗ ��� ������ ∗ � 
The statements above hold true for sample layers that do not absorb light at the wavelengths used in 
the SPR spectrum measurement. In practice, it means that the imaginary component k for the 
refractive index = 0, which is the case for the majority of organic sample layers. However, if the layer 
absorb  light, �� � �, then there is a unique solution for the sample layer in the ��� � �� � ��� ∗ �
pace. 
For instance, one can utilize laser wavelengths 670 nm and 785 nm that are aligned to irradiate 
simultaneously the same spot on the measured surface. Hence, the layer thickness can expected to be 
the same for both wavelengths. The complex refractive index can be input as an independent variable 
for the background (pure metal layer) modeling, or as a linearly dependent variable between the two 
used wavelengths for reasons described above. Overall, the two-wavelength method combined with 
the angul r sc nning has b en demonst a ed efficient for char cterizing adsorbed (organic) thin and 
thick layers on surfaces [71, 310, 312, 313]. 
6.1.4 Data n lysis: Surface mass den ity calculations 
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface [91, 314]. The 
surface mass densities can be alculated by using the de Feijter equation [305] derived from the 
definition of refractive index increment of adsorbed biomolecules �� ��� : 
  (18) ���� � �
�����
��  
wh re n� is the re ract ve index of a solution of biomolec le p with conc ntration ��, n� is th
refractive index of medium and �� ���  repr sents the concentration (ma ) dependency of refractive 
index. Thus the surface density ��� is defined as the Gibbs surface excess: 
  (19) �� � ���� 
where �� is the thickness of the adsorbed layer. By combining the two equations above, and 
eliminating ��, the de Feijter equation relating the surface density to the refractive index increment 
and the layer thickness becomes: 
  (20) �� � � ����������� ���   
Since the instrument signal is an important factor to take into account, the latter equation is derived 
further to include the instrument signal: 
  (21) �� � � ��� � ������  
and thus: 
  (22) �� � � ����������� ���     
where the constant k is the instrument (sensor, wavelength) dependent coefficient for sensitivity, and 
Θ is the θSPR shift obtained from the sensorgram where the θSPR is observed as a function of time. For 
 
Since the instrument signal is an important factor to take into account, the 
latter equation is derived further to include the instrument signal:
 (21) 
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  (17) ���2 �� ���� � �� ∗ ��� ������ ∗ � 
The statements above old true for ample layers that do not absorb light at the wav lengths used in
the SPR spectrum measurement. In practice, i  means that the imaginary component k for the
refractive index = 0, which is the case for the majority of organic sample layers. However, if the layer 
absorbs light, �� � �, then there is a unique solution for the sample layer in the ��� � �� � ��� ∗ � 
space. 
For instance, ne c n utilize laser wave ngths 670 nm and 785 nm th t re aligned to irradiat
simultaneously the same spo  on th  measured surface. Hence, the layer thickness can exp cted to be
th  same for both wavelengths. The complex refractive ind x can be input as an independent variable
for the backgrou d (pure m tal layer) modeling, or as a line l  depe de t variable between the two
used wavelengths or reasons described above. Overall, the two-wavelength method combined with 
the angular scanning has been demon trated efficient for ch racterizing a sorbed (organic) thin and 
thick layers on surfaces [71, 310, 312, 313]. 
6.1.4 Data analysis: Surface mass density calculations 
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface [91, 314]. The 
surface mass densities can be calculated by using the de Feijter equation [305] derived from the 
definition of refractive index increment of adsorbed biomolecules �� ��� : 
  (18) �� � �
�� ��
��  
where n� is the refractiv  index of a solution of b omolecul  p with concentration ��, n� is the 
refractive index of medium and �� ���  represents the concentration (mass) dependency of refractive 
index. Thus the surface density ��� is defined as the Gibbs surface excess: 
  (19) �� � ���� 
where �� is the thickness of the adsorbed layer. By combining the two equations above, and 
eliminating ��, the de Feijter equation relating the surface density to the refractive index increment 
and the layer thickness becomes: 
  (20) �� � � ����������� ���   
Since the instrument signal is an important factor to take into account, the latter equation is derived 
further to include the instrument signal: 
  ( 1) � �� ��� � ������  
and thus: 
  (22) �� � � ����������� ���     
where the constant k is the instrument (sensor, wavelength) dependent coefficient for sensitivity, and 
Θ is the θSPR shift obtained from the sensorgram where the θSPR is observed as a function of time. For 
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and thus:
 (22) 
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The statements above hold true for sample layers that do not absorb light at the wavelengths used in 
the SPR spectrum measurement. In practice, it means that the imaginary component k for the 
refractive index = 0, which is the case for the majority of organic sample layers. However, if the layer 
absorbs light, �� � �, then there is a unique solution for the sample layer in the ��� � �� � ��� ∗ � 
space. 
For instance, one can utilize laser wavelengths 670 nm and 785 nm that are aligned to irradiate 
simultaneously the same spot on the measured surface. Hence, the layer thickness can expected to be 
the same for both wavelengths. The complex refractive index can be input as an independent variable 
for the background (pure metal layer) modeling, or as a linearly dependent variable between the two 
used wavelengths for reasons described above. Overall, the two-wavelength method combined with 
the angular scanning has been demonstrated efficient for characterizing adsorbed (organic) thin and 
thick layers on surfaces [71, 310, 312, 313]. 
6.1.4 Data analysis: Surface mass density calculations 
The θSPR has a correlation with the mass that adsorbs onto the SPR sensor surface [91, 314]. The 
surface mass densities can be calculated by using the de Feijter equation [305] derived from the 
definition of refractive index increment of adsorbed biomolecules �� ��� : 
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where n� is the refractive index of a solution of biomolecule p with concentration ��, n� is the 
refractive index of medium and �� ���  represents the concentration (mass) dependency of refractive 
index. Thus the surface density ��� is defined as the Gibbs surface excess: 
  (19) �� � ���� 
where �� is the thickness of the adsorbed layer. By combining the two equations above, and 
eliminating ��, the de Feijter equation relating the surface density to the refractive index increment 
and the layer thickness becomes: 
  (20) �� � � ����������� ���   
Since the instrument signal is an important factor to take into account, the latter equation is derived 
further to include the instrument signal: 
  (21) �� � �� � ��� � ������  
and thus: 
  (22) �� � � ����������� ���     
where the constant k is the instrument (sensor, wavelength) dependent coefficient for sensitivity, and 
Θ is the θSPR shift obtained from the sensorgram where the θSPR is observed as a function of time. For where the constant k is the instrument (sensor, wavelength) depe dent coefficient 
for sensitivity, and Θ is the θSPR shift obtained from the sensorgram where the θSPR 
is observed as a function of time. For thin layers the k × dp can be approximated 
as a constant. The value can be experimentally defined, or by theoretical modeling 
of SPR peaks. In order to gain the conversion coefficient for calculating the 
surface mass densities, comparably good approximations can be achieved using a 
value of   = 0.182 cm3/g. As an example, for the SPR Navi 200 instrument 
(BioNavis Ltd., Tampere, Finland) it means that for 670 nm wavelength  Γp = 
ΔΘ (mDeg) * 550 g/cm2 and for 785 nm wavelength Γp = ΔΘ (mDeg) * 1050 
g/cm2. However, the aforementioned relationship holds true best for certain types 
of proteins. Some of the limitations and possible caveats of these approximations 
are discussed in the literature [314].
6.2 SPR IN BIOMEDICAL APPLICATIONS
As an optical technique, SPR is very sensitive and assays are generally performed 
without the use of labels. The real-time nature of SPR allows for time-resolved 
monitoring of events from rapid interaction phenomena in the order of few 
milliseconds to long-term monitoring of several hours. In addition, the prerequisite 
for the amount of starting materials is low. Thorough reviews on the subject and 
its applications can be found for example in the following references [50, 83, 315, 
316]. In brief, SPR has been extensively used in life and materials sciences for 
monitoring a plethora of interactions and surface properties; for instance glucose 
and urea detection, immunoassays, DNA binding assays, real-time kinetics of drugs 
binding to various targets, graphene layers characterization [317] and living cell 
interactions with drugs [318].
6.2.1 SPR as a biophotonic tool for studying small drugs
Initially SPR started as an immunosensing tool [315], and soon after it was found a 
potential technique for a number of applications in the analysis of small molecules, 
for instance drugs.  Meticulous overviews and examples of various assays have 
been provided e.g. by Rich et al. [319] and Shankaran et al. [320]. Essentially the 
cornerstone for small drug assays using SPR is to establish a well-defined and stable 
biosensor surface onto which the ligand is immobilized and the consequent steps with 
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the small drug analyte are performed. Hydrogel surfaces, particularly hydrophilic 
carboxymethyl-modified dextran (CMD) hydrogels, offer many advantages when 
used as an SPR sensor surface [321]. In general, a highly branched 3D CMD hydrogel 
surface is best applied for small molecular weight analyte detection whereas a 2D 
CMD surface performs better in the presence of large analytes, for instance liposomes 
and EVs. 
Intriguingly, a pivotal perception can be made when the timeline of SPR is 
scrutinized with caution; a vast majority of the studies have focused on traditional 
interaction kinetics – which are obviously valuable as such but an evident need exists 
for fresh approaches in SPR-based small drug studies. The advent of novel SPR 
instrumentation allows for re-thinking the opportunities. For instance by utilizing 
the MP-SPR, SPR assays can be designed from a new standpoint. Because multiple 
parameters are acquired in the measurement, simultaneous characterization of 
interaction events and surface properties is enabled. When combined with rigorous 
analysis of experimental data, and computational modeling approaches, new bio-
functional assays can be constituted. Essentially, in such assays the experimental 
in vitro environment is built to mimic the natural biological milieu, and the 
computational methods of choice complement the obtained experimental data. This, 
in turn, can open up unexpected venues in the discovery and development of small 
drugs. For example, a major hindrance in the development of therapeutic agents 
[322, 323] against Alzheimer’s disease (AD) is the inadequate mechanistic insight 
of small molecule binding coordination and/or lack of tools to demonstrate their 
potential to disrupt the detrimental oligomerization of Aβ peptides [324, 325]. SPR-
based bio-functional assays can provide real-time, label-free methods to overcome 
such barriers in the development of novel compounds.
6.2.2 Bionanophotonics: SPR for studying liposomes
To date the primary aim in nanomedicine is the development of safe and 
effective DDCs. One of the crucial aspects is to design drug preparations that 
fulfil the requirements during the multiple and complex interactions at the nano-
bio interfaces [1]. Essentially, the nano-bio interface includes three important 
components that affect the overall performance of the DDC. The first component 
is the physicochemical characteristics of the nanocarrier surface. Secondly, the 
events occurring at the solid-liquid interface phenomena while the carrier interacts 
with the surrounding medium. Thirdly, the events occurring at the solid-liquid 
interface between the nanocarrier and biological structures (e.g. cell membranes). 
In particular, the lack of knowledge of the overall mechanistic behavior of the 
DDC at the solid-liquid interfaces is one of the major contributors in troublesome 
DDC development. As previously touched on, bionanophotonics can offer tools for 
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mechanistic understanding to facilitate the somewhat rocky steps of nanocarrier 
engineering. 
Importantly, liposomes represent a group of DDCs that have been approved for 
therapeutic use. Liposomal drug delivery systems (LDSs) have been investigated 
with SPR in various instances. Examples include drug-liposome interactions [326], 
rapid monitoring of solute leakage from liposomes [327], and liposome interactions 
with model receptor surfaces [328]. When liposomes are administered into the blood 
circulation in the body, they encounter a highly dynamic environment. Complex 
interactions with different biomolecular specimens affect the circulation time and 
bioavailability of the LDS [256, 329]. Essentially a dynamic layer consisting of 
proteins and various plasma components is adsorbed onto the surfaces of LDSs; the 
layer is typically called the “protein corona” and it can be furthermore divided into 
“hard corona” and “soft corona” according to the physicochemical characteristics of 
the layer [330]. Such layer can direct the macrophages of reticular endothelial system 
(RES) to recognize and eliminate the LDSs from the circulation as foreign particles. 
The PEGylation and other hydrophilic shielding methods have been widely used to 
prevent the premature clearance of LDSs [145, 331]. However, such coatings can 
provoke increased immunogenicity and drastic hypersensitivity responses against 
the existing LDSs have been observed [143, 332]. The effects of PEGylation coatings 
– and other surface modifications of LDSs have been studied to an extent but 
significant cavities exist among the current methodologies [329, 333]. Firstly, the 
studies have been carried out investigating diluted serum which is not an adequate 
model system for thorough understanding of the liposome-serum interactions. The 
diluted serum is far from its native state and thus the results can be ambiguous. 
Secondly, liposomes interacting with individual serum proteins have been studied 
with SPR but the downside of those studies is that more than 200 corona proteins 
have been identified. It is an uphill battle to screen through such an amount of 
proteins on an individual basis. Due to the undisputable biological significance of the 
liposome-serum interactions and particularly the protein corona formation, novel 
label-free bio-functional in vitro assays are needed to probe these interactions at 
early stages of LDS development. Furthermore, such assays would offer considerable 
in vivo relevance for the purposes of LDS design processes.
6.2.3 Bionanophotonics: SPR for studying EVs
The EVs represent a typical group of complex biological nanostructures whereby 
carbohydrates, lipids, proteins and nucleic acids are present. In general, SPR devices 
have been successfully utilized in the EV research for example in molecular profiling 
[334] and determining the concentration of EVs – which, however, still remains a 
puzzle without a universally adopted method in the EV research [335].
75
Since the EVs are a group of large scale analytes which have low diffusion rates 
in SPR measurements, an important point to be taken into account is whether the 
binding phenomena are being observed under mass-transport-limited conditions 
[311]. In general, mass-transport-limited binding can occur when the binding of 
the analyte to the surface-immobilized ligand is faster than the diffusion of the 
analyte from the bulk solution to the sensor surface. The same phenomenon applies 
reversibly when the analytes are leaving the surface in the dissociation phase; in 
mass-transport-limited conditions the analyte can re-bind to free ligand before 
diffusing back into the bulk solution. In essence, large analytes which have low 
diffusion rates (e.g. EVs), and analytes having fast association rates (in relation 
to the diffusion rate) are prone to this effect. In order to minimize the bias in 
analysis, i.e. to strive for operating in the kinetics-driven conditions, very low surface 
concentrations of ligands and high flow rates must be used – which occasionally 
requires optimization of the experimental setting. During the data analysis phase it 
is also possible to use kinetic fitting algorithms that take into account the conditions 
with a “mass transport” rate constant [336].
The antibody (for example anti-CD9 and anti-CD63) immobilization onto the 
SPR biosensor surface has been used to profile the protein content of EVs [219]. 
Figure 12 illustrates the protocol exploiting immobilized anti-CD63 antibodies 
that are targeted against the CD63 tetraspanin protein found in the membrane 
structures of most EVs. However, the tetraspanin proteins such as CD9 and CD63 
are abundantly expressed in the membranes of several EV types, and these assays 
lack the specificity for the purposes of cancer diagnostics, for example. The tumor-
associated EVs could act as biomarkers for cancer diagnostics [104, 337], or models 
for biomimetic DDCs [250, 251]. However, the application of tumor-originating 
EVs as biomarkers is still difficult. The most pertinent problem appears the lack of 
compounds or other means that could provide specific targeting to EVs. The vigorous 
efforts to address this problem have also led to humane misinterpretations of the 
obtained data [338]. In order to acquire valid and accurate data on the structures and 
interactions of EVs, multiple measurement methods are often needed. A demand 
for a specific EV detection platform tenaciously exists as the highly selective EV 
recognition is considered as one of the “holy grails” in the EV research. Furthermore, 
even though the EV characterization methods have evolved, surprisingly many 
fundamental physicochemical characteristics of EVs are laborious to determine. 
For example, determining the mass of a single EV, the biological binding kinetics 
of different EV types, or defining the overall biochemical composition of EVs lack 
tools. And should be preferably done with label-free and reliable assays.
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Figure 12. A schematic representation of an MP-SPR measurement using two excitation wavelengths 
(670 nm and 785 nm) to detect EVs. A self-assembled monolayer (SAM) can be constructed ex situ 
onto the gold sensor surface for example with MuOH (11-mercapto-1-undecanol) + Biotin-PEG-
Thiol (biotinylated hexa(ethylene glycol)) undecane thiol (85:15 mol %). Consequently, streptavidin 
is immobilized in situ on the SAM having biotin counterpart available. Lastly, the EVs that have 
tetraspanin protein CD63 on their membranes can be captured using immobilized (biotinylated) 
capturing ligand, anti-CD63. 
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(670 nm and 785 nm) to detect EVs. A self-assembled monolayer (SAM) can be constructed ex 
situ onto the gold sensor surface for example with MuOH (11- ercapto-1-undecanol) + Biotin-PEG-
Thiol (biotinylated hexa(ethylene glycol)) undecane thiol (85:15 mol %). Consequently, streptavidin 
is immobilized in situ on the SAM having biotin counterpart available. Lastly, the EVs that have 
tetraspanin protein CD63 on their membranes can be captured using immobilized (biotinylated) 
capturing ligand, anti-CD63.
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7 CONCLUSIONS OF THE LITERATURE
Biophotonics can provide complementary information to answer the unsolved 
questions in the field of biopharmaceutical research. Such issues are for instance 
the perpetual need for new in vitro methodology for the purposes of small drug 
development and the necessity to better understand the pit holes and opportunities 
in the nanocarrier development. However, caution should be exercised to avoid 
oversimplification by claiming that biophotonics can replace the existing methods 
like label-based imaging techniques, proteomics or various chromatographic 
analysis. Instead, the most informed decisions can be made when the existing 
methodologies are complemented with new approaches.
The current state of biopharmaceutical research has some prominent gaps 
that can be bridged by developing biophotonic technology, methods and data 
analysis techniques. Namely, the resilient photoluminescence problems in Raman 
spectroscopy hinders its widespread use in many applications – for instance solid 
state analysis of small molecular weight drugs. There is a need to develop novel 
technology in order to overcome those drawbacks. Furthermore, techniques and 
methods for rigorous biochemical characterization of extracellular vesicles on a 
single vesicle level are highly warranted in the field. Such studies could highlight and 
clarify the diverse functions of extracellular vesicles in living systems, and elucidate 
their potential to act as nano-medical drug delivery carriers. Advanced Raman 
spectroscopy techniques, for instance Raman tweezers, enable measurements of 
biological samples, and they provide high specificity to various chemical structures. 
Hence, such techniques may bring new insights into the prevailing difficulties 
confronted in extracellular vesicle research.  
In addition, the SPR-based in vitro methodologies today are somewhat delimited 
to monitor merely the interaction kinetics of analytes – regardless the size scale of 
analytes; small or large. The MP-SPR technology holds a wealth of opportunities 
for designing in vitro protocols whereby the analysis of interaction kinetics can 
be combined with sophisticated surface characterization. That, in turn, allows for 
developing bio-functional assays whereby the experimental in vitro platforms have 
increased in vivo relevance. The biopharmaceutical industry is constantly seeking 
methods to either accelerate the slow and arduous drug design process or to reduce 
the astronomical expenditures related to drug development – or both. To facilitate 
such hardships, MP-SPR platforms could be utilized for testing prospective small 
drugs in biomimetic environments or for investigating the various phenomena at 
the nano-bio interface that e.g. liposomal drug delivery carriers encounter when 
administered into the blood circulation. On the other hand, an MP-SPR platform 
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could act as a diagnostic tool for specifically detecting and characterizing cancerous 
extracellular vesicles.
It is worth pointing out that it would be favorable to perform the abovementioned 
analysis in real time without the need of any labels that may alter or bias the measured 
quantities. In the optimal sequence of events computational simulations and well-
refined data analysis methods in combination with complementary experimental 
methodologies can be used to yield valuable qualitative and quantitative information.
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8 AIMS OF THE STUDY
The overall aim of this Thesis was to develop biophotonic technologies, methods 
and data analysis approaches for modern biopharmaceutical research. The specific 
aims can be distinguished as follows:
I Demonstrate the effectiveness of the new time-gated Raman spectroscopy 
system in small drug studies where robust fluorescence suppression is utterly 
needed to acquire interpretable Raman spectral data.
II Develop a biologically relevant experimental in vitro bio-functional MP-SPR 
platform combined with computational simulations to study, how small drugs 
can interfere the aggregation of Aβ peptides that are known to contribute 
to the neurodegenerative progression of Alzheimer’s Disease. Demonstrate 
the feasibility of the developed platform using a novel molecule, spin-labeled 
fluorene (SLF).
III Utilize Raman tweezers technology and multivariate spectral data analysis to 
investigate and characterize single extracellular vesicles isolated from several 
different cell lines. Demonstrate that the obtained spectral data can be used 
to interpret the biochemical variation between different types of vesicles.
IV Design an in vitro bionanophotonic MP-SPR platform for advanced liposome-
based drug delivery carrier (DDC) engineering. To better understand the 
interactions at the bio-nano interface, dynamic flow conditions, undiluted 
(100%) serum, and novel data analysis methods are employed.
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9 SYNOPSIS OF THE MAIN RESULTS
The main results of the studies (I-IV) are illustrated in Figures 13 and 14. In Figure 
13 are represented the studies where Raman spectroscopy was used to investigate 
small drug molecules (I) and EVs as larger scale analytes (III). Correspondingly, 
Figure 14 represents the studies where SPR was used to characterize SLF as a 
potential small drug molecule (II) against AD. Liposome-serum interactions were 
scrutinized in (IV) to demonstrate the feasibility of SPR for larger scale analytes.
Small drug molecules having varying levels of photoluminescence, more 
specifically fluorescence, were measured with the time-gated Raman and 
conventional CW Raman systems (I). The technical advances of the time-
gated Raman instrumentation showed significant improvement in fluorescence 
suppression over the conventional CW Raman systems. The applicability of the 
LTRS system for EV characterization on a single-vesicle basis was demonstrated 
in (III). Meticulous Raman spectra analysis revealed differences in the biochemical 
contents on the membranes of the investigated EV populations originating from 
healthy and cancerous cells.
An SPR-based study of using a small drug candidate, SLF, in hampering the 
Aβ peptide aggregation was introduced in (II). The approach was unprecedented; 
biomimetic environments of various Aβ aggregation schemes were built on a SPR 
sensor surface. Interaction kinetics between the SLF and the different Aβ forms 
were determined. Concurrently, it was possible to address that the SLF is capable 
of acting as a decelerating agent in the Aβ aggregation. In the last stage of SPR 
studies, the attention was paid to elucidate the role of surface modification of the 
model liposomes to serum complement system activation (IV). Four different 
types of surface-immobilized liposomes were let to interact in dynamic flow 
conditions with undiluted (100%) serum. This novel approach demonstrated that 
the physicochemical content of the liposomes played a role in the formation of soft 
and hard protein corona.
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Figure 13. A summary of the main results of Raman spectroscopy studies. The entities are numbered 
with Roman numerals according to the order of appearance in this Thesis; (I) Time-gated Raman 
system development and optimization for solid state pharmaceuticals, (III) LTRS system for single 
EV studies. 
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Figure 14. A summary of the main results of MP-SPR studies. The entities are numbered with Roman 
numerals according to the order of appearance in this Thesis; (II) MP-SPR assay platform for 
studying SLF and amyloid-β aggregation, (IV) MP-SPR platform for studying liposome interactions 
with undiluted serum. 
Figure 14. A summary of the main results of MP-SPR studies. The entities are numbered with Roman 
numerals according to the order of appearance in this Thesis; (II) MP-SPR assay platform for studying SLF 
and amyloid-β aggregation, (IV) MP-SPR platform for studying liposome interactions with undiluted serum.
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10 OVERVIEW OF THE MATERIALS AND METHODS
The Table 6 summarizes the essential materials and methods used in the studies.
Table 6. The materials and methods and their purpose used in publications I-IV.
Publication Material / Method / Technique Purpose
I
• Caffeine anhydrate
• Ranitidine hydrochloride  
  (polymorphic form II)
• Indomethacin (crystalline γ-form)
• Indomethacin (amorphous)
• Continuous wave (CW) Raman  
  instrument at 785 nm excitation  
  wavelength
• CW Raman instrument at 532 nm  
  excitation wavelength
• Time-gated picosecond Raman  
  instrument at 532 pulsed excitation  
  wavelength & CMOS SPAD detector
• MATLAB® software
• OriginPro 8.6 software
• Gaussian 09 software
• GaussSum 2.2 software
• GaussView 5.0 software
• Non-fluorescent model compound
• Fluorescent model compound
• Fluorescent model compound
• Fluorescent model compound
• Reference system
• Reference system
• Novel Raman system
• Data analysis
• Data analysis
• Quantum chemical calculations 
  (QCC)
• QCC
• Visualization of QCC results
II
• Hexafluoro-2-propanol (HFIP)
• Dimethyl sulfoxide (DMSO)
• Biotin-PEG-SH
• 11-Mercapto-1-undecanol
• Streptavidin
• Biotin
• β-amyloid peptide (1-40)
• Biotin labeled β-amyloid peptide (1-40)
• Low ionic strength buffer (25 mM TRIS,  
  1 mM EDTA, pH 8.0)
• High ionic strength buffer (25 mM TRIS,  
  150 mM NaCl, pH 7.0)
• Dynamic Light Scattering (DLS)
• Gold sensor slides (Thickness of Au layer  
  50 nm)
• MP-SPR 200TM instrument with 670 nm  
  and 785 nm excitation wavelengths
• SPR NaviTM Data Viewer 4.0 software
• TraceDrawer 1.6 software
• SPR Navi LayerSolver 1.0.2 software
• OriginPro 8.6 software
• Autodock Vina 1.1.2 software
• GROMACS 5.0.4 software
• Automated Topology Builder server v. 2.2
• VMD software
• Solvent
• Solvent
• Self-assembled monolayer  
  component
• Self-assembled monolayer  
  component
• Biosensor development
• Reference compound
• Investigation of Aβ aggregation
• Investigation of Aβ aggregation
• Monomer peptide preparation
• Oligomer peptide preparation
• Particle size analysis
• Biosensor development
• Next-generation SPR system
• Data analysis
• Data analysis; kinetics evaluation
• Data analysis; layer  
  characterization
• Data analysis
• Molecular docking simulations
• Molecular dynamics simulations
• Molecular dynamics simulations
• Visualization of simulation results
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III
• Laser Tweezers Raman Spectroscopy  
  system (home-built) at 785 nm excitation  
  wavelength
• Cell culturing using cell lines; Human  
  lung carcinoma (A549), Human  
  hepatocarcinoma (Hu-7), Mouse  
  embryonic fibroblast (3T3), Human 
  lung normal fibroblast (IMR90), Human  
  ovarian carcinoma (SKOV3), Human acute 
  T-cell leukaemia (Jurkat),  Human acute  
  myeloblastic leukaemia (Kasumi-1),  
  Human prostate cancer (LNCaP)
• Total Exosome Isolation Reagent
• Differential centrifugation
• Trypsin treatment
• Size-exclusion chromatography
• Transmission electron microscopy (TEM)
• Immunoblot analysis
• Nanoparticle tracking analysis (NTA)
• Zetasizer Nano Z
• MATLAB® software 
• Laser trap system for Raman  
  spectroscopy
• Sources for extracellular vesicles  
  (total 8 different types)
• Exosome isolation; commercial  
  precipitation reagent as a chemical 
  method
• Exosome isolation; physical  
  method
• Cleavage of EV surface membrane  
  proteins
• Purification of trypsin-treated EVs
• EV characterization; shape
• Confirm EV isolation and digestion  
  of EV surface proteins by trypsin
• EV characterization; size  
  distribution and confirmation of  
  nanoparticle contamination
• Zeta potential measurements for  
  EVs
• Data analysis
IV
• Undiluted (100%) serum; 7 healthy and  
  fasted donors
• FLIR TG165 imaging IR thermometer
• Liposome samples; Replicas of the  
  Doxil© formulation with and without PEG  
  (DOX+PEG and DOX), Positively charged  
  liposomes with oligo-guanidyl lipid  
  derivative (OGD), In situ PEG-coated OGD 
  liposomes (OGD+PEG)
• Human native complement component  
  C3b
• Limulus Amoebocyte Lysate (LAL) assays 
• Zetasizer APS DLS
• Zetasizer Nano ZS
• MP-SPR 200TM instrument with 670 nm  
  and 785 nm excitation wavelengths
• Gold sensor slides (Thickness of Au layer  
  50 nm) with 6 kDa thin carboxymethyl  
  dextran hydrogel layer functionalized with 
  dodecyl lipid anchors
• SPR Navi LayerSolver 1.2.1 software
• SPR NaviTM Data Viewer 4.0 software
• TraceDrawer 1.6 software
• Origin Pro 8.6 software
• Interaction studies with surface- 
  immobilized model liposomes
• Heat homogeneity monitoring of  
  serum samples
• Model liposomes for surface  
  immobilization and investigation  
  of the nano-bio interface using  
  undiluted serum in flow conditions   
  (i.e. biomimetic environment
• For studying kinetic behavior with  
  model liposomes
• Endotoxin detection
• Physicochemical characterization  
  of liposomes; hydrodynamic  
  diameter
• Physicochemical characterization  
  of liposomes; surface charge
• Next-generation SPR system
• Biosensor development; for  
  immobilizing model liposomes
• Data analysis; layer  
  characterization
• Data analysis
• Data analysis; interaction kinetics
• Data analysis
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11 (I) Fluorescence-Suppressed Time-Resolved 
Raman Spectroscopy of Pharmaceuticals Using 
Complementary Metal-Oxide Semiconductor 
(CMOS) Single-Photon Avalanche Diode (SPAD) 
Detector
Adapted from (License CC BY-NC 4.0): Rojalin T, Kurki L, Laaksonen T, 
Viitala T, Kostamovaara J, Gordon KC, Galvis L, Wachsmann-Hogiu S, 
Strachan CJ, Yliperttula M. Fluorescence-Suppressed Time-Resolved 
Raman Spectroscopy of Pharmaceuticals Using Complementary Metal-
Oxide Semiconductor (CMOS) Single-Photon Avalanche Diode (SPAD) 
Detector. Analytical and Bioanalytical Chemistry 408: 761-774, 2016. 
Copyright © 2015 Rojalin T. et al. http://dx.doi.org/10.1007/s00216-015-9156-6
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Abstract In this work, we utilize a short-wavelength, 532-nm
picosecond pulsed laser coupled with a time-gated comple-
mentary metal-oxide semiconductor (CMOS) single-photon
avalanche diode (SPAD) detector to acquire Raman spectra
of several drugs of interest. With this approach, we are able
to reveal previously unseen Raman features and suppress the
fluorescence background of these drugs. Compared to tradi-
tional Raman setups, the present time-resolved technique has
two major improvements. First, it is possible to overcome the
strong fluorescence background that usually interferes with
the much weaker Raman spectra. Second, using the high pho-
ton energy excitation light source, we are able to generate a
stronger Raman signal compared to traditional instruments. In
addition, observations in the time domain can be performed,
thus enabling new capabilities in the field of Raman and
fluorescence spectroscopy. With this system, we demonstrate
for the first time the possibility of recording fluorescence-
suppressed Raman spectra of solid, amorphous and crystal-
line, and non-photoluminescent and photoluminescent drugs
such as caffeine, ranitidine hydrochloride, and indomethacin
(amorphous and crystalline forms). The raw data acquired by
utilizing only the picosecond pulsed laser and a CMOS SPAD
detector could be used for identifying the compounds directly
without any data processing. Moreover, to validate the accu-
racy of this time-resolved technique, we present density func-
tional theory (DFT) calculations for a widely used gastric acid
inhibitor, ranitidine hydrochloride. The obtained time-
resolved Raman peaks were identified based on the calcula-
tions and existing literature. Raman spectra using non-time-
resolved setups with continuous-wave 785- and 532-nm
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excitation lasers were used as reference data. Overall, this
demonstration of time-resolved Raman and fluorescence mea-
surements with a CMOS SPAD detector shows promise in
diverse areas, including fundamental chemical research, the
pharmaceutical setting, process analytical technology (PAT),
and the life sciences.
Keywords Raman . Time resolved . CMOSSPAD .
Pharmaceuticals . Fluorescence suppression . Process
analytical technology (PAT)
Introduction
Raman spectroscopy is beneficial for diverse types of quanti-
tative and qualitative analyses in fundamental chemical re-
search [1], life sciences [2, 3], and pharmaceutical research
and development, for example during dosage form
manufacturing, storage, and administration [4, 5]. Other dis-
ciplines include material analysis and mineralogy. However,
major limitations to its use have included photoluminescence
frequently masking the Raman signal [6], weak Raman scat-
tering, and insufficiently sensitive detectors. Some of these
problems have been resolved with improvements in hardware,
such as the development of efficient, low-noise, silicon-based
array detectors, stable high-power diode lasers, and high-
resolution spectrometers [7]. Thus, Raman has becomewidely
applied in both basic and applied chemistry. Despite the sig-
nificant technical advances, the weak signal and simulta-
neous ly s t rong ly in t e r f e r ing background f rom
photoluminescence are still hindrances in Raman spectrosco-
py. This is particularly problematic in the biomedical, life
science, and pharmaceutical settings where the analysis of
biological samples and drug molecules typically suffers from
strong photoluminescence backgrounds. At the same time,
there is an unquestionable need for label-free technologies
with sufficient temporal resolution for the detection of in situ
real-time phenomena. Such measurements include, for exam-
ple, phase transformation analysis of various drugs and exper-
iments with living cells [8].
The photoluminescence (PL) phenomena can be divided
into various types according to the specific molecular relaxa-
tion sequences that take place after the absorption of an inci-
dent photon [9]. However, fluorescence is usually the main
component of photoluminescence and also the one that over-
laps spectrally with the Raman spectrum, making it very dif-
ficult to remove from Raman measurements. Strong fluores-
cence is typically created in conjugated double bonds and
polycyclic aromatic rings, which are common structures in
many drugs and biological molecules. This fluorescence fre-
quently occurs on the same wavelength range as the Raman
fingerprint in a given experiment, and as fluorescence is usu-
ally a much stronger phenomenon, it can completely
overwhelm the Raman signal. The means to alleviate this
fluorescence problem in Raman spectrometry can be essen-
tially divided into continuous-wave (CW) and time-resolved
approaches. In addition, various algorithm-based methods re-
lying on the spectral post-processing have been introduced. In
order to clarify why these methods are typically used, several
statements related to photochemical and physical mechanisms
of photoluminescence phenomena are needed. Herein, we as-
sume that a laser with the center wavelength λL is used as the
excitation source. Firstly, the Raman phenomenon is an inelas-
tic scattering process present at all excitation wavelengths,
whereas fluorescence requires a nonzero electronic molecular
absorption coefficient at λL. The intensity of Raman scattering
is approximately proportional to 1
λ4L
. Thus, as a rule of thumb,
shorter wavelength lasers give rise to stronger Raman signal
intensities. Secondly, the spectral shape of fluorescence from a
collection of identical fluorophores is independent of λL while
the Raman spectrum as a whole is moved to shorter or longer
wavelengths along with the excitation. Thirdly, the temporary
storage of energy within the molecule after the absorption and
relaxation processes entails a characteristic statistical average
delay (having an exponential distribution with a certain expec-
tation value) before the emission of a fluorescence photon.
This is manifested as the fluorescence Btail^ after a short ex-
citation pulse. Theoretically, Raman scattering is an instanta-
neous process, and it does not involve such delays. However,
significant temporal broadening can be observed, which oc-
curs in thick scattering samples; it could be so that the analyte
molecules deeper in the sample will interact with the excita-
tion photons even hundreds of picoseconds later than the mol-
ecules on the surface [10, 11]. Methods to determine the decay
rate of Raman scattering have also been introduced [12]. It
turns out that the time dimension provides, in a sense, the most
general way to deal with fluorescence in Raman spectrometry.
In the following, the CW and time-resolved approaches are
briefly described.
In 1976, Funfschilling and Williams resolved the
fluorescence-related problems for the first time [13]. They
exploited the previously known method of phase sensitive
detection that had been effectively applied in nuclear magnetic
resonance (NMR), electron paramagnetic resonance (EPR),
and photoelectron spectroscopy. The common basis for those
methods was to shift the signals of interest away from the
interfering background. Thus, by modulating the Raman ex-
citation wavelength, the Raman signal could be recovered
from the overlapping fluorescence signal. Later on, a wave-
length differential technique was developed and became
known as shifted excitation Raman difference spectroscopy
(SERDS) [14]. To some extent, differential techniques are
applicable to separate fluorescence and Raman signals [15].
Noteworthy approaches include frequency and polarization
modulations. The advantage of these differential methods lies
in the possibility to separate the non-shifted continuous-
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wavelength (CW) fluorescence and Raman signals in a quan-
titative way. However, in general, these techniques have their
limitations, for example acquiring two separate spectra for
post-processing in order to resolve the Raman signals.
Since the Raman intensity is proportional to the fourth
power of the excitation laser’s frequency, the shorter wave-
length (i.e., higher frequency) lasers give rise to a stronger
Raman signal intensity. However, increasing the excitation
photon energy increases also the likelihood of a sample to
contain electronically excitable chromophores, each one of
which may contribute to fluorescence. Conversely, decreasing
photon energy decreases the number of such chromophores.
Using λL in the NIR range (typically 785–1064 nm) often
makes the fluorescence-to-Raman signal ratio decrease mark-
edly or even vanish. FTIR-Ramanmay be considered the gold
standard here. The downsides include the required detector
technology (e.g., InGaAs) having a high dark current, which,
combined with low Raman efficiency, leads to a reduced
signal-to-noise ratio (SNR) [16]. The required high laser pow-
ers can also lead to sample damage and destruction by heating.
Using λL in the UV range (<400 nm) has two advantages:
Raman efficiency is high and while fluorescence might be
present, it resides in the longer (VIS) wavelengths and thus
does not overlap with the Raman spectrum. However, the
phenomenon that UV excited Raman does not suffer from
fluorescence since it occurs in a different wavelength range
is only true for excitation wavelengths in the deep UV below
260 nm. The downsides include the generally increased diffi-
culty in making optics, lasers, detectors, and high-resolution
spectrographs for UV, along with the sample degradation due
to high photon energy compared to the VIS range [7]. Using
algorithms solely without any instrument-based means to sub-
tract the fluorescence background also has drawbacks. For
instance, even though the fluorescence profile of the measured
sample is relatively recognizable and smooth, a subtraction
algorithm produces only an estimate on fluorescence; relevant
spectra features may be subtracted, thus biasing the result.
Moreover, an additional problem with subtracting fluores-
cence is that the shot noise will remain. Finally, using
photobleaching as a means to exterminate the fluorescence-
generating chromophore groups of the molecules can be slow
and cause physical changes like burning to the samples. In
addition, photobleaching is not a suitable technique for living
organism- and cell-based assays.
Next, we consider the time-resolved approach to Raman
spectrometry. Several different types of time-gated Raman
systems has been demonstrated, among others those based
on an intensified charge-coupled device (ICCD) [17], a streak
camera, and an optical Kerr gate [18]. The ICCD can reach
<100 ps time gate width, and the full optical Kerr gate, com-
bined with a suitable laser, can reach time resolution of a few
picoseconds or better. The main drawbacks of these systems
compared to the current system based on a complementary
metal-oxide semiconductor (CMOS) single-photon avalanche
diode (SPAD) matrix and microchip laser are related to the
inherent complexity, bulkiness, and/or cost. Instead, the tech-
nology at hand in principle enables the development of robust,
compact, and affordable time-gated Raman spectrometers
with <100 ps time resolution. This follows from the facts that
the CMOS SPAD detector does not require extreme cooling
unlike scientific CCDs, and the laser technology is also poten-
tially compact. Therefore, this technology offers great promise
as practical instrumentation and replacement of CW Raman
systems not only in the field of pharmaceuticals but also in
general.
A schematic temporal shape of a Raman band with a PL
background is shown in Fig. 1. The curves represent schemat-
ically the time evolution of the Raman, PL, and total emission
intensity following an incident excitation pulse. The elastic
part (Rayleigh scattering and Fresnel reflection) has not been
depicted. As mentioned before, the Raman process differs
from the luminescence mechanisms with respect to the nature
and magnitude of the associated delays between photon inci-
dence and emission. The typical time scales for Raman are in
the sub-picosecond to picosecond range [12, 19], whereas
those of fluorescence (the fastest spontaneous PL process)
are in the 10-ps to 100-ns range [9]. Thus, if we take the laser
pulse width Δt=150 ps, the shape of the depicted Raman
pulse is very close to that of the excitation pulse apart from
a scaling factor. Using a fast photodetector such as a SPAD,
one can choose to record only the part of the emission pulse
containing the Raman pulse, in other words rejecting the PL
tail. Essentially, the associated photon noise is also rejected—
and this is the one fundamental advantage of a time-resolved
Raman measurement over any possible CW Raman measure-
ment, including differential techniques [20]. However, careful
inspection of Fig. 1 and the actual measurement data shows
that with our 150-ps excitation pulse, some luminescence is
emitted already during the pulse. This part of the PLwe hence-
forth call residual fluorescence (RFL). These issues will be
discussed in more detail later in this article.
In the present study, we demonstrate for the first time the
use of a novel detector system based on CMOS SPAD tech-
nology for the study of several pharmaceutical compounds.
Here, we utilize the power of combining a picosecond pulsed
laser with the time-resolved detection system to efficiently
reject the fluorescence and record detailed Raman spectra for
those compounds. Using a fast CMOS SPAD detector, we are
able to choose and to record only the part of the emission pulse
containing the Raman scattering by rejecting the fluorescence
tail. The drug molecule response is recorded during the short
laser pulses, and the CMOS SPAD detector is synchronized
with the laser pulse. However, typically, a part of fluorescence,
RFL, temporally overlaps the Raman signal and cannot be
rejected by time gating. To overcome the RFL, we present a
convenient algorithm to enhance the accuracy of acquired
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Raman spectra. We use a time-gated Raman to measure the
Raman spectra of four pharmaceutical compounds. These
were selected to include caffeine, as an easy reference com-
pound; ranitidine HCl as a previously less studied and difficult
compound; and indomethacin in both amorphous and crystal-
line forms, as particularly difficult ones suffering from strong
fluorescence issues. The capabilities of the new setup were
explored and compared to a conventional CW Raman
instrument.
Materials and methods
Materials The studied drugs were caffeine anhydrate (Orion
Pharma, Helsinki, Finland), ranitidine hydrochloride poly-
morphic form II (Hawkins Pharmaceutical Group,
Minnesota, USA), and indomethacin (crystalline γ-form,
Hangzhou Dayangchem, China). The molecular structures of
the studied compounds are presented in Table 1. Amorphous
indomethacin was prepared by heating the crystalline powder
in an aluminum dish for ∼15 min. All the other chemicals
were measured as received. In conventional Raman measure-
ments, the compounds were measured in sample holders with
the powdered drug layer height of approximately 2 cm. In the
time-resolved Raman measurements, a smaller amount of
drug (approximately 100–200 mg) was placed onto a sample
holder. The laser beam was directed onto the samples from
above with both setups.
Ramanmeasurements at 785 nm The Ramanmeasurements
at 785 nm were performed using a CW Raman RXN1-PhAT-
785-D-laser Invictus 785 nm (Kaiser Aerospace & Electronics
Company, USA). The probe was PhAT System Probehead
(Kaiser Optical Systems, Inc., USA), with collimated incident
radiation and a sampling diameter of approximately 6 mm.
The average laser power on the sample was ∼20 mW. The
detector was a charge-coupled device (CCD), 1024×256
EEC MPP Type (Kaiser Optical Systems, Inc., MI, USA)
cooled to −70 °C. The measurements were performed at am-
bient temperature and humidity, with dark background sub-
traction. Raman shift calibration was performed using cyclo-
hexane. The CW 785-nm Raman spectra presented in this
paper are an average of ten scans, each with an acquisition
time of 3 s and a spectral resolution of approximately 4 cm−1.
Raman measurements at 532 nm A continuous excitation
laser beam was focused down to a micrometer-sized spot on
standard substances through a confocal Ramanmicroscope. A
frequency doubled Nd:YAG, 532 nm linear polarized excita-
tion laser (∼20 mW) was used in combination with ×20
(Nikon, NA 0.40) and ×10 (Nikon, NA 0.25) microscope
objectives. The spectra were acquired using a CCD camera
(Andor Newton DU970-BV, Andor Technology plc, Belfast,
UK) behind a grating (600 g mm−1) spectrograph with a spec-
tral resolution of 2–3 cm−1. Integration times of the signal
were 0.5, 1, 2, and 5 s.
Time-gated picosecond Raman The time-resolved measure-
ments were performed using a laboratory setup with the fol-
lowing specifications: The excitation source was a custom-
made 532-nm Nd:YVO microchip pulsed laser. The average
power used was 14 mW, repetition rate 40 kHz, pulse width
150 ps, focus diameter 50 μm, pulse energy 0.35 μJ, peak
power 2 kW, and maximum irradiance 28 MW cm−2. To
Fig. 1 Schematic representation
of the laser excitation, Raman,
and photoluminescence signals
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alleviate photobleaching effects, the focal point was periodi-
cally moved over an area of about 1 mm2 by utilizing a
custom-made galvo-mirror arrangement. The spectrograph slit
was 50 μm, with ×1.7 magnification, 3.4 nm mm−1 disper-
sion, and about 13 cm−1 spectral resolution. The detector was
the 128×8 CMOS SPAD matrix detector developed by
Kostamovaara’s group in the University of Oulu. The detector
accumulates single-photon events in an internal time histo-
gram consisting of four bins. Only one of these bins was used
as the Btime gate^ in the data analysis presented below. The
instrument response function (IRF) is dominated by the laser
pulse shape, SPAD response shape, and time gate width of the
electronic width generator. The FWHM of the IRF, which is a
measure of the system’s time resolution, was approximately
250 ps. This approximation has been demonstrated earlier in
the literature [16]. The time-resolved spectral datasets were
collected by sequentially moving the gate in 50-ps steps using
the electronic delay generator. The data acquisition and setup
control was maintained by a digital microchip, field-
programmable gate array (FPGA). Data acquisition software
and setup control were carried out by in-house programs,
which were coded using LabVIEW (National Instruments
Corporation, TX, USA) language. The data was processed
and 3D graphics were plotted using Matlab (MathWorks,
MA, USA). The measurements were performed at ambient
temperature and humidity, and spectra were the sum of 1.2×
108–1.7×109 pulses corresponding to overall measurement
times in the range of 1–12 h. The signal level (counts/laser
pulses/pixel) was kept at the suitably low level of a few per-
cent at maximum to avoid signal distortion by photon
counting pile-up effects. It is to be noted that the acquisition
of a time-gated Raman spectrum alone, without the need to
collect the whole temporal shape using a 50-ps step size, can
be done in a fraction of the timementioned above, for instance
in the order of minutes or seconds. In future versions of the
hardware, larger detectors and adjustable laser repetition rates
enable bringing the measurement times to a level that is prac-
tical in even field and industrial process applications. The
schematic illustration of the Raman and fluorescence events
is presented in Fig. 1.
Residual fluorescence background subtraction The RFL
subtraction was performed by assuming that the fluorescence
is the only contributing factor in the Bvalleys^ of the time-
resolved Raman spectra. That signal can then be used to esti-
mate the contribution of fluorescence to the signal intensity in
the same time range as the Raman scattering (i.e., where the
Raman peaks occur). Unfortunately, the acquired Raman data
can be difficult to use for this, as the valleys are at varying
heights due to baseline shift and no simple control value can
be chosen. In order to get data to be internally comparable, the
whole Raman spectrum was first baseline corrected at each
Table 1 The chemical structures and physical characteristics of the studied compounds
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time step using a built-in function (msbackadj) of Matlab.
Next, a control value was chosen as the control valley area
where it was assumed that the signal is pure fluorescence with
no Raman scattering. For better representation of fluores-
cence, an average signal from three adjacent wavenumber bins
was used. The pure Raman spectra were obtained by eliminat-
ing the amount of fluorescence by subtracting the control val-
ley from the overall time-resolved response signal.
Fluorescence decay estimations The fluorescence decay es-
timations were performed assuming that the tested compounds
do not have multiple fluorescent components. Thus, a single-
exponential decay model, which fits well for gross estimations
performed herein, was chosen for the fluorescence decay es-
timations. Furthermore, the fluorescence decay estimations
were based on the assumption that there is only negligible
delay between photon absorption and the molecule’s relaxa-
tion to the lowest vibrational level in the first excited electron-
ic state before transitioning to the electronic ground state by
emitting a photon (fluorescence) and non-radiatively (internal
conversion) with the rate constants kF and knr, respectively.We
used a single-exponential decay model based on Eqs. (1) and
(2):
N tð Þ ¼ N0e− k Fþknrð Þt; ð1Þ
in which N0 is the population of excited molecules imme-
diately after a very short (delta function) laser pulse.
ΦF tð Þ ¼ k FN tð Þ; ð2Þ
in which ΦF is the instantaneous fluorescence intensity
(photons per unit time) at time t. The overall response function
of the instrument is essentially a convolution of the shape of
the laser pulse, the IRF, and the exponential decay shape that
is described by the characteristic photoluminescence behavior
of the sample. To perform the fluorescence decay time esti-
mations for the samples, single-exponential fitting was done
to the tail part of the collected data using Eqs. (1) and (2),
where applicable. Ideally, the influence of the laser pulse
and IRF would be differentiated from the exponential part.
However, instead of attempting a de-convolution process to
separate the exponential part from the effect of the laser pulse
and IRF, estimates of the prospective error were performed
with approximate simulations that are described in the
BDiscussion^ section.
Quantum chemical calculations Density functional theory
calculations were performed for vibrational mode assignment
of the ranitidine HCl spectra (modeled as ranitidineH+).
Molecular optimization and vibrational frequency calculations
were performed with Gaussian 09 [21] software using density
functional theory (DFT), and the B3-LYP functional with the
6-31G(d) basis set. The predicted vibrational modes were
scaled with the recommended factor of 0.9614 [22] using
GaussSum 2.2 [23] software and visualized using
GaussView (v. 5.0, Gaussian, Inc. Wallingford, CT, USA).
Results
CWRamanmeasurements at 785 and 532 nm The conven-
tional CW Raman spectra of the model drugs were measured
in the region 800–1800 cm−1. This spectral range encom-
passes the informative Raman features in both the fingerprint
and group frequency regions. The CW Raman spectra are
shown in Fig. 2A–H. In the Electronic Supplementary
Material (ESM) Tables S1–S4, the Raman peaks for every
drug are assigned between 800 and 1800 cm−1, based on the
quantum chemical calculations published previously or per-
formed in this study. In the tables, selected peaks are assigned
for CW non-time-resolved measurements and time-resolved
measurements. The spectra have been normalized from 0 to 1,
and in order to represent raw spectra, they have not been
smoothed.
Panels A and B of Fig. 2 show the Raman spectra of caf-
feine for CW 785-nm excitation source and CW 532-nm ex-
citation source, respectively. Very low fluorescence intensity
can be observed, and the Raman peaks can be easily recog-
nized. Panels C and D of Fig. 2 show the acquired CW 785-
and 532-nm Raman spectra for ranitidine hydrochloride. A
relatively large fluorescence background hampers the inter-
pretation of both, and only a handful of weak Raman peaks
really stand out. In Fig. 2E, F, for the crystalline form of
indomethacin, a fluorescence background is present, but ob-
servable Raman peaks can be separated with both setups.
Using the CW 785-nm excitation source for amorphous indo-
methacin, Fig. 2G, does not show any spectral details as fluo-
rescence dominates the whole spectrum. As observed in
Fig. 2H, the experiment with the CW 532-nm setup reveals
more interpretable spectral features.
On the basis of these CW measurements, all the samples
had undef ined background increase , ind ica t ing
photoluminescence, except for caffeine. Using the CW 785-
nm setup, the most fluorescent sample appears to be amor-
phous indomethacin, followed by ranitidine hydrochloride
and gamma crystalline indomethacin. However, with the
CW 532-nm instrument, the most fluorescent drug is
Fig. 2 The Raman spectra obtained using the CW 785-nm Raman
spectrometer for caffeine (A), the CW 532-nm Raman spectrometer for
caffeine (B), the CW 785-nm Raman spectrometer for ranitidine
hydrochloride (C), the CW 532-nm Raman spectrometer for ranitidine
hydrochloride (D), the CW 785-nm Raman spectrometer for crystalline
indomethacin (E), the CW 532-nm Raman spectrometer for crystalline
indomethacin (F), the CW 785-nm Raman spectrometer for amorphous
indomethacin (G), and the CW 532-nm Raman spectrometer for
amorphous indomethacin (H). All spectra are normalized from 0 to 1
b
T. Rojalin et al.
92
Fluorescence-suppressed time-resolved Raman spectroscopy
93
ranitidine hydrochloride, followed by amorphous indometha-
cin and then gamma crystalline indomethacin.
Time-resolved Raman measurements The time-resolved
spectra for the model drugs are represented in Fig. 3A–D. In
the panels, black lines correspond to acquired raw data, blue
spectra represent the baseline- and photoluminescence-
corrected data, and the 3D representations show the evolution
of the measured signal in time dimension. The measurement
region was 800–1800 cm−1. The time-resolved spectra
(Fig. 3A–D) were recorded separately for the regions 800–
1300 and 1300–1800 cm−1. The reason for this is related to
the length difference between the detector array and the spec-
trum produced by the spectrograph in the current setup. The
spectra have not been smoothed.
Figure 3A illustrates the time-resolved Raman spec-
trum for caffeine. Very little fluorescence is observed.
However, for ranitidine HCl and both forms of indo-
methacin (Fig. 3B–D), the fluorescence background is
substantially reduced, and more Raman details in the
spectra can be seen. As described earlier in this text,
the residual fluorescence (RFL) can be subtracted with
simple data manipulation. This is demonstrated below for
amorphous indomethacin as an example. Figure 4A, B
illustrates the acquired raw data. In the next step, the
baseline correction is performed, as shown in Fig. 4C,
D. A control valley at 1056 cm−1 was chosen as the
control area where it is assumed that the signal is pure
fluorescence with little or no Raman photons. As the
shape of the fluorescence does not change much in time,
the contribution of this control valley was subtracted
from the overall response signal, Fig. 4E, F. The method
was able to isolate the Raman peaks, as the 3D spectrum
is now homogenously flattened everywhere except the
Raman peak areas. In particular, the region between
950 and 1250 cm−1 becomes clear with this treatment
and four strong and sharp Raman peaks can be easily
seen. The estimated decay time for the control valley
was the same as the decay time estimated for the raw
data. Therefore, the spectral treatment was able to pre-
serve the shape of the fluorescence signal and to isolate
the fluorescence free time-resolved Raman response. In
summary, this straightforward data processing enhances
the interpretation possibilities even further, as the blue
spectra show in Fig. 3A–D.
With the present CMOS SPAD detector, three different
factors are simultaneously defined: the time distribution of
detected photons (Fig. 3A–D: the 3D panel representations;
time axis), the photon intensity (Fig. 3A–D: the 3D panel
representations; intensity axis), and the energies of photons
that arrive at the detector (Fig. 3A–D: the 3D panel repre-
sentations; wavenumber axis). Thus, an informative repre-
sentation of photon distribution is obtained as represented
in the panels. The 3D representations show the exact
starting point of the increase in Raman signal immediately
after the laser pulse, as well as the fluorescence rise and
decay. For example, in Fig. 3D for amorphous indometha-
cin, in the time domain, the maximum signal from Raman
scattering occurs shortly after the laser shot (yellow- and
red-colored peak regions). Moreover, the fluorescence ap-
pears to start dominating the response signal at ca. 2.5 ns
(blue, decaying slope). It is worth stressing that in the case
of relatively thick scattering samples, temporal broadening
of Raman signals may have contribution to the time at
which the fluorescence starts dominating the response sig-
nal [10, 11]. Importantly, this is a sample-specific phenom-
enon and depends on the sample’s fluorescence. The time-
domain analysis can be utilized to estimate the fluorescence
decay times, which we introduce in the BDiscussion^ sec-
tion. Another observation that can be made in the spectra
of Figs. 2 and 3 is that the shape of the fluorescence back-
ground is negative for the measurements recorded with CW
785-nm excitation, changing to a positive slope in the time-
resolved measurements. This effect can be attributed to the
different excitation wavelength and to the fact that the NIR
experiment is performed at the edge of the sensitivity curve
of the CCD detector.
Discussion
Fluorescence rejection with the pulsed picosecond laser
and the CMOS SPAD detector
The time-resolved setup used in this study has a 532-nm
pulsed laser, and it is combined with the CMOS SPAD
detector having relatively fast electronic gating possibility
to temporally resolve the Raman spectrum from the fluo-
rescence background. An example can be seen with the
amorphous form of indomethacin, which is yellow in col-
or. With the non-time-resolved CW 785-nm setup, it was
not possible to detect any Raman peaks due to the fluo-
rescence, and another CW 532-nm instrument had to be
used to acquire interpretable Raman spectrum. With the
time-resolved CMOS SPAD system, the analysis could
be conveniently done at once for all the model
Fig. 3 Time-resolved Raman spectra. Panels represent the 2D,
traditional Raman spectra (left) and the 3D spectra (right). The 2D plots
are reconstructed from two separate measurements after normalization of
the data. The vertical line separates the two measurements. The acquired,
unprocessed raw data is shown in the 3D plots to give a clear view of the
events in the time domain after the laser pulse; the initial rise of signal
after the laser pulse consists mainly of Raman scattering, and the settling
of the signal consists of the decaying fluorescence signal. The drugs
shown in the panels are A caffeine, B ranitidine hydrochloride, C
indomethacin (crystalline), and D indomethacin (amorphous)
b
T. Rojalin et al.
94
Fluorescence-suppressed time-resolved Raman spectroscopy
95
compounds. Furthermore, the other benefits of Raman
spectroscopy, such as minimal sample preparation, signifi-
cant amount of chemical information, and lack of sensitiv-
ity to sample water content, are preserved. Combined with
the fluorescence-suppressed Raman spectra, the time-
domain studies could be a useful tool in Raman spectros-
copy to evaluate various changes in a system such as
phase transitions or changes in the chemical content of
the medium in cell cultures. At the end of this discussion,
we preliminarily address the potential of exploiting the
time-dimension analysis parallel to the fluorescence-
suppressed Raman data. The effect of time resolution is
shown in Fig. 3; the spectra are shown as 2D and 3D
representations. The 2D spectra represent the spectrum
with the highest Raman scattering intensity collected after
the laser shot, i.e., it corresponds to one specific time
point in the 3D spectrum. This is close to the CW
Raman spectra in appearance (Fig. 2), and in terms of
signal-to-noise ratio, it is clearly better. On the other hand,
if one is interested in the Raman and fluorescence signals’
time evolution, the 3D data show the stack of spectra
from moments before the emission pulse, the rise of
Raman and fluorescence signals, and the decay of fluores-
cence. Further spectral treatments with simple algorithms
can be used to fully eliminate the contribution of residual
fluorescence (Fig. 3: BL- and PL-corrected data, Fig. 4)
from the time-resolved spectra. It is noteworthy that the
time-resolved raw spectra alone are able to show Raman
details on all the tested compounds. This makes the in-
strument potentially able to, for example, identify
Fig. 4 Acquired Raman data
from amorphous indomethacin
(A, B), baseline-corrected data
(C, D), and fluorescence-
subtracted data (E, F). Panels on
the left illustrate the intensity vs.
time measurements for each
wavenumber shown as a 3D
stack. Panels on the right are also
the top views
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compounds or different solid-state forms. However, in ac-
curate quantitative analysis, the algorithm-treated data can
be more useful.
Analysis of the measured drugs—new possibilities
with the time-resolved Raman
The Raman shifts for selected peaks from the CW 785-nm,
CW 532-nm, and the time-resolved spectra are shown in ESM
Tables S1–S4. For all crystalline samples, the band positions
are in close agreement. Raman band assignments have been
previously published using DFT calculations for caffeine and
crystalline and amorphous indomethacin, and these are also
included in ESM Tables S1, S3, and S4. Computational
chemistry-based band assignments have not previously been
published for ranitidine hydrochloride, and thus, density func-
tional theory calculations have been included in this study
(modeled as ranitidineH+) and prominent bands assigned in
ESM Table S2, together with their corresponding eigenvector
diagrams in ESM Fig. S2.
Although the thermodynamically stable crystalline forms
of drugs are most commonly used in solid dosage forms, dis-
ordered amorphous forms of poorly soluble drugs, such as
indomethacin, are of much interest to the pharmaceutical in-
dustry as a means to increase their apparent solubilities and
associated dissolution rates. The time-resolved setup is capa-
ble of revealing the fine structure of both forms, whereas with
the CW non-time-resolved instruments, obtaining Raman
spectra for both forms was more arduous. This is of utmost
importance in the pharmaceutical setting where discrimination
between crystalline and amorphous forms of substances is
required in order to determine phase transitions or ratios of
the two forms in a mixture. Moreover, as the time-resolved
setup was able to reveal even subtle Raman spectral features,
differentiation between solid-state forms of compounds can be
made with this novel Raman system. In the following section,
we discuss in more detail the band assignments for the model
drugs and describe in conceptual level some benefits that the
detailed Raman spectra can offer in pharmaceutical formula-
tion and processing contexts, as well as the novelty value of
these Raman measurements compared to traditional methods
and instruments.
Caffeine (1,3,7-trimethylpurine-2,6-dione) Caffeine is a
well-known central nervous system stimulant, found in many
dietary products and occasionally used to stimulate the cardiac
and bronchial systems. Caffeine is sensitive to polymor-
phism—and, from a pharmaceutical point of view, is an inter-
esting compound for closer examination due to the fact that
different polymorphs have potentially varying physicochemi-
cal properties as well as pharmacological activities [24]. For
caffeine, both experimental and computational Raman data
are well established; Fig. 2A, B; Fig. 3A; and ESM Table S1
show the measured Raman spectra and band assignments for
caffeine, respectively. In the present study, caffeine was cho-
sen to act as an easily measured reference drug. As expected,
spectra acquired byCWand time-resolved setups clearly show
the bands, and the peaks are in accordance between the instru-
ments and with the DFT-based calculated values that can be
found in the literature [24, 25]. The contributions from C–C,
C–N, C=N, and C=O bonds can be easily used in, e.g., che-
mometric analysis.
Ranitidine HCl (N-[2-[[[5-[(dimethylamino)methyl]-2-
furanyl]methyl]thio]ethyl]-N-methyl-2-nitro-l, l-
ethenediamine hydrochloride) Ranitidine HCl is a widely
used gastric acid inhibitor, acting as an H2 receptor antagonist.
Ranitidine HCl has two major polymorphs, form I and form II
[26]. Different solid-state forms or polymorphs of the same
compound exhibit different pharmaceutically important phys-
ical properties such as crystal habit (morphology), melting
point, and aqueous solubility. Therefore, identification and
characterization of the solid-state forms is important. In the
case of ranitidine HCl, form II exhibits favorable filtration and
drying characteristics over form I due to morphological differ-
ences, and this practical advantage was the basis for its much
disputed patent upon its serendipitous discovery by Glaxo
Group Ltd in 1981. Part of the patent disputes focused on
difficulties in analysis of the solid-state forms. Raman spec-
troscopy has since been shown to be a convenient technique
for this purpose [27]. Here, we present for the first time the
quantum chemical calculations to determine Raman peaks for
ranitidine HCl. On the basis of computational chemistry we
performed, the furan ring and CH2 (1170 cm
−1), the CH2
groups (asymmetric rock at 1254 cm−1 and wag 1301 cm−1),
furan (symmetric stretch at 1533 cm−1), and the CH2SCH2
group (symmetric wag at 1276 cm−1) contribute to the
Raman spectrum of ranitidine HCl. According to Fig. 2C, D;
Fig. 3B; and ESM Table S2, the CW 785-nm Raman system
has very limited capability to resolve interpretable peaks,
whereas the CW 532-nm and the time-resolved CMOS
SPAD instruments accomplish better to provide peaks that
are relatively well in line with the DFT calculated values.
However, these observations begin to show the limitations
of conventional CW Raman setups; one has to rely on
multiple-wavelength systems to measure various samples,
which is not often feasible or even possible. Interestingly,
the Raman peak at 1185 cm−1 has been evaluated to be char-
acteristic of ranitidine HCl polymorphic form II whereas the
peak at 1208 cm−1 would describe the existence of form I [28].
In Fig. 3B, 1186 and 1206 cm−1 exhibit shoulders of other
peaks, suggesting the existence of both polymorphic forms in
the sample. Furthermore, if the time-resolved representation
of the 2D spectrum, in Fig. 3B (black line showing the ac-
quired raw data), was chosen to be constructed from a slightly
different time point, the feature at 1186 cm−1 appeared more
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dominant (data not shown), and the signal was not swamped
by the otherwise strong fluorescent background, leading to the
hypothesis that form II was dominant in the sample. This
observation shows an important feature which is available
with the time-resolved CMOS SPAD technique. Namely, by
varying the time point (sampling point), from which the 2D
Raman spectrum is constructed, it is possible to utilize the
acquired raw data without further processing. A CW system
at 532 nm performed better over the CW785-nm system in the
case of ranitidine HCl, but in general, the apparent fluores-
cence rejection factor is very low, even with the time-resolved
Raman setup. It is worth stressing that the relatively low fluo-
rescence rejection factor might be due to a short lifetime fluo-
rescent impurity contribution that is difficult to sort out regard-
less of the system used. Nonetheless, compared to the conven-
tional CW systems, which have no possibility to examine the
spectra in the time dimension and at different time points after
the laser shot, the potential of this time-resolved technique
becomes clearer.
Indomethacin (crystalline) (2-[1-(4-chlorobenzoyl)-5-
methoxy-2-methylindol-3-yl] acetic acid) Indomethacin is
a non-steroidal anti-inflammatory drug. The crystalline γ-
form is the most stable form of indomethacin at room temper-
ature, and it exists as dimers in this solid-state form [29]. In the
present study, Fig. 2E, F; Fig. 3C; and ESMTable S3 show the
experimental and calculated data for crystalline indomethacin.
Variations between the measured and calculated values exist
for some peaks; however, the same trend can be observed in
an earlier study [30]. Nonetheless, the measured positions for
the peaks with the CW Raman systems and the time-resolved
setup match up relatively well, and the characteristic chloro-
benzene and indole ring contributions as well as oxygen and
nitrogen containing stretching vibrations are clearly observed
in the spectra.
Indomethacin (amorphous) For poorly water-soluble drugs,
the amorphous form has a significant advantage over the crys-
talline form, with a higher dissolution rate and apparent solu-
bility, but the downside is reduced stability during processing
and storage [31]. Thus, e.g., the manufacturing process in-
volving amorphous forms can be hard to control. Raman spec-
troscopy has proven to be the most sensitive method for the
investigation of various amorphous forms of indomethacin
when the forms have been studied with different techniques
and multivariate analysis [32]. However, a 1064-nm FT-
Raman accessory has been a prerequisite to acquire an inter-
pretable Raman spectrum without prior bleaching for amor-
phous indomethacin. Figure 2G, H; Fig. 3D; and ESM
Table S4 show the experimental and calculated data for amor-
phous indomethacin. Herein, with the 785-nm CW Raman
system, a useful Raman spectrum was practically impossible
to acquire. The CW experiment at 532-nm excitation gave
quite visible Raman peaks; however, the sample was not
chemically stable with 5-s integration times, leading to a dra-
matically raised baseline and subsequent saturation of the de-
tector due to photoluminescent degradation products. Thus,
the integration time of 2 s was chosen to be used with the
CW 532-nm setup.
When using the 532-nm excitation laser and time-resolved
detection, we are able to acquire a detailed Raman spectrum
for amorphous indomethacin. In an attempt to avoid the laser-
induced sample degradation, the galvo-mirror arrangement
was used to move the laser beam spot on the sample constant-
ly. Thus, we get the advantage of the short-wavelength exci-
tation source giving rise to higher Raman scattering intensities
while fluorescence is simultaneously efficiently suppressed by
the time-resolved technique. A similar inconsistency between
DFT calculated peak values and measured peak values is seen
as in the case of the crystalline form of indomethacin.
However, the spectra in Fig. 3C, D reveal detailed features
that can be conveniently utilized to investigate crystalline
and amorphous forms of indomethacin. For instance, the re-
gion between wavenumbers 1080–1450 cm−1 shows clear
shifts in peak intensities, shapes, and positions. Similar differ-
ences are also seen in the range of 1500–1700 cm−1.
The acquisition of accurate Raman spectra of both forms
can be performed with effective fluorescence suppression
without the need to switch between systems or perform exces-
sive data processing. Therefore, the time-resolved technique
presented here could open up new possibilities, e.g., in ana-
lyzing the phase transition processes in pharmaceutical set-
tings and investigating compounds that are known to be labo-
rious to measure with Raman instruments due to weak signals
and interfering fluorescence backgrounds.
Preliminary perspectives on the capabilities of the time-
dimension analysis The current time-gated measurement sys-
tem has two main capabilities: first, rejection of sufficiently
long-lived fluorescence or other background radiation from a
Raman signal, and on the other hand, measuring the spectrally
resolved fluorescence decay shape. We applied the previously
described single-exponential tail fitting to the studied samples.
Now, since caffeine does not have a fluorescence background
to speak of, and ranitidine HCl has very short fluorescence
lifetime, the only meaningful results are found in indometha-
cin. However, in the case of ranitidine HCl, even with the
time-resolving capacity in the present study being restricted
by the compound’s short fluorescence lifetime and thus the
setup’s time resolution, we were still able to make an estimate
of the fluorescence lifetime of ranitidine HCl. Namely, we
could tell whether the fluorescence lifetime was short or
long—a feature not available on conventional Raman setups.
The fitted, uncorrected lifetimes for indomethacin are about
2.1 ns for crystalline indomethacin and 2.3 ns for amorphous
indomethacin. According to a rough simulation model we
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performed, the actual, de-convolved lifetimes are approxi-
mately 100–200 ps shorter (data not shown). The exponential
fittings on the measured data are shown in ESM Fig. S1. The
capabilities of the system to measure general fluorescence
decay shapes (e.g., find parameters of multi-exponential de-
cays) will be expanded in the future. This involves determi-
nation of the instrument response function (IRF) in the sense
that its effects can be de-convolved. For measuring the actual
vibrational dynamics associated with the Raman processes
[12, 19], neither the time nor the wavelength resolution of
our system is sufficient. Nevertheless, in our current data,
one can detect certain ambiguities concerning the temporal
shapes of certain Raman peaks; these observations merit a
further study with higher temporal resolution in order to as-
certain their origin and significance.
Conclusion
We have shown the potential of fast, picosecond pulsed 532-
nm laser excitation coupled with a fast and sensitive CMOS
SPAD detector to overcome the known Achilles heel, fluores-
cence, in Raman spectroscopy. In addition, compared to the
conventional methods, we are potentially able to have more
detailed structural information on our sample molecules with
Raman spectroscopy by utilizing the efficiently fluorescence-
suppressed and accurate Raman spectra, and the time-domain
detection capability. The technical advantages of this CMOS
SPAD detector have been previously discussed elsewhere
[16]. Now, we demonstrate for the first time a step towards
applications with this time-resolved Raman system.We record
fluorescence-suppressed Raman spectra of solid, amorphous
and crys ta l l ine , and non-photo luminescent and
photoluminescent drugs such as caffeine, ranitidine hydro-
chloride, and indomethacin (amorphous and crystalline
forms). The raw data acquired by utilizing only the picosec-
ond pulsed laser and a CMOS SPAD detector proved useful
for identifying the compounds directly without any data pro-
cessing. Relatively straightforward algorithms can further di-
minish the fluorescence contribution in the acquired spectra,
showing potential for accurate quantitative analysis. In sum-
mary, our major findings were as follows. Firstly, by utilizing
the high photon energy 532-nm pulsed excitation source, we
are able to observe accurate Raman spectra features. The
quantum mechanical calculations for one of our model drugs,
ranitidine hydrochloride, the comparison to existing literature,
and experiments performed with CW 785- and 532-nm
Raman setups verified this. Secondly, we are able to diminish
the strong fluorescence backgrounds, especially on amor-
phous indomethacin. The findings with our model drugs indi-
cate the applicability of this time-resolved Raman technique to
overcome the ever-present problems of weak signal and fluo-
rescence in Raman spectroscopy—not only in pharmaceutical
settings but also in many other fields that would benefit from
the accurate chemical information Raman spectroscopy offers.
Several applications in the field of pharmaceutical industry
and bio- and life sciences would benefit from the time-
domain assays with Raman spectroscopy. For example, phase
transition processes, cellular uptake studies, and cell culture
studies regarding changes of the chemical concentrations in
the culture medium or nanoparticle uptake studies would be
potential areas for future research. Another potential option
for further studies would be an investigation of several drug
molecules in amorphous and crystalline solid-state forms. The
setup described is potentially a powerful and convenient tool
to overcome current fluorescence-related limitations of
Raman spectroscopy for laboratory and off-laboratory use,
while simultaneously providing complementary information
for Ramanmeasurements in the form of time-domain analysis.
The advantages of using this CMOS SPAD technique over the
existing instruments (for example [17, 18]) are practical and
robust operation of the system, compact size, and affordable
cost. In the case of varying samples in terms of fluorescence
interference, the CMOS SPAD setup can be feasibly used for a
range of samples without the need to change from one instru-
ment to another. Thus, it offers a very potential choice of
instrument for the field of Raman spectroscopy. Having
showed that this new Raman technique effectively suppresses
fluorescence, we envisage that it has also widespread applica-
tion in different pharmaceutical and biopharmaceutical con-
texts that have previously suffered from fluorescence
phenomena.
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Table S1 Selected peak assignments for caffeine
CW 785 
nm (cm-1) 
CW 532 
nm (cm-1) 
Time-
resolved 
(cm-1) 
DFT values 
(cm-1) 
Predicted description 
927 928 928 927 imidazole in-plane ring deformation [1] 
1071 1071 1070 1073 C-C stretching + C-N stretching [1] 
1240 1239 1240 1241 C-C stretching + C-N stretching [1] 
1600 1599 1595 1599 C=N, C-N stretching + CH3 symmetric bending [1] 
1656 1654 1650 1654 C = C stretching [1] 
1698 1696 1691 1698 C = O stretching [1] 
Table S2 Selected peak assignments for ranitidine hydrochloride
CW 785 
nm (cm-1) 
CW 532 
nm (cm-1) 
Time-
resolved 
(cm-1) 
DFT values 
(cm-1) 
Predicted description 
1186 1185 1186 1170 Furan ring and CH2
- - 1206 1203 CH2 symmetric rock with furan ring 
- 1259 1262 1254 CH2 asymmetric rock 
- 1274 1274 1276 CH2SCH2 symmetric wag 
- 1301 1302 1301 CH2 wag 
- - 1524 1533 Furan symmetric stretch 
Table S3 Selected peak assignments for indomethacin (crystalline) 
CW 785 
nm (cm-1) 
CW 532 
nm (cm-1) 
Time-
resolved 
(cm-1) 
DFT value 
(cm-1) 
Predicted description
1088 1086 1085 1074 C-C stretching, in-plane chlorobenzene ring breathing [2] 
1222 1219 1218 1222 
C-C stretching, out-of-phase C-O-C stretching, out-of-phase C-N-C 
stretching (mainly dimer) [2]
1263 1264 1262 1254 
Out-of-phase C-N-C stretching (monomer) and out-of-phase N-C-C 
stretching (dimer), out-of-phase C-O-C stretching, in-plane indole and 
chlorobenzene ring deformations, C-O stretching (dimer) [2] 
1396 1394 1394 1408 C-C stretching, in-phase C-H inversion [2] 
1588 1590 1584 1595 Chlorobenzyl ring deformation, C-C stretching [2] 
1620 1618 1614 1615 C-O stretching, indole ring deformation [2] 
1698 1698 1691 1705 C=O stretching [2] 
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Table S4 Selected peak assignments for indomethacin (amorphous) 
  
  
CW 785 
nm  (cm-1) 
CW 532 
nm (cm-1) 
Time-
resolved 
(cm-1) 
DFT value 
(cm-1) 
Predicted description
- 1091 1089 1074 C-C stretching, in-plane chlorobenzene ring breathing [2] 
- 1222 1219 1222 
C-C stretching, out-of-phase C-O-C stretching, out-of-phase C-N-C stretching (mainly 
dimer) [2] 
- 1259 1258 1254 
Out-of-phase C-N-C stretching (monomer) and out-of-phase N-C-C stretching (dimer), 
out-of-phase C-O-C stretching, in-plane indole and chlorobenzene ring deformations, C-O 
stretching (dimer) [2] 
- 1394 1390 1408 C-C stretching, in-phase C-H inversion [2] 
- 1590 1584 1570 In-plane indole ring deformation [2] 
- - 1606 1615 C-O stretching, indole ring deformation [2] 
- 1670 1673 1705 C=O stretching [2] 
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Fig. S1 Single exponential fittings on the response functions for the fluorescence decay estimations. 
Panels: A) caffeine (wavenumber range 1800 cm-1-1300 cm-1), B) caffeine (1300 cm-1-800 cm-1), C) 
crystalline indomethacin (1800 cm-1-1300 cm-1), D) crystalline indomethacin (1300 cm-1-800 cm-1), 
E) amorphous indomethacin (1800 cm-1-1300 cm-1), F) amorphous indomethacin  (1300 cm-1-800 
cm-1) 
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Fig. S2 Eigenvector diagrams for prominent modes of ranitidine HCl (modeled as ranitidineH+).  
Values are calculated frequencies as presented in Table S2 
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ABSTRACT
The soluble oligomeric form of the amyloid 
beta (Aβ) peptide is generally recognized as 
the major causative agent in the molecular 
pathogenesis of Alzheimer’s disease (AD). We 
have previously developed a pyrroline-nitroxyl 
fluorene compound (SLF) that blocks the 
toxicity of Aβ. Here we introduce the multi-
parametric surface plasmon resonance (MP-
SPR) approach to quantify SLF binding and 
effect on the self-association of the peptide. MP-
SPR provides a label-free, real-time approach 
for measuring the interaction of SLF with 
soluble Aβ. Kinetic analysis of SLF binding 
to oligomeric Aβ and measurements of layer 
thickness alterations inform on the mechanism 
underlying the ability of SLF to inhibit Aβ 
toxicity and its progression towards larger 
oligomeric assemblies. Remarkably, depending 
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on the oligomeric state of Aβ, distinct binding 
affinities for SLF are revealed by MP-SPR. The 
Aβ monomer and dimer uniquely possess sub-
nanomolar affinity for SLF, as well as a weaker 
binding state of ~20 µM. Sub-nanomolar 
binding is not found in oligomeric Aβ, which 
displays an affinity for SLF on the order of 100 
µM. To complement these experiments we 
carried out molecular docking simulations to 
explore how SLF interacts with the Aβ-peptide. 
Docking calculations predict Aβ-peptide folds 
around the SLF molecule shielding it from 
aqueous surroundings. The binding energy 
calculated for this interaction is on par with 
the lower affinity interaction measured by MP-
SPR. The MP-SPR results together with in silico 
modeling provide essential affinity data on how 
small molecules interact with Aβ and allow us 
to develop a new general method for examining 
protein aggregation. 
INTRODUCTION
Alzheimer’s Disease (AD) is a progressive, 
devastating neurodegenerative disease that 
currently affects nearly five million people in 
US alone. The incidence of AD is expected to 
triple by 2050 (1). Although the etiology of AD is 
complex, multiple lines of genetic, histological 
and biochemical evidence suggests the amyloid 
peptide (Aβ) is the primary causative agent (2). 
The Aβ is constitutively released in the brain 
through proteolytic processing of the amyloid 
precursor protein (APP), which is, in turn, 
cleaved sequentially by β and γ secretases, 
two aspartyl proteases. Both the rate and site 
of APP cleavage, as well as the efficiency of Aβ 
clearance determine eventual neuropathology. 
Aβ is an intrinsically disordered peptide that 
undergoes a dynamic aggregation pattern that 
can ultimately lead to Aβ plaques deposited in 
the brain (3,4). 
Importantly, numerous studies have 
established that the soluble oligomeric form 
of Aβ (AβO) represents the neurotoxic form 
of the peptide (5-7). Hence, there is significant 
interest in identifying compounds that inhibit 
Aβ oligomerization. To date diverse set of small 
molecules have been found to interfere with Aβ 
oligomerization and amyloid fibril formation, 
although the binding coordination and 
structural mechanism for inhibition remains 
unknown (8-12). A major obstacle to the 
development of such therapeutic agents is the 
dynamic structure of the soluble Aβ peptide; 
toxicity results from various oligomeric forms 
present throughout the aggregation pathway 
(13). 
We have previously shown that a novel, 
bifunctional compound can block both Aβ 
toxicity and oligomer growth (14,15). This small 
molecule, named spin-labeled fluorene (SLF), 
contains a fluorene moiety for Aβ-targeting as 
well as a nitroxide spin label (Fig. 1). Biophysical 
studies indicate that SLF disrupts and inhibits 
oligomer growth (14,15). The protective effect 
of SLF against Aβ toxicity is augmented by 
the free radical scavenging property of the 
nitroxide spin label (14,16), which is efficient 
in addressing the strong oxidative element of 
AD pathogenesis (17-20).
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represents the neurotoxic form of the peptide (5-7). Hence, there is significant interest in identifying 
compounds that inhibit Aβ oligomerization. To date diverse set of small molecules have been found 
to interfere with A oligomerization and amyloid fibril formation, although the binding 
coordination and structural mechanism for inhibition remains unknown (8-12). A major obstacle to 
the development of such therapeutic agents is the dynamic structure of the soluble Aβ peptide; 
toxicity results from various oligomeric forms present throughout the aggregation pathway (13).  
 
We have previously shown that a novel, bifunctional compound can block both A toxicity and 
oligomer growth (14,15). This small molecule, named spin-labeled fluorene (SLF), contains a 
fluorene moiety for A-targeting as well as a nitroxide spin label (Fig. 1). Biophysical studies 
indicate that SLF disrupts and inhibits oligomer growth (14,15). The protective effect of SLF 
against A toxicity is augmented by the free radical scavenging property of the nitroxide spin label 
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Fig. 1. The chemical structure of spin-labeled fluorene (SLF), a novel compound that disrupts the 
formation of amyloid plaques. The amyloid binding moiety is shown in red, and the nitroxide spin 
label in black. 
 
Although the toxic state of A is ill-defined, multiple lines of evidence correlate toxicity with 
oligomers on the order of 10-60 kDa that contain a high degree of conformational disorder 
distributed amongst oligomers in dynamic equilibrium (reviewed in (21)). Depending on the 
conditions, these oligomers progress to larger aggregates or transition into fibrillar-competent 
species. Obtaining a quantitative description of A structure and toxicity remains a challenge, and 
the dynamic nature of oligomeric A further complicates efforts to address the mechanism of small 
molecule modulators of A toxicity. We have therefore employed a label-free approach using 
surface-immobilized A to measure SLF binding affinity to different oligomeric states of the 
peptide. The method, multi-parametric surface plasmon resonance (MP-SPR), is additionally useful 
because it also detects changes in layer thickness (22), and thereby provides information on how 
small molecule binding can modulate A self-association.   
Fig. 1. The chemical struct re of spin-labeled fluorene 
(SLF), a novel compound that disrupts the formation of 
amyloid plaques. The amyloid binding moiety is shown 
in red, and the nitroxide spin label in black.
Although the toxic state of Aβ is ill-defined, 
multiple lines of evidence correlate toxicity 
with oligomers on the order of 10-60 kDa 
that contain a high degree of conformational 
disorder distributed amongst oligomers in 
dynamic equilibr um (rev ewed in (21)).
Depending on the conditions, these oligomers 
progress to larger aggregates or transition 
into fibrillar-competent species. Obtaining a 
quantitative description of Aβ structure and 
toxicity remains a challenge, and the dynamic 
nature of oligomeric Aβ further complicates 
efforts to address the mechanism of small 
molecule modulators of Aβ toxicity. We have 
therefore employed a label-free approach 
using surface-immobilized Aβ to measure SLF 
binding affinity to different oligomeric states 
of the peptide. The method, multi-parametric 
surface plasmon resonance (MP-SPR), is 
additionally useful because it also detects 
changes in layer thickness (22), and thereby 
provides information on how small molecule 
binding can modulate Aβ self-association.  
MP-SPR is a feasible technique for studying 
label-free biomolecular interaction measured 
in real-time, providing detailed analysis 
of affinity and kinetics of small molecule 
interactions as well as a unique method for 
measuring peptide and protein self-assembly 
(23). We use the MP-SPR to demonstrate, how 
the Aβ self-assembly and aggregation can be 
hampered with our novel SLF molecule. The 
measurements provide kinetic constants for 
distinct SLF-Aβ interaction modes, leading to 
a better understanding of the role SLF plays 
in modulating Aβ aggregation and toxicity. 
Furthermore, by calculating layer thickness, 
the molecular masses deposited onto the MP-
SPR sensors are modeled in terms of oligomer 
size. We demonstrate that MP-SPR is an 
effectiv  t ol for observing Aβ self-assembly 
and evaluating agents that can modulate 
peptide aggregation. Finally, we carried out 
molecular dynamics simulations of the SLF-
Aβ interaction, providing insights into possible 
conformati nal states that correlate to a lowered 
toxicity and aggregation propensity for the Aβ 
peptide. This work represents a continuation 
in our development of the synergistic 
combination of label-free analytics and 
molecular dynamics to obtain key mechanistic 
insights of pharmaceutical relevance (24). The 
developed in vitro methodology represents 
a bio-functional assay platform where the 
biological environment is mimicked in order 
to enhance the in vivo relevance of the study. 
The platform can also provide a potential multi-
purpose tool for other resembling studies where 
the protein aggregation plays a role.
RESULTS
For all the MP-SPR measurements we used two 
separate wavelengths, 670 nm and 785 nm. 
However, the response for each of the lasers of 
both flow channels was grouped by wavelength 
and only the 670 nm laser signals for the 
sensorgrams and MP-SPR angular spectra are 
shown for easy reading.  The mobile phase in 
experiments consisted of the buffer specific to 
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the form of Aβ applied in the MP-SPR analysis. 
Initially, the physicochemical characterization 
of SLF was performed in four schemes 
whereby different Aβ peptide compositions 
and oligomeric Aβ peptide compositions were 
mimicked and investigated. Thus the mobile 
phase for monomer analysis consisted of the low 
ionic strength buffer (25 mM Tris, 1 mM EDTA, 
pH 8.0) and for AβO consisted of high ionic 
strength buffer (25 mM Tris, 150 mM NaCl, pH 
7.0). In order to demonstrate that the chosen 
approaches using low and high ionic strength 
buffers for monomer and oligomer analysis, 
respectively, yield the desired conditions, 
dynamic light scattering (DLS) measurements 
were performed. As determined by the DLS, 
monomeric Aβ displays a mean diameter 1.4 
nm, in agreement with earlier measurements of 
the Aβ monomer (25). In contrast, the 4-hour 
AβO species have an average hydrodynamic 
radius of ~75 nm. The results are shown in 
Table 2.
SLF binds Aβ monomer with a very 
high affinity. We have shown in previous 
work that, the SLF small molecule binds to 
soluble Aβ oligomers and protects against Aβ-
induced cell death (14,15). To characterize the 
binding of spin labeled fluorenes to Aβ, we 
employed real-time, label-free detection of SLF 
binding to biotinylated Aβ tethered to a SAM 
as shown schematically in Fig. 2. 
We first measured the SLF binding 
kinetics to the immobilized monomeric Aβ 
alone. Affinity measurements were carried 
out by flowing increasing concentrations of 
SLF over the surface, which has been shown 
advantageous in the SPR study of high-affinity 
molecular interactions (26-28). Serial injections 
of increasing concentrations of SLF over the 
biotinylated Aβ (Fig. 3, blue trace) result in 
an increase in baseline maintained after the 
dissociation phase, indicative of SLF binding 
Aβ and retained as a binary Aβ/SLF complex. 
Similarly increasing concentrations of SLF 
injected over the control sensor surface (Fig. 
3, green trace) show no increase in the baseline, 
indicative of lack of non-specific binding of SLF 
to the streptavidin functionalized SAM surface.
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Fig. 2. Schematic diagram of the MP-SPR sensor surface construction (the MBP-Thiol 
SAM/streptavidin + biotinylated Aβ/analyte assembly). The sensor surface is coated with biotin-
functionalized (for streptavidin binding) PEG derivative [MuOH: Biotin-PEG-thiol (85:15 mol %)]. 
The MBP-Thiol SAM surface is then coated with streptavidin, which immobilizes with high affinity 
and specificity to biotin. Injection of biotinylated Aβ results in the attachment of Aβ to the sensor 
surface biotin binding to the available sites of the immobilized streptavidin-biotin bond. The 
analytes (SLF and/or Aβ) are then flowed over the surface of immobilized Aβ, and SLF binding 
and/or Aβ self-association result in signal amplification. The volume of all injections is 300 μL and 
flow rate is 10 μL/mL for streptavidin, biotin, and Aβ, and 20 μL/mL for SLF. 
 
We first measured the SLF binding kinetics to the immobilized monomeric Aβ alone. Affinity 
measurements were carried out by flowing increasing concentrations of SLF over the surface, which 
has been shown advantageous in the SPR study of high-affinity molecular interactions (26-28). 
Serial injections of increasing concentrations of SLF over the biotinylated Aβ (Fig. 3, blue trace) 
result in an increase in baseline maintained after the dissociation phase, indicative of SLF binding 
Aβ and retained as a binary Aβ/SLF complex. Similarly increasing concentrations of SLF injected 
over the control sensor surface (Fig. 3, green trace) show no increase in the baseline, indicative of 
l ck of on-specific binding of SLF to the streptavidin functionalized SAM surface. 
 
Fig. 2. Schematic diagram of the MP-SPR sensor 
surface construction (the MBP-Thiol SAM/streptavidin + 
biotinylated Aβ/analyte assembly). The sensor surface 
is coated with biotin-functionalized (for streptavidin 
binding) PEG derivative [MuOH: Biotin-PEG-thiol (85:15 
mol %)]. The MBP-Thiol SAM surface is then coated with 
streptavidin, which immobilizes with high affinity and 
specificity to biotin. Injection of biotinylated Aβ results in 
the attachment of Aβ t  the sensor surface biotin binding 
to the available sites of the immobilized streptavidin-biotin 
bond. The analytes (SLF and/or Aβ) are then flowed over 
the surface of immobilized Aβ, and SLF binding and/or Aβ 
self-association result in signal amplification. The volume 
of all injectio s is 300 μL and flow rate is 10 μL/mL for 
streptavidin, biotin, and Aβ, and 20 μL/mL for SLF.
.
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SLF binding was best fit according to the 1:2 
binding model, indicating that Aβ contains at 
least two distinct sites or modes for SLF binding 
(Fig. 4A). The presence of two binding sites 
or modes for SLF within Aβ is also consistent 
with molecular dynamics simulations (see 
below). As seen in Table 1, using the 1:2 
fitting model, we acquire two affinity constants, 
KD1 and KD2. Respectively, the Bmax1 and Bmax2 
values are calculated (Table 1). In general, the 
Bmax1 and Bmax2 indicate the maximum signal 
obtained, which is dependent for example on 
the number of immobilized ligands or receptors 
on the surface. Hereby, the Bmax1 and Bmax2 
show the relative amount of SLF binding to 
corresponding binding sites. It is of note 
that the other parameters of the interaction 
kinetics analysis (ka1, kd1, etc.) are shown in 
the Supplemental Information Table S1. 
The first value, KD1 (~ 1.5×10
-5 M) tells about a 
relatively strong binding of SLF. On the other, 
the KD2 (<1×10
-9 M) shows that a very strong 
binding of SLF also takes place to Aβ, indicating 
binding at some sites is effectively irreversible 
on the time scale of these measurements. 
Because the calculation for KD2 carries a high 
level of uncertainty as determined within the 
time domain of these experiments, its value 
cannot be accurately determined. However, 
we can conclude that KD2 corresponds to a 
binding affinity of 1 nM or less. The lack of SLF 
dissociation is also reflected in the time-resolved 
presentation of the MP-SPR signals where the 
baseline raises after each concentration.  The 
significance of the high affinity binding of SLF 
to the Aβ monomer is discussed below. Overall, 
the 1:2 fitting model sufficiently accommodates 
the measured data, with a comparatively low χ2 
value = 34.39.  The success of the fitting can also 
be estimated in the curves of Fig. 4A, where 
the bold red line is the measured data, and the 
dotted line represents the fitting.
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Fig. 3. SLF binds biotinylated Aβ with high affinity. MP-SPR signal response after injections of 
increasing concentrations of SLF in both flow channels (10, 20, 30, and 40 μM). The sensor 
surfaces were pre-coated with 10 μM biotinylated monomeric Aβ in the upper flow chamber (blue 
trace) and the control consisting of 1 mM biotin in the lower channel (green trace). The arrows 
indicate the time when the injections into both channels were made. 
 
SLF binding was best fit according to the 1:2 binding model, indicating that A contains at least 
two distinct sites or modes for SLF binding (Fig. 4A). The presence of two binding sites or modes 
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Fig. 3. SLF binds biotinylated Aβ with high affinity. MP-SPR signal response after injections of increasing concentrations 
of SLF in both flow channels (10, 20, 30, and 40 μM). The sensor surfaces were pre-coated with 10 μM biotinylated 
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Fig. 4. Binding kinetics show Aβ presents two binding sites.  The sensorgrams are extracted from 
binding of SLF to the tethered monomers of biotinylated Aβ alone (A), or a surface consisting of 
native Aβ monomers bound to the biotin-tethered Aβ monomers (B). The native Aβ monomer in 
(B) was injected at 10 μL/min. The flow rate SLF addition in both (A) and (B) was 20 μL/min. The 
sensorgrams are shown as a red line, and the fits are shown as a black dashed line. The kinetic 
parameters obtained from the fits are shown in Table 1. 
 
Table 1.  Calculated affinity values for different interaction scenarios of Aβ/SLF binary complexes. 
Data was processed and fitted using TraceDrawer™ for MP-SPR Navi™. Values in parenthesis represent 
the statistical uncertainty.  *An upper limit for KD2 is given, as precision in fits cannot be obtained due to the 
limited dissociation of SLF binding in these samples. 
 Bmax1 
(Signal) 
Bmax2 
(Signal) 
KD1 
(M) 
KD2 
(M) 
2 
SLF with biotinylated 
Aβ monomer 
123.73 
(± 8.0710-1) 
119.58 
(± 4.2810-1) 
1.4910-5 
(± 8.8110-7) 
<110-9* 34.39 
SLF with native Aβ 
bound to biotinylated 
Aβ monomer 
137.69 
(± 1.05100) 
947.24  
(±6.4010-1) 
4.0610-5 
(± 2.3610-6) 
<110-9* 23.30 
SLF with AβO 440.06  
(±1.18100) 
1530.53  
(±8.4910-1) 
1.0810-4 
(±-1.4810-5) 
1.2110-4 
(±-1.8010-7) 
41.63 
SLF with AβO 
pretreated with SLF 
499.48 
(± 1.25100) 
1169.44 
(± 1.09100) 
1.1510-4 
(± 1.0610-5) 
9.8410-5 
(± 1.1110-7) 
44.63 
 
SLF binds to non-biotinylated Aβ similar to biotinylated Aβ. To compare the binding of SLF to 
non-biotinylated Aβ we ran another control set-up by flowing 10 μM non-biotinylated Aβ in low 
aggregation buffer twice over the biotinylated Aβ, at 10 μL/min for 30min, in low aggregation 
buffer. Under these conditions, we predict a native monomer binding to the tethered A, resulting in 
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SLF binds to non-biotinylated Aβ similar to biotinylated Aβ. To compare the binding of SLF to 
non-biotinylated Aβ we ran another control set-up by flowing 10 μM non-biotinylated Aβ in low 
aggregation buffer twice over the biotinylated Aβ, at 10 μL/min for 30min, in low aggregation 
buffer. Under these conditions, we predict a native monomer binding to the tethered A, resulting in 
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SLF binds to non-biotinylated Aβ similar 
to biotinylated Aβ. To compare the binding 
of SLF to non-biotinylated Aβ we ran another 
control set-up by flowing 10 μM non-biotinylated 
Aβ in low aggregation buffer twice over the 
biotinylated Aβ, at 10 μL/min for 30min, in 
low aggregation buffer. Under these conditions, 
we predict a native monomer binding to the 
tethered Aβ, resulting in a mostly dimeric 
species on the surface. As shown in Fig. 5, 
injection of the monomer increases the baseline 
in both channels, consistent with the native Aβ 
monomer pairing with the tethered Aβ species. 
After the baseline was stabilized we injected the 
same series of increasing concentrations of SLF 
over the biotinylated Aβ, as shown in Fig. 5. 
As before, we kept the injection and flow buffer 
in low aggregation conditions to minimize Aβ 
self-association as much as possible. MP-SPR 
measurements show a similar binding pattern 
of SLF to non-biotinylated Aβ as the binding to 
biotinylated Aβ (Fig. 4B). The fitting model is 
again consistent with Aβ containing at least two 
binding sites or modes for SLF, KD values of the 
same order as SLF binding to biotinylated Aβ 
(affinity parameters shown in Table 1.).  This 
result suggests that dimeric Aβ also contains 
the capacity to bind SLF with a sub-nanomolar 
affinity.
Oligomeric Aβ lacks very high binding 
affinity. We next investigated SLF binding to 
complexes of oligomeric Aβ (AβO) associated 
with the surface-immobilized Aβ. AβO was 
prepared in an aggregation-promoting buffer 
as described in Experimental Procedures, and 
measured by MP-SPR (Fig. 6, green trace). 
Kinetic analysis of the AβO/SLF complexes 
was also performed using the 1:2 fitting model 
that takes into account the probability of AβO 
having at least two binding sites or modes 
Fig. 5. High affinity SLF binding is also observed with native monomeric Aβ. In the first injection, both sensor surfaces 
containing biotin-tethered Aβ monomer were coated with 10 μM native monomeric Aβ. The MP-SPR signal response 
was then followed after injections of various concentrations of SLF, 10, 20, 30, and 40 μM in the upper flow channel 
(blue trace), and 10 μM SLF, followed by 3 injections of low ionic strength buffer in the lower channel (green trace). 
SLF and buffer were injected at 20 μL/min.
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a mostly dimeric species on the surface. As shown in Fig. 5, injection of the monomer increases the 
baseline in both channels, consistent with the native A monomer pairing with the tethered A 
species. After the baseline was stabilized we injected the same series of increasing concentrations of 
SLF over the biotinylated Aβ, as shown in Fig. 5. As before, we kept the injection and flow buffer 
in low aggregation conditions to minimize Aβ self-association as much as possible. MP-SPR 
measurements show a similar binding pattern of SLF to non-biotinylated Aβ as the binding to 
biotinylated Aβ (Fig. 4B). The fitting model is again consistent with Aβ containing at least two 
binding sites or modes for SLF, KD values of the same order as SLF binding to biotinylated Aβ 
(affinity parameters shown in Table 1.).  This result suggests that dimeric A also contains the 
capacity to bind SLF with a sub-nanomolar affinity. 
 
 
Fig. 5. High affinity SLF binding is also observed with native monomeric Aβ. In the first 
injection, both sensor surfaces containing biotin-te hered Aβ onomer were coated with 10 μM 
native monome ic Aβ. The MP-SPR signal r sponse was the  followed after injections of various 
concentrations of SLF, 10, 20, 30, and 40 μM in he upper flow channel (blue trace), and 10 μM 
SLF, followed by 3 injections of low ionic strength buffer in the lower channel (gre n trace). SLF 
and buffer were inj cted at 20 μL/min. 
 
Oligomeric A lacks very high binding affinity. We next investigated SLF binding to complexes 
of oligomeric A (AO) associated with the surface-immobilized A. AO was prepared in an 
aggregation-promoting buffer as described in Experimental Procedures, and measured by MP-SPR 
(Fig. 6, green trace).  Kinetic analysis of the AβO/SLF complexes was also performed using the 1:2 
fitting model that takes into account the probability of AβO having at least two binding sites or 
modes for SLF (Table 1; Fig. 7A). A substantially higher error (i.e. higher 2 values) was observed 
when evaluated by the 1:1 model. Interestingly, in these oligomeric samples both KD: s are of the 
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Fig. 6. SLF binding to oligomeric Aβ (AβO). MP-SPR signal response after two successive injections of 10 μM AβO, 
with (blue trace) or without (green trace) pretreatment of the AβO with 20 μM SLF. After baseline stabilized, increasing 
concentrations (10, 20, 30 and 40 μM) of SLF were applied through both flow channels. Mobile phase consisted of 
the high ionic strength, pH 7.0 buffer.
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same order of magnitude (~10-4-10-5 M).  Thus, the pre-assembled AβO lacks the very high affinity 
binding, displaying a comparable lower affinity for SLF in both KD1 and KD2. This finding suggests 
that monomeric/dimeric A displays a uniquely high affinity binding site for SLF, which may also 
serve to dock other amyloidophilic compounds as well. 
 
 
Fig. 6. SLF binding to oligomeric A (AO). MP-SPR signal response after two successive 
injections of 10 μM AβO, with (blue trace) or without (green trace) pretreatment of the AO with 
20 M SLF. After baseline stabilized, increasing concentrations (10, 20, 30 and 40 μM) of SLF 
were applied through both flow channels.  Mobile phase consisted of the high ionic strength, pH 7.0 
buffer. 
 
 
 
Fig. 7. Binding kinetics of SLF onto oligomeric Aβ.  The sensorgrams are extracted from SLF binding to AβO associated 
with tethered monomers of biotinylated Aβ.  The binding of SLF to AβO pretreated with 20 μM SLF is shown in Panel 
(A). The binding of SLF to AβO alone is shown in Panel (B).  The AβO samples were injected at 10 μL/min, and the 
SLF solution’s flow rate was 20 μL/min. The sensorgrams are shown as a red line, and the fits are shown as a black 
dashed line. The kinetic parameters obtained from the fits are shown in Table 1.
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Fig. 7. Binding kinetics of SLF onto oligomeric Aβ.  The sensorgrams are extracted from SLF 
binding to AO associated with tethered monomers of biotinylated Aβ.  The binding of SLF to AO 
pretreated with 20 M SLF is shown in Panel (A). The binding of SLF to AO alone is shown in 
Panel (B).  The AβO samples were injected at 10 μL/min, and the SLF solution’ flow rate was 20 
μL/min. The sensorgrams are shown as a red line, and t e fits are shown as a black dashed line. The 
kinetic parameters obtained from the fits are shown in Table 1. 
 
In order to evaluate how SLF affects AβO binding, we compared the MP-SPR response of AβO 
applied over the surface of immobilized A (Fig. 6, green trace) to AO pre-incubated with a 2-fold 
molar ratio of SLF (Fig. 6, blue trace). As shown over the first two injections, AO without SLF 
pretreatment binds and sharply returns to baseline, however AO with SLF pretreatment displays a 
prominent dissociation phase, suggesting that AO pretreated with SLF is a more optically-active 
entity than AO without SLF pretreatment. Thus the initial interaction signals induced by the 
pretreated AO are also stronger. In addition, the dissociation of loosely bound SLF can be clearly 
seen in the case of pretreated AO, as it resembles the dissociation kinetics observed when the 
compound is consecutively injected over AO. As with the previous SLF binding schemes, the SLF 
binding to pretreated AβO was performed using the 1:2 binding model (Fig. 7B), which yields KD 
values similar to AβO without SLF pretreatment (Table 1). Noteworthy are the injections of SLF 
after adsorption of AO or AO pretreated with SLF on the surface. As indicated by the smaller 
increase in the baseline of the sample pretreated with SLF (pretreated AO; blue trace), a smaller 
net SLF binding is observed, consistent with this sample having a lower binding capacity for 
additional SLF.  
 
SLF inhibits the self-association of Aβ. To investigate if SLF inhibits the self-association of Aβ, 
we compared the binding of Aβ pre-mixed with SLF (at 1:2 molar ratio based on our previous two 
binding sites or modes results) with the binding of Aβ alone. Both sample solutions and flow 
solvent were in low aggregation conditions, favoring monomeric Aβ. As shown in Fig. 8, we 
flowed monomeric Aβ+SLF (blue trace) and monomeric Aβ alone (green trace) over the non-
biotinylated Aβ immobilized on the sensor surface. The Aβ without SLF was retained on the sensor 
surface in a much higher amount, as revealed by the increase in the baseline (green trace) and 
Aβ+SLF was retained in a much lesser quantity as shown by the lower baseline (blue trace). This 
result is consistent with previous spectroscopic studies showing that SLF inhibits Aβ self-
association (14,15). 
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for SLF (Table 1; Fig. 7A). A substantially 
higher error (i.e. higher χ2 values) was observed 
when evaluated by the 1:1 model. Interestingly, 
in these oligomeric samples both KD: s are of 
the same order of magnitude (~10-4-10-5 M). 
Thus, the pre-assembled AβO lacks the very 
high affinity binding, displaying a comparable 
lower affinity for SLF in both KD1 and KD2. This 
finding suggests that monomeric/dimeric Aβ 
displays a uniquely high affinity binding site 
for SLF, which may also serve to dock other 
amyloidophilic compounds as well.
In order to evaluate how SLF affects AβO 
binding, we compared the MP-SPR response of 
AβO applied over the surface of immobilized Aβ 
(Fig. 6, green trace) to AβO pre-incubated with 
a 2-fold molar ratio of SLF (Fig. 6, blue trace). 
As shown over the first two injections, AβO 
without SLF pretreatment binds and sharply 
returns to baseline, however AβO with SLF 
pretreatment displays a prominent dissociation 
phase, suggesting that AβO pretreated with SLF 
is a more optically-active entity than AβO without 
SLF pretreatment. Thus the initial interaction 
signals induced by the pretreated AβO are 
also stronger. In addition, the dissociation 
of loosely bound SLF can be clearly seen in 
the case of pretreated AβO, as it resembles 
the dissociation kinetics observed when the 
compound is consecutively injected over AβO. 
As with the previous SLF binding schemes, the 
SLF binding to pretreated AβO was performed 
using the 1:2 binding model (Fig. 7B), which 
yields KD values similar to AβO without SLF 
pretreatment (Table 1). Noteworthy are the 
injections of SLF after adsorption of AβO or 
AβO pretreated with SLF on the surface. As 
indicated by the smaller increase in the baseline 
of the sample pretreated with SLF (pretreated 
AβO; blue trace), a smaller net SLF binding is 
Fig. 8. SLF inhibits Aβ self-association. MP-SPR signal response after injections of native monomeric Aβ (10 µM) over 
a surface of tethered Ab monomers. Sample without SLF addition is shown by the green trace (lower channel). The 
same sample mixed with 20 μM SLF is given by the blue trace (upper channel). In both channels the mobile phase is 
the low ionic strength buffer, pH 8.0, with a flow rate of 10 μL/min.
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Fig. 8. SLF inhibits Aβ self-association. MP-SPR signal response after injections of native 
monomeric Aβ (10 µM) over a surface of teth red Ab monomers. Sample w thout SLF addition is
shown by the green trac  (lower channel). The same sample mixed with 20 μM SLF is given by the 
blue trace (upper channel). In both channels the mobile phase is th  low ionic strength buffer, pH 
8.0, with a flow rate of 10 μL/min. 
 
SLF mediated oligomerization of Aβ can also be detected by change in layer thickness. Since 
the theoretical findings (29-31), the multi-wavelength approach in MP-SPR for surface 
characterization has been successfully demonstrated in multiple applications (32-34). The unique 
solution for the apparently interconnected thickness (d) and refractive index (n) of the sample layer 
can be found from the intersection of two continuum solutions, thus the MP-SPR measurements 
performed at multiple wavelengths can provide a direct indication of the layer thickness, thereby 
quantification of the mass added to the surface (32,33).  
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observed, consistent with this sample having a 
lower binding capacity for additional SLF. 
SLF inhibits the self-association of 
Aβ. To investigate if SLF inhibits the self-
association of Aβ, we compared the binding of 
Aβ pre-mixed with SLF (at 1:2 molar ratio based 
on our previous two binding sites or modes 
results) with the binding of Aβ alone. Both 
sample solutions and flow solvent were in low 
aggregation conditions, favoring monomeric 
Aβ. As shown in Fig. 8, we flowed monomeric 
Aβ+SLF (blue trace) and monomeric Aβ 
alone (green trace) over the non-biotinylated 
Aβ immobilized on the sensor surface. The 
Aβ without SLF was retained on the sensor 
surface in a much higher amount, as revealed 
by the increase in the baseline (green trace) 
and Aβ+SLF was retained in a much lesser 
quantity as shown by the lower baseline (blue 
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Fig. 9. Layer modeling results for different situations of Aβ layer build-up. Panel A represents 
the biomolecular layer formation from the measurements in Fig. 8, where the SLF hampers the self-
assembly processes of Aβ. Panel B shows the layer construction from the measurement in Fig. 8 
where SLF was not present in the measurement, resulting in greater peptide aggregation (increased 
layer thickness). 
 
The MP-SPR angular spectra in Fig. 9 represent the whole layer modeling procedure with 
intermediate steps shown, based on the data in Fig. 8. We started the modeling by determining first 
the background for our measured layer system, i.e. the metal (gold) layer. It should be noted that 
this background modeling step was performed with the inclusion of the SAM layer into the 
background calculation for two reasons; firstly, the contribution of SAM layer was considered very 
small to the measured MP-SPR angular spectra, and secondly, previous observations support the 
estimate that the calculation does not suffer from inaccuracies within the context of this analysis 
(34). The layer after the streptavidin immobilization was measured next, and lastly the final 
situation after injection of the native A monomer. For clarity, the 670 nm laser data is shown in 
Fig. 9 panels (the 785 nm laser data not shown), and the measured MP-SPR angular spectrum is 
shown with dashed lines in part of the first two steps, and with solid line at the end of the 
experiment. A shift in the MP-SPR angular spectrum resonance angle to higher angles is observed 
as the peptide layer is building up in the lower sample channel (Fig. 9B and the inset displaying the 
SPR peak minimum (SPR) shift; see also Fig. 8A green trace). The corresponding shift is distinctly 
smaller in the MP-SPR angular spectrum representing the upper channel where the SLF was 
disrupting the Aβ self-assembly and oligomerization (Fig. 9A and inset; see also Fig. 8A blue 
trace). The measured and modeled MP-SPR angular spectra at the final situation are in relatively 
good agreement for both sample channel layers. Thus we can consider the calculated layer 
thicknesses (31.89 nm and 1.33 nm) and refractive indices (1.34070 and 1.37139, respectively) 
being relatively good and descriptive in the context of this analysis. 
 
The layer thickness is clearly increased when SLF was not present in comparison to the situation 
where SLF was disrupting the self-assembly of the Aβ (Table 2). Furthermore, an interesting 
physical phenomenon can be observed in the refractive indices (RIs); the thinner layer (1.33 nm) 
without Aβ aggregation has a higher RI than the thicker layer (31.89 nm). This is in agreement with 
previous observations where a thin molecule layer can possess a higher RI than a thicker layer. 
Since the molecules can be assembled in a thin layer much more densely than in a sparse, 
aggregated layer, the light is also refracted more in a denser (but virtually thinner) layer. Another 
possibility lies in the different swelling properties of the layers; the water-based buffer content of 
Fig. 9. Layer modeling results for different situations of Aβ layer build-up. Panel A represents the biomolecular layer 
formation from the measurements in Fig. 8, where the SLF hampers the self-assembly processes of Aβ. Panel B shows 
the layer construction from the measurement in Fig. 8 where SLF was not present in the measurement, resulting in 
great r peptide aggregation (increas d layer thickness).
trace). This result is consistent with previous 
spectroscopic studies showing that SLF inhibits 
Aβ self-association (14,15).
SLF mediated oligomerization of Aβ 
can also be detected by change in layer 
thickness. Since the theoretical findings 
(29-31), the multi-wavelength approach in 
MP-SPR for surface characterization has 
been successfully demonstrated in multiple 
applications (32-34). The unique solution for 
the apparently interconnected thickness (d) and 
refractive index (n) of the sample layer can be 
found from the intersection of two continuum 
solutions, thus the MP-SPR measurements 
performed at multiple wavelengths can provide 
a direct indication of the layer thickness, 
thereby quantification of the mass added to 
the surface (32,33). 
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The MP-SPR angular spectra in Fig. 9 represent 
the whole layer modeling procedure with 
intermediate steps shown, based on the data in 
Fig. 8. We started the modeling by determining 
first the background for our measured layer 
system, i.e. the metal (gold) layer. It should 
be noted that this background modeling step 
was performed with the inclusion of the SAM 
layer into the background calculation for two 
reasons; firstly, the contribution of SAM layer 
was considered very small to the measured MP-
SPR angular spectra, and secondly, previous 
observations support the estimate that the 
calculation does not suffer from inaccuracies 
within the context of this analysis (34). The 
layer after the streptavidin immobilization was 
measured next, and lastly the final situation 
after injection of the native Aβ monomer. For 
clarity, the 670 nm laser data is shown in Fig. 
9 panels (the 785 nm laser data not shown), 
and the measured MP-SPR angular spectrum 
is shown with dashed lines in part of the first 
two steps, and with solid line at the end of the 
experiment. A shift in the MP-SPR angular 
spectrum resonance angle to higher angles is 
observed as the peptide layer is building up 
in the lower sample channel (Fig. 9B and 
the inset displaying the SPR peak minimum 
(θSPR) shift; see also Fig. 8A green trace). The 
corresponding shift is distinctly smaller in the 
MP-SPR angular spectrum representing the 
upper channel where the SLF was disrupting 
the Aβ self-assembly and oligomerization 
(Fig. 9A and inset; see also Fig. 8A blue 
trace). The measured and modeled MP-SPR 
angular spectra at the final situation are in 
relatively good agreement for both sample 
channel layers. Thus we can consider the 
calculated layer thicknesses (31.89 nm and 
1.33 nm) and refractive indices (1.34070 and 
1.37139, respectively) being relatively good and 
descriptive in the context of this analysis.
The layer thickness is clearly increased 
when SLF was not present in comparison to 
the situation where SLF was disrupting the self-
assembly of the Aβ (Table 2). Furthermore, 
an interesting physical phenomenon can be 
observed in the refractive indices (RIs); the 
thinner layer (1.33 nm) without Aβ aggregation 
has a higher RI than the thicker layer (31.89 
nm). This is in agreement with previous 
observations where a thin molecule layer can 
possess a higher RI than a thicker layer. Since 
the molecules can be assembled in a thin layer 
much more densely than in a sparse, aggregated 
layer, the light is also refracted more in a denser 
(but virtually thinner) layer. Another possibility 
lies in the different swelling properties of the 
layers; the water-based buffer content of the 
denser bio-molecule layer is smaller than the 
buffer content in the sparse, aggregated layer, 
thus resulting to the observed difference 
in refractive indices. The hydrodynamic 
diameters determined by the DLS analysis 
are shown in the Table 2. When the SLF was 
present, the Aβ peptide layer thickness is close 
to the hydrodynamic diameter of monomeric 
Aβ. When the SLF was not present and the Aβ 
self-association was let to happen freely, the Aβ 
peptide thickness resembles the hydrodynamic 
diameter of oligomeric Aβs.
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Signal-to-mass conversions for surface 
mass density (Γ) evaluations. The mass 
deposition calculations revealed features that 
may be related to the binding properties of SLF 
or its capability to reduce the Aβ aggregation – or 
both.  In order to evaluate the utility of surface-
deposited molecular mass measurement for 
determining the extent to which SLF can 
modulate Aβ self-assembly, we made two sets 
of surface mass density calculations; one set 
to determine the extent of SLF binding, and a 
second set to measure the effect of SLF on Aβ 
self-assembly. The latter case is discussed in 
more detail in the Supplemental Information. 
With respect to both sets, surface mass density 
calculations correlate the layer thickness 
measurements to kinetic analysis and are 
thereby complementary to the evaluation of 
binding sites identified by kinetic parameters. 
As described in Experimental Procedures, 
the sensorgrams (i.e. the SPR peak minimum 
(θSPR) shift vs. time) used for the signal-to-mass 
conversions were generated from the full MP-
SPR angular spectra, and TIR-corrected with 
regard to the possible bulk effect. Baseline 
correction and normalization were applied for 
the recorded sensorgrams in order to make 
the observed shifts comparable with each 
other and between different datasets. Surface 
mass densities were then calculated from the 
sensorgrams as described in Experimental 
Procedures. Measurements of surface mass 
density alterations resulting from SLF additions 
to monomeric and oligomeric Aβ are shown in 
Fig. 10, and the calculated values reported in 
Table 3.  Injections of SLF over a range of 10 µM 
to 40 µM to the tethered Aβ monomer results in 
a surface mass density increase of ~120 ng/cm2 
(Fig. 10A). With the same SLF treatment to 
Aβ comprised of tethered monomers exposed 
to 2 injections of monomeric native peptide, 
we observe a surface mass density increase of 
~66 ng/cm2 (Fig. 10B). This result is similar to 
what is observed when the same range of SLF is 
injected over tethered Aβ monomer interacting 
with AβO pretreated with SLF, where a mass 
density increase of ~69 ng/cm2 is calculated 
(Fig. 10C). A slightly higher increase in the 
surface mass density is obtained when SLF is 
added to AβO alone, ~84 ng/cm2 (Fig. 10D). 
This result is consistent with the kinetic analysis 
above reflecting AβO has a lower capacity 
for additional SLF binding following SLF 
pretreatment.
Table 2. Layer thickness and refractive index calculations from the data in Fig. 9. For comparison, the hydrodynamic 
diameters of Aβ monomers and Aβ oligomers determined by DLS are shown.
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the denser bio-molecule layer is smaller than the buffer content in the sparse, aggregated layer, thus 
resulting to the observed difference in refractive indices. The hydrodynamic diameters determined 
by the DLS analysis are shown in the Table 2. When the SLF was present, the Aβ peptide layer 
thickness is close to the hydrodynamic diameter of monomeric Aβ. When the SLF was not present 
and the Aβ self-association was let to happen freely, the Aβ peptide thickness resembles the 
hydrodynamic diameter of oligomeric Aβs. 
 
Table 2. Layer thickness and refractive index calculations from the data in Fig. 9. For comparison, 
the hydrodynamic diameters of Aβ monomers and Aβ oligomers determined by DLS are shown. 
Flow channel Layer Thickness (nm) Refractive Index 
Upper (SLF present) 1.33 1.37139 
Lower (SLF not present) 31.89 1.34070 
 
Hydrodynamic diameter (nm) 
Monomeric Aβ 1.4 
Oligomeric Aβ 75 
 
Signal-to-mass conversions for surface mass density (Γ) evaluations. The mass deposition 
calculations revealed features that may be related to the binding properties of SLF or its capability 
to reduce the Aβ aggregation – or both.  In order to valuate he utility of surface-deposited 
molecular mass measurement for determining the exte t to hich SLF c n modulate A self-
assembly, we made two set of surfac  mass density calculations; one s t to determine the extent of 
SLF binding, and a second set to measure the effect of SLF on A self-assembly. The latter case is 
discussed in more detail in the Supplemental Information. With resp ct to both sets, surface mass 
density calculations c rrelate th  layer thickness measurem nts to kinetic analysis and are thereby 
complem ntary to the ev luation of binding sites identified by kinetic parameters.  
 
As described in Experimental Procedur s, the sensorgrams (i. . the SPR peak minimum (SPR) shift 
vs. time) used for the signal-to-m ss conv r ions were generat d from the full MP-SPR angular 
spectra, and TIR-correct d with regard to the possible bulk effect. Baseline correction and 
normalizati n were applied for the recorded sensor rams in order to make he observed shifts 
comparable with each other and between ifferent datasets. Surface mass d nsities were then 
calculated from the s nsorgrams as described in Exp rimental Pr cedures. Measur ments of 
surface mass density alterations esulting from SLF additions to monomeric and oligomeric A are 
shown in Fig. 10, and the calculated values r ported in Table 3.  Injection  of SLF ove  a range of 
10 µM to 40 µM to the tethered Aβ monomer results n a surface mass density increase of ~120 
ng/cm2 (Fig. 10A). With the same SLF treatment to A c mpris d of tethered monomers exposed 
to 2 injectio s of monom ric native eptide, we observe a su f ce mass density increase of ~66 
ng/cm2 (Fig. 10B). This result is simila  to what is observed when the same range of SLF is injected 
over tethered A monomer interacting with AO pretreated with SLF, where a mass density 
increase of ~69 ng/c 2 is calculated (Fig. 10C).  A slightly higher increas  in the surface mass 
density is obtained when SLF is added to AβO alone, ~84 ng/cm2 (Fi . 10D).  This result is 
consistent with the kinetic analysis above reflecting AO has a lower capacity for additional SLF 
binding following SLF pretreatment. 
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Table 3. Surface mass density calculations for the different 
SLF interaction schemes.
SLF Interaction Surface mass density (Γ) (ng/cm2)
Tethered Aβ monomer 120
Monomeric native Aβ 66
AβO pretreated with SLF 69
AβO only 84
Based on the results of kinetic analysis in Fig. 
5, it is somewhat surprising that injections 
of native monomeric Aβ to the tethered 
monomeric Aβ resulted in a lower net surface 
mass density increase compared to the tethered 
peptide alone (~66 ng/cm2 and ~120 ng/cm2, 
respectively). However, these samples are not 
comparable as the measurements in Fig. 10B 
were carried out with two separate injections 
of monomeric Aβ.  Thus, rather than being 
comprised primarily of dimeric species as in 
Fig. 5, it is likely the additional injection of Aβ 
in Fig. 10B results in the formation of small 
oligomers. This interpretation is consistent 
with our finding of weaker SLF binding to 
further progressed AβO species (Table 1).
Fig. 10. Surface mass density calculations. Calculations for different SLF interaction schemes with tethered monomeric 
Aβ alone (A); native monomeric Aβ bound to tethered monomers (B); AβO pretreated with SLF at a 1:2 molar ratio 
bound to tethered monomers (C); AβO bound to tethered monomers (D). The traces have been normalized in order 
to calculate the approximate surface mass density that is generated by the SLF molecules when they are interacting 
and associating to investigated forms of Aβ.
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Table 3. Surface mass density calculations for the different SLF interaction schemes. 
SLF I teraction Surface mass density (Γ) (ng/cm2) 
Tethered Aβ monomer 120 
Monomeric native Aβ 66 
AβO pretreated with SLF 69 
AβO only 84 
 
Based on the results of kinetic analysis in Fig. 5, it is somewhat surprising that injections  native 
monomeric A to the tethered monomeric A resulted in a lowe  net urfac mass de sity increase 
compared to the tethered peptide alone (~66 ng/cm2 and ~120 ng/cm2, respectively). However, 
these samples are not comparable as the measurements in Fig. 10B were carried out with two 
separate injections of monomeric A.  Thus, rather than being comprised primarily of dimeric 
species as in Fig. 5, it is likely the additional injection of A in Fig. 10B results in the formation of 
small oligomers. This interpretation is consistent with our finding of weaker SLF binding to further 
progressed AβO species (Table 1). 
 
 
Fig. 10. Surface mass density calculations. Calculations for different SLF interaction schemes 
with tethered mo omeric A alone (A); nativ  nomeric β bound to tethered mon mers (B); 
AβO pretreated with SLF at a 1:2 molar ratio bound to tethered monomers (C); AβO bound to 
tethered monomers (D). The traces have been normalized in order to calculate the approximate 
surface mass density that is generated by the SLF molecules when they are interacting and 
associating to investigated forms of Aβ. 
 
Molecular docking and molecular dynamics simulations as a computational tool for modeling 
SLF interaction with Aβ-peptides. We carried out docking calculations to find out the most potent 
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Molecular docking and molecular 
 dynamics simulations as a computa-
tional tool for modeling SLF interaction 
with Aβ-peptides. We carried out docking 
calculations to find out the most potent interac-
tion sites for SLF at the surface of Aβ-peptide. 
Since the Aβ-peptide is a highly dynamic and 
disordered peptide when in solution, we carried 
out a single 20 ns long simulation (referred to 
as S1) in order to generate four structures for 
docking calculations (see Table 4.). In this 
fashion, it was possible to estimate the degree 
to which the binding sites and free-energies are 
affected by the possible secondary structure 
changes and amino acid side chain conforma-
tions. The RMSD of the Aβ-peptide backbone 
was stabilized after 3 ns (See Fig. 11A). In addi-
tion, the secondary structure of the Aβ-peptide 
did not deviate considerably from the starting 
conformation although some minor changes 
were expected, as it is known (35-38) that this 
structure is weakly ordered in aqueous solu-
tion (See Fig. 11B). We chose four structural 
snapshots starting from time point separated 
by 5 ns intervals for docking. The docking re-
sults are shown in (Fig. 11). The lowest binding 
free-energies are marked next to the peptide 
conformations in each case. The docking results 
generated using several Aβ-peptide conforma-
tions indicate that there is no specific binding 
site for SLF (See Fig. 11C). Nevertheless, the 
binding free-energies varied between -7.5 and 
-6.8 kcal/mol and this was in good agreement 
with the SPR derived binding free energies of 
-6.8 and -6.2 kcal/mol (KD1 with native bioti-
nylated or non-biotinylated Aβ, respectively). 
Notably, these biding energies are on par with 
from simulations of Aβ and a bromo-fluorene 
containing a dimethyl-amino group in the posi-
tion of our spin-label (39). We therefore have 
a reasonable thermodynamic basis for the low 
docking free energies that are observed ex-
perimentally; consistent with an interaction 
between the Aβ-peptide and SLF that does not 
involve a specific binding site. However, our 
simulations did not find a docking configura-
tion on the order of -20 kcal/mol, which would 
account for the sub-nanomolar binding also 
observed within preparations of monomer/
dimer samples.
Table 4. Simulated systems and the length of simulations.
Simulation time Molecules Reason
S1 20 ns Aβ-peptide+water For docking purposes
S2 100 ns Aβ-peptide+SLF+water (site 1) For probing SLF and Aβ interactions
S3 100 ns Aβ-peptide+SLF+water (site 2) For probing SLF and Aβ interactions
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Since the results of the docking calculations 
indicated that the interaction between the SLF 
with the Aβ-peptide were strong yet mostly 
non-specific, we carried out two 100 ns long 
molecular dynamics simulations that we refer 
to as simulations S2 and S3, to probe the 
behavior of the SLF molecule at the surface of 
the Aβ-peptide. MD simulations were started 
with the SLF either at the lowest free-energy 
binding site of the 15 ns or 20 ns snapshot. The 
snapshots and atomic contacts between the SLF 
molecules and the Aβ-peptide revealed that the 
SLF molecule stays at the surface of the Aβ-
peptide (See Fig. 12). By careful inspection of 
the simulation trajectories and atomic contacts 
it was found that the Aβ-peptide can at least 
transiently fold around the SLF molecule 
during both simulations (See Fig. 12).  To 
estimate the effect of a SLF induced binding 
pocket to its binding free-energy, we docked the 
molecule once again to the Aβ-peptide structure 
of simulation S2 after the 100 ns simulation. 
The docking calculation results showed that 
the refolding of the Aβ-peptide around the 
SLF molecule resulted in a small free-energy 
of binding increase up to -8.5 kcal/mol.
Fig. 11. Docking calculation results for four snapshots derived from S1 simulation. (A) The secondary structure of 
Aβ-peptide as a function of S1 simulation time. Aβ-peptide has been rendered using cartoon representation and 
colored according to the secondary structure.  (B) The root mean square deviation of (RMSD) Aβ-peptide backbone 
as a function of time. (C) The binding free-energies of SLF generated by the Autodock Vina are shown next to SLF 
molecules in kcal/mol (van der Waals representation). Purple color indicates α-helix, white random coil, and cyan turn 
structure. The SLF molecule is rendered van der Waals spheres and colored according to atom types. White spheres 
are hydrogen atoms, cyan carbon, red oxygen, blue nitrogen, and pink bromine atoms.
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Fig. 11. Docking calculation results for four snapshots derived from S1 simulation. (A) The 
secondary structure of Aβ-peptide as a function of S1 simulation time. Aβ-peptide has been 
rendered using cartoon representation and colored according to the secondary structure.  (B) The 
root mean square deviation of (RMSD) Aβ-peptide backbone as a function of time. (C) The binding 
free-energies of SLF gen rated by the Autodock Vina are shown next to SLF mol cules i  kcal/mol 
(van der Waals representation). Purple color indicates α-helix, w ite random coil, and cyan t rn 
structure. The SLF molecule is rendered van der Waals spheres and colored according to atom 
types. White spheres are hydrogen atoms, cyan carbon, red oxygen, blue nitrogen, and pink bromine 
atoms. 
 
Since the results of the docking calculations i dicated that the interaction between the SLF with the 
Aβ-pepti e were strong yet mostly non-specific, we carried out two 100 ns l ng m lecular 
dynamics simulations that we refer to as simulations S2 and S3, to probe the behavior of the SLF 
molecule at the surface of the Aβ-peptide. MD simulations were started with the SLF either at the 
lowest free-energy binding site of the 15 ns or 20 ns snapshot. The snapshots and atomic contacts 
between the SLF molecules and the Aβ-peptide revealed that the SLF molecule stays at the surface 
of the Aβ-peptide (See Fig. 12). By careful inspection of the simulation trajectories and atomic 
cont cts it was found that th  Aβ-peptide can at least transiently fold arou d the SLF molecule 
during both simulations (See Fig. 12).  To estimate the effect of a SLF induced binding pocket to its 
binding free-energy, we docked the molecule once again to the Aβ-peptide structure of simulation 
S2 after the 100 ns simulation. The docking calculation results showed that the refolding of the Aβ-
peptide around the SLF molecule resulted in a small free-energy of binding increase up to -8.5 
kcal/mol. 
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DISCUSSION
As there is ample evidence in the literature that 
the neuronal damage in AD is derived from the 
toxicity of soluble Aβ oligomers (6,40), there 
remains, however, much to be discovered 
regarding the toxicity of the Aβ oligomers due 
to the many faces of the complex aggregation 
pattern of Aβ. The relationship between 
function and structure is altered to a higher 
degree when a dynamic oligomerization/
aggregation pattern yields oligomers with a 
large number of interchangeable, yet distinct 
conformational polymorphisms (41). It is thus 
very possible that Aβ toxicity is associated with 
the process of aggregation and its many resulting 
species rather than a specific oligomeric state 
(21,41,42).  
The SLF interaction kinetics analysis was 
started using a relatively simple 1:1 modeling. 
However, it was not descriptive or consistent 
with the experimental data in any of the four 
Fig. 12. Snapshots from the beginning and end of SLF simulations S2 and S3 (top). Number of contacts between SLF 
and Aβ-peptide as a function of simulation time (bottom). Aβ-peptide has been rendered using cartoon or wireframe 
representation and colored according to the secondary structure. Purple color indicates α-helix, white random coil, 
blue 310-helix, and cyan turn structure. SLF molecule is rendered van der Waals spheres and colored according to atom 
types. White spheres are hydrogen atoms, cyan carbon, red oxy
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Fig. 12. Snapshots from the beginning and end of SLF simulations S2 and S3 (top). Number of 
contacts between SLF and Aβ-peptide as a function of simulation time (bottom). Aβ-peptide has 
been rendered using cartoon or wireframe representation and colored according to the secondary 
structure. Purple color indicates -helix, white random coil, blue 310-helix, and cyan turn structure. 
SLF molecul  is ren ered van der Waals spheres and colored according to atom types. White 
spheres are hydrogen atoms, cyan carbon, red oxygen, blue nitrogen, and pink bromine atoms. 
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calculated scenarios – the Chi2 values being 
in the order of ~500-700 (data not shown). 
On the basis of our previous studies (e.g. 
references 14-16) we had an initial hypothesis 
that the SLF may express multivalent binding. 
Thus a 1:2 binding model was employed 
yielding significantly more accurate fitting. 
The relatively small Chi2 values for the four 
calculated scenarios are shown in Table 1, 
and the molecular docking simulations support 
these perceptions providing rationale for 
using the 1:2 binding model in the interaction 
kinetics calculations. For monomeric Aβ, KD1 
of 15 µM and KD2 in the sub-nanomolar range 
were calculated. When SLF interacts with a 
surface comprised of native monomeric Aβ 
bound to a tethered Aβ monomer, KD1 (41 µM) 
and KD2 (sub-nanomolar) are on par with the 
tethered monomer. It is noteworthy that the 
lack of appreciable SLF dissociation within 
the high affinity (KD2) binding mode produces 
relatively large uncertainty in its calculated 
value.  Although the current methodology 
cannot precisely generate KD2 values for the 
monomer/dimer samples, we designate these 
affinities as “subnanomolar”, which represents 
a conservative upper limit for the observed 
binding behavior. Nevertheless, these results 
indicate Aβ maintains a highly avid SLF binding 
in both the monomer or dimer states.
For oligomeric Aβ, the affinity of AβO 
for SLF is substantially lower, with both KD1 
and KD2 in the 100 µM range (Table 1.). In 
addition, the Bmax1 and Bmax2 values (Table 1.) 
report about the relative amount of SLF binding 
to corresponding binding sites, i.e. in the 1:2 
binding model those sites are represented 
by the affinity values KD1 and KD2. As SLF 
Fig. 13.  Schematic for Aβ-SLF interactions. Experimental and in silico evidence suggests the central hydrophobic 
core encompassing residues 17-21 in the peptide as the target for small molecule and peptide-based inhibitors of Aβ 
aggregation and/or fibrillation (39,43-46). Our simulations, as well as those by Li et al. on a related fluorene compound 
(39), suggest a non-specific interaction of SLF around the hydrophobic core of Aβ (residues 17-21) with binding 
energies correlating to micromolar affinity. However, the basis for the high affinity SLF binding to the monomer is not 
clearly evident. One possibility is that high affinity binding requires tertiary pocket available in the monomer that is 
not present in the oligomer, which to favor a largely disordered antiparallel arrangement (47-49). For example, such 
a pocket could be formed by a β-hairpin fold of the monomer (50,51). Oligomers of Aβ in hairpin conformations have 
been observed in Aβ modified with a disulfide cross-link (52), however these species have increased neurotoxicity as 
opposed to the non-toxic SLF oligomers (14,15). 
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The SLF interaction kinetics analysis was started using a relatively simple 1:1 modeling. However, 
it was not descriptive or consistent with the experimental data in any of the four calculated 
scenarios – the Chi2 values being in the order of ~500-700 (data not shown). On the basis of our 
previous studies (e.g. references 14-16) we had an initial hypothesis that the SLF may express 
multivalent binding. Thus a 1:2 binding model was employed yielding significantly more accurate 
fitting. The relatively small Chi2 values for the four calculated scenarios are shown in Table 1, and 
the molecular docking simulations support these perceptions providing rationale for using the 1:2 
binding model in the interaction kinetics calculations. For monomeric A, KD1 of 15 M and KD2 in 
the sub-nanomolar range were calculated. When SLF interacts with a surface comprised of native 
monomeric Aβ bound to a tethered Aβ monomer, KD1 (41 M) and KD2 (sub-nanomolar) are on par 
with the tethered monomer. It is noteworthy that the lack of appreciable SLF dissociation within the 
high affinity (KD2) binding mode produces relatively large uncertainty in its calculated value.  
Although the current methodology cannot precisely generate KD2 values for the monomer/dimer 
samples, we designate these affinities as “subnanomolar”, which represents a conservative upper 
limit for the observed binding behavior. Nevertheless, these results indicate A maintains a highly 
avid SLF binding in both the monomer or dimer states. 
 
For oligomeric A, the affinity of AO for SLF is substantially lower, with both KD1 and KD2 in the 
100 M range (Table 1.). In addition, the Bmax1 and Bmax2 values (Table 1.) report about the relative 
amount of SLF binding to corresponding binding sites, i.e. in the 1:2 binding model those sites are 
represented by the affinity values KD1 and KD2. As SLF interactions are tested across the various A 
configurations of tethered monomer, dimer, AβO and SLF-pretreated AβO, the relationships of 
Bmax1 and Bmax2 values shift from (~ 1:1  1:7  1:3  1:2.5), respectively, thus indicating that 
the secondary SLF binding site (KD2) already becomes more occluded in the dimer configuration. 
This is consistent with the slightly weaker KD2 value obtained for the A dimer (~ 10-13 M) vs. the 
tethered monomer (~ 10-15 M), although again these values should be viewed with caution due to 
the inherent uncertainty of calculating dissociation values in this regime. It is to be noted that the 
secondary binding site of SLF becomes slightly more crowded in the case of AβO vs. SLF-
pretreated AβO in terms of the relationship of Bmax values (1:3 vs. 1:2.5). This implies that the SLF 
binding capacity of AβO is slightly higher than that of the SLF-pretreated AβO. Furthermore, these 
results suggest that inter-peptide interactions preclude a high affinity binding conformation that is 
available to the monomer. A schematic summarizing SLF binding and its effect on the A oligomer 
growth is shown in Fig. 13. 
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interactions are tested across the various Aβ 
configurations of tethered monomer, dimer, 
AβO and SLF-pretreated AβO, the relationships 
of Bmax1 and Bmax2 values shift from (~ 1:1 → 1:7 
→ 1:3 → 1:2.5), respectively, thus indicating 
that the secondary SLF binding site (KD2) 
already becomes more occluded in the dimer 
configuration. This is consistent with the slightly 
weaker KD2 value obtained for the Aβ dimer (~ 
10-13 M) vs. the tethered monomer (~ 10-15 M), 
although again these values should be viewed 
with caution due to the inherent uncertainty of 
calculating dissociation values in this regime. 
It is to be noted that the secondary binding 
site of SLF becomes slightly more crowded 
in the case of AβO vs. SLF-pretreated AβO in 
terms of the relationship of Bmax values (1:3 
vs. 1:2.5). This implies that the SLF binding 
capacity of AβO is slightly higher than that of 
the SLF-pretreated AβO. Furthermore, these 
results suggest that inter-peptide interactions 
preclude a high affinity binding conformation 
that is available to the monomer. A schematic 
summarizing SLF binding and its effect on the 
Aβ oligomer growth is shown in Fig. 13.
The very high binding affinity detected 
in the monomer could also arise from an 
induced fit within a local binding pocket 
requiring a backbone configuration that is 
not favored in the oligomer. For example, in 
X-ray structures of Orange G and a peptide 
of the central hydrophobic core two modes 
of small molecule binding were found (43). 
One mode being a highly specific binding to 
a beta zipper structure and the second being a 
non-specific interaction at an adjacent cavity. 
Other backbone conversions may also underlie 
a high affinity induced fit for SLF binding.  For 
example, we have previously shown that SLF 
generates a circular dichroism spectral shape 
resembling the polypro (II) structure (15). 
Studies by Danielsson et al (53) suggest that in 
the peptide monomer, the backbone within the 
N-terminal portion of Aβ (including the central 
core of 17-21) readily converts between β and 
polypro(II)-like conformations, with the later 
state being less prone to aggregation. Thus, it 
is also possible that SLF binds and stabilizes a 
specific secondary structural state occupied by 
the monomer.
Although SLF inhibits oligomer growth and 
reduces the size of preassembled oligomers, 
previous FCS (fluorescence correlation 
spectroscopy) analyses indicate that these 
complexes assemble into a smaller, more stable 
form of AβO (15) (Fig. 13).  Thus, regardless 
of the mode of high affinity SLF binding in 
the monomer, initial thermodynamic forces 
driving monomeric Aβ and SLF interaction 
are not available in the oligomer.  In addition 
to the steric factors discussed above, other 
considerations can be a reduction of the 
hydrophobic effect on binding once the peptide-
SLF is buried in the oligomer or, given that 
SLF has both H-bond acceptors and donors, 
the interference of coordinating H-bonds by 
groups involved in intermolecular H-bonds.
Layer thickness analysis provided additional 
support for the ability of SLF to slow the 
progression of Aβ oligomerization, by showing 
that there is significantly more Aβ deposited 
on the sensor surface in the absence of SLF 
than in the presence of SLF, in fact factor of 
30 more (Table 2). The optical modeling 
performed on the basis of the measured full 
SPR angular spectra yielded consistent results 
with the DLS measurements. When the SLF 
was hampering the self-association of the 
Aβs, close to monomeric Aβs formed ~ 1.33 
nm peptide layer onto the sensor surface in 
low aggregation buffer flow. On the other, the 
DLS demonstrated the mean hydrodynamic 
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diameter of ~ 1.4 nm when the Aβs were 
measured in the similar low aggregation 
buffer conditions. Furthermore, the modeled 
Aβ layer when SLF was not present can be 
interpreted as an early oligomerized Aβ layer, 
the optical modeling showing the thickness 
of 31.89 nm (as displayed in Table 2). To 
support this, the DLS measurements showed 
the mean hydrodynamic diameter of ~ 75 nm 
for the AβOs. It is worth emphasizing that both 
the MP-SPR measurements were carried out 
in low aggregation buffer whereas the DLS 
measurements for the AβOs were performed 
in high aggregation buffer, which may explain 
the difference in the latter thickness and mean 
hydrodynamic diameter (31.89 nm vs. 75 nm). 
Nevertheless, a clear trend – the Aβ layer 
thickness growing towards the measured mean 
hydrodynamic diameter of AβO – can already 
be seen if the SLF is not employed to prevent 
those processes. In addition, these perceptions 
also underline the fact that the four different 
experimental schemes for investigating the 
physicochemical properties and interactions 
of SLF can be considered to have successfully 
encompassed the monomeric or close-to-
monomeric states of Aβs to oligomerized forms 
of Aβs (AβO).
The surface mass density analysis 
complemented the perceptions that the closer 
to the monomeric state the Aβ are, the more 
prone they are to avid SLF binding. However, 
some precautions should be included in the 
surface concentration analysis performed on the 
basis of the MP-SPR signals and the de Feijter 
equation. Firstly, even though the variations 
in the refractive index of the medium (nm in 
Eq. (6)) are typically small, the differences in 
  for biomolecules in different buffers may 
have distinct variations (54-56). In addition, 
the refractive index increment is dependent 
of the measurement wavelength. In general, 
lower refractive indices can be found with 
increasing wavelength. Another point to take 
into account is the degree of hydration that 
varies in the protein layers, thus inducing 
possible variation to the calculations. To 
sum the mentioned caveats, a uniform   
value for proteins can be challenging to define 
accurately, and its applicability depends on 
the desired level of accuracy in the analysis. 
For example, in biophysical studies focusing 
on protein interactions, the refractive index 
increment is utilized to measure the protein 
concentrations or surface layer thickness, and 
the small errors lie within a tolerable range 
(57). However, the value for increment   
= 0.182 cm3/g can be considered to provide 
adequate accuracy within the context of this 
analysis since other experimental errors 
may contribute to a larger extent to these 
calculations than the value for increment alone. 
Hence, we can conclude that these calculations 
yielded satisfactory approximations on the 
masses of molecules deposited onto the sensor 
surface during the interactions, in addition to 
providing additional mechanistic insight into 
the molecular interactions of Aβ peptides and 
the role played by SLF.
Based on docking calculations and MD 
simulations we suggest that the binding of 
SLF to the surface of the Aβ-peptide is non-
specific since the binding site and energies were 
seen to depend on the both the amino acid side 
chain conformations and secondary structure 
fluctuations. These results are verified by the 
experimental results that show binding energy 
is in rough agreement with our simulation 
results. Furthermore, the MD simulations 
indicated that the SLF remains at the surface 
of the Aβ-peptide and can be surrounded 
or shielded by the peptide. The docking 
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calculations produced binding free-energies 
that were comparable to the KD-values produced 
by several of the experiments (-8.5 kcal/mol). 
We were, however, not able to produce binding 
free-energies comparable with the highest KD 
reported by the experiments. (~-20 kcal/mol). 
As seen in our simulations, it is possible that 
the structure of the Aβ-peptide refolds when it 
interacts with SLF so that it can better shield the 
hydrophobic SLF molecule from its aqueous 
surroundings. Consequently, the shielding 
of SLF by the Aβ-peptide could increase the 
binding free-energy of SLF considerably as was 
shown by our subsequent docking calculations. 
Admittedly, since the Aβ-peptide is weakly 
structured, our simulations were clearly not 
able to sample the accessible phase space of 
this complex molecule completely, thus the 
specific highest KD value conformations were 
probably missed for this reason. Our results 
are in broad agreement with the majority 
of the KD measurements, however, indicate 
that the non-specific binding mechanism, 
involving alteration of the Aβ-peptide to shield 
the SLF is a probable mechanism. A further, 
more rigorous simulation study, involving 
several simulations of microsecond lengths 
and greater, could find the higher KD binding 
conformation, however, it is beyond the scope 
of the current study. We hypothesize that the 
SLF molecule binds strongly to the surface of 
the Aβ-peptide and modify its conformational 
fluctuations in a way which could hinder the 
aggregation of the peptides. It is known that the 
Aβ-peptide is mostly unfolded in the aqueous 
solution although it possesses transient 
structural fluctuations depending on the 
physicochemical surroundings (58,59). Some 
of these transient structures such as β-sheets 
are more prone to the formation of initial Aβ-
peptide aggregation nuclei (60) and thus, if 
the stochastic prevalence of these structures 
are minimized by novel drug agents such as 
SLF, it could possibly be a practical therapy to 
inhibit the aggregation of Aβ-peptides.
CONCLUSIONS
In summary, in this work we have presented a 
novel method for studying protein aggregation 
and small molecules interactions, while 
presenting valuable kinetic binding data. The 
new findings suggest that SLF not only prevents 
Aβ oligomerization, but that the effect is 
expected to be significantly greater at early stage 
of peptide aggregation. In fact, the rationale 
of targeting monomeric Aβ prior to neurotoxic 
oligomer formation has been previously 
postulated (61). To our knowledge, the findings 
present the first biomolecular layer thickness 
and refractive index evaluations to measure the 
accumulation and aggregation of Aβ, a process 
central to the elucidation of AD pathogenesis. We 
envisage that the demonstrated biofunctional 
assay methodology could offer a valuable tool 
to probe for various biophysical phenomena, 
therapeutic agents binding kinetics – not 
only in the context of AD, but possibly other 
diseases as well, where protein aggregation 
is the mechanism of interest, like plaque 
formation in cardiovascular disease, and other 
neurodegenerative diseases.
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EXPERIMENTAL PROCEDURES
Materials. Hexafluoro-2-propanol (HFIP) 
was purchased from Sigma-Aldrich (catalog 
number 105228-25G, St. Louis, MO).  Dime-
thyl sulfoxide (DMSO) was purchased from 
Fisher Scientific (catalog number D12345, 
Pittsburgh, PA). Biotin-PEG-SH was pur-
chased from Nanocs Inc. (catalog number 
PG2-BNTH-5k, New York, NY). 11-Mercapto-
1-undecanol (HS(CH2)11OH) was obtained from 
Sigma Aldrich, St. Louis, MO (catalog number 
447528-1G). The thiols were used as received. 
Streptavidin was purchased from Thermo Sci-
entific (catalog number 43-4301, Pittsburgh, 
PA). Biotin was purchased from Sigma Aldrich 
(catalog number B4501-500MG) St. Louis, 
MO). β-amyloid peptide (1-40) (Seq: DAE-
FRHDSGYEVHHQKLVFF AEDV GS NKGAI-
IGLMVGGVV) and Biotin labeled β-amyloid 
peptide (1-40) (Seq: Biotin-DAEFRHDSGY 
EVHHQKLVFFAEDVGSNKGAIIGLMVGG-
VV) were purchased from EZBiolab Inc., Car-
mel, IN. Spin-labeled fluorene HO-4160 (SLF) 
was synthesized as described in (16).
Preparation of amyloid beta (Aβ) 
peptide samples. To prepare monomers 
of biotinylated or native Aβ, the Aβ peptide 
was dissolved in HFIP and incubated at 
room temperature with gentle rocking for 
48-72 hours. Vacuum evaporation was then 
used to remove the HFIP, resulting in a 
monomeric Aβ pellet. Immediately before 
the given experiment, the HFIP-treated 
pellet was warmed to room temperature and 
reconstituted in 10 μL of fresh DMSO. The Aβ 
in DMSO stock solution was then diluted in 
low ionic strength buffer (25 mM Tris, 1 mM 
EDTA, pH 8.0) to a 10 μM final concentration 
of the peptide monomer and the sample used 
immediately. For oligomeric Aβ (AβO), the 
DMSO Aβ stock was diluted into high ionic 
strength buffer (25 mM Tris, 150 mM NaCl, 
pH 7.0) to a final concentration of 40 μM and 
allowed to incubate at room temperature for 4 
hours.  Just prior to MP-SPR measurements the 
AβO solution was centrifuged at 15,000 x g for 
5 minutes for amorphous aggregate removal. 
The supernatant contained the AβO used for 
MP-SPR measurements. As demonstrated 
previously (14,62) these oligomeric preparations 
are anti-amyloid (A11)-positive oligomers, with 
a 40 μM solution producing particles at 4-hours 
of ~10 nm in diameter by AFM imaging. The 
AβO 40 μM solutions were diluted to 10 μM in 
high aggregation buffer just prior to injection 
into MP-SPR fluidic channels.
To produce SLF labeled AβO, we treated the 
4 hrs AβO incubations with either 80 μM SLF 
(1:2 Aβ/SLF molar ratio to saturate Aβ binding 
sites) or vehicle, and allowed these solutions to 
incubate at room temperature for 4 hrs. Just 
prior to MP-SPR measurements the AβO/SLF 
and AβO/vehicle solutions were centrifuged at 
15,000 x g for 5 minutes, and the supernatant 
removed for MP-SPR measurements.
Characterization of monomer and 
oligomer preparations by dynamic light 
scattering. Particle size analysis of was carried 
out at using dynamic light scattering (DLS) with 
a Brookhaven 90Plus instrument that monitors 
scattered light at 90° to the excitation. For 
monomer samples, Aβ(1-40) was HFIP-treated 
and dried. Immediately before measurement, 
dried pellets were dissolved in DMSO and 
diluted into either low salt buffer, pH 8.0 (for 
monomeric preparations) or diluted into high 
salt buffer, pH 7.0 (for oligomeric preparations). 
Monomeric samples were measured for 20 
minutes, immediately after solvation into 
aqueous buffer to a concentration of 10 μM. 
Oligomeric samples were first incubated for 
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4-hr incubation in high ionic strength buffer. 
All samples were filtered through 0.22 μm filter 
to remove dust particles and large amorphous 
aggregates just prior to measurement. The 
average hydrodynamic radius was calculated 
using the ZetaPlus Particle Sizing Software 
Version 3.57 (Brookhaven Instruments). The 
calculated hydrodynamic diameters of Aβ monomers 
was ~1.4 nm, while the AβO species have an average 
hydrodynamic radius of ~75 nm.
MP-SPR measurements. MP-SPR 
measurements were performed using SPR-Navi 
200TM instrument (BioNavis Ltd., Tampere, 
Finland). The MP-SPR instrument allows for 
expanded SPR sensing, having the capability 
to record the full SPR angular spectra over a 
wide angular range (~ 40-78 degrees). The 
instrument was equipped with two different 
wavelength lasers (670 nm and 785 nm) for 
plasmon excitation in two independent fluidic 
channels, which are integral parts of a PDMS 
flow cell (volume of each flow cell 1 µL). The 
liquid flows were controlled via a peristaltic 
pump and a 12-port chromatography injector, 
the typical flow rates varying between 10-100 
µL/min, and in this particular study, between 
10-20 µL/min. The scanning angle feature and 
utilization of two or more wavelengths enables 
recording full SPR angular spectra (intensity of 
reflected light as a function of angle of incidence) 
in real time. These, in turn, can be used to model 
and calculate e.g. the layer thicknesses (d) and 
refractive indices (n) for the studied molecular 
layers as well as kinetic parameters for the 
interaction phenomena using well-established 
physical models. Additional technical details 
are given in Supplemental Information.
Preparation of the gold sensors for 
MP-SPR measurements. We used the SPR 
NaviTM gold sensor slides SPR102-AU-10 (Au as 
the plasmonic layer, d = 50 nm) provided by 
BioNavis for all of our MP-SPR measurements. 
To functionalize the gold sensor surface we 
followed the standard protocol, as described 
by (23) and adapted it to using biotinylated Aβ 
peptide as the ligand layer as shown in Fig. 
2.  We constructed a supramolecular assembly 
composed of a self-assembled monolayer 
(SAM) to which we attached the biotinylated Aβ 
peptide to form the functionalized gold sensors. 
Before surface assembly, the plain gold sensors 
were cleaned with absolute ethanol, and dried 
with nitrogen gas. First, we reconstituted the 
11-Mercapto-1-undecanol and the biotin-PEG-
SH in absolute ethanol to form a MuOH: Biotin-
PEG-thiol (85:15 mol %, 5mM) (MBP-thiol) 
SAM solution. An adsorbed biotinylated, self-
assembled monolayer (SAM) was generated 
directly on the gold sensor; the mixed, MBP/
PEG thiols make a better self-assembly layer 
than PEG-thiol alone by resisting non-specific 
protein adsorption. The gold sensors were 
then immediately immersed in an MBP-thiol 
SAM solution, in a glass Petri dish, gold face 
up, and incubated for at least 16hrs, at room 
temperature, in the dark and the MBP-thiol 
was allowed to adsorb onto the gold sensor. 
The Petri dish was sealed with wax paper to 
prevent evaporation. Subsequently, the gold 
sensors were removed from the solution, 
washed in absolute ethanol and dried with 
nitrogen gas and loaded into the instrument. 
The second molecular layer was constructed 
by immobilization of streptavidin monitored 
in situ with the MP-SPR instrument, as 200 
μg/ml of Streptavidin in DI water, was flown 
over the MBP-thiol SAM sensor surface at 10 
μl/min. After a stable baseline was obtained 
we proceeded to build the third molecular 
layer by injecting 10μM biotinylated Aβ in 
low aggregation buffer (25 mM Tris, 1 mM 
EDTA, pH 8.0) at 10μL/min, followed by low 
128
aggregation buffer until a stable baseline was 
noted. For the control channel (shown in Fig. 
3, green trace) we followed the same procedure 
for the first and second layer, except that the 
third layer was built by flowing 300 μL of 1mM 
biotin, at 10 μl/min until a stable baseline 
was noted. Peptide/peptide and peptide/SLF 
interactions were detected by measuring the 
shift in the SPR peak minimum (θSPR) before 
and after each sample injection.
To investigate SLF/Aβ binding, various SLF 
dilutions (10 µM, 20 µM, 30 µM, 40 µM) in 
low ionic strength buffer, pH 8.0, were flowed 
over the biotinylated Aβ biosensor surface at 
the concentrations indicated in the figures. 
Non-specific binding was tested by application 
of the same SLF dilutions over the MBP-Thiol 
SAM/Streptavidin/biotin surface without Aβ. 
Similarly, to check for non-specific Aβ binding, 
10 μM of non-biotinylated Aβ was flowed 
over the MBP-Thiol SAM/Streptavidin/biotin 
surface.
Physical principles of the interaction 
kinetics analysis. Kinetic analyses were 
performed using the SPR Navi™ Data Viewer 
4.0 (BioNavis Ltd., Tampere, Finland) and 
the TraceDrawer 1.6 software (Ridgeview 
Instruments AB, Vänge, Sweden) - data 
shown in Table 1. Graphs in all figures were 
constructed using OriginPro 8.6 (Northampton, 
Massachusetts, USA). We started the kinetic 
analysis by selecting the desired interactions 
of each particular scheme. The kinetic fitting 
is based on the sensorgrams, which show the 
change in the SPR resonance angle (change in 
the SPR peak minimum (θSPR)) as a function 
of time (Fig. 4). We performed the analysis of 
SLF interactions in 4 different schemes; (i) SLF 
interacting with biotinylated Aβ, (ii) with native 
(non-biotinylated) Aβ, (iii) with AβO, and (iv) 
with AβO pretreated with SLF at a molar ratio 
of 1:2. The sensorgrams were baseline corrected 
by using a baseline level correction algorithm. 
Consequently, the bulk- and baseline-corrected 
sensorgrams were processed in the fitting phase 
with two different binding models within the 
TraceDrawer 1.6 software. SLF-Aβ interaction 
schemes were best fit using the 1:2 model 
appropriate for binding to two independent 
targets on a solid support. The mathematical 
description of the two used models is extensively 
described elsewhere (e.g. (63,64)). As the 
refractive properties of DMSO can change the 
bulk conditions quite drastically, the fitting was 
performed by taking into account the possible 
bulk effect the DMSO may have had during 
the experiment. The injection of an analyte 
dissolved in the DMSO typically induces a 
clear shift in the total internal reflection (TIR) 
angle. Since the full SPR angular spectrum is 
recorded, the bulk correction can be performed 
by subtracting the contribution of the TIR shift 
from the overall change in the angular position 
of the SPR peak minimum.
Basic SPR theory and physical 
principles of layer thickness modeling. 
The fundamental mathematical depiction of 
SPR is derived from the Maxwell’s equations, 
and has been described profoundly for example 
in (64-67). Briefly, when the matching of 
incident light photons and plasmons occurs, 
the resonance condition is met:
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the instrument. The second molecular layer was constructed by immobilization of streptavidin 
monitored in situ with the MP-SPR instrument, as 200 μg/ml of Streptavidin in DI water, was flown 
over the MBP-thiol SAM sensor surface at 10 μl/min. After a stable baseline was obtained we 
proceeded to build the third molecular layer by injecting 10μM biotinylated Aβ in low aggregation 
buffer (25 mM Tris, 1 mM EDTA, pH 8.0) at 10μL/min, followed by low aggregation buffer until a 
stable baseline was noted. For the control channel (shown in Fig. 3, green trace) we followed the 
same procedure for the first and second layer, except that the third layer was built by flowing 300 
μL of 1mM biotin, at 10 μl/min until a stable baseline was noted. Peptide/peptide and peptide/SLF 
interactions were detected by measuring the shift in the SPR peak minimum (SPR) before and after 
each sample injection. 
 
To investigate SLF/Aβ binding, various SLF dilutions (10 µM, 20 µM, 30 µM, 40 µM) in low ionic 
strength buffer, pH 8.0, were flowed over the biotinylated Aβ biosensor surface at the 
concentrations indicated in the figures. Non-specific binding was tested by application of the same 
SLF dilutions over the MBP-Thiol SAM/Streptavidin/biotin surface without A. Similarly, to check 
for non-specific Aβ binding, 10 μM of non-biotinylated Aβ was flowed over the MBP-Thiol 
SAM/Streptavidin/biotin surface. 
 
Physical principles of the interaction kinetics analysis. Kinetic analyses were performed using 
the SPR Navi™ Data Viewer 4.0 (BioNavis Ltd., Tampere, Finland) and the TraceDrawer 1.6 
software (Ridgeview Instruments AB, Vänge, Sweden) - data shown in Table 1. Graphs in all 
figures were constructed using OriginPro 8.6 (Northampton, Massachusetts, USA). We started the 
kinetic analysis by selecting the desired interactions of each particular scheme. The kinetic fitting is 
based on the sensorgrams, which show the change in the SPR resonance angle (change in the SPR 
peak minimum (SPR)) as a function of time (Fig. 4). We performed the analysis of SLF interactions 
in 4 different schemes; (i) SLF interacting with biotinylated Aβ, (ii) with native (non-biotinylated) 
Aβ, (iii) with AβO, and (iv) with AβO pretreated with SLF at a molar ratio of 1:2. The sensorgrams 
were baseline corrected by using a baseline level correction algorithm. Consequently, the bulk- and 
baseline-corrected sensorgrams were processed in the fitting phase with two different binding 
models within the TraceDrawer 1.6 software. SLF-A interaction schemes were best fit using the 
1:2 model appropriate for binding to two independent targets on a solid support. The mathematical 
description of the two used models is extensively described elsewhere (e.g. (63,64)). As the 
refractive properties of DMSO can change the bulk conditions quite drastically, the fitting was 
performed by taking into account the possible bulk effect the DMSO may have had during the 
experiment. The injection of an analyte dissolved in the DMSO typically induces a clear shift in the 
total internal reflection (TIR) angle. Since the full SPR angular spectrum is recorded, the bulk 
correction can be performed by subtracting the contribution of the TIR shift from the overall change 
in the angular position of the SPR peak minimum. 
 
Basic SPR theory and physical principles of layer thickness modeling. The fundamental 
mathematical depiction of SPR is derived from the Maxwell’s equations, and has been described 
profoundly for example in (64-67). Briefly, when the atching of incident light photons and 
plasmons occurs, the resonance condition is met: 
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where c is the speed of light in vacuum, ω is the light frequency, θ0 is the angle of incidence of the 
light beam, and ε0, ε1, ε2 are the dielectric constants of the prism, the metal, and the medium in 
contact with it, respectively. In general, the dielectric constant ε and refractive index n for a given 
where c is the speed of light in vacuum, ω is the 
light frequency, θ0 is the angle of incidence of 
the light beam, and ε0, ε1, ε2 are the dielectric 
constants of the prism, the metal, and the 
medium in contact with it, respectively. In 
general, the dielectric constant ε and refractive 
index n for a given material can be expressed 
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in their complex forms as 
, and , where , n and k are the 
complex refractive index, real- and imaginary 
part of the complex refractive index, respectively. 
The quantity  denotes permeability, occurring 
in Maxwell’s equations. Since the majority 
of materials are non-magnetic at optical 
frequencies, μ can be approximated very close 
to 1. Similarly, , ε and   are the complex 
dielectric constant, real- and imaginary part 
of the complex refractive index. As a sum of 
the definitions made here, the refractive index 
and dielectric constant are related as  . 
For the layer thickness and refractive index 
modeling, the shape and quantities associated 
with the SPR spectra were utilized. The spectra 
can be described with Fresnel’s equations as 
the reflectivity of a multilayered system for 
p-polarized light. In practice, the modeling and 
solving for the matrix formalism was performed 
by mathematical fitting tools, or dedicated 
software. The layer thicknesses and refractive 
indices of the thin bio-molecular layers were 
solved by the two-wavelength method with 
angular scanning in all our experiments (29-
31). LayerSolver 1.0.2 (BioNavis Ltd., Tampere, 
Finland) software was used for modeling and 
solving for the layer properties.
The thicknesses of the modeled layers were 
linked as common variables in the modeling 
performed with the LayerSolver, i.e. the layer 
thickness was expected to be the same for both 
wavelengths since the MP-SPR angular spectra 
were measured from the same spot in the upper 
and lower sample channels. The complex 
refractive index was input as an independent 
variable for background (pure metal layer) 
modeling, or as a linearly dependent variable 
between the two used wavelengths.
Physical principles of the surface 
mass density calculations. The molecular 
mass that binds onto the SPR sensor surface 
has a well-defined correlation with the observed 
MP-SPR angular spectrum – in particular, 
the SPR resonance angular shift (57,64). 
Importantly, since water is very weakly optically 
active compound in SPR measurements, only 
the deposited dry mass is detected (68). In 
order to calculate the surface mass densities 
of biomolecules deposited onto the sensor 
surface, a surface mass density (Γ) conversion 
coefficient of  = 0.182 cm3/g was used. 
Consequently, that yields a conversion factor 
Δ1 mdeg = Δ (Γ) ~ 0.6 ng/cm2. This has been 
shown to serve as a good approximation for 
proteins, although limitations and caveats have 
been noted (57), and are discussed in the text.
Molecular docking, molecular 
dynamics simulations and analysis. 
Autodock Vina 1.1.2 (69) was utilized to find the 
most probable binding sites and free-energies 
for SLF at the surface of Aβ-peptide. We chose 
to carry out the initial docking calculations to 
the solution structure of Aβ (1-40) solved with 
NMR (70). The PDB code for the structure is 
1IYT. The PDB structure consists of several 
different conformations for the Aβ-peptide, but 
we chose to use only the first one since our 
aim was also to carry out 20 ns MD simulation 
(referred as S1) for Aβ-peptide in water 
surroundings. The docking calculations were 
repeated for structures that were derived from 
S1 simulation (2 ns intervals). All non-polar 
hydrogens of Aβ-peptide and SLF were merged 
to the corresponding heavy atoms, which is a 
perquisite for Autodock docking calculations. 
In general, the docking parameters were kept 
to their default values. One rotatable dihedral 
present in the SLF molecules were set to 
flexible. The size of the docking grid was set 
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to 47 Å x 47 Å x 47 Å, which overlaid the entire 
Aβ-peptide.
All molecular dynamics simulations were 
carried out using the GROMACS 5.0.4 package 
(71) and the GROMOS54A7 force field (72). 
The GROMOS54A7 force field parameters for 
SLF were generated with Automated Topology 
Builder (ATB) server version 2.2 (73,74). The 
SPC model was used for water molecules (75). 
To maintain zero net charge in the simulated 
systems three Na+ counter ions were added. 
All MD simulations were carried out under 
the isobaric–isothermal (NPT) ensemble with 
periodic boundary conditions. A time step of 
2 fs was used for integrating the equations of 
motion. The v-rescale and Berendsen algorithms 
were employed to maintain physiological 
temperature at 310 K (0.1 ps-1) and an isotropic 
pressure of 1 bar (1.0 ps-1) (76). The cutoff for 
Lennard-Jones interactions were set to 1.4 
nm. For long-range electrostatics the particle 
mesh Ewald (PME) method was employed 
with a real-space cutoff of 1.4 nm (77). The 
LINCS algorithm was applied to constrain all 
bonds (78). The simulated systems consisted 
of one Aβ-peptide, one SLF molecule (except 
one simulation where the SLF molecules 
was not present), three Na+ counter ions and 
4719 water molecules. Three different MD-
simulations were carried out. The simulated 
system 1 (S1) consisted of only the Aβ-peptide, 
ions and water molecules. This simulation was 
performed up to 20 ns as previously described, 
solely to obtain four independent initial docking 
conformations. In the simulation systems 2 
(S2) and 3 (S3) the SLF molecule was initially 
present in the docking sites 1 and 2 that were 
produced by the initial docking calculation. S2 
and S3 systems were simulated up to 100 ns. 
The secondary structure of the Aβ-peptide was 
analyzed using the gmx do_dssp analysis tool 
included in the GROMACS simulation package 
(79). The root mean square deviation (RMSD) 
of the Aβ-peptide was analyzed with the gmx 
rms program. The number of contacts was 
calculated using the gmx mindist program, 
which is also included in the GROMACS 
simulation package. The maximum distance for 
contacts between SLF and Aβ-peptide atoms 
were set to 0.6 nm. VMD were used to visualize 
the docking and simulation results (80).
ACKNOWLEDGMENTS
Financial support by the Academy of Finland 
(grants: #263861 and #292253), Tekes – the 
Finnish Funding Agency for Innovation EV-
Extra-Tox project and the Professor Pool 
– Orion Research Foundation are gratefully 
acknowledged. CSC – The IT Center for 
Science (Helsinki, Finland) is acknowledged 
for providing supercomputer facilities.  The 
authors also acknowledge support from the 
UC Davis STAIR Program to JCV.
CONFLICT OF INTEREST
T.R. receives a stipend from BioNavis Ltd, the 
manufacturer of instrumentation used in this 
study.
AUTHOR CONTRIBUTIONS
SH and TR designed and conducted the MP-
SPR experiments, and analyzed the results. 
SH designed and performed the dynamic 
light scattering experiment and analyzed the 
results. TR and TV designed all the biophysical 
modeling and fitting for the MP-SPR data, and 
131
analyzed the results. AK and AB performed the 
molecular dynamics simulations and analyzed 
the results. SWH and MY analyzed data and 
wrote parts of the manuscript. JCV initiated 
the project, coordinated the experiments, and 
oversaw the manuscript preparation, with 
writing contributions from all authors.
REFERENCES
1. Hebert, L. E., Weuve, J., Scherr, P. A., and 
Evans, D. A. (2013) Alzheimer disease in the 
United States (2010-2050) estimated using 
the 2010 census. Neurology 80, 1778-1783
2. Viola, K. L., and Klein, W. L. (2015) Amyloid 
beta oligomers in Alzheimer’s disease 
pathogenesis, treatment, and diagnosis. Acta 
Neuropathol 129, 183-206
3. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, 
M. J., and Selkoe, D. J. (2002) Amyloid-β 
oligomers: their production, toxicity and 
therapeutic inhibition. Biochemical Society 
Transactions 30, 552-557
4. De Simone, A., Kitchen, C., Kwan, A. H., 
Sunde, M., Dobson, C. M., and Frenkel, D. 
(2012) Intrinsic disorder modulates protein 
self-assembly and aggregation. Proceedings 
of the National Academy of Sciences of the 
United States of America 109, 6951-6956
5. Kayed, R., Head, E., Thompson, J. L., 
McIntire, T. M., Milton, S. C., Cotman, C. W., 
and Glabe, C. G. (2003) Common structure 
of soluble amyloid oligomers implies common 
mechanism of pathogenesis. Science 300, 
486-489
6. Klein, W. L., Stine, W. B., Jr., and Teplow, 
D. B. (2004) Small assemblies of unmodified 
amyloid beta-protein are the proximate 
neurotoxin in Alzheimer’s disease. 
Neurobiology of aging 25, 569-580
7. Cheon, M., Chang, I., Mohanty, S., Luheshi, 
L. M., Dobson, C. M., Vendruscolo, M., and 
Favrin, G. (2007) Structural reorganisation 
and potential toxicity of oligomeric species 
formed during the assembly of amyloid fibrils. 
PLoS Comput Biol 3, 1727-1738
8. Bartolini, M., Bertucci, C., Bolognesi, M. L., 
Cavalli, A., Melchiorre, C., and Andrisano, V. 
(2007) Insight into the kinetic of amyloid beta 
(1-42) peptide self-aggregation: elucidation 
of inhibitors’ mechanism of action. 
Chembiochem 8, 2152-2161
9. Sgarbossa, A. (2012) Natural biomolecules 
and protein aggregation: emerging strategies 
against amyloidogenesis. Int J Mol Sci 13, 
17121-17137
10. Aulic, S., Bolognesi, M. L., and Legname, G. 
(2013) Small-molecule theranostic probes: 
a promising future in neurodegenerative 
diseases. Int J Cell Biol 2013, 150952
11. Jameson, L. P., Smith, N. W., and Dzyuba, S. 
V. (2012) Dye-binding assays for evaluation 
of the effects of small molecule inhibitors on 
amyloid (abeta) self-assembly. ACS Chem 
Neurosci 3, 807-819
12. Wang, Q., Yu, X., Li, L., and Zheng, J. (2014) 
Inhibition of amyloid-beta aggregation in 
Alzheimer’s disease. Curr Pharm Des 20, 
1223-1243
13. Oddo, S., Caccamo, A., Smith, I. F., Green, 
K. N., and LaFerla, F. M. (2006) A dynamic 
relationship between intracellular and 
extracellular pools of Abeta. Am J Pathol 168, 
184-194
14. Petrlova, J., Kalai, T., Maezawa, I., Altman, R., 
Harishchandra, G., Hong, H. S., Bricarello, D. 
A., Parikh, A. N., Lorigan, G. A., Jin, L. W., 
Hideg, K., and Voss, J. C. (2012) The influence 
of spin-labeled fluorene compounds on the 
assembly and toxicity of the abeta Peptide. 
PLoS One 7, e35443
132
15. Altman, R., Ly, S., Hilt, S., Petrlova, J., 
Maezawa, I., Kalai, T., Hideg, K., Jin, L. 
W., Laurence, T. A., and Voss, J. C. (2015) 
Protective spin-labeled fluorenes maintain 
amyloid beta peptide in small oligomers 
and limit transitions in secondary structure. 
Biochim Biophys Acta 1854, 1860-1870
16. Kalai, T., Petrlova, J., Balog, M., Aung, H. H., 
Voss, J. C., and Hideg, K. (2011) Synthesis 
and study of 2-amino-7-bromofluorenes 
modified with nitroxides and their precursors 
as dual anti-amyloid and antioxidant active 
compounds. Eur J Med Chem 46, 1348-1355
17. Cai, Z., Zhao, B., and Ratka, A. (2011) 
Oxidative stress and beta-amyloid protein in 
Alzheimer’s disease. Neuromolecular Med 13, 
223-250
18. Rosini, M., Simoni, E., Milelli, A., Minarini, 
A., and Melchiorre, C. (2014) Oxidative stress 
in Alzheimer’s disease: are we connecting the 
dots? Journal of medicinal chemistry 57, 
2821-2831
19. Sultana, R., and Butterfield, D. A. (2010) 
Role of oxidative stress in the progression of 
Alzheimer’s disease. J Alzheimers Dis 19, 341-
353
20. Rochet, J. C. (2007) Novel therapeutic 
strategies for the treatment of protein-
misfolding diseases. Expert Rev Mol Med 9, 
1-34
21. Hubin, E., van Nuland, N. A., Broersen, K., 
and Pauwels, K. (2014) Transient dynamics 
of Abeta contribute to toxicity in Alzheimer’s 
disease. Cell Mol Life Sci 71, 3507-3521
22. Kubiak-Ossowska, K., Cwieka, M., Kaczynska, 
A., Jachimska, B., and Mulheran, P. A. (2015) 
Lysozyme adsorption at a silica surface using 
simulation and experiment: effects of pH on 
protein layer structure. Phys Chem Chem 
Phys 17, 24070-24077
23. Ihalainen, P., Majumdar, H., Viitala, T., 
Törngren, B., Närjeoja, T., Määttänen, A., 
Sarfraz, J., Härmä, H., Yliperttula, M., 
Österbacka, R., and Peltonen, J. (2013) 
Application of Paper-Supported Printed Gold 
Electrodes for Impedimetric Immunosensor 
Development. Biosensors 3, 1-17
24. Bunker, A., Magarkar, A., and Viitala, T. 
(2016) Rational design of liposomal drug 
delivery systems, a review: Combined 
experimental and computational studies 
of lipid membranes, liposomes and their 
PEGylation. Biochim Biophys Acta 
25. Snyder, S. W., Ladror, U. S., Wade, W. S., 
Wang, G. T., Barrett, L. W., Matayoshi, E. D., 
Huffaker, H. J., Krafft, G. A., and Holzman, T. 
F. (1994) Amyloid-beta aggregation: selective 
inhibition of aggregation in mixtures of 
amyloid with different chain lengths. Biophys 
J 67, 1216-1228
26. Karlsson, R., Katsamba, P. S., Nordin, H., 
Pol, E., and Myszka, D. G. (2006) Analyzing 
a kinetic titration series using affinity 
biosensors. Analytical biochemistry 349, 
136-147
27. Myszka, D. G., Jonsen, M. D., and Graves, B. J. 
(1998) Equilibrium Analysis of High Affinity 
Interactions Using BIACORE. Analytical 
biochemistry 265, 326-330
28. Palladino, P., Aura, A., and Spoto, G. (2015) 
Surface plasmon resonance for the label-free 
detection of Alzheimer’s β-amyloid peptide 
aggregation. Analytical and Bioanalytical 
Chemistry, 1-6
29. Peterlinz, K., and Georgiadis, R. (1996) Two-
color approach for determination of thickness 
and dielectric constant of thin films using 
surface plasmon resonance spectroscopy. 
Optics Communications 130, 260-266
30. Zhou, M., Otomo, A., Yokoyama, S., and 
Mashiko, S. (2001) Estimation of organic 
molecular film structures using surface–
plasmon resonance spectroscopy. Thin Solid 
Films 393, 114-118
133
31. Grassi, J. H., and Georgiadis, R. M. 
(1999) Temperature-dependent refractive 
index determination from critical angle 
measurements: Implications for quantitative 
SPR sensing. Analytical chemistry 71, 4392-
4396
32. Liang, H., Miranto, H., Granqvist, N., 
Sadowski, J. W., Viitala, T., Wang, B., and 
Yliperttula, M. (2010) Surface plasmon 
resonance instrument as a refractometer 
for liquids and ultrathin films. Sensors and 
Actuators B: Chemical 149, 212-220
33. Granqvist, N., Liang, H., Laurila, T., Sadowski, 
J., Yliperttula, M., and Viitala, T. (2013) 
Characterizing ultrathin and thick organic 
layers by surface plasmon resonance three-
wavelength and waveguide mode analysis. 
Langmuir 29, 8561-8571
34. Granqvist, N., Yliperttula, M., Välimäki, S., 
Pulkkinen, P., Tenhu, H., and Viitala, T. (2014) 
Control of the Morphology of Lipid Layers by 
Substrate Surface Chemistry. Langmuir 30, 
2799-2809
35. Zhang, S., Iwata, K., Lachenmann, M. J., Peng, 
J. W., Li, S., Stimson, E. R., Lu, Y., Felix, A. 
M., Maggio, J. E., and Lee, J. P. (2000) The 
Alzheimer’s peptide a beta adopts a collapsed 
coil structure in water. J Struct Biol 130, 130-
141
36. Lim, K. H., Henderson, G. L., Jha, A., 
and Louhivuori, M. (2007) Structural, 
dynamic properties of key residues in Abeta 
amyloidogenesis: implications of an important 
role of nanosecond timescale dynamics. 
Chembiochem 8, 1251-1254
37. Yan, Y., and Wang, C. (2006) Abeta42 is 
more rigid than Abeta40 at the C terminus: 
implications for Abeta aggregation and 
toxicity. J Mol Biol 364, 853-862
38. Yan, Y., Liu, J., McCallum, S. A., Yang, D., 
and Wang, C. (2007) Methyl dynamics of the 
amyloid-beta peptides Abeta40 and Abeta42. 
Biochem Biophys Res Commun 362, 410-414
39. Li, J., Liu, R., Lam, K. S., Jin, L. W., and Duan, 
Y. (2011) Alzheimer’s disease drug candidates 
stabilize A-beta protein native structure 
by interacting with the hydrophobic core. 
Biophys J 100, 1076-1082
40. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, 
R., Glabe, C. G., Yang, A., Gallagher, M., 
and Ashe, K. H. (2006) A specific amyloid-
beta protein assembly in the brain impairs 
memory. Nature 440, 352-357
41. Kayed, R., and Lasagna-Reeves, C. A. (2013) 
Molecular mechanisms of amyloid oligomers 
toxicity. J Alzheimers Dis 33 Suppl 1, S67-78
42. Tiwari, M. K., and Kepp, K. P. (2016) 
β-Amyloid pathogenesis: Chemical properties 
versus cellular levels. Alzheimer’s & Dementia 
12, 184-194
43. Landau, M., Sawaya, M. R., Faull, K. F., 
Laganowsky, A., Jiang, L., Sievers, S. A., Liu, 
J., Barrio, J. R., and Eisenberg, D. (2011) 
Towards a pharmacophore for amyloid. PLoS 
Biol 9, e1001080
44. Minicozzi, V., Chiaraluce, R., Consalvi, V., 
Giordano, C., Narcisi, C., Punzi, P., Rossi, G. 
C., and Morante, S. (2014) Computational and 
experimental studies on beta-sheet breakers 
targeting Abeta1-40 fibrils. The Journal of 
biological chemistry 289, 11242-11252
45. Okuno, H., Mori, K., Okada, T., Yokoyama, 
Y., and Suzuki, H. (2007) Development 
of aggregation inhibitors for amyloid-beta 
peptides and their evaluation by quartz-
crystal microbalance. Chem Biol Drug Des 
69, 356-361
46. Hilbich, C., Kisters-Woike, B., Reed, J., 
Masters, C. L., and Beyreuther, K. (1992) 
Substitutions of hydrophobic amino acids 
reduce the amyloidogenicity of Alzheimer’s 
disease beta A4 peptides. J Mol Biol 228, 
460-473
47. Cerf, E., Sarroukh, R., Tamamizu-Kato, 
S., Breydo, L., Derclaye, S., Dufrene, Y. F., 
134
Narayanaswami, V., Goormaghtigh, E., 
Ruysschaert, J. M., and Raussens, V. (2009) 
Antiparallel beta-sheet: a signature structure 
of the oligomeric amyloid beta-peptide. The 
Biochemical journal 421, 415-423
48. Ahmed, M., Davis, J., Aucoin, D., Sato, 
T., Ahuja, S., Aimoto, S., Elliott, J. I., Van 
Nostrand, W. E., and Smith, S. O. (2010) 
Structural conversion of neurotoxic amyloid-
beta(1-42) oligomers to fibrils. Nat Struct Mol 
Biol 17, 561-567
49. Mitternacht, S., Staneva, I., Hard, T., and 
Irback, A. (2011) Monte Carlo study of the 
formation and conformational properties of 
dimers of Abeta42 variants. J Mol Biol 410, 
357-367
50. Larini, L., and Shea, J. E. (2012) Role of beta-
hairpin formation in aggregation: the self-
assembly of the amyloid-beta(25-35) peptide. 
Biophys J 103, 576-586
51. Fawzi, N. L., Phillips, A. H., Ruscio, J. Z., 
Doucleff, M., Wemmer, D. E., and Head-
Gordon, T. (2008) Structure and dynamics of 
the Abeta(21-30) peptide from the interplay of 
NMR experiments and molecular simulations. 
Journal of the American Chemical Society 
130, 6145-6158
52. Sandberg, A., Luheshi, L. M., Sollvander, S., 
Pereira de Barros, T., Macao, B., Knowles, T. 
P., Biverstal, H., Lendel, C., Ekholm-Petterson, 
F., Dubnovitsky, A., Lannfelt, L., Dobson, 
C. M., and Hard, T. (2010) Stabilization of 
neurotoxic Alzheimer amyloid-beta oligomers 
by protein engineering. Proceedings of the 
National Academy of Sciences of the United 
States of America 107, 15595-15600
53. Danielsson, J., Jarvet, J., Damberg, P., and 
Graslund, A. (2005) The Alzheimer beta-
peptide shows temperature-dependent 
transitions between left-handed 3-helix, beta-
strand and random coil secondary structures. 
FEBS J 272, 3938-3949
54. Qian, R., Mhatre, R., and Krull, I. (1997) 
Characterization of antigen-antibody 
complexes by size-exclusion chromatography 
coupled with low-angle light-scattering 
photometry and viscometry. Journal of 
Chromatography A 787, 101-109
55. Ball, V., and Ramsden, J. J. (1998) Buffer 
dependence of refractive index increments of 
protein solutions. Biopolymers 46, 489-492
56. Arwin, H. (1986) Optical properties of thin 
layers of bovine serum albumin, γ-globulin, 
and hemoglobin. Applied Spectroscopy 40, 
313-318
57. Zhao, H., Brown, P. H., and Schuck, P. (2011) 
On the distribution of protein refractive index 
increments. Biophysical journal 100, 2309-
2317
58. DuBay, K. F., Pawar, A. P., Chiti, F., Zurdo, J., 
Dobson, C. M., and Vendruscolo, M. (2004) 
Prediction of the absolute aggregation rates 
of amyloidogenic polypeptide chains. J Mol 
Biol 341, 1317-1326
59. Chiti, F., Stefani, M., Taddei, N., Ramponi, 
G., and Dobson, C. M. (2003) Rationalization 
of the effects of mutations on peptide and 
protein aggregation rates. Nature 424, 805-
808
60. Fernandez-Escamilla, A. M., Rousseau, F., 
Schymkowitz, J., and Serrano, L. (2004) 
Prediction of sequence-dependent and 
mutational effects on the aggregation of 
peptides and proteins. Nat Biotechnol 22, 
1302-1306
61. Cohen, S. I., Linse, S., Luheshi, L. M., 
Hellstrand, E., White, D. A., Rajah, L., Otzen, 
D. E., Vendruscolo, M., Dobson, C. M., and 
Knowles, T. P. (2013) Proliferation of amyloid-
beta42 aggregates occurs through a secondary 
nucleation mechanism. Proceedings of the 
National Academy of Sciences of the United 
States of America 110, 9758-9763
135
62. Hong, H. S., Maezawa, I., Budamagunta, M., 
Rana, S., Shi, A., Vassar, R., Liu, R., Lam, K. S., 
Cheng, R. H., Hua, D. H., Voss, J. C., and Jin, 
L. W. (2010) Candidate anti-Abeta fluorene 
compounds selected from analogs of amyloid 
imaging agents. Neurobiology of aging 31, 
1690-1699
63. Karlsson, R., and Fält, A. (1997) Experimental 
design for kinetic analysis of protein-protein 
interactions with surface plasmon resonance 
biosensors. Journal of immunological 
methods 200, 121-133
64. Albers, W. M., and Vikholm-Lundin, I. (2011) 
Surface Plasmon Resonance on Nanoscale 
Organic Films, Springer, New York
65. Maier, S. A. (2007) Plasmonics: fundamentals 
and applications. in Springer Science & 
Business Media. 
66. Hayt, W. H., and Buck, J. A. (2001) 
Engineering electromagnetics, 
67. Sadowski, J. W., Korhonen, I. K. J., and 
Peltonen, J. P. K. (1995) Characterization 
of thin films and their structures in surface 
plasmon resonance measurements. OPTICAL 
ENGINEERING 34, 6
68. De Feijter, J., Benjamins, D. J., and Veer, 
F. (1978) Ellipsometry as a tool to study 
the adsorption behavior of synthetic and 
biopolymers at the air–water interface. 
Biopolymers 17, 1759-1772
69. Trott, O., and Olson, A. J. (2010) AutoDock 
Vina: improving the speed and accuracy 
of docking with a new scoring function, 
efficient optimization and multithreading. J 
computational chemistry 31, 455-461
70. Vivekanandan, S., Brender, J. R., Lee, S. 
Y., and Ramamoorthy, A. (2011) A Partially 
Folded Structure of Amyloid-Beta(1-40) in 
an Aqueous Environment. Biochemical and 
biophysical research communications 411, 
312-316
71. Pronk, S., Páll, S., Schulz, R., Larsson, P., 
Bjelkmar, P., Apostolov, R., Shirts, M., Smith, 
J., Kasson, P., van der Spoel, D., Hess, B., and 
Lindahl, E. (2013) GROMACS 4.5: a high-
throughput and highly parallel open source 
molecular simulation toolkit. Bioinformatics 
29, 845-854
72. Schmid, N., Eichenberger, A. P., Choutko, 
A., Riniker, S., Winger, M., A.E., M., and 
W.F., v. G. (2011) Definition and testing of 
the GROMOS force-field versions 54A7 and 
54B7. Eur Biophys J. 40, 843-856
73. Malde, A. K., Zuo, L., Breeze, M., Stroet, 
M., Poger, D., Nair, P. C., Oostenbrink, C., 
and Mark, A. E. (2011) An Automated Force 
Field Topology Builder (ATB) and Repository: 
Version 1.0. Journal of Chemical Theory and 
Computation 7, 4026-4037
74. Koziara, K., Stroet, M., Malde, A., and Mark, 
A. (2014) Testing and validation of the 
Automated Topology Builder (ATB) version 
2.0: prediction of hydration free enthalpies. 
J Comput Aided Mol Des. 28, 221-233
75. Berendsen, H. J. C., Postma, J. P. M., van 
Gunsteren, W. F., and Hermans, J. (1981) 
INTERACTION MODELS FOR WATER IN 
RELATION TO PROTEIN HYDRATION. in 
Intermolecular Forces (Pullman, B. ed.), D. 
Reidel Publishing Company. pp 331-342
76. Berendsen, H. J. C., Postma, J. P. M., van 
Gunsteren, W. F., DiNola, A., and Haak, J. 
R. Molecular dynamics with coupling to an 
external bath. J. Chem. Phys. 81, 3684-3690
77. Essmann, U., Perera, L., Berkowitz, M. L., 
Darden, T., Lee, H., and Pedersen, L. G. (1995) 
A smooth particle mesh Ewald method. J. 
Chem. Phys. 103, 8577-8593
78. Hess, B., Bekker, H., Berendsen, H. J. C., and 
Fraaije, J. G. E. M. (1997) LINCS: A Linear 
Constraint Solver for Molecular Simulations. 
J. Comput. Chem. 18, 18-1463
136
79. Kabsch, W., and Sander, C. (1983) Dictionary 
of protein secondary structure: pattern 
recognition of hydrogen-bonded and 
geometrical features. Biopolymers 22, 2577-
2637
80. Humphrey, W., A., D., and Schulten, K. 
(1996) VMD: visual molecular dynamics. J 
Mol Graph. 14, 33-38
137
MP-SPR ADDITIONAL DETAILS
The usefulness of MP-SPR for accurate 
biosensing measurements is primarily due to 
two factors. Firstly, for monochromatic (laser) 
light and a defined prism-metal-dielectric 
combination, the angle of incidence at which 
the plasmon resonance occurs, depends on 
the dielectric constant (i.e. refractive index; 
dielectric constant and refractive index are 
related by ε=n2) of the medium adjacent to 
the metal surface. This, in turn, is an excellent 
means to monitor with high sensitivity nano-
scale physical and biochemical events occurring 
at the surface or at the vicinity of the surface. Of 
importance, the changes caused by the physical 
and chemical reactions in the medium and at 
the vicinity of the surface are straightforwardly 
reflected to the observed resonance angle as a 
SPR angle dip shift. Secondly, the shape of the 
SPR curve as a whole is dependent primarily 
on the thickness and optical properties of 
the metal layer. In particular, when the full 
SPR curve data provided by two different 
wavelength lasers is recorded with the MP-SPR 
instrument, the thickness and refractive indices 
of thin (bio) molecule films can be calculated 
with certain limitations as discussed later 
in this text. The multi-parametric approach 
allows us also to exploit the detection of total 
internal reflection angle (TIR angle) to avoid 
the unwanted bulk-effect occasionally biasing 
the interpretation of kinetic measurements in 
SPR. Furthermore, with this novel approach, 
we are able to observe the intensity changes of 
reflectance induced by the different absorption 
and scattering properties of the biofilm layers to 
draw conclusions of the compositions of those 
layers.
SUPPLEMENTAL INFORMATION
Table S1. All the calculated affinity values and parameters for different interaction scenarios of Aβ/SLF binary complexes. 
Data was processed and fitted using the TraceDrawer™ for MP-SPR Navi™.
Bmax1
(Signal)
Bmax2
(Signal)
ka1
(1/(M*s))
kd1
(1/s)
KD1
(M)
ka2
(1/(M*s))
kd2
(1/s)
KD2
(M)
χ2
SLF with 
biotinylated Aβ 
monomer
123.73
(± 8.07x10-1)
119.58
(± 4.28x10-1)
2.92x102
(± 4.95x103)
4.34x10-3
(± 4.28x10-5)
1.49x10-5
(± 8.81x10-7)
1.70x101
(± 4.15x103)
6.09x10-14
(± 1.69x104)
3.58x10-15
(± 1.67x10-2)
34.39
SLF with native 
Aβ bound to 
biotinylated Aβ 
monomer
137.69 
(± 1.05x100)
947.24 
(±6.40x10-1)
4.00x102 
(± 6.90x103)
1.62x10-2 
(± 1.32x10-5)
4.06x10-5 
(± 2.36x10-6)
1.69x100
(± 5.88x102)
7.78x10-13 
(± 1.70x104)
4.60x10-13 
(± 8.29x10-2)
23.30
SLF with AβO
440.06 
(±1.18x100)
1530.53 
(±8.49x10-1)
2.20x102 
(±1.63x103)
2.38x10-2 
(±1.74x10-5)
1.08x10-4 
(±-1.48x10-5)
1.88x100 
(±1.26x103)
2.28x10-4 
(±1.15x10-5)
1.21x10-4 
(±-1.80x10-7)
41.63
SLF with AβO 
pretreated with 
SLF
499.48
(± 1.25x100)
1169.44 
(± 1.09x100)
1.78x102
 (± 1.95x103)
2.05x10-2
(± 1.17x10-5)
1.15x10-4 
(± 1.06x10-5)
2.04x100 
(± 1.82x103)
2.01x10-4 
(± 1.59x10-5)
9.84x10-5 
(± 1.11x10-7)
44.63
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Additional details on relating Aβ self-
assembly and aggregation processes in terms 
of total surface mass density generated by 
the deposition of molecular mass during the 
interactions. In contrast to the surface mass 
density changes by SLF deposition alone, our 
aim was to evaluate how the SLF reduces the 
total amount of surface-deposited mass by 
inhibiting Aβ self-association. We chose two 
time points at which the baseline was considered 
stable after the injections, and calculated the 
surface mass densities at those points. In brief 
review of the experimental arrangement, both 
of the sample channel surfaces were pre-coated 
in situ in constant buffer flow (10 µL/min) with 
non-biotinylated Aβ to achieve a biomimetic 
situation for Aβ aggregation in the consequent 
Aβ and SLF injections. In the upper sample 
channel we made an injection of Aβ+SLF 
mixture (pretreated AβO) with molar ratio 1:2 
(10 µM:20 µM) on the basis of our previous 
experiments and hypothesis that there exists 
two SLF binding sites in Aβ peptides. Into 
the lower sample channel we injected only 
10 µM of Aβ without any SLF present. We 
repeated the described injections twice. In 
the upper flow channel with SLF present, we 
calculated surface mass densities of ~26 ng/
cm2 at time point (1), and only ~6 ng/cm2 at 
time point (2), resulting to overall surface mass 
density increase of ~32 ng/cm2. In the lower 
flow channel without any SLF, the calculated 
surface mass densities were ~92 ng/cm2 at 
time point (1), and ~45 ng/cm2 at time point 
(2), the overall increase at ~137 ng/cm2 after 
the injections. Hence, the surface mass density 
evaluations support our previous observations 
that the SLF is capable of hindering the Aβ self-
assembly and aggregation processes.
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Fig. S1. Total surface mass densities on the sensor surface when SLF was shown to prevent Aβ self-
association. The green sensorgram trace showing the lower channel deposition, and the blue trace 
representing the upper channel events. Arrows as guides to the eye to depict the difference in deposited 
masses. The calculated total surface mass densities are mainly due to the Aβ accumulation onto the surface. 
In the upper channel with SLF present after the first injection and baseline stabilization at first time point (1) 
surface mass density ~26 ng/cm2 was observed. After the second injection at second time point (2) surface 
mass density of only ~6 ng/cm2 was detected. In the lower channel without SLF hindering the molecular 
mass accumulation the detected surface mass densities at corresponding time points were ~92 ng/cm2 and 
~45 ng/cm2, respectively. Finally, the total surface mass densities acquired at the end of the interactions were 
~32 ng/cm2 in the upper channel, and ~137 ng/cm2 in the lower channel. 
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Single exosome study reveals subpopulations
distributed among cell lines with variability related to
membrane content
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Current analysis of exosomes focuses primarily on bulk analysis, where exosome-to-exosome variability cannot
be assessed. In this study, we used Raman spectroscopy to study the chemical composition of single exosomes.
We measured spectra of individual exosomes from 8 cell lines. Cell-line-averaged spectra varied considerably,
reflecting the variation in total exosomal protein, lipid, genetic, and cytosolic content. Unexpectedly,
single exosomes isolated from the same cell type also exhibited high spectral variability. Subsequent spectral
analysis revealed clustering of single exosomes into 4 distinct groups that were not cell-line specific. Each group
contained exosomes from multiple cell lines, and most cell lines had exosomes in multiple groups. The
differences between these groups are related to chemical differences primarily due to differing membrane
composition. Through a principal components analysis, we identified that the major sources of spectral
variation among the exosomes were in cholesterol content, relative expression of phospholipids to cholesterol,
and surface protein expression. For example, exosomes derived from cancerous versus non-cancerous cell lines
can be largely separated based on their relative expression of cholesterol and phospholipids. We are the first
to indicate that exosome subpopulations are shared among cell types, suggesting distributed exosome
functionality. The origins of these differences are likely related to the specific role of extracellular vesicle
subpopulations in both normal cell function and carcinogenesis, and they may provide diagnostic potential
at the single exosome level.
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E
xosomes are nanosized extracellular vesicles (EVs)
formed by nearly all types of cells of intracellular
multivesicular bodies (MVBs). They are released
into the extracellular space when the MVBs fuse with the
plasma membrane. Recently, they have been intensely
studied due to discoveries that exosomes (a) transport
functional mRNA, miRNA, (1,2) and DNA (3); (b) are
expressly packaged by cells for highly specific endogenous
and exogenous intercellular communication (4); (c) are
constitutively integrated in immune cell physiology (5);
and (d) are heavily implicated in numerous pathologies,
particularly cancer (6,7). Exosome secretion is also now
understood to be fundamental in healthy intercellular
communication, and exosomes can be isolated from most
§These authors contributed equally to this manuscript.
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biological fluids (blood, urine, lymph, etc.) for potential
use as biomarkers, since their protein, lipid, genetic, and
metabolic content, in addition to frequency of genera-
tion, can be altered in diseased cells. Based on the clear
evidence that cells actively direct the packing of lipids,
protein, RNA, and various cytosolic small metabolites
into exosomes, we sought to apply broad chemical spec-
troscopy to single exosomes for the identification of
chemically distinct subpopulations arising from sorting
choices during exosome biogenesis or post-translational
modification of exosomes after synthesis/release.
Many factors may contribute to perceived chemical
dispersity for single exosomes, including exosome isola-
tion techniques (e.g. differential centrifugation vs. com-
mercial precipitation reagents may isolate disparate levels
of exosome subpopulations) and also biological mechan-
isms. For example, exosomal transmembrane proteins
exist in various states of post-translational modification
[e.g. glycosylation (8)] or lipid/sterol activation (9,10).
Finally, while we follow the ISEV characterization guide-
lines to ensure that the vesicles studied in this paper are
exosomes [as opposed to microvesicles (MVs) and other
EVs] (11), even this definition is rapidly evolving and
may not be soon applicable, hence the continued im-
portance of studies that better define exosomes and their
subpopulations.
To explore the chemical content of individual EVs,
we utilized Laser tweezers Raman spectroscopy (LTRS).
Raman spectroscopy is awell-established, non-destructive,
and non-contact method for determining the chemical
makeup of a variety of samples (12). Its label-free nature
makes it a natural choice for in vivo diagnostics and
longitudinal studies of cells and tissues over time (13,14).
Raman spectroscopy has been successfully applied to
a variety of biomedical problems, including cancer detec-
tion (15,16), studies of bone health (17,18), response
of cells to drugs (19), and quantification of analytes in
biofluids (20,21), among many others (22,23).
Among the many forms of Raman spectroscopy,
LTRS holds particular promise for study of exosomes. In
LTRS, a tightly focused laser beam traps and holds small
particles at the laser’s focal point. A confocal detection
setup collects Raman scattering only from a precise focal
volume, allowing cellular and subcellular objects to be
studied individually. This method has been used to study,
for example, individual cancerous and non-cancerous cells
(24,25), the activation response of individual immune
cells (26), as well as smaller, nanoscale objects such as lipid
droplets in milk (27), latex beads (28), and subcellular
organelles (29). These studies highlight the power of
Raman spectroscopy to determine the chemical content
from individual micro- and nanoparticles, which are
well below the limit of detection for conventional ‘‘wet
chemistry’’ methods that require a large amount of
starting material for analysis. A prior study examined
clusters of exosomes, trapped simultaneously in the laser
focus, using LTRS, with the disadvantage of obtaining
population-averaged information (30). This study found
ensemble exosomal chemical differences following cell
starvation, highlighting Raman spectroscopy’s ability
to discriminate between different exosome subpopula-
tions (30). Here, we used LTRS to examine single exosomes
andMVs isolated from both cancerous and non-cancerous
cells to characterize their heterogeneity in chemical
content. In this study, exosomes were isolated using
both commercial isolation reagents and ultracentrifuga-
tion, whereas MVs were separated via ultracentrifu-
gation. Because of the overlapping size distribution
of exosomes and MVs when purified with ultracentri-
fugation, we define MVs as those vesicles pelleted at
20,000g, whereas exosomes are those vesicles pelleted
at 110,000g.
By analysing the Raman spectra of many indivi-
dual exosomes derived from a multitude of cell lines, we
were able to identify several subpopulations of exosomes
that appeared to be shared across cell lines, suggesting
conserved biological function. Additionally, cancerous
and non-cancerous cell types appear to differ in relative
production of exosome subpopulations, as identified by
principal component analysis (PCA). Furthermore, we
compared the spectral differences found by PCA to known
membrane constituents aswell as to principal components
derived from a data set consisting of native and trypsinized
EVs. This comparison revealed that the dominant chemi-
cal differences between these subpopulations are mostly
reflected in the content of the EVs’ membranes. These
results provide information about exosome variability
at the single vesicle level that will further elucidate the
role of exosome subtypes with regard to their phenotype
and ultimate biological function.
Materials and methods
Raman spectroscopy of single extracellular vesicles
Setup and spectral acquisition
As described below, exosomes were first isolated from cell
culture and measured one at a time using our Raman
trapping system, as shown schematically in Fig. 1. All
measurementsweremade using the home-built LTRS system
described previously (14,19). Briefly, 25 mWof light from a
single mode, 785 nm laser (CrystalLaser, Reno, NV), was
coupled into an inverted microscope (IX-71, Olympus,
Center Valley, PA) outfitted with a 60, 1.2-NA water
immersionobjective.The lightwas focusedby theobjective to
a diffraction-limited spot (1mm1mm3mm in size),
capable of trapping cells and other small particles such as
lipid droplets and exosomes (14,27). The trapping laser
additionally excited Raman scattering from the trapped
object, and backscattered light was collected back through
the objective. A dichroic beam-splitter and edge filter
Zachary J. Smith et al.
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(Chroma Technology, Bellows Falls, VT) separated the
Raman scattered light from the backscattered excitation
light. The filtered Raman signal was focused into a multi-
mode optical fibre where it was delivered to a SpectraPro
2300i spectrograph (Princeton Instruments, Trenton, NJ).
The dispersed spectrum was measured by a TE-cooled Pixis
100 CCD (Princeton Instruments).
After vesicle preparation, suspensionswere diluted 10100
times in PBS and placed on a quartz coverslip, used to avoid
the strong spectral background from glass. The specific
dilution factor for each sample was chosen empirically with
the goal of having, on average,B1EVper field of viewof the
microscope at any 1 time. This step helped to ensure that only
single EV particlesweremeasured byourRaman system and
to decrease the chance that a second vesicle would wander
into the trapping laser beam during spectral acquisition. In
order to acquire a spectrum, the stage was manually steered
to trap an exosome or MV in solution. The vesicle was levi-
tated away from the quartz coverslip to reduce the signal
strengthof the substrate.The small volumeof thevesicles and
the correspondingly small amount of material contained
within them necessitated long exposure times to acquire
spectra with acceptable signal-to-noise ratios. In our experi-
ments, we recorded ten 30-s spectral frames from each
particle.
Following data collection, spectra were imported into
MATLAB for all subsequent data processing, described
below.
Spectral data processing
All spectra were corrected for cosmic rays using a median
threshold filter described previously (31). By comparing
spectra pixel-wise across the 10 frames, outlier values
caused by cosmic rays can be easily detected and their
value replaced by the frame-wise median. Following
this correction, the 10 frames from each vesicle were
averaged for an equivalent integration time of 5min
per vesicle. The spectra were first smoothed using the
Whittaker smoother proposed by Eilers (32) with a
Lagrange parameter of 5. Following smoothing, the
spectra were background corrected by subtracting off
the spectral background from quartz, PBS buffer, total
exosome isolation reagent (TEIR), and a fifth order
polynomial to account for autofluorescence and other
background deviations. Coefficients for each component
of the estimated background were determined using an
asymmetric least squares (AsLS) model, with a value of
the asymmetry parameter of p0.001 (33,34). For
exosome samples isolated using the TEIR reagent kit,
we found that the reagents remained attached to the
exosomes after purification. The TEIR reagents gave an
unexpectedly strong signal, whose removal from each
exosome spectrum was verified by comparing exosomes
isolated using TEIR and those isolated by ultracentrifu-
gation from the same cell culture, as described in the
Supplementary File. Following background correction,
all spectra were normalized to the area under the curve of
the broad peak at 1,450 cm1, a stand-in for total organic
content and a standard normalization region (26,35). The
y-axis of the Raman spectra then represents the propor-
tion of individual chemical groups relative to the total
organic content within an individual vesicle. This allows
PCA to represent differences in chemical composition,
Fig. 1. Schematic diagram of exosome isolation and measurement of single-exosome Raman spectra. (a) Media from cultured cells are
purified using a commercial isolation kit or differential centrifugation; (b) purified exosomes are trapped in the laser beam of a home-
built microscope system, and Raman spectra are collected, yielding (c) a database of spectra of single exosomes.
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rather than differences in chemical concentration, as
might be encountered, for example, between vesicles of
identical content but different size.
Principal components analysis was performed using
the built-in MATLAB function princomp. Following
principal component decomposition, the first 10 princi-
pal component scores for each exosome were submitted
to hierarchical clustering analysis using Ward’s method
for creating linkages based on Euclidean pairwise dis-
tances. This analysis was performed using MATLAB’s
built-in function linkage.
In contrast to the fits of background spectra to the raw
spectral data, which were performed with AsLS fitting,
fits of principal component spectra shown in the Supple-
mentary File (36) were performed via standard least-
squares modelling.
Extracellular vesicle preparation and isolation using
the TEIR reagent kit
Cell culture
Human lung carcinoma A549 cell line, human hepatocar-
cinoma Huh-7 cell line, and mouse embryonic fibroblast
3T3 cell line were cultured in Dulbecco’s modified Eagle
mediumwith 10% foetal bovine serum (FBS), 100 units/mL
penicillin, and 100mg/mL streptomycin. Human lung
normal fibroblast IMR90 cell line was cultured in Eagle’s
minimum essential medium with 10% FBS, 100 units/mL
penicillin, and 100mg/mL streptomycin. Human ovarian
carcinoma SKOV3 cell line was cultured in McCoy’s 5A
modified medium with 10% FBS, 100 units/mL penicillin,
and 100mg/mL streptomycin. Human acute T-cell leukae-
mia Jurkat cell line and human acute myeloblastic
leukaemia Kasumi-1 cell line were cultured in RPMI-
1640 medium with 10% FBS, 100 units/mL penicillin, and
100mg/mL streptomycin at 378C and 5%CO2. All cell lines
were cultured at 378Cand 5%CO2 andweremaintained by
splitting upon reaching 80% confluence.
Exosome isolation using commercial precipitation reagent
Exosomes were isolated from cell-conditioned media as
previously described (37). Briefly, cells were plated at
25% confluency in a T-150 flask and incubated in
appropriate conditioned medium (CM). CM contained
exosome-depleted FBS (bovine-derived exosomes were
removed from 30% FBS/media by ultracentrifugation at
100,000g for 18 h) to ensure that the resulting exosomes
in the cell culture medium originated from the plated cells.
After 48 h, the cell culture media was collected and
centrifuged at 300g for 10min, 2,000g for 20min,
and 10,000g for 1 h, to remove live cells, dead cells, and
cell debris/MVs, respectively.
The exosome-containingCMwas incubatedwith one-half
the total volume of TEIR (4478359; Life Technologies†,
Grand Island, NY, USA) at 48C overnight before final
centrifugation at 10,000g for 1h at 48C. The super-
natant was aspirated to waste and the exosome pellet was
resuspended in 1 phosphate-buffered saline (PBS). These
exosomes were used in downstream analysis andwere stored
at 208C until thawing just prior to use. Exosomes were
stored typically for less than 1week at 208C and never for
longer than 4weeks.
Preparation of LNCaP exosomes and MVs via
differential centrifugation, treatment with trypsin
Cell culture
LNCaP prostate cancer cell line was used as the source
for EVs. The cells were grown at 378C and 5% CO2
humidified atmosphere in RPMI-1640 medium supple-
mented with 10% EV-cleared FBS, 20 units/mL of
penicillin, and 20 mg/mL of streptomycin (Gibco Invitro-
gen, Carlsbad, CA). The EV-cleared FBS was prepared
by overnight (20 h) ultracentrifugation at 110,000g and
48C of regular FBS using an L-70 ultracentrifuge
with rotor type 50.2 Ti (Beckman Coulter, Brea, CA)
with approximately 22mL of supernatant per adaptor
tube as described in Ref. (38). The FBS supernatant was
then collected and filtered through a 0.22-mm Steritop
filter device (Millipore, Billerica, MA). The cells were
maintained at 6090% confluence in T-175 cell culture
flasks with 25 mL of medium, and CM was collected
after 23 days of culture 3 times per week.
Vesicle isolation using differential centrifugation
EVs were isolated from cell-conditioned medium using
a differential centrifugation protocol as described pre-
viously (3). After collection, any cells and large debris
were removed from the CM by centrifugation at 2,500g
and 48C for 25min in 50mL Falcon tubes with an
Eppendorf Centrifuge 5810 Rwith swinging bucket rotor
(Hamburg, Germany). The supernatant was then centri-
fuged at 20,000g and48C for 1 h to pellet MVs using
a Sorvall RC 5C centrifuge with SLA-1500 rotor (Thermo
Scientific, Waltham, MA) with approximately 125mL of
supernatant per adapter tube. The pellet (MVs) was
suspended in 100mL of Dulbecco’s PBS buffer (DPBS,
Gibco Invitrogen) and the supernatant was centrifuged at
110,000g and 48C for 2h to pellet exosomes using L-
70 ultracentrifuge with Type 50.2 Ti rotor with approxi-
mately 22mL of supernatant per adaptor tube. Because of
the overlapping size distributions of the exosomes and
MVs, and because of the confusion that still exists about
the exact nature of these vesicles’ characteristics and
defining properties, we adopt the convention in this paper
that all vesicles pelleted at 20,000g are referred to as
MVs, whereas those pelleted at 110,000g are referred to
as exosomes. The clear separation obtained between these 2
populations as probed by Raman spectroscopy confirms
that these preparation protocols do isolate distinct EV
subpopulations. After the ultracentrifugation, the super-
natant was removed and the pellets (EVs) were collected
with 100mL of DPBS. The collected EV samples were then
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stored in 208C for short-term (maximum 1week) storage.
Three MV and exosome samples collected during 1 week
were pooled together, suspended into a total volume of
1mL with DPBS and concentrated by ultracentrifugation
at 170,000g and 48C for 3h using an Optima MAX-
XP ultracentrifuge with a TLA-55 rotor (Beckman Coul-
ter). The supernatant was removed from the EV pellets,
leaving 3050 mL to resuspend the pellets, after which they
were stored in 808C.
Cleavage of surface proteins by trypsin treatment
To cleave the membrane protein segments outside of
the EVs, the EV samples were incubated in 1mL of 0.25%
(w/v) trypsin (Gibco Invitrogen) in DPBS for 1 h in
378C. One-half of each sample was treated with trypsin
and the other half served as a point of comparison for the
effect of the treatment. The effect of trypsin treatment
was assessed by western blotting of membrane proteins
CD9 and CD63 as described below (39).
Size-exclusion chromatography
The trypsin-treated EVs and their control samples were
purified by size-exclusion chromatography to separate
the trypsin, cleaved protein segments, and other small
molecules from the EVs as described by Boing et al. (40).
For each sample, a column was prepared with 10mL
of sepharose CL-2B (GE Healthcare Life Sciences, Little
Chalfont, UK) in DPBS running buffer, both degassed
under vacuum. The samples were loaded into the column
and 11 fractions of 0.5mL were collected immediately
from the start of the run. The presence of small particles in
the fractions was confirmed with NTA (see below) from
Fractions 710, with the highest particle concentrations
usually found in Fractions 8 and 9. Fractions 710 were
then pooled together and concentrated by ultracentrifuga-
tion at 170,000g as described above.
EV characterization
Electron microscopy of exosomes and EVs
TEIR-isolated vesicles were diluted in 1 PBS and re-
pelleted at 100,000g for direct resuspension in 2% (w/v)
paraformaldehyde with 5 mL being deposited on Formvar
carbon-coatedEMgrids. The gridswerewashed, transferred
to 1% glutaraldehyde, contrasted in a solution of uranyl
oxalate, and then contrasted and embedded in methyl
celluloseuranyl acetate according to a previously reported
methodology (37). The grids were examined in a Philips/
FEI BioTwin (Amsterdam, Netherlands) CM120 trans-
mission electron microscope at 80 kV. Representative
images from A549 exosomes are shown in Fig. 2a (left),
showing the expected cup-shaped morphology.
ForLNCaP,MVsboth treatedwith trypsin anduntreated
were imaged by cryo-electron microscopy. Then, 3mL of
concentrated EV samples was added onto carbon TEM
grids purified with a Gatan Solarus (Model 950) plasma
cleaning system and frozen with Vitrobot (FEI) in liquid
nitrogen. The gridswere analysed by a JEOL JEM-3200FSC
field emission cryo-TEMwith 170 kV.Results are shown in
Fig. 2a (middle, right), where the native circular morphol-
ogy is seen in both treated and untreated MVs.
Immunoblot analysis to confirm exosome isolation
For exosomal western blots, 40 mg exosome aliquots were
lysed in SDS sample buffer: 2% (w/v) sodium dodecyl
sulphate, 125mM TrisHCl, pH 6.8, 12.5% (v/v) glycerol,
and 0.02% (w/v) bromophenol blue. They were incubated
with 50mM DTT where necessary (i.e. not for anti-CD9
and anti-CD63 probing), heated for 5min at 958C, and
spun to precipitate insoluble material (2min, 14,000g).
Protein was loaded onto gels according to the concentra-
tion as measured by BCA assay (Pierce, Rockford, IL),
by first assuring no worse than ‘‘low’’ purification
according to the ratio of vesicle counts by NTA to pro-
tein concentration (41). For whole cell lysates, cells were
lysed in RIPA buffer (Thermo Scientific) with protease
inhibitor and centrifuged at 18,000g at 48C for 30min
to remove cell debris, and protein concentration of
the cleared supernatants was determined by BCA assay.
Exosomal and whole cell lysate proteins (20 mg per lane)
were subjected to electrophoresis on 1-mm 10-well
NuPAGE 412% (w/v) Bis-Tris Precast gels (Thermo-
Fisher Scientific) performed at 90 V for 30min and then
120 V until complete in NuPage MOPS buffer using an
Xcell SurelockTM gel tank (ThermoScientific). Following
electrophoresis, the proteins were transferred onto nitro-
cellulose membranes (ThermoFisher Scientific) for 2 h at
48C and subsequently probed with the following anti-
bodies: mouse monoclonal anti-CD63 (ThermoFisher
Scientific), mouse monoclonal anti-CD9 (ThermoFisher
Scientific), rabbit polyclonal anti-tsg101 (SigmaAldrich,
St. Louis, MO, USA), and rabbit polyclonal anti-calnexin
(Cell Signaling Technology, Danvers, MA, USA). Sec-
ondary antibodies (HRP-conjugated) were goat anti-
rabbit and goat anti-mouse immunoglobulin (Santa Cruz
Biotechnology, Dallas, TX, USA). All antibodies were
prepared fresh at 1:1,000 dilutions (except anti-tsg101 at
1:500) in 5% (w/v) non-fat dairy milk in Tris-Buffered
Saline with TweenTM (TBST) buffer (also used to block
membranes). Immuno-active bands were detected on a
(Bio-Rad ChemiDocTM: Hercules, CA, USA) MP Imag-
ing System after 5min ECL substrate incubation. Blots
were re-probed as necessary to conserve exosome protein.
The results of the western blot (shown in Fig. 2b) are
consistent with exosome properties and thus validate the
collection methodology used in this manuscript.
Immunoblot analysis to confirm digestion of surface
proteins by trypsin
EV samples and cell lysates were lysed with RIPA buffer
in the presence of a protease inhibitor mixture (Sigma
Aldrich) and prepared with 2 Laemmli buffer (Bio-Rad)
in non-reducing conditions. Using SDSpolyacrylamide
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gel electrophoresis (PAGE), 50mg of proteins was separated
into 12% Mini-PROTEAN TGXTM gels (Bio-Rad) and
transferred to a Protran nitrocellulose membrane (What-
man International Ltd, Kent, United Kingdom) at 100 V
and 30 mA for 1 h. Blots were blocked in 5% (w/v) non-
fat dry milk powder (Valio, Helsinki, Finland) in Tris-
buffered saline Tween 20 (TBS-T) and then incubated for
1 h at room temperature (RT) with either mouse mono-
clonal anti-human CD9 (clone ALB 6; Santa Cruz
Biotechnology) or anti-CD63 (clone H5C6; BD Phar-
mingenTM, San Jose, CA, USA), both diluted in 5% non-
fat dry milk in TBS-T. The membranes were washed
3for 10min and incubated with goat anti-mouse IgG-
HRP secondary antibody diluted in 2.5% non-fat dry
milk powder in TBS-T for 45min at RT. The membranes
were washed 3for 10min with TBS-T, developed
using a LuminataTM Crescendo Western HRP Substrate
(Millipore) and visualized with Amersham HyperfilmTM
ECL (GE Healthcare Limited). As shown in Fig. 2c, the
LNCaP MVs and exosomes as well as the cell lysates are
positive for CD9 and CD63. However, the trypsinization
treatment cleaves the cellular surface proteins as shown in
the trypsinized microvesicles (TMVs) and exosomes.
Nanoparticle tracking analysis
For the LNCaP cells, purified EV samples were analysed
by NTA (36) using Nanosight model LM14 (Malvern,
Malvern, UK) equipped with a blue (404 nm) laser and
sCMOS camera. The samples were diluted in DPBS
to obtain a suitable concentration for the analysis
(320108 particles/mL) and three 90-s videos were
recorded from the samples using camera level 13. The
data were analysed using NTA 3.0 software with the
detection threshold set to 3 and screen gain at 10 to track
Fig. 2. Characterization of extracellular vesicles by electron microscopy, Western blot, k-potential, and nanoparticle tracking analysis
(NTA). (a) Electron micrographs of exosomes purified by total exosome isolation reagent (TEIR) (left, conventional TEM showing cup-
shaped morphology), vesicles purified by differential centrifugation (middle, Cryo-EM showing native circular morphology), and
trypsin-treated vesicles (right, cryo-EM). (b) Western blots of CD63, CD9, tsg101, and calnexin from exosomes and cell lysates for
3 representative cell lines (20 mg per lane). (c) Western blot of CD9 and CD63 for LNCaP microvesicles (MVs) and exosomes (EXOs)
and trypsinized microvesicles (TMVs) and exosomes (TEXOs) (50 mg per lane). (d) Averaged NTA-determined size distributions
for exosomes and microvesicles purified by TEIR and differential centrifugation (DC). Shaded areas represent 91 standard error.
(e) k-potential for LNCaP extracellular vesicles.
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as many particles as possible with little background. These
settings have been chosen to closely match prior studies
that have used NTA to detect exosomes as small as 30 nm
(4244). Results are shown in Fig. 2d, with the solid lines
depicting mean distributions across the replicate measure-
ments and the shaded areas showing the standard error.
As expected,MVs have a larger mean size compared to the
smaller exosome population. Number densities have been
normalized to their maximum value.
We also show a characteristic size NTA result obtained
from A549 cells isolated by the commercial TEIR reagent
as described above (blue curve in Fig. 2d). These data
were recorded by a separate NanoSight LM10 instrument
(illumination at 488 nm) equipped with a perfusion pump.
The A549 sample was diluted 1000 in freshly filtered
PBS (filtered using a 0.01-mm filter). The filtered PBS
was confirmed via NTA to be free of nanoparticle
contamination. Diluted exosome samples were passed
3 times through 0.2-mm nylon syringe filters and placed
on the NTA instrument at RT. The blue curve in Fig. 2d
represents the average and standard error of 6 consecutive
measurements. Each repetition recorded 60 s of data,
with 30 s of sample flow between replicates.
Zeta potential measurements
For the LNCaP cells, zeta potentials were measured
from the purified EV samples with a Zetasizer Nano Z
(Malvern), with 3 replicates measured from each sample.
The particle concentrations in the samples were prepared
at approximately 5108/mL in DPBS using particle size
concentrations obtained by paired NTA, such that each
sample had similar particle concentrations. The results
are shown in Fig. 2e, where it is evident that exosomes
and MVs have distinctly different zeta potentials
(p8104), further providing evidence that the dif-
ferential centrifugation effectively separated exosomes
and MVs.
Results and discussion
Raman spectra of exosomes isolated from
7 cancerous and non-cancerous cell lines
LTRS spectra were recorded from exosomes isolated
from 7 cell lines divided among cancerous (5) and non-
cancerous (2) lines of epithelial and myeloid origin.
A schematic diagram of the experiment is shown in
Fig. 1. In Fig. 1a, culture media containing exosomes and
other contaminating particles are collected, purified, and
concentrated to yield a vial with a dense suspension of
exosomes. That sample is then diluted and placed on
a home-built Raman microscope, where single exosomes
are trapped in a laser beam as shown in Fig. 1b. Raman
scattered light is collected from each exosome, yielding
a database of Raman spectra (Fig. 1c). Between 10 and
20 exosomes from each cell line were measured, with
the mean spectra and 91 standard deviation shown in
Fig. 3a. The Raman spectra largely resemble those in the
literature acquired from single cells and other biological
tissues, and the chemical assignment of the major bands
in the exosome spectra can be found in Ref. 30. The mean
spectra show striking variability between exosomes derived
from different cell lines. Several consistent differences
can be observed, including (a) the height of the peak at
�700 cm1, which is significantly elevated in the exosomes
derived from non-tumour cell lines 3T3 and IMR90, (b) the
shape of the 1,0001,100 cm1 and 1,2001,300 cm1
regions, and (c) the 1,6001,700 cm1 region, which
distinguishes the A549, SKOV3, and Jurkat lines from the
others. These areas are highlighted in Fig. 3a, d, and e,
as a visual aid.
Performing a PCA on the full data set reveals principal
component loadings that recapitulate the differences that
are apparent by visual inspection, as well as other, subtler
differences, as shown in Fig. 3d. The chemical assign-
ments for the major features in the principal components
are given in Table I.
The first 3 components represent 33, 18, and 10% of
the variance, respectively, in the data set. Thus, cumula-
tively they represent 61% of the total variance. Scores for
the first 3 principal component axes are shown in Fig. 3b
and c. To avoid confusion with the principal components
analysis performed on measurements of trypsin-treated
EVs, described in the next section, we give these principal
components the subscript ‘‘7c’’ to reflect that they ori-
ginate from a data set composed of 7 cell lines. In the
data set shown in Fig. 3, distinct clusters of exosomes
can be identified using hierarchical clustering analysis,
performed as described in the Materials and Methods
section, using the first 10 principal component scores
for each exosome (see Supplementary File).
Based on this hierarchical clustering analysis, each
individual exosome was assigned to 1 of 4 clusters based
on its spectrum. The cluster membership of each exosome
is indicated in Fig. 3b and c by varying symbols, as shown
in the legend. Shaded regions are provided as visual aids
to highlight the different cluster regions. For example,
Cluster 1 is represented by a star symbol and contains
the majority of the Jurkat, SKOV3, and A549 exosomes
within the region highlighted by the shaded blue oval.
Interestingly, the exosomes derived from the 2 non-
tumour cell lines (represented by gold and black colour)
fall almost exclusively into Clusters 2 and 3 (represented
by circles and triangles, respectively). To identify the
specific spectral features of each cluster, we plotted the
cluster-averaged spectra in Fig. 3e.
The cluster-averaged spectra reveal clear differences
between exosomes from different subgroups. Here, the
differences between each group are even more pronounced
than in the cell-line-averaged spectra inFig. 3a, as expected
given that many cell lines have exosomes in more than
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Fig. 3. Analysis of Raman spectra from single exosomes derived from 7 cancerous and non-cancerous cell lines. (a) Average Raman
spectra (solid lines) and 91 standard deviation (shaded areas) of exosomes. Black line separates normal (imr90, 3t3) and cancerous
cellderived exosomes (others). (b) First and second and (c) second and third principal component scores for each cell line. Colours
represent cell lines, whereas shapes represent cluster membership, as shown in the legend (right). Clusters are based on a linkage analysis
as described in the Supplementary File. Coloured regions throughout figure and dashed line in (c) provided as visual aids. (d) The first 3
principal component loading vectors, calculated from the full exosome spectral data set from all 7 cell lines. (e) Averaged spectra from
Clusters 1 through 4. Spectra in panels (a), (d), and (e) offset for clarity.
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1 cluster. Because the differences do not correspond to
cell type, we hypothesize that there may be several separate
classes of exosomes, varying in content and specific
biological directive. The preference of each cell line to
create exosomes of a given type is likely to be driven by
that cell’s role within the organism as a whole and to be
heavily influenced by the cellular environment (e.g. tumour
microenvironment). The paucity of exosomes from nor-
mal cell lines in Clusters 1 and 4 suggests that whatever
function these exosomes serve is performed with greater
frequency in cancerous versus normal cells. In fact, a close
inspection of Fig. 3c reveals that the majority of the
exosomes from non-tumour cells (black and gold colour)
fall on the low end of the PC7c 3 axis. A dashed line is
provided as a visual aid to highlight this discrimination.
Identifying themeaning of these principal component axes
will allow us to identify what chemical changes are present
within each exosome group compared to the others.
Our hypothesis is that the primary spectral differences
represented by the first 3 principal component axes are
cholesterol content, surface protein expression, and relative
expression of phospholipids to cholesterol, respectively.
Comparing the major peaks in PC7c 1 to Table I reveals a
strong spectral similarity with cholesterol, whereas PC7c 3
shows an inverse relationship between phospholipids and
cholesterol [which have been previously shown to have
an inverse relationship in exosomal membrane composi-
tion (52)]. This hypothesis is further strengthened by
comparing these principal components with reference
spectra for cholesterol (SigmaAldrich, C8667), phospha-
tidylcholine (SigmaAldrich, P3556), and phosphatidy-
lethanolamine (SigmaAldrich, P7693), which agree with
prior reports in the literature (53), and are provided for
visual comparison alongside PC7c 1 and 3 in Fig. 4.
The spectral similarity between the principal compo-
nents and the spectra of pure chemicals can be quantified
through least-squares curve fitting, as described in the
Supplementary File. Fitting PC7c 3 with a mixture
of cholesterol and phospholipids yields a curve that
faithfully reproduces the principal component’s major
peaks (Pearson’s correlation coefficient r0.82; see
Supplementary Fig. 4). Since Raman spectroscopy is
a quantitative technique whose signal is linear with
chemical concentration, the fit coefficients can be used to
Fig. 4. Comparison of lineshapes of principal components 1 and 3, shown in Fig. 3d, and pure spectra of cholesterol,
phosphatidylcholine, and phosphatidylethanolamine (black traces).
Table I. Literature assignments of major spectral features
in Fig. 3(d).
Position (cm1) Peak assignment Reference
700 Cholesteryl ester (45)
840 Saccharide/amines (45,46)
882 Tryptophan side-chain in proteins (47)
1,066 Chain CC stretching in lipids (48)
1,298 CH2 deformations in lipids (49)
1,450 CH2 and CH3 deformations in
proteins and lipids
(49)
1,651 CC stretching in lipids (50)
1,668 Amide I vibrations in proteins
Cholesteryl ester
(45,51)
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determine quantitative relationships between chemicals
represented by this principal component. As described
in detail in the Supplemental File, the spectral fitting
coefficients indicate that PC7c 3 represents a specific
exchange ratio between cholesterol and phospholipid,
where increasing values on this axis represent phospholi-
pid molecules added to the membrane at the cost of
cholesterol, at a 1:1 ratio of cholesterol/phospholipid.
Thus, increasing values on the first principal component
axis represent increased total cholesterol concentration,
while increasing values on the third principal component
axis represent an increase in the ratio of phospholipids
to cholesterol.
Although this simple comparison of PCs to pure
chemical components allows a good understanding of
PC7c 1 and PC7c 3, the chemical meaning of the second
principal component is not as clear from its overall shape.
Comparing its major peaks with those in Table I, we
see that the peaks primarily originate from proteins
and protein-associated saccharides. Given that cholester-
ol and phospholipids are membrane components, our
hypothesis is that PC7c 2 also represents a membrane
component, namely membrane-associated proteins. To
confirm our hypothesis that its shape represents surface
protein expression, we ran a control experiment where we
looked at spectral differences between native and trypsin-
treated exosomes, described below.
Raman spectra of extracellular vesicles after
treatment with trypsin
Exosomes and MVs were isolated from cultures of
LNCaP cells via differential centrifugation of the culture
medium as described in the Materials and Methods
section. Following isolation, both exosome and MV
samples were treated with trypsin, a proteolytic enzyme,
to cleave the extracellular portion of most membrane
proteins from the surface of the vesicles, leaving them
‘‘bald.’’ Trypsin is a digestive enzyme that works by
cleaving peptides at certain sites (54), thus breaking
large proteins into smaller subunits. Trypsinization is a
widely applied technique, used regularly for proteomic
sample processing and in cell culture, either to break down
cell adhesion proteins or to efficiently strip away surface
protein (55). After trypsinization of the EVs isolated in
this study [following a previously reported procedure (39)],
Western blot analysis (see Materials andMethods section)
was used to confirm the removal of tetraspanins CD9 and
CD63, transmembrane proteins that are highly expressed
at exosomalmembranes. Becausewe found in our previous
experiments that purification with the TEIR left a ‘‘coat-
ing’’ of the reagent around exosomes (see Ref. (56) and
Supplementary File), we used differential centrifugation to
purify these vesicles to ensure that the TEIR reagent did
not interfere with the digestions of membrane proteins by
trypsin.
LTRS spectra were recorded from �7 to 10 vesicles
from each group. Both mean spectra and 91 standard
deviation are shown in Fig. 5a. Subtle spectral differences
can be observed between exosomes and MVs, particularly
in the region around 1,000 cm1. Differences between
trypsinized and native vesicles can also be seen, particu-
larly in the protein- and lipid-rich 1,2001,400 cm1
region. To quantify these differences, principal compo-
nents analysis was performed on the data set. The first 3
principal component loadings are shown in Fig. 5b. Here
we labelled each PC with the subscript ‘‘Tr’’ to indicate
that they are the principal components from the trypsin-
treatment data set and to prevent confusion with the PCs
from the 7 cell line experiment, above. These 3 loadings
explain 30, 19, and 15% of the variance in the data set,
respectively. Thus, the 3 loadings cumulatively explain
64% of the total variance. In Fig. 5c we plotted the first
2 principal component scores for each individual vesicle,
revealing the magnitude and consistency of the separa-
tion between exosomes and MVs and between trypsin-
treated and -untreated vesicles.
Figure 5c reveals consistent differences between
native exosomes and native MVs, along both the PCTr 1
and PCTr 2 axes, which we hypothesize to be related
to the membrane composition, given the different intra-
cellular origin of the different vesicle types. Specifically, as
these differences disappear after the trypsin treat-
ment, both PCs are likely to be related to membrane
protein content. This suggests that PCTr 1 and PCTr 2
report on particular surface proteins that both distin-
guish exosomes and MVs and are removed by trypsin
treatment.
Comparing the principal component loadings from this
data set to the previous data set of 7 different cell lines
reveals startling similarities, as shown in Fig. 6. Although
the first PC axes for the 2 experiments look quite different,
this is to be expected, as in one experiment the primary
differentiator would be expected to be the difference
between exosomes and MVs (likely surface protein con-
tent), whereas in the other case the differentiator is
hypothesized to be related to cholesterol content. The
lineshapes of the second and third component loadings
are remarkably similar between the 2 experiments (PC7c
2 and PCTr 2 have a Pearson’s correlation coefficient of
r0.74, whereas PC7c 3 and PCTr 3 have a correlation
coefficient of r0.92).We have a priori knowledge that the
difference between the trypsin-treated and -untreated
vesicles, which lies primarily along the PCTr 2 axis, is the
surface protein content [see Western blot data, Fig. 2c,
Materials and Methods section]. The similarity between
the second loadings in both data sets strongly suggests that
PC7c 2 reports on surface protein expression. However,
PCTr 1 also reports on surface protein expression, and thus
PC7c 2 may be a mixture of PCTr 1 and 2. As shown in the
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Supplementary Fig. 5, fitting these curves to PC7c 2 yields
a fit that reproduces the major peaks of PC7c 2 (Pearson’s
correlation coefficient of 0.8). Based on this fit, as well
as the position of the trypsinized samples in the PCTr
space (upper left corner, Fig. 5c), we can then hypothesize
that increasing values on the PC7c 2 axis corresponds
to decreasing surface protein expression.
Conclusions
The current standard practice for exosome analysis relies
on bulk isolation and purification from expensive, large-
scale in vitro cell culture, typically followed by intensive
physicochemical analysis, including numerous proteomic,
genomic, and sizing techniques. However, it is increas-
ingly clear that conventional analytical tools lack the
sensitivity to explore the substantial heterogeneity re-
ported for EVs or are too costly and time-consuming to
justify pilot studies. Here, we applied LTRS to truly study
the chemical content of exosomes on a vesicle-by-vesicle
basis. Additionally, because Raman spectroscopy is a so-
called label-free technique, it does not require prior
knowledge of, for example, specific surface proteins for
fluorophore conjugation and can study EVs in close
approximations to their biological milieu.
Fig. 5. Analysis of Raman spectra from single LNCaP-derived extracellular vesicles with and without trypsin treatment. (a) Average
Raman spectra (solid lines) and91 standard deviation (shaded areas). (b) The first 3 principal component loading vectors, calculated
from the trypsin-treatment data set. (c) The first 2 principal component scores for individual vesicles, according to the loading vectors
shown in (b). Coloured areas in (c) provided as visual aids. Spectra in (a) and (b) offset for clarity.
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However, LTRS does have some limitations. Its primary
limitation is signal strength. Raman scattering is a
weak process, generally considered to be on the order of
1 million times weaker than fluorescence labelling. This
necessitates long integration times (5min in our experi-
ments) to measure a spectrum from a single exosome.
Furthermore, as discussed in the Supplementary File,
because we use bright-field imaging to find and trap
exosomes, we are likely biased to looking at exosomes
of approximately 100 nm and larger. As signal scales with
the cube of the radius, measuring smaller exosomes may
require even longer integration times. However, many
groups are currently researching methods to speed up
measurements by multiplexing measurements (57) or
employing ‘‘smart’’ detection strategies (5861). These
advances maymake LTRSmore approachable as a general
analysis technique for exosomes. Another limitation
of Raman spectroscopy is that, in complex chemical
mixtures such as cells or exosomes, it is difficult for
Raman spectroscopy to differentiate between many pro-
teins, especially those at very low concentrations. There-
fore, many Raman studies limit themselves to quantifying
broad classes of molecules (total protein content, total
lipid content, total nucleic acid content, etc.), rather than
quantifying the amount of a particular biomolecule (e.g.
CD63). We must be careful, then, to limit our conclusions
to the information provided by Raman spectroscopy.
In the quantitative analysis we present above, we hypothe-
size that Raman spectroscopy reports on an exosome’s
surface protein expression level. However, here we
must clearly highlight the fact that 2 exosomes may have
identical amounts of surface protein, yet be expressing
very different types of protein, and Raman spectroscopy
may not be able to provide that more detailed information.
Additionally, our experiments also have some limita-
tions. In this study, no density gradient purification
steps were performed, and thus protein aggregates or
other contaminants may have been present in our sample.
However, we would expect such particles to have quite
different Raman spectral signatures from exosomes that
were not observed in the particles we studied. Never-
theless, we cannot fully eliminate the possibility of these
aggregates contaminating our measurements. In perform-
ing our experiments, and as detailed in the Supplementary
File, we have acquired extensive circumstantial evidence
that the measurements we make arise from single exo-
somes. This evidence comes from confirming our ability
to trap and record signals from standard particles in
the exosome size range, substantiating via nanoparticle
tracking analysis (NTA) that no or few particles exist in
our samples outside the exosome size range. This point
confirms that we can observe discrete jumps and drops
in signal as exosomes enter and leave our laser trap; it
shows that our exosome signal for our recorded measure-
ments does not fluctuate over time (as might be expected
from multiple exosomes entering the trap). However,
we have no direct measurements of the size of the particles
measured within the optical trap, and thus the presence
of clusters of small numbers of exosomes cannot be
rigorously excluded. Despite these limitations, the work
described here demonstrates that Raman spectroscopy has
Fig. 6. Comparison of the first 3 principal component loadings from the trypsin and cell line experiments. Spectra are offset for clarity.
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significant power in quantitatively analysing molecules on
a single-to-few-exosome level.
A major finding of this study is the observation
of significant variation in the chemical content of EVs
reported by Raman spectroscopy. For example, Fig. 5
clearly shows the separation by Raman spectroscopy
between exosomes and MVs released from the same cell
culture, as prepared by differential centrifugation. Figure
3 also demonstrates that among exosomes from different
cell lines, there are strong similarities among the spectra,
yet consistent spectral differences that lead to grouping of
exosomes into 4 major subpopulations by a hierarchical
clustering analysis. These subpopulations are not due to
different cell origin, as many cell lines have exosomes in
many subpopulations, and all subpopulations contain
exosomes from multiple cell lines. Yet, there are some
subgroups of exosomes that are preferred by some cell
lines versus others. For example, exosomes from non-
cancerous cells primarily fall into subgroups 2 and 3. This
suggests that each subtype of exosome may play a
particular functional role that is common across cell lines.
A principal components analysis of this data set
yields insights into the chemical differences between the
different EV subpopulations. The second major finding of
this study is that these differences are primarily due to
membrane content of the EVs. The shapes of the first
and third principal components are closely matched
with spectra of known membrane constituents. Namely,
the first principal component has a spectral shape very
similar to that of cholesterol, while the third principal
component represents the inverse relationship between
cholesterol content and phospholipid content in the
membrane, as confirmed by fitting this lineshape to pure
chemical spectra. Therefore, increasing values along
the PC7c 1 axis corresponds to increasing cholesterol
content, while increasing values along the PC7c 3 axis
corresponds to increased phospholipid content at the
expense of cholesterol, with a 1:1 molecular substitution
ratio. Notably, non-cancerous cell-derived exosomes seem
to be much more enriched in cholesterol, while being
relatively depleted in phospholipid, compared to cancer-
ous cell-derived exosomes. This is the first time the content
of EV membranes has been examined at the individual
vesicle level, highlighting the fact that achieving this
level of quantitative chemical detail at the single vesicle
level would be difficult or impossible using conven-
tional methods of exosome chemical analysis. However,
it is relatively straightforward with LTRS given its
linear relationship to chemical components within the
few femtolitre measurement volume.
Treating EVswith trypsin cleaves the external domain of
mostmembrane proteins, leading to an expected alteration
in the Raman spectra of these vesicles. Comparing native
and treated EVs, native exosomes and MVs are clearly
distinguished by their Raman spectra, whereas trypsin-
treated ones are not. This difference suggests that these
vesicles are distinguished primarily by their membrane
components that are altered by trypsinization, such as
tetraspanins as shown in the Western blots in Fig. 2c.
Furthermore, analysis of trypsin-treated and native EVs
leads to the construction of principal components that
bear a strong resemblance to those constructed through
analysis of exosomes from several different cell lines,
discussed above. In particular, the second principal com-
ponent from the 7 cell line experiment (PC7c 2) can bewell-
fit by the first and second principal components of the
trypsin experiment (PCTr 1 and 2), lending significant
confidence to the conclusion that PC7c 2 reports on surface
protein expression, with increasing values along this
axis corresponding to decreased surface protein content.
Meanwhile, cholesterol content, which PC7c 1 demon-
strated to be a key variable among exosomes fromdifferent
cell lines, was not a significant contributor to the separa-
tion between exosomes and MVs from a single cell line.
As mentioned above, Raman spectroscopy has limited
speed, meaning that our analysis is necessarily limited
to relatively small numbers of exosomes. Measuring avery
large number of exosomes could ensure a more robust and
accurate representation of the true spectral variation
within the data set, compared to noise-induced variations.
However, comparing the results of the 7 cell line experi-
ment with the trypsin experiment, we are encouraged by
the similarities of the principal components analysis of
these 2 independent data sets. Each spectral decomposi-
tion was performed using different numbers of measured
exosomes, yet the spectral shapes of the first few principal
components were largely preserved. This result suggests
that these early principal components are quite robust
despite the modest number of exosomes studied in total.
Our study highlights the need for the development
of new analytical techniques that can study individual
vesicles. In light of the observed vesicle-to-vesicle hetero-
geneity, bulk measurements of EVs may not be enough to
fully understand their biological function and variability.
Our data demonstrate the existence of multiple popula-
tions of exosomes shared among cell lines and suggest
further studies aimed at taking vesicles grouped by Raman
spectroscopy, or other physical or chemical separation
methods, and subjecting them to further analysis to deter-
mine the differences in intravesicle cargo and membrane
protein content of exosomes produced by even a single cell
line. Such studies could help elucidate the various functional
relationships between an exosome’s construction and the
ultimate role it plays in cell function, cellular communica-
tion, and, for cancerous cells, carcinogenesis.
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Effect of the Total Isolation Reagent on the Exosome Spectrum 
 
Preparation of exosomes is typically performed by ultracentrifugation. However, to alleviate 
the experimental difficulty of and length of time required for ultracentrifugation, exosome 
isolation kits are commercially available from several manufacturers. These kits allow exosomes 
to be pelleted at low centrifuge speeds, as described in the Methods section, above. In this 
Figure S1. Raman spectra of total exosome isolation reagent (black) and trapped exosomes (colored). 
Numerical removal of the total isolation reagent by AsLS yields a spectrum (blue) in good agreement 
with exosomes prepared by ultracentrifugation (green). Spectra offset for clarity. 
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work we use one standard kit, the Total Exosome Isolation Reagent from Life Technologies 
(catalog # 4478359).  
 
The spectrum of this reagent is shown as the black trace in Figure S1. Interestingly, although the 
exosomes are rinsed and resuspended in PBS buffer following separation and pelleting, a strong 
remnant of the isolation reagent's signal is clearly present in the spectra of individual trapped 
exosomes. The spectrum of an exosome from an a549 cell culture where the isolation reagent 
was not included as part of the background model described above is shown in red in Fig. S1. 
Including the isolation reagent's spectrum in the background model leads to the spectrum 
shown in blue. Finally, we isolated a549 exosomes by gold-standard ultracentrifugation, leading 
to the spectrum shown in green. Comparing these curves seems to suggest that the isolation 
reagent works by coating the exosomes, causing them to precipitate more easily during 
centrifugation. However, this coating remains even after washing and resuspension. A previous 
report of Raman measurements of exosomes in the literature (62) did not correct for this 
effect, and it appears that the majority of the spectral signal they report is due not to the 
exosomes themselves but to the isolation reagent coating the exosomes. However, by including 
the isolation kit's spectrum in our background model, AsLS efficiently removes the 
contaminating peaks, giving rise to a corrected spectrum that agrees well with exosome spectra 
produced by the more laborious ultracentrifugation. The agreement between our ASLS-
corrected spectra from kit-prepared exosomes and ultracentrifuged exosomes is further 
confirmed by the correspondence between the principal component lineshapes computed from 
seven cell lines shown in Fig. 3 (prepared with the TEIR reagent), and the principal component 
lineshapes computed from the trypsin experiment shown in Fig. 5 (computed from 
ultracentrifuged samples). 
 
Evidence for Measurements of Single Exosomes 
 
A B 
Figure S2. (A) Raw, frame-level data from a single exosome. (B) Integrated area under the 1450 cm-1 
peak for 10 individual exosomes, showing <1% variation. 
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In our experiments we purposely choose a large dilution factor to ensure that typically less than 
one exosome is present, on average, in a field of view of our microscope. Thus, even over the 5 
minute duration of our Raman measurements, we do not expect multiple exosomes to wander 
into our trapping beam. Our 5 minute measurements are broken up into 10 frames of 30 
seconds each. We can break the data from a single measurement up into those individual 30 
second frames, and see that our signal over time does not change its intensity (as might be 
expected if a new exosome enters the trap). A representative exosome measurement is shown 
below (Figure S2 (A)), where the raw data shows no fluctuations over time. Integrating the 
signal in the 1450 cm-1 wavenumber peak and normalizing it to the mean value across the 5 
minute measurement (Figure S2 (B)), we see that there is less than a 1% fluctuation in the 
signal over time.  
To investigate the case where we expect multiple exosomes to be trapped over time, we 
prepared a dense suspension of exosomes such that an exosome would wander into the trap 
without any user intervention on the time scale of 30-60s. We then recorded Raman spectra at 
10s intervals, periodically translating the stage to “clear” the laser focus of any trapped 
exosomes, to examine the change in Raman signal over time. The results of that study are 
shown in Figure S3, where the integrated area under the 1450 cm-1 peak is shown as a function 
of time and showing the clear, discrete decreases when the trap is cleared, and increases when 
individual exosomes enter the trap. 
 
This is strong evidence that we can observe signals from individual exosomes, and can trap and 
release them with our laser tweezers setup. We can also see discrete changes in intensity when 
Figure S3 – Integrated Raman signal under 1450 cm-1 peak over time. Red arrows mark stage motions 
to “clear” the optical trap. Green arrows mark stepwise increases in signal due to exosomes appearing 
in trap. Note the increase at approximately frame number 30, where a second exosome enters the trap 
causing a distinct rise in signal. 
158
new exosomes enter the trapping beam. Given that we are sensitive to individual exosomes, 
that our signal undergoes no changes during the 5 minute measurements we perform, and 
based on our NTA data where the dominant particles in each sample fall within the size range 
of exosomes, we believe that our signal originate from single particles in the exosome size 
range. 
 
However, one caveat to this must be acknowledged. In our experiments we use bright field 
imaging to identify particles. One remaining question is whether we see the smallest exosomes, 
or only those above a certain size. To address the question of whether bright field imaging can 
observe particles in the exosome size range, we selected several synthetic particles with known 
size distributions:  
1. NIST-traceable 50 nm polystyrene beads,  
2. 100 nm silver nanoparticles,  
3. 130 nm PEG micelles,  
4. 160nm core-shell gold-glass nanoparticles (60nm gold core, 50nm-thick glass shell), and  
5. NIST-traceable 220 nm polystyrene beads.  
 
We present in Figure S4 example data from NIST-traceable 220 nm polystyrene beads (Duke 
Scientific, 5022A). Figure S4 (A) shows three representative, unprocessed bright field images of 
the polystyrene beads taken by our system showing the high contrast for these larger particles. 
Figure S4 (B) shows a time-course similar to Figure S3, where we can see individual polystyrene 
beads trapped and released by our system. The advantage of the stronger Raman signal from 
polystyrene is that we have much faster time resolution, confirming that beads enter and exit 
the trap causing step-wise changes in the Raman signal. Finally, by integrating the time-course 
in Figure S4 (B) we get a high-quality Raman spectrum as shown in Figure S4 (C), confirming our 
ability to record Raman spectra from individual nanoparticles. This data confirms our ability to 
observe individual nanoparticles and record Raman spectra from them using bright-field 
imaging as a feedback mechanism. However the smallest particles, the 50 nm polystyrene 
beads, were not observable under bright field illumination, while all other particles were. Due 
to the apparent similarity in optical contrast between polystyrene and extracellular vesicles, we 
believe that when we use bright-field to identify single particles, we very likely are biased 
towards selecting particles that are ~100 nm and larger. In the future it may be more 
advantageous to use light scattering (such as that used in NTA) rather than imaging as a 
feedback mechanism to detect a trapped particle. We emphasize here that it was possible to 
record Raman spectra from trapped 50 nm polystyrene beads, even though it was impossible to 
deterministically trap them using bright-field imaging. Therefore, given an appropriate feedback 
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mechanism (such as light scattering or dark-field imaging) to know when a particle is trapped, 
the LTRS method can still be used to acquire spectra of single exosomes in this size range. 
 
Figure S4 – Raman trap measurements of individual NIST-traceable nanoparticles. (A) Bright field 
images of 3 separate 220nm polystyrene beads. (B) Integrated intensity under the 1004 cm-1 peak over 
time as individual nanoparticles enter and are released from the trap. (C) Raman spectrum of 
polystyrene nanoparticles obtained by integrating the entire timecourse shown in (B). 
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Hierarchical Clustering of Cell Line Spectra 
Following principal components decomposition, we plot the first 10 principal component 
loadings, shown in Figure S5 (first three curves identical to Fig. 3 (D)). Projecting the Raman 
spectra onto these 10 principal component axes yields 10 scores.  A hierarchical clustering 
analysis, performed as described in the Methods section, above, using these scores, yields a 
dendrogram as shown in Figure S6. The dendrogram describes spectral distance, where 
branches of the dendrogram tree are connected based on the similarity of one spectrum to 
another. This similarity is assessed by computing pairwise distances between each spectrum in 
the 10-space described by first 10 principal components.  Spectra with small pairwise distances 
are more similar to each other (have more similar PC scores). The dendrogram tree has been 
extended to the level of individual exosomes, with each terminus label color-coded as in Fig. 3 
in the main text.  The dendrogram reveals four major clusters, with clusters 2 and 3 having a 
heavy representation from exosomes of non-tumor cell lines. Spectra from each cluster can be 
averaged to yield cluster-averaged spectra as shown in Figure 3 (E) from the main text.  
Figure S5. The first ten principal component loading vectors, calculated from the full exosome 
spectral dataset from all seven cell lines. 
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Fitting Principal Component Axes from Seven Cell Lines to Pure Components and Principal 
Components of Control Experiments 
 
Pure component spectra of membrane lipid components were fit to the shape of the 3rd 
principal component axis from the seven cell lines experiments using standard least-squares 
fitting, with the result shown in Figure S7. Note that the pure spectra in Figure S7 are scaled by 
their fit coefficient, so cholesterol, for example, has a negative fit coefficient and therefore is 
the negative of the lineshape shown in Fig. 4 from the main text, above. A 5th order polynomial 
was also included in the model to account for baseline fluctuations between the two 
experiments. The fit has a high correlation (r=0.82) with the PC7c 3. The fitting coefficients can 
be used to quantitatively determine the molecular relationship between cholesterol and 
phospholipid represented by the principal component. The pure components were measured 
from solid forms of the chemicals that fully filled the confocal measurement volume of the LTRS 
system. Thus, the focal volume was filled with a certain number of molecules related to the 
density and molecular weight of the chemical being measured. Given this, the total number of 
molecules measured per focal volume can be calculated following Equation S1, below, where 
NA is Avogadro’s number: 
 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
𝑉𝑉𝑚𝑚𝑚𝑚𝑉𝑉𝑚𝑚
= 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑(
𝑔𝑔
𝑚𝑚𝑚𝑚
) ×
1
𝑀𝑀𝑚𝑚𝑚𝑚.𝑊𝑊𝑊𝑊.
(
𝑚𝑚𝑚𝑚𝑚𝑚
𝑔𝑔
) × 𝑁𝑁𝐴𝐴(
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
𝑚𝑚𝑚𝑚𝑚𝑚
) (Equation S1) 
Figure S6. Dendrogram showing the clustering result using the first 10 principal components. Labels 
are color coded as in Figure 2. 
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Cholesterol, phosphatidylcholine, and phosphatidylethanolamine have similar densities (1.067, 
1.019, and 1.0, respectively). Thus, the primary determinant in the number of molecules per 
measurement volume is the molecular weight of each component (386.95 for cholesterol, 768 
for phosphatidylcholine, and 744 for phosphatidylethanolamine). Thus, each pure component 
spectrum represents the signal from a certain number of molecules of that pure chemical, 
which could be determined by multiplying Eq. S1 by a highly accurate measure of the 
measurement volume Vmeas. However, even in the absence of that information, because Vmeas is 
constant between experiments, ratios of fit coefficients can be used to quantitatively 
determine the ratios of different molecules represented by PC7c 3.  The coefficients of the fit 
are: 
 
−0.42 × 𝑐𝑐ℎ𝑜𝑜𝑜𝑜. + 0.28 × 𝑝𝑝ℎ𝑜𝑜𝑜𝑜𝑝𝑝ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑜𝑜𝑐𝑐ℎ𝑜𝑜𝑜𝑜𝑎𝑎𝑜𝑜𝑜𝑜 +  0.6 × 𝑝𝑝ℎ𝑜𝑜𝑜𝑜𝑝𝑝ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑜𝑜𝑜𝑜𝑎𝑎ℎ𝑎𝑎𝑜𝑜𝑜𝑜𝑜𝑜𝑎𝑎𝑎𝑎𝑎𝑎𝑜𝑜𝑜𝑜 
  
where “chol,” “phosphatidylcholine” and “phosphatidylethanolamine” represent one unit 
spectrum of pure crystals of these compounds. Taking the ratio of the fit values for cholesterol 
and phospholipids, where each fit value is scaled by the number of molecules represented by 
each unit spectrum using Eq. S1, we can determine the ratio of cholesterol to phospholipid 
represented by PC7c 3, as shown in Eq. S2, below: 
 
−0.42
386.95
÷ (
.28
768
+
.6
744
) ≈ 1 (Equation S2) 
Figure S7. Least squares fit of the 3rd principal component from Figure 3 (D) to the pure 
spectra of cholesterol, phosphatidylcholine, and phosphatidylethanolamine shown in Figure 
4. Spectra offset for clarity. 
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Therefore, PCTr 3 represents an exchange of cholesterol for phospholipids, with an exchange 
ratio of 1 cholesterol molecule for 1 phospholipid. 
 
A similar fitting can be carried out for the 2nd principal component from the 7 cell lines 
experiment (PC7c 2), which is hypothesized to report on membrane protein.  In this case, we 
have a priori knowledge that PCTr 1 and PCTr 2 from the trypsin experiment are related to 
membrane protein (as they are the dominant sources of spectral difference between native and 
trypsinized exosomes and microvesicles). Therefore, we can attempt to fit PC7c 2 with PCTr 1 
and PCTr 2 of the trypsin experiment. The results of this fit are shown below, in Figure S8 (fit 
coefficients = -0.22*PCTr 1 + 0.43*PCTr 2). Similar to above, note that PCTr 1 in this case has a 
negative fit coefficient and is therefore the inverse lineshape compared to its presentation in 
Fig. 4(B). The fit has a high correlation with PC7c 2 (r = 0.8), and provides strong support for the 
hypothesis that PC7c 2 and PCTr 1 and 2 report on the same quantity: surface protein expression.  
 
 
 
 
 
Figure S8. Least squares fit of the 2nd principal component from Figure 3 (D) by the 1st 
and 2nd principal components from the trypsin control experiment shown in Figure 5 (B). 
Spectra offset for clarity. 
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Multi-parametric surface plasmon resonance platform
for studying liposome-serum interactions and protein corona
formation
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Seppo Meri3 & Marjo Yliperttula1,2 & Tapani Viitala1 & Arto Urtti1,4
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Abstract When nanocarriers are administered into the blood
circulation, a complex biomolecular layer known as the
Bprotein corona^ associates with their surface. Although the
drivers of corona formation are not known, it is widely accept-
ed that this layer mediates biological interactions of the
nanocarrier with its surroundings. Label-free optical methods
can be used to study protein corona formation without inter-
fering with its dynamics. We demonstrate the proof-of-
concept for a multi-parametric surface plasmon resonance
(MP-SPR) technique in monitoring the formation of a protein
corona on surface-immobilized liposomes subjected to
flowing 100 % human serum. We observed the formation of
formulation-dependent Bhard^ and Bsoft^ coronas with dis-
tinct refractive indices, layer thicknesses, and surface mass
densities. MP-SPR was also employed to determine the
affinity (KD) of a complement system molecule (C3b) with
cationic liposomes with and without polyethylene glycol.
Tendency to create a thick corona correlated with a higher
affinity of opsonin C3b for the surface. The label-free plat-
form provides a fast and robust preclinical tool for tuning
nanocarrier surface architecture and composition to control
protein corona formation.
Keywords Multi-parametric surface plasmon resonance
(MP-SPR) . Protein corona . Soft corona . Liposome .
Complement system . Opsonin
Introduction
Nanomedicine has advanced several research fields (e.g.,
cancer and gene therapy, medical imaging) by enabling the
targeted delivery of therapeutic and diagnostic molecules
while protecting the sensitive cargo [1, 2]. Hydrophilic
molecules, such as polyethylene glycol (PEG), are used
to shield nanocarriers from unspecific protein binding that
may change biodistribution, decrease cellular uptake, and
lead to premature nanocarrier clearance by the mononucle-
ar phagocyte system (MPS) [3]. In fact, PEG can increase
the average circulation time of liposomal drugs from mi-
nutes to up to days [3]. However, it is widely accepted that
the steric hindrance provided by PEG and other hydrophil-
ic coatings does not abrogate unspecific protein binding,
and these coatings can act as immune activators [4–7].
Since severe hypersensitivity reactions to nanocarriers
have been reported in clinical use, improved preclinical
methods to assess the safety of nanocarriers are needed
[2, 4, 5, 8–10]. In particular, label-free methods to predict
biological interactions of nanocarriers are warranted, as
labels may lead to biased results [2, 11]. The safety of
Otto K. Kari and Tatu Rojalin contributed equally to this work
Electronic supplementary material The online version of this article
(doi:10.1007/s13346-016-0320-0) contains supplementary material,
which is available to authorized users.
* Tapani Viitala
tapani.viitala@helsinki.fi
1 Centre for Drug Research and Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University of Helsinki,
Viikinkaari 5, P.O. Box 56, FI-00014 Helsinki, Finland
2 Department of Pharmaceutical and Pharmacological Sciences,
University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
3 Department of Bacteriology and Immunology, Immunobiology
Research Program, Faculty of Medicine, and HUSLAB, Division of
Clinical Microbiology, Haartmaninkatu 3, P.O. Box 21,
FI-00014 Helsinki, Finland
4 School of Pharmacy, University of Eastern Finland, Yliopistonranta
1, FI-70211 Kuopio, Finland
Drug Deliv. and Transl. Res.
DOI 10.1007/s13346-016-0320-0
Author's personal copy
167
nanocarriers can be improved by decreasing the immuno-
genicity of nanocarriers, or by increasing their cellular
targeting, both of which are affected by the proteins
adsorbed on the nanocarrier surface.
After nanocarrier introduction into the blood circulation,
their surface is rapidly covered with a complex and dynamic
layer of biomolecules such as proteins, lipids, and other plasma
components [3, 12–14]. This layer is often referred to as the
Bprotein corona^ and it is further divided into a stable Bhard
corona^ and a diffuse secondary layer of proteins, the Bsoft
corona^ [3, 12–14]. Following the pioneering work of
Cedervall et al. [14] to characterize the kinetics of protein co-
rona formation on nanoparticle surfaces, protein-nanocarrier
interactions have received increasing attention [15, 16]. At
present, the influence of the protein corona on the fate of the
nanocarriers in the body has been clearly demonstrated
[3, 11, 13, 17]. Proteomic characterization of the protein corona
has helped to identify nanocarrier-specific protein finger-
prints—not a simple task considering the highly dynamic na-
ture of the protein corona [15, 17–20]. More recently, the focus
has shifted towards exploiting protein corona formation for
extracellular and intracellular targeting, understanding its evo-
lution, and its role in mediating physiological responses to
nanocarriers [8, 15, 17, 20]. However, there is still a need to
increase our understanding of the protein corona phenomenon
and its dynamics due to its biological significance.
The prevailing hypothesis on the dynamics of corona for-
mation assumes the formation of a highly dynamic but slowly-
developing hard corona with a limited number of proteins
[11, 14, 18]. This paradigm was challenged by Tenzer et al.
[17], who reported the formation of a highly complex and
particle-specific protein corona on all nanoparticles tested in
30 s. The rapid formation and composition of the protein co-
ronas could not be explained merely by the physicochemical
properties of the nanoparticles, and at longer incubation times,
the protein composition changed only quantitatively but not
qualitatively [17]. According to the authors, the rapid forma-
tion of a protein fingerprint is sensible considering the highly
dynamic nature of physiological systems, which have evolved
to Breact instantly^ to preserve homeostasis. The effect of
dynamic incubation on protein corona formation was recently
demonstrated with PEG-modified liposomes when static in-
cubation was compared to flow conditions mimicking blood
flow dynamics [12]. Over 200 corona proteins were identified,
with 108 proteins common to both incubation conditions,
whereas 10 and 99 proteins were observed only after incuba-
tion in static or dynamic conditions, respectively [12]. For
increased in vivo relevance, the protein corona formation
should therefore be tested in flow conditions.
The studies by Palchetti et al. [12] and Tenzer et al. [17]
indicate the presence of complement system proteins in the
corona. This is not surprising considering the nature of these
proteins as the probes of the immune system, and the non-
allergic hypersensitivity reactions that have been reported fol-
lowing the administration of PEGylated liposomes (e.g.,
Doxil©) that has been linked to complement system activation
[5, 9]. For instance, covalent depositions of C3b on the surface
of nanocarriers lead to an increased MPS clearance rate and a
tendency to activate an innate immune response [3, 21, 22].
C3b is an activated opsonin formed from the central comple-
ment protein C3, at which all three activation pathways con-
verge for amplification [21]. Complement proteins can carry
out their functions by binding both to the native nanocarrier
surface and through attachment to surface-bound proteins
such as albumin [23]. Therefore, for reduced immunogenicity,
nanocarrier surfaces should not favor the binding of C3b or
other complement components [5, 9, 21].
Most analytical techniques are not suitable to study the soft
corona on nanocarriers [12, 16, 17, 20]. Biophysical analytical
approaches tomonitor the soft corona could provide important
information, and there is a growing interest in Raman spec-
troscopy, quartz crystal microbalance (QCM), and surface
plasmon resonance (SPR) to study the evolution of corona
formation in real time [16, 20]. The SPR phenomenon has
been widely used for biosensing applications, including the
interaction kinetics of individual proteins and complement
system components on biomaterial surfaces [24]. Previous
SPR studies on the interactions of nanocarriers with blood
proteins have employed diluted plasma [13, 23, 25]. The sur-
face of biosensors can be functionalized with specific chem-
istries of interest, proteins, or a hydrogel and lipid matrix that
can be used to capture nanocarriers on the sensor surface—an
approach we utilize in this work among others [14, 25–27].
SPR permits the sensitive label-free monitoring of mo-
lecular interactions [28, 29]. It is based on propagating
waves of surface plasmons produced on a metal surface
upon excitation with light. The conditions for exciting the
surface plasmons are dependent on the refractive index of
the medium in contact with the metal surface, and the mo-
lecular mass changes on the metal surface. In essence, the
binding of molecules such as proteins to the metal surface
can be detected as a change in the SPR peak angular posi-
tion, θSPR. Figure 1 illustrates a set of idealized full SPR
angular spectra; the solid red and blue traces representing
measured spectra and the black and orange dotted lines
showing calculated counterparts for the red and blue spec-
tra, respectively. The main components of spectra are
marked as① the angular position of total internal reflection
(TIR) event and② the angular position of SPR peak mini-
mum, referred to as θSPR in this manuscript. As the analytes
are deposited onto the sensor surface, a shift towards larger
angular values takes place in the θSPR (Fig. 1②). However,
the angular position of TIR may also undergo a change
towards larger values if the refractive properties of running
buffer and injected analyte differ significantly (Fig. 1①).
This bulk effect, in turn, can be compensated for in the
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θSPR, and thus, the remaining part of the angular change
mainly represents the binding event at the surface. In gen-
eral, the full SPR angular spectra contain all the physical
information to solve for the layer thicknesses and refractive
indices; the shape and quantities associated with the SPR
curve are utilized. A more profound mathematical descrip-
tion of solving for the layer thickness and refractive index is
given in Materials and Methods section. Lastly, it is worth-
while pointing out, that the full SPR angular spectra are
used to solve for deposited layer thicknesses and refractive
indices, whereas the sensorgrams are utilized for determin-
ing the interaction kinetics parameters. Importantly, in the
sensorgrams, the θSPR (displayed in Fig. 1 as red and blue
dots) is followed in real time which allows for calculating
the kinetic parameters if the injected analyte concentrations
are known.
Multi-parametric surface plasmon resonance (MP-SPR)
refers to an adaptation of the SPR technology that can be
used to optically characterize biomolecular layers in more
detail and with thicknesses of up to several micrometers
[28] (Fig. 1). Traditionally, the incident angle of minimum
reflectance has been monitored over a narrow angular area
near the θSPR. With the MP-SPR technique, the full SPR
angular spectrum is recorded by scanning over a wide an-
gular range (~40–78°) and multiple parameters can be ac-
quired simultaneously; for example, the angular position of
the TIR angle, the angular position of θSPR, the half-width
of the main SPR peak, and the change in the main SPR
peak intensity at θSPR can be monitored in real time. The
combination of two or more wavelengths and a scanning
angle feature makes it possible to record the entire SPR
angular spectrum as a function of time. Unlike with other
SPR instruments that employ only one wavelength, the
MP-SPR adaptation allows for determination of layer
thicknesses, refractive indices, and surface mass densities
in addition to traditional kinetic association and dissocia-
tion events [28, 30, 31]. These features provide new op-
portunities for a more detailed surface characterization of
protein coronas, which we have explored in this work. In
this paper, we describe the proof-of-concept for an
MP-SPR method to monitor the formation of protein co-
ronas on nanocarriers in real-time at the interface of
flowing undiluted serum. We also demonstrate the use of
MP-SPR to determine the affinity of a complement system
probe molecule C3b interaction with the sensor-
immobilized liposome surface.
Materials and methods
Serum preparation Blood drawn from seven healthy and
fasted donors using Vacutainer glass tubes without clot acti-
vator (BD, Franklin Lakes, NJ, USA) was left to clot for
30 min at 22 °C, followed by centrifugation at 2500 × g for
5 min and 3500 × g for 5 min. The serum fractions were
collected manually and pooled together with serum from other
donors in aseptic conditions, and stored in aliquots at −80 °C.
Before SPR measurements, aliquots were thawed rapidly in a
37 °C water bath until 90 % thawed. Heat homogeneity was
checked with a FLIR TG165 imaging IR thermometer (FLIR
Systems, Inc., OR, USA) to avoid bubble formation inside the
SPR flow channel due to temperature changes.
Liposome samples The film re-hydration method followed
by extrusion through a polycarbonate membrane was used to
prepare liposome samples [32]. Control liposomes were rep-
licas of the Doxil© (Johnson and Johnson, NJ, USA;
marketed in Europe under the name Caelyx© by Janssen-
Cilag International NV, Beerse, Belgium) formulation with
and without PEG (referred to as DOX + PEG and DOX,
respectively) but without doxorubicin [32]. The molar ratio
of fully hydrogenated soy phosphatidylcholine (HSPC), cho-
lesterol and N-(carbonyl-methoxypolyethylene glycol 2000)-
1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium
Fig. 1 An idealized example of two measured full SPR angular spectra
(red and blue solid curves) and the fitted spectra (black and orange dotted
curves, respectively). The shape and quantities associated with the SPR
curve are used to fit the measured data and, consequently, solve for
surface-deposited layer thicknesses (d) and refractive indices (n). The
calculation is carried out in a stepwise numerical iteration routine
whereby the parameters (d and n) for each layer are calculated utilizing
the information provided by two independent excitation wavelengths
(670 and 785 nm). For clarity, instead of displaying four measured
curves, spectra recorded from one wavelength are depicted in the
figure. The shift in angular position of total internal reflection (TIR) is
used to compensate for bulk effect caused by the differences between the
running buffer and injected sample; e.g., serum injection into the flow
system consisting of a running buffer induces a significant change in the
TIR angle (①). In order to estimate the signal for the binding event to the
surface, the TIR shift contribution can be compensated by a subtraction
from the overall signal. In general, binding events are detected as a shift in
θSPR (②)
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salt (DSPE-PEG2000) or 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE) was 55:40:5, respectively
[32]. After preparation the DOX and DOX + PEG liposome
stock suspensions were stored at 4 °C until use. For SPR
measurements, the DOX and DOX + PEG liposome samples
were adjusted to a 3 mM total lipid concentration.
Positively charged liposomes with oligo-guanidyl lipid de-
rivative (OGD) with a 0.2 mg/ml total lipid concentration in
HEPES 10 mM and NaCl 150 mM (pH 7.4) buffer solution
were freeze dried after preparation and stored at −20 °C until
use [33]. For SPR measurements, the OGD liposomes sam-
ples were quickly thawed and vortexed. The OGD liposomes
adsorbed on the sensor surface were then coated in situ ac-
cording to a charge-to-charge association process with a
polyanionic-PEG block-copolymer (PEG) with a concentra-
tion of 0.1085 mg/ml in HEPES 10 mM and NaCl 150 mM
(pH 7.4) buffer solution (OGD + PEG).
Endotoxin detection The presence of endotoxins was tested
using Limulus Amoebocyte Lysate (LAL) assays: Pierce LAL
chromogenic endotoxin quantitation kit (Thermo Fisher
Scientific, Waltham, MA, USA) and Pyrogent Plus Gel Clot
LAL at 0.06 EU/ml sensitivity (Lonza, Basel, Switzerland).
Assays were performed according to manufacturers’ instruc-
tions using endotoxin-free consumables. Test samples were
incubated using a Thermomixer C heating block (Eppendorf
AG, Hamburg, Germany). Absorbance (405 nm) was mea-
sured using a Spectrostar Nano plate reader (BMG Labtech,
Ortenberg, Germany) and calculated using the accompanying
MARS software. Inhibition and enhancement controls and
transmissivity measurements of the liposome solution at assay
wavelength were performed to rule out liposome interference
with the LAL assays.
Physicochemical characterization of liposome samples
Hydrodynamic diameter measurements were performed at
25 °C with a Zetasizer APS DLS automated plate sampler
(Malvern Instruments, Malvern, United Kingdom). Results
are reported as size distributions (average hydrodynamic
diameter ± S.D.) derived from relative signal intensities and
in the form of a polydispersity index (PDI). Surface charge of
the liposomes was determined by measuring the ζ-potential in
DTS 1070 folded capillary cells (Malvern Instruments) by
using a Zetasizer Nano ZS instrument (Malvern Instruments).
MP-SPR measurements Measurements were performed
with a SPR Navi™ 200 (BioNavis Ltd., Ylöjärvi, Finland)
instrument. The setup was equipped with two incident laser
wavelengths, 670 nm and 785 nm, two independent flow
channels, inlet tubing and outlet (waste) tubing. Both of the
flow channels were measured in parallel with 670 nm and
785 nm incident light. The measurement temperature was
kept constant at 20 °C, and the flow rates used for liposome
immobilization and for serum interactions were 50 and
100 μL/min, respectively. Liposomes were captured and
immobilized on SPR sensors consisting of a thin 6-kD
carboxymethyl dextran hydrogel layer functionalized with
dodecyl lipid anchors [26, 34]. The SPR sensors were used
repeatedly after rejuvenation with an injection series of
Hellmanex II 2 % (Hellma Analytics, Müllheim, Germany)
orCHAPS20mM(Sigma-Aldrich), ethanol 80% (AltiaOyj,
Rajamäki, Finland) and deionized water from a Milli-Q
water purification system (Merck KGaA, Darmstadt,
Germany). In between measurements, the sensors were
stored immersed in CHAPS at 4 °C. During the SPR mea-
surements, the functionalized gold sensor slides were first
subjected to the running buffer for respective liposome for
approximately5–10minuntil a stable baselinewas achieved.
In the second phase, the liposomes were injected into both
flow channels for 10min, and lastly, sensor surfaces contain-
ing the immobilized liposome species were subjected to
100 % serum. The PEGylation step for the OGD liposomes
was performed in situ with a polyanionic-PEG block-copol-
ymer after liposome immobilization to create a surface with
OGD + PEG, whereas DOX + PEG liposomes contained
PEG prior to immobilization.
MP-SPR data analysis The shape and quantities associated
with the SPR curve are utilized for the layer thickness and
refractive index calculations. The SPR spectrum can be de-
scribed with Fresnel’s equations as the reflectivity of a multilay-
ered system for p-polarized light [28, 30]. In essence, the layers
are assumed linear, homogenous, and isotropic. The calculation
is based on a 2 × 2 scattering matrix that is derived from
Fresnel’s complex-amplitude reflection and transmission coef-
ficients. The matrix represents the summarized optical proper-
ties of the system; the properties are expressed as a product of
the interface and layer matrices of the entire structure.
Furthermore, the intermediate zones between different layers
are introduced into Fresnel’s equations as new layers. Thus,
the thickness of the intermediate layer describes the average
roughness of the surface, whereas its complex refractive index
corresponds to the light losses via scattering and plasmon
decoupling into radiative modes (essentially the imaginary part
of the complex refractive index). The benefit of this approach is
that only Fresnel’s equations can be used without the need to
apply, e.g., scattering theories. In practice, the modeling and
solving for the matrix formalism is performed by mathematical
fitting tools or dedicated software. To solve for the layer thick-
nesses and refractive indices of the thin biomolecular layers, a
two-wavelength method combined with angular scanning over
a wide range of incident light angles is particularly efficient
[35–37]. The measured full angular SPR spectrum and matrix
formalism are utilized to model the layers. Even though the
overall mathematics behind the calculations is relatively com-
plicated, the solving process can be simplified to a level that the
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modeling still produces accurate results for most of the situa-
tions that deal with common materials and biological mole-
cules. Additionally, the sources for error are feasible to track
due to the known limitations of these evaluations. It is worth
emphasizing that the multi-wavelength approach for surface
characterization has been successfully implemented in previous
studies [26, 31, 38, 39].
The general solution for a multilayered, optically active
system that is connected with measurable and controllable
quantities, can be derived using the aforementioned transfer
matrix formalism of 2 X 2 matrices. In the complex refractive
index n ¼ nþ ik the real part n corresponds to the refraction
of light, and the complex coefficient k to the extinction or
absorption of light by the material. Furthermore, the relation-
ship n ¼ ﬃﬃεp connects the refractive index and dielectric con-
stant. Finally, in practical experiments, the surface plasmon
wave vector (ksp) is considered to contain all the information
and constants that affect the measured SPR spectra and lead to
differences in SPR spectra measured at multiple wavelengths.
Therefore, the continuum solution for surface plasmon wave
vector (ksp) in one set of conditions can be deducted to de-
scribe the mathematical relationship between (ksp), the mate-
rial layer thickness d, and the refractive index n:
ksp∝n*d
However, the definition above describes only one continu-
um solution for the (ksp). The unique solution for the appar-
ently interconnected thickness d and refractive index n of the
sample layer build in the given experimental conditions can be
found from the intersection of two continuum solutions.
Therefore, a measurement in two different media or multiple
wavelengths is needed [28, 31]. In the mathematical treatment
of the two-wavelength method, the refractive index n has also
a wavelength dependency, dn/dλ. The unique solution for lay-
er thickness d and refractive index n can be found by solving
for the equations:
ksp1 ¼ nλ1*d
ksp2 ¼ nλ2*d
where ksp1 denotes the surface plasmon vector for wavelength
1, nλ1 the refractive index for wavelength 1, ksp2 the surface
plasmon vector for wavelength 2, and nλ2 the refractive index
for wavelength 2, and:
nλ2 ¼ nλ1 þ dndλ * λ2−λ1:ð Þ
and:
ksp1 ¼ nλ1*d
ksp2 ¼ nλ1 þ dndλ * λ2−λ1ð Þ
� �
*d
The statements above hold true for sample layers that do
not absorb light at the wavelengths used in the SPR spec-
trum measurement. In practice, it means that the imaginary
component k for the refractive index = 0, which is the case
for the majority of organic sample layers. However, if the
layer absorbs light, k ≠ 0, and there is a unique solution for
the sample layer in the ksp = (n + ik) * d space, one can uti-
lize laser wavelengths 670 and 785 nm that are aligned to
irradiate simultaneously the same spot in each sample
channel. The thicknesses of modeled layers can be linked
as common for both wavelengths in the modeling step, i.e.,
the layer thickness is expected to be the same for both
wavelengths since the SPR angular spectra are measured
from the same spot. The complex refractive index can be
inputted as an independent variable for background (e.g.,
pure metal layer) modeling, or as a linearly dependent var-
iable between the two used wavelengths for reasons de-
scribed above.
The SPR Navi LayerSolver v. 1.2.1 (BioNavis Ltd.,
Ylöjärvi, Finland) software was used for the layer thick-
ness (d) and refractive index (n) modeling and calcula-
tions. In essence, the modeling and calculation of layer
thickness and refractive index were carried out using the
two-wavelength method. The LayerSolver allows for mul-
tiple SPR spectra processing, and a stepwise approach for
calculations where the biophysical properties of the mo-
lecular layers are determined by numerical iteration one
layer at a time. The software was used to simultaneously
solve the thickness and refractive index based on full SPR
angular spectra measured with two different wavelength
lasers (670 and 785 nm) at the same time point [28, 30].
The numerical iteration is performed by the embedded
algorithms in LayerSolver software. The equations de-
scribed in section BMP-SPR data analysis^ constitute the
physical cornerstone for the calculation routines in
LayerSolver. As input variables, the following layer thick-
ness and refractive index values were used: for OGD,
d = 45–70 nm and n = 1.357–1.355; for DOX, d = 80–
120 nm and n = 1.357–1.352; for OGD and DOX soft
corona, d = 20–70 nm and n = 1.37–1.38; for OGD and
DOX hard corona d = 5–10 nm and n = 1.38–1.39. In the
optical modeling performed in this work, the thickness
values were defined as global variables for the two wave-
lengths used and the refractive indices were defined as
independent variables for the iteration cycles.
Interaction kinetics were modeled with TraceDrawer v.
1.6 (Ridgeview Instruments AB, Vänge, Sweden) soft-
ware. The calculation of interaction parameters is based
on well-established kinetic models [40]. Herein, a one
binding site model was used for determining the affinity
of the human native complement component C3b (diluted
in Dulbecco’s phosphate-buffered saline, obtained from
Merck KGaA, Darmstadt, Germany) interacting with
immobilized OGD or OGD + PEG liposomes. According
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to the supplier, the C3b protein used should display at least
60 % of its physiological activity. A concentration series
0.00833, 0.0833, and 0.833 mol (determined with a MWof
180 kDa from 0.0015, 0.015, and 0.15 mg/ml) fitting with
negligible dissociation phases was performed for the mea-
sured C3b sensorgrams in order to calculate the kinetic
parameters for C3b. In general, molecular mass that binds
onto the SPR sensor surface has a well-defined correlation
with the observed SPR angular spectrum and the SPR res-
onance angle shift in particular. Hence, the surface mass
densities of C3b can be calculated by using the de Feijter
equation that is derived from the definition of refractive
index increment of adsorbing biomolecules, with some
limitations [41, 42]. For the used SPR Navi™ 200 instru-
ment and 670-nm laser wavelength, the actual surface mass
density conversion coefficient can be defined using a value
of dn

dc = 0.182 cm
3/g. In this study, to convert the ob-
served SPR signal responses to surface mass densities (Γ),
we used the conversion factor Δ 1 mdeg = Δ (Γ)~0.6 ng/
cm2 for the lower limit of deposited surface mass density.
To estimate the error in the calculation, we also defined the
higher limit using the conversion factor Δ 1 mdeg = Δ
(Γ)~1.0 ng/cm2.
Results and discussion
Liposome immobilization and serum interaction with the
immobilized liposomes Figure 2 illustrates the measurement
scheme for serum interaction studies with the liposomes.
Undiluted serum was used instead of anticoagulated plasma
since it contains a functioning complement system. Roman
numerals are used consistently to refer to the modeled physi-
cal events. Figures 3 and 4 (a, b), and Figs. 5 and 6 (a, b)
display the MP-SPR sensorgrams and full SPR angular spec-
tra, respectively, with: (I) the liposome layer after immobili-
zation onto the sensor surface, (II) serum interaction with li-
posomes and ensuing soft corona formation, and (III) the hard
corona after restoration of buffer flow. In this work, the term
soft corona is used to refer to the combination of a denser
corona layer accompanied by a more diffuse layer of weakly
interacting proteins. The averages of the modeled and calcu-
lated layer thicknesses (d) and refractive index (n) values of
three independently repeated measurements are found in
Table 1 for OGD and OGD + PEG liposomes and in Table 2
for DOX and DOX + PEG liposomes. In order to emphasize
the highly dynamic behavior of the modeled systems, to take
into account the possible sensitivity of differential equations to
initial conditions provided as inputs in LayerSolver, and to
estimate the uncertainties in experimental procedures and cal-
culations, we chose to define a range for the calculated (d) and
(n) values. Thus, instead of representing one set of (d) and (n)
values, our intentionwas to determine the dlow and nlow aswell
as dhigh and nhigh, between which the calculated values could
potentially vary. The dlow, nlow, dhigh, and nhigh values were
calculated by using a consistent set of initial values throughout
the layer modeling. Table S1 presents the results of physico-
chemical characterization (size, PDI, and ζ-potential) and en-
dotoxin determination. The results for each individual exper-
iment are found in Table S2 for OGD and OGD + PEG lipo-
somes and Table S3 for DOX and DOX + PEG liposomes. In
order to show that the observed events are not dependent on
the flow channel used, the immobilized liposome species were
interchanged between the flow channels from experiment to
experiment.
OGD and OGD + PEG liposome interaction with 100 %
serum Figure 3a shows the real-time sensorgrams from one
measurement demonstrating OGD liposome immobilization
onto the SPR sensor in both channels, followed by the
Fig. 2 Schematic representation of the experimental setup using an
MP-SPR Navi™ 200 instrument (instrument image courtesy of
BioNavis Ltd., Ylöjärvi, Finland). a Liposomes were captured from in-
flow and immobilized onto functionalized sensors. Measurements were
run in parallel with the same serum source to compare the effect of
hydrophilic coating molecules on protein corona formation. b
Simplified representation of the sensor surface to demonstrate the distinct
layers of interest in the modeling step. Roman numerals indicate (I) the
OGD liposome layer after immobilization onto the sensor and in situ
functionalization with the polyanionic-PEG block-copolymer (blue), (II)
serum interaction with liposomes and following soft corona formation,
and (III) the hard corona after restoration of buffer flow
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PEGylation step in channel 2 (CH2) at t ~ 30 min to form
OGD + PEG. In channel 1 (CH1) with plain OGD liposomes,
the signal remains at a constant level during running buffer
injection. Figure 3b and Table 1 present the serum interaction
results.
Figure 4 a, b present the full SPR spectra from real-time ex-
periments for OGD and OGD + PEG liposomes at time points
when the upper and lower boundaries for layer thicknesses
and refractive indices were determined. First, the functional-
ized gold sensor surface with a 6-kDa carboxymethyl dextran
hydrogel matrix with dodecyl lipid anchors was measured and
modeled (black line), followed by the (I) immobilized
liposome layer, (II) soft corona and (III) hard corona. For
clarity, the measured metal layer and OGD or OGD + PEG
liposome layers are displayed without the fitted curves, where-
as the soft and hard corona layers are depicted with both mea-
sured and fitted curves. Based on the stepwise numerical iter-
ation procedure in LayerSolver, where the previous layer acts
as a background to solve for the thickness and refractive index
of the consequent layer, the modeling yields fairly good align-
ment between the calculated and measured SPR spectra
throughout the procedure. Typically, the SPR angular peak
minimum tends to shift towards larger angles as molecules
(mass) adsorbing onto the surface and consequently change
the refractive index in close vicinity to the surface. Thus, the
Fig. 3 MP-SPR sensorgrams for immobilization of OGD liposomes and
their interaction with serum. a Liposome immobilization to both channels
with PEG modification in situ at t~30 min for CH2. Thickness (d) and
refractive index (n) of liposome layers have been modeled and calculated
at time point I. b Serum interaction (from 40 to 60 min) with the
immobilized OGD (CH1) or OGD + PEG (CH2) liposomes at a flow
speed of 100 μL/min. Thickness (d) and refractive index (n) were
modeled and calculated at II for soft corona, and at III for hard corona
after restoration of buffer flow
Fig. 4 Layer modeling for OGD and OGD + PEG liposomes using the
measured full SPR angular spectra. a SPR peak minimum shifts for the
measured and modeled phases from the metal sensor surface (black line)
to plain OGD (I) liposome immobilization, (II) soft corona, and (III) hard
corona. b Corresponding events for OGD + PEG
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surface plasmon coupling condition undergoes a change that
can be observed as a shift in the peak minimum angular posi-
tion [27, 43, 44]. The biomolecular layer build-up is clearly
seen in Fig. 4 (insets in a and b) where the SPR peak mini-
mum shifts from the value observed for the metal (black
traces) to the right when liposomes are associating with the
surface (red traces) and both the total internal reflection (TIR)
angle and the SPR peak minimum shifts further to the right
when a soft corona forms (blue solid trace and the correspond-
ing fitted purple dashed line). Interestingly, when the hard
corona layer is revealed after restoration of buffer flow, the
peak minimum value shifts back to the left (green solid traces
and the navy blue dashed fitted lines)—which is an expected
phenomenon when serum with a much higher refractive index
is replaced by a buffer solution with lower refractive index
(affects mainly TIR angular position) and when components
of the looser soft corona layer dissociate, leaving a denser
layer on the surface of immobilized liposomes.
As shown in Table 1, the immobilized OGD liposomes
form on average a slightly thinner layer on the sensor surface
(40.4–55.5 nm) compared to the PEGylated OGD layer (44.4–
60.9 nm), with basically the same refractive index for both
systems. The slightly larger thickness for the ODG + PEG
layer can be attributed to the additional PEG layer deposited
on the adsorbed OGD liposome layer, whereas the additional
PEG layer will not significantly affect the refractive index due
to the high water content in the PEG layer. AlthoughMP-SPR
signal response levels exceeding ~500 mdeg suggest that
Fig. 5 MP-SPR sensorgram for DOX and DOX + PEG liposome
immobilization and interaction with serum. a Liposome immobilization
onto the sensor surface with DOX in CH1 and DOX + PEG in CH2. The
liposome layer thickness has been modeled and calculated at time point I.
b Serum interaction (from 35 to 55 min) with DOX (CH1) or DOX +
PEG (CH2) liposomes at a flow speed of 100 μL/min. Thickness (d) and
refractive index (n) were modeled and calculated for soft corona (II) and
hard corona (III) after restoration of buffer flow
Fig. 6 Layer modeling for DOX and DOX + PEG liposomes using the
measured full SPR angular spectra. a SPR peak minimum shifts for the
measured and modeled phases from the metal sensor surface (black line)
to plain DOX (I) liposome immobilization, (II) soft corona, and (III) hard
corona. b Corresponding events for DOX + PEG
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saturation of the sensor was achieved by both OGD and
OGD + PEG, it is noteworthy that the SPR curve produced
by MP-SPR is an average of the entire sensor surface; factors
such as the non-homogeneous placement of liposomes, gaps
in the layers, or the formation of multilayers can also influence
the layer thicknesses and refractive indices observed [45].
Morphological changes in the shape of the liposome due to
the interactions with the functionalized sensor surface and the
shear stress from buffer flow are also expected, and they ac-
count for the differences to hydrodynamic diameters mea-
sured in bulk (Table S1).
Following serum injection, a thicker soft corona layer
(34.2–106.0 nm) forms on the plain OGD liposome layer
compared to the OGD + PEG liposome layer (22.2–
63.2 nm). The plain OGD liposome layer presents surface
charges that favor the association of passing serum compo-
nents. Moving beyond the presumption that steric PEG pro-
tection decreases protein adsorption to liposome surfaces, we
hypothesize that this observation can be explained by higher
opsonisation and possible surface-induced activation of the
complement system by the OGD liposome bearing oligo-
guanidyl moieties and traces of endotoxin (Table S1) [12,
21, 24]. Complement activation leads to the recruitment of
other complement components and formation of enzyme
convertases that amplify the activation process by catalyzing
opsonin production and their surface deposition in high quan-
tities, thereby producing more molecular mass on the surface
[21, 24]. The tendency to activate the complement system is
influenced by the amount and orientation of PEG molecules
on the surface of liposomes [5, 46, 47]. However, the standard
deviation of soft corona layer thickness in the case of OGD +
PEG is relatively large (±57.2 at upper boundary) and a more
definitive conclusion warrants further studies. Despite the dif-
ference in soft corona layer thicknesses, refractive indices in
the same range for OGD and OGD + PEG suggest a similar
consistency, presumably related to the more diffuse and rap-
idly exchanging nature of the soft corona layer at the vicinity
of the surface. Finally, when a buffer rinse is performed after
serum injection, a significantly thicker and denser hard corona
layer remains on the surface of the plain OGD liposomes
compared to OGD + PEG, which may report of complement
activation and deposition of covalently bound complement
end products onto the surface. To our knowledge, this is the
first time when MP-SPR is used to optically characterize
Table 1 OGD and OGD + PEG liposomes and serum interaction
results. The calculated values are low and high limits for layer thickness
(d) with corresponding refractive index (n) values as averages (±standard
deviation) of three independent measurements for: (I) immobilized OGD
liposomes with and without PEG modification; (II) soft protein corona
formation following serum interaction; and (III) the residual hard corona
after buffer flow restoration when a stable baseline is observed
(I) Liposome (II) Soft corona (III) Hard corona
OGD Low High Low High Low High
d 40.4 ± 9.3 55.5 ± 16.0 34.2 ± 2.1 106.0 ± 17.4 9.6 ± 1.0 16.4 ± 0.9
n 1.35302 ± 0.0021 1.34996 ± 0.00151 1.39701 ± 0.0080 1.37742 ± 0.0016 1.44627 ± 0.0072 1.41121 ± 0.0035
OGD + PEG Low High Low High Low High
d 44.4 ± 4.2 60.9 ± 8.1 22.2 ± 14.5 63.2 ± 57.2 4.6 ± 2.7 8.6 ± 6.4
n 1.35679 ± 0.00292 1.35263 ± 0.00215 1.37931 ± 0.0178 1.38013 ± 0.0071 1.39524 ± 0.0393 1.37531 ± 0.0227
Refractive indices extracted during fitting procedure: serum 1.34960, buffer 1.33535
Table 2 DOX and DOX + PEG liposomes and serum interaction
results. The calculated values are low and high limits for layer thickness
(d) with corresponding refractive index (n) values as averages (±standard
deviation) of three independent measurements for: (I) the immobilized
DOX and DOX + PEG liposome layer; (II) soft protein corona formation
following serum interaction; and (III) the residual hard corona after buffer
flow restoration when a stable baseline is observed
(I) Liposome (II) Soft corona (III) Hard corona
DOX Low High Low High Low High
d 99.1 ± 5.0 153.2 ± 8.2 37.5 ± 1.7 86.8 ± 19.6 3.4 ± 1.2 6.6 ± 1.9
n 1.36237 ± 0.0010 1.35680 ± 0.0009 1.41742 ± 0.0046 1.42930 ± 0.0175 1.39440 ± 0.0034 1.38614 ± 0.0063
DOX + PEG Low High Low High Low High
d 37.3 ± 4.7 49.1 ± 2.9 25.8 ± 4.8 60.0 ± 18.0 7.6 ± 0.9 13.0 ± 0.8
n 1.34971 ± 0.0017 1.34722 ± 0.0002 1.39711 ± 0.0069 1.37730 ± 0.0026 1.42353 ± 0.0075 1.39187 ± 0.0085
Refractive indices extracted during fitting procedure: serum 1.34960, buffer 1.33535
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properties of protein corona layers. These results provide clear
support for the existence of a distinct, more diffuse soft corona
layer on top of the hard corona [13, 17, 20].
DOX and DOX + PEG liposome interaction with 100 %
serum Figures 5 and 6 show the real-time sensorgrams and
the full angular SPR spectra, respectively, for DOX and
DOX + PEG liposomes. The layer thicknesses and refractive
indices are shown in Table 2. In Fig. 4a, DOX liposomes
without PEG were immobilized to CH1 and DOX + PEG to
CH2. Since DOX + PEG liposomes were already PEGylated
ex situ, a separate functionalization step on the sensor was not
needed. The clearly larger signal response for the DOX lipo-
some layer compared to the DOX + PEG liposome layer can
be explained by the different penetration properties of the
liposomes into the carboxymethyl dextran hydrogel matrix
and interactions with the dodecyl lipid anchors depending on
liposome properties. Lundquist and her colleagues have dem-
onstrated that the hydrophilic PEG coating on liposomes de-
creases interactions with lipid anchors, preventing deep pene-
tration into the carboxymethyl hydrogel matrix on the Biacore
L1 chip [48]. The lower layer thickness for DOX + PEG
liposomes could therefore be a result of smaller penetration
PEGylated liposomes into the hydrogel, and stronger interac-
tion of the plain DOX liposomes with the dodecyl moieties. It
is important to note, however, that layer thicknesses and re-
fractive indices cannot be interpreted solely by visual inspec-
tion of the sensorgrams. For example, the sensorgram in Fig. 5
(b, II) shows a higher signal for DOX+ PEG liposomes during
soft corona formation, but in Table 2 (II) the average calculat-
ed soft corona layer thickness is slightly smaller for DOX +
PEG liposomes. To explain these occasional abnormalities in
signal behavior in brief, the modeled layer thickness (d) and
refractive index (n) are dependent on the relative SPR peak
minimum shift compared to the previous (lower) layer and its
SPR peak minimum position, as well as the intensity fluctua-
tions and SPR minimum peak width observed in the SPR
angular spectra. Our modeling approach is a layer-by-layer
evaluation procedure where the next layer is built by using
the previous layer as a starting point for subsequent steps, in
particular, the protein corona determinations at II and III.
Since the initial signal levels of DOX liposome immobiliza-
tion compared to DOX + PEG are significantly higher
(Fig. 5a), this difference can be expected to have a distorting
effect on the subsequent protein corona modeling steps.
Therefore, in addition to performing accurate modeling and
calculations based on the full angular SPR curves and using
data from several reproducible experiments, careful inspection
of the signal levels at these different phases is needed in order
to correctly interpret the phenomena taking place at the
surface or in its near vicinity. Layer thicknesses and
refractive indices for subsequent serum interactions were
calculated as described previously. As previously perceived
in the layer modeling process for OGD and OGD + PEG,
hereby a similar observation can be made on the relatively
good alignment between the measured and calculated SPR
spectra.
Table 2 represents the modeled and calculated values of
DOX liposomes forming on average a 99.1–153.2 nm layer
on the sensor surface with an average refractive index of
1.35680–1.36237. The immobilized DOX + PEG liposomes
form a significantly thinner layer with an average of 37.3–49.1
and with a lower refractive index range of 1.34722–1.34971.
We speculate that the exceedingly high signal produced by
plain DOX liposomes is a consequence of its lipophilic inter-
actions with the lipid anchors, promoted by the smaller size
and absence of oligo-guanidyl moieties comparing to plain
OGD liposomes, which are likely to lead to the formation of
liposome multilayers instead of monolayers on the sensor sur-
face [45, 48]. After serum injection, a soft corona of 37.5–
86.8 nm forms on DOX liposomes with a refractive index of
1.41742–1.42930, whereas the layer thickness on DOX +
PEG is slightly thinner 25.8–60.0 ± 18.0 nm. As with the
liposome layer, the refractive index range of the DOX +
PEG soft corona layer is lower 1.37730–1.39711. After resto-
ration of buffer flow, a significantly thinner hard corona re-
mains on DOX compared to DOX + PEG (3.4–6.6 vs. 7.6–
13.0 nm). Interestingly, the refractive index of DOX hard co-
rona is lower than the soft corona for the same liposome, or the
hard corona observed on DOX + PEG (1.38614–1.39440 vs.
1.39187–1.42353, respectively). We hypothesize that these
could be explained by a higher amount of light refracting
species remaining at the vicinity of the surface, but may also
be caused by events such as restructuring and phase transfor-
mations taking place in the biomolecular layers [49]. Based on
the observations on the possible distorting effect of the signif-
icantly higher signal response in the DOX liposome immobi-
lization step, contrasting DOX liposome results reliably with
the three other liposome types would require further optimi-
zation of sensor saturation levels. Therefore, for proof-of-con-
cept, we limit our discussion to compare protein corona for-
mation on OGD and OGD + PEG to DOX + PEG as a
Bbenchmark^ liposome formulation.
Comparison of OGD and OGD + PEG with DOX + PEG
serum interaction eventsWhen the serum interaction events
described in Tables 1 and 2 are compared, some important
observations can be made. Firstly, refractive indices of soft
corona layers on OGD and OGD + PEG liposomes are clearly
smaller than the refractive indices of soft corona layers on
DOX + PEG liposomes. This disparity is not dependent on
the liposomes having PEG or not. This may be in relation to
the differences in the properties of these liposome species, for
example surface lipophilicity or hydrophilicity, surface charge
and rheological properties, which translate into different com-
positions for the protein corona [17, 26]. Secondly, OGD
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liposomes favor a soft corona layer formation that is slightly
thicker and denser than in the case of OGD + PEG or DOX +
PEG liposomes (34.2–106.0 vs. 22.2–63.2 and 25.8–60.0 nm,
respectively). Absence of PEG increases the lipophilicity of
the surface, and increased protein binding is expected [49].
Dynamic conditions may also contribute to this effect, as pro-
tein coronas formed on PEG-modified liposomes under dy-
namic conditions tends to be thicker than those resulting from
static incubations, i.e. around ~20–25 nm thicker [12]. For
OGD and in a lesser extent for OGD + PEG, the presence of
OGD oligo-guanidyl moieties and traces of endotoxin on the
surface might also attract specific serum components, as we
discussed earlier [15]. Thirdly andmost interestingly, the plain
OGD liposomes induce the formation of a thicker (9.6–
16.4 nm) and denser (1.41121–1.44627) hard corona layer
as a result of interaction with serum components compared
to the other liposome samples. This is in line with the results
of Walczyk et al. [13], who presented a range of 11–12 nm for
Bprotein shell thickness^ prior to extensive washing and
around 10.5 nm after washing using differential centrifugal
sedimentation of polystyrene model nanoparticles incubated
for up to 6 h with diluted plasma.
C3b interaction with immobilized OGD and OGD + PEG
liposomesUsing MP-SPR, we determined the affinity and sur-
face density mass of the opsonin C3b on the OGD and OGD +
PEG liposome surfaces. This was done in order to gain insight
whether the observed differences in the serum interaction stud-
ies could be explained at least in part by immunogenic proper-
ties of the nanocarriers—the increased tendency to recruit op-
sonins from the serum and, possibly, activate the complement
system. C3b is a 180-kDa fragment that results from the cleav-
age of anaphylatoxin C3a from complement component C3
[21, 24]. C3b is able to covalently bind to amino or hydroxyl
groups on artificial surfaces through its exposed thioester [21,
24]. After immobilization of OGD or OGD + PEG liposomes
to sensor surfaces in parallel channels, a series of C3b concen-
trations was injected into both channels: 0.00833, 0.0833, and
0.833 mol. As shown in Fig. 7, a clearly larger stepwise SPR
response signal is achieved in terms of C3b interacting with
OGD surface without PEG (a) in comparison to OGD lipo-
some surface with PEG (b). The calculated results for deposited
C3b surface mass densities were Γ(total) ~410–680 ng/cm2 for
OGD liposomes without PEG, and Γ(total) ~120–200 ng/cm2
for OGD liposomeswith PEG. These results are consistent with
the findings of the serum interaction measurements. The calcu-
lated equilibrium dissociation constants for C3b match up rea-
sonably well between the different liposome interaction
schemes: for C3b interacting with OGD and OGD + PEG,
KD,OGD = 3.8 × 10
−8 M and KD,OGD+PEG = 7.2 × 10
−8 M were
obtained, respectively. To the best of our knowledge, this is the
first time the C3b affinities have been determined on biomate-
rial surfaces and on intact surface-immobilized liposomes.
Based on these results, we demonstrate a connection be-
tween the tendency of the surface to adsorb serum compo-
nents and a preference of C3b for the surface. Hence, the
observed differences in interaction experiments of OGD lipo-
somes with undiluted serum, as discussed above, may be in
relation to complement system activation. In particular, the
observed significant difference in the hard corona composition
formed onto the OGD liposome layer without PEGmay report
that the OGD liposomes without PEG are capable of inducing
more drastic opsonisation-related responses than the OGD
liposomes with PEG. Unfortunately, since the OGD lipo-
somes (but not the PEG added to functionalize these lipo-
somes in situ to form OGD + PEG) used were shown to
contain traces of endotoxins, it is not possible to reliably link
increased opsonisation to PEG conformation or liposome
properties at this stage. However, these observations merit
further studies using other complement trigger molecules, as
well as assays to confirm complement activation taking place
Fig. 7 C3b binding affinity and surface mass density onto OGD and OGD + PEG liposomes
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at the surface, such as using antibodies specific to C3b degra-
dation products such as C3c [25].
In summary, we have demonstrated a convenient way to
bind clinically relevant samples of nanocarriers to sensor sur-
faces and to study their interactions with full serum. Our focus
was on intact liposomes that we modified with hydrophilic
coating molecules before and after immobilization to sensor,
which has not been reported previously. This method can be
applied with relative ease to assess the effect of different
surface modifications on unspecific protein binding with
different types of nanocarriers. The main limitation in the
present work was the use of serum instead of plasma; for
instance, fibrinogen that is not present in the serum is known
to bind to PEG-coated liposomes [12]. This is explained in
part by our interest in the complement activating properties of
surface-immobilized liposomes, which cannot be studied in
EDTA-anticoagulated plasma. We demonstrated that undilut-
ed serum can be successfully used in the interaction studies,
but we suggest that any blood product without cells—such as
plasma or serum that has been depleted of some component or
associated to a certain disease state—is equally suited for this
experimental setup. In regard to the safety of nanocarriers, the
possibility to link the production of secondary inflammatory
mediators to surface events would provide complementary
evidence of the immunogenic properties of nanocarriers.
Even though it is difficult to replicate the in vivo conditions
in blood circulation in vitro, the dynamic flow and
temperature-controlled conditions improve the in vivo rele-
vance of the presented method. Using MP-SPR and layer-
by-layer modeling, we were able to separately identify distinct
soft and hard coronas. The possibility to identify and elute
these biomolecular layers from the surface of nanocarriers
might provide interesting opportunities: for example, coupling
MP-SPR technology to other analysis instruments such as LC-
MS could permit dissecting subclasses of the protein corona,
and producing snapshots of the protein corona at different
times [16, 17, 20].
Conclusions
In this study, we have developed a flexible, highly modifiable,
and sensitive one-instrument MP-SPR technology platform
that can be used for interaction studies using undiluted serum
with nanocarriers in controlled dynamic settings. We explored
its essential capabilities with four different liposomes and
conclude that MP-SPR is suitable for optical characterization
of the formation and evolution of protein coronas on
nanocarrier surfaces. Our reproducible measurements clearly
demonstrated the formation of a distinct soft corona. In addi-
tion, we were able to determine binding affinity (KD) for an
essential opsonin, C3b, directly on a biomaterial surface.
Therefore, the described label-free platform provides a
powerful preclinical tool for tuning nanocarrier surface archi-
tecture and composition to control protein corona formation.
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Table S1. Physicochemical characterization and endotoxin determination results for DOX, DOX+PEG, OGD and OGD+PEG 
liposomes. Results are presented as average ( standard deviation) for hydrodynamic diameter and ζ-potential. Results for endotoxins 
are reported in EU/ml and described as positive (+) and negative (-) based on two complementary assays. 
 Hydrodynamic 
diameter Polydispersity index  ζ-potential Endotoxin 
DOX 98.12  14.80 nm 0.324 -1.42  0.16 mV <0.1 EU/ml (-) 
DOX 
+PEG 105.07  2.64 nm 0.017 -1.90  0.17 mV <0.1 EU/ml (-) 
OGD 227.03  19.28 nm 0.254 +20.10  0.40 mV >1.0 EU/ml (+) 
OGD 
+PEG 248.43  30.40 nm 0.328 -1.84  0.41 mV >1.0 EU/ml (+)
a 
a) OGD+PEG liposome tested after the charge-to-charge association process tested positive for endotoxin, but the polyanionic-PEG 
block-copolymer solution alone contained <0.1 EU/ml of endotoxin. 
 
 
Table S2. The compiled modeling results of separate experiments for OGD and OGD+PEG liposomes and serum interactions. The 
calculated values are low and high limits for layer thickness (d) with corresponding refractive index (n) values from all three 
independent measurements and their average ( standard deviation). Refractive indices extracted during fitting procedure: serum 
1.34960, buffer 1.33535. 
 
 (I) Liposome  (II) Soft corona (III) Hard corona 
O
G
D
 
 Low High Low High Low High 
1 39.97 51.08 32.7 94.28 9.73 16.0 
2 31.31 42.15 33.37 97.72 10.5 17.45 
3 49.88 73.27 36.61 126.05 8.59 15.79 
d 40.3867 ± 9.29201 55.5 ± 16.0239 
34.2267 ± 
2.09104 
106.017 ± 
17.4344 
9.60667 ± 
0.96095 16.4133 ± 0.9039 
1 39.97 1.35166 1.40034 1.37681 1.44632 1.41075 
2 31.31 1.34876 1.40279 1.37927 1.45346 1.41491 
3 49.88 1.34947 1.38789 1.37619 1.43904 1.40797 
n 1.35302 ± 0.0021 
1.34996 
± 0.00151 
1.39701 
± 0.00799 
1.37742 
± 0.00163 
1.44627 
± 0.0072 
1.41121 
± 0.0035 
O
G
D
+P
EG
 
 Low High Low High Low High 
1 48.0 61.94 22.63 54.75 3.2 4.99 
2 45.44 68.51 36.53 124.19 7.73 15.99 
3 39.72 52.35 7.5 10.64 2.99 4.8 
d 44.3867 ± 4.23931 
60.9333 
±8.1269 22.22 ± 14.5193 
63.1933 ± 
57.2439 4.64 ± 2.67808 8.6 ± 6.4 
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1 1.35643 1.35295 1.38403 1.37284 1.3802 1.36849 
2 1.35987 1.35461 1.39426 1.38047 1.43979 1.40062 
3 1.35406 1.35034 1.35963 1.38709 1.36573 1.35681 
n 1.35679 ± 0.00292 
1.35263 
± 0.00215 
1.37931 
± 0.01779 
1.38013 
± 0.00713 
1.39524 
± 0.03925 
1.37531 
± 0.02269 
 
 
Table S3. The compiled modeling results of separate experiments for DOX and DOX+PEG liposomes and serum interactions. The 
calculated values are low and high limits for layer thickness (d) with corresponding refractive index (n) values from all three 
independent measurements and their average ( standard deviation). Refractive indices extracted during fitting procedure: serum 
1.34960, buffer 1.33535. 
 
 (I) Liposome  (II) Soft corona (III) Hard corona 
D
O
X
 
 Low High Low High  Low High 
1 104.01 161.5 39.48 88.5 3.85 7.45 
2 93.98 145.02 36.32 105.39 1.98 4.39 
3 99.16 153.05 36.63 66.41 4.26 7.81 
d 99.05 ± 5.015905 153.19 ± 8.240892 
37.47667 ± 
1.741848 
86.76667 ± 
19.54772 
3.363333 ± 
1.215415 6.55 ± 1.879255 
1 1.36309 1.35754 1.42127 1.4351 1.39668 1.39222 
2 1.36128 1.35579 1.42137 1.40966 1.39603 1.37973 
3 1.36275 1.35706 1.41862 1.44315 1.39048 1.38648 
n 1.362373 ± 0.000962 
1.356797 
± 0.0009 
1.41742 
± 0.00457 
1.429303 
± 0.017481 
1.39440 
± 0.00341 
1.38614 
± 0.00625 
D
O
X
+P
EG
 
 Low High Low High Low High 
1 40.8 50.64 20.27 51.26 6.65 12.17 
2 31.98 45.78 27.62 48.07 8.25 13.57 
3 39.2 50.87 29.36 80.68 7.96 13.36 
d 37.3267 ± 4.69895 
49.0967 ± 
2.87462 25.75 ± 4.8249 
60.0033 ± 
17.9774 7.62 ± 0.85247 
13.0333 ± 
0.75501 
1 1.34788 1.34742 1.40478 1.38021 1.41521 1.38219 
2 1.35118 1.34706 1.39126 1.37628 1.42977 1.39814 
3 1.35008 1.34719 1.39528 1.3754 1.42562 1.39527 
n 1.34971 ± 0.00168 
1.34722 
± 0.00018 
1.39711 
± 0.00694 
1.37730 
± 0.00256 
1.42353 
± 0.0075 
1.39187 
± 0.0085 
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15 GENERAL DISCUSSION AND FUTURE OUTLOOK
15.1 RAMAN SPECTROSCOPY OFFERS OPPORTUNITIES FOR   
 CREATIVE SOLUTIONS IN BIOPHARMACEUTICS 
Due to its high specificity for vibrational modes of various chemical bonds, 
Raman spectroscopy is a practical tool for characterization of new NMEs or for 
monitoring the solid state behavior of drugs – for instance in the pharmaceutical 
research and development [277, 278]. Major obstacles in the widespread use of 
Raman spectroscopy have been the weak Raman scattering signals and strong 
photoluminescence signals swamping the Raman lines in spectra [265, 279]. In 
order to overcome these limitations, a number of technical and spectral post-
processing improvements have been introduced with the intention to separate the 
photoluminescence, and recover the Raman signal [280, 282, 339]. In particular, 
the realization of the benefits of a streak camera, i.e. an intensified charge-coupled 
device (ICCD), and an optical Kerr gate brought about significant advancements to 
the problem [340, 341]. Those techniques are called time-resolved methods, and 
are based on the idea of exploiting the time difference between photoluminescence 
and Raman phenomena. Hence, the “slow” photoluminescence and “fast” Raman 
signals can be distinguished by using a sequenced detecting technique whereby the 
almost instantaneously scattered Raman photons are mainly detected whereas most 
of the photoluminescence-originating photons are not detected. However, all of the 
aforementioned systems have suffered from inherent complexity, bulkiness, and/or 
cost – and the photoluminescence suppression was still inadequate. In these studies, 
a robust, compact, and affordable time-gated Raman spectrometer with <100 ps 
time resolution was used (I). Its advantages over the existing Raman instrumentation 
are based on a fast, picosecond pulsed 532 nm laser excitation coupled with a fast 
and sensitive complementary metal-oxide semiconductor single-photon avalanche 
diode (CMOS SPAD) detector. In the time-gated instrument, the time-resolved 
detection is carried out by synchronizing the detector and pulsed laser excitation. 
While detecting during a narrow time window, the 128 × 8 CMOS SPAD matrix 
detector accumulates single-photon events in an internal time histogram consisting 
of bins. That allows for efficient separation of Raman and photoluminescence signals. 
From the technical standpoint, the CMOS SPAD detector does not require excessive 
cooling unlike conventional scientific charge-coupled device (CCD) detectors, and 
the used laser technology is compact. 
Raman is a prominent technology for analysis in life sciences, including biomedical 
and pharmaceutical settings offering detailed chemical information on the samples. 
In the best sequence of events, such analysis can be performed label-free, without 
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labor intensive sample preparation steps. However, as with many other Raman-
based applications, the disadvantage is the strong photoluminescence background 
signals. The features of the new instrument gave rise to a question whether the 
favorable properties of the time-gated system could be effectively used for such 
analysis. Hence, four different pharmaceutical compounds – of which some were 
highly photoluminescent – were investigated with the new system (I). In comparison 
with continuous wave (CW) 532 nm and 785 nm Raman instruments, unparalleled 
improvement was accomplished by demonstrating effective photoluminescence 
suppression and capability to record highly accurate Raman spectra. Additionally, 
time-resolved fluorescence spectra can be acquired by the sequential sampling of 
the fluorescence emission at various temporal phases. This opens a new window 
to Raman spectroscopy; time-resolved fluorescence information can be collected to 
monitor e.g. molecular interactions while molecular structures are revealed by the 
Raman emission. The findings indicate that the new Raman spectrometer could be 
used in several applications in the field of life sciences. For instance, phase transition 
processes in the pharmaceutical industry or cellular nanoparticle uptake studies in 
the biomedical settings.
The results encouraged for envisaging whether the new Raman technology could 
be also exploited for nanomedical investigations such as EVs. Indeed, a couple 
of favorable properties stand out. First, the Raman phenomenon is an inelastic 
scattering process occurring at all excitation wavelengths (λE), and the intensity 
of Raman scattering is approximately proportional to (1/ λ4E). Hence, the shorter 
excitation wavelengths give rise to stronger Raman signal intensities. On the other 
hand, surface enhanced Raman spectroscopy (SERS) is known to amplify the weak 
Raman signals by orders of magnitude [342]. The physics of enhancement is based 
on triggering localized surface plasmons on the irregular or patterned noble metallic 
surfaces, e.g. gold or silver. Different shaped and sized metal substrates or metal 
nanocolloids have been used for Raman signal enhancement [342-344]. Taken all 
these into account, (i) relatively high Raman scattering could be accomplished with 
the 532 nm excitation wavelength, (ii) effective photoluminescence suppression 
could be achieved, and (iii) the use of SERS could improve further the acquired 
Raman signal. Thereby the time-gated system could provide a prospective tool for 
EV characterization.
In order to take an initial step towards Raman-based EV characterization, another 
type of Raman instrument was employed; the Laser Tweezers Raman Spectroscopy 
(LTRS) (III). An ambitious goal was set to characterize a broad number of different 
EV types on a single-vesicle basis. The underlying motivation was to circumvent 
the limitations of measuring a pool of or clusters of vesicles [300]. In general, 
the downside of measuring several particles simultaneously is that it provides an 
average over a multimodal sample having different subpopulations [345, 346]. Thus, 
it can potentially underestimate the roles of subpopulations. The same applies to 
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EV samples that typically embody distributions in characteristics such as vesicle 
size or overall biochemical content. For the first time, single EVs originating from 
non-cancerous (2 different) and cancerous (5 different) cell lines were investigated 
(III) with the aim of distinguishing them on the basis of their biochemical contents. 
By visual inspection, the collected Raman data was not easily sorted out. Therefore 
advanced data analysis methods, PCA and hierarchical clustering analysis were 
employed, and the analysis was complemented with rigorous and established 
EV characterization methods; electron microscopy, western blotting, NTA, and 
ζ-potential measurements. The observed differences between different types of EVs 
were evidently related to their membrane contents. To peel off the membrane protein 
segments outside of one type of cancerous vesicles, LNCaP, a trypsin treatment was 
carried out. This in turn further facilitated the data interpretation generated by the 
multivariate analysis. Eventually significant variation in the biochemical content 
between different EV types was observed. The spectral differences led to grouping 
of EVs into 4 major subpopulations of vesicles by hierarchical clustering analysis. 
The subpopulations were not due to different cell origin. Instead, several cell lines 
had EVs in several subpopulations. Additionally, all subpopulations had EVs from 
multiple cell lines. In essence, some subgroups of exosomes were preferred by some 
cell lines versus the others. This indicated that each subpopulation of EV may play 
a particular functional role that is common across certain cell lines. The perceived 
chemical differences were primarily due to variation in cholesterol, phospholipid, 
and protein content of the membranes of EVs.
15.2 THE POTENTIAL OF MULTI-PARAMETRIC SPR FOR  
 THE BIOPHARMACEUTICAL FIELD
SPR has gained a strong foothold in the life sciences – including the biopharmaceutical 
field. It is a feasible technique for a broad range of affinity studies and interaction 
kinetics evaluations [50, 105, 163, 315, 316, 320, 347]. Although a versatile 
technology, more could be accomplished with regard to the applications. New 
inventions are continuously needed to develop in vitro assays that would provide 
not only statistically orchestrated data but also biologically relevant results. In 
this Thesis such assays are called bio-functional assays. In the context of SPR it 
means designing methodologies that can provide – in addition to the conventional 
parameters that are expected from SPR measurements, i.e. affinities, association and 
dissociation constants – simultaneously data and perceptions that have not been 
traditionally available when using SPR. In an ideal situation, the methodologies 
can be brought into general use for a group of assays that deal with similar types of 
physicochemical scenarios. Examples of this orientation are highlighted in the next 
chapters where the studies (II and IV) are described; the emphasis is to introduce 
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methodologies that could be implemented in the future to a broad range of studies 
having potentially similar dilemmas. In order to develop such assays, essentially 
some instrument-related novelties are needed with sophisticated data analysis and 
a flicker of courage to analyze the acquired data thoroughly. The technical advances 
can be achieved with the use of a next-generation MP-SPR technology. The MP-
SPR enables scanning and recording the full angular SPR spectra over a broad 
range of incident light angles, and measurements can be performed with multiple 
excitation wavelengths. These features allow for obtaining more data than with the 
conventional SPR instruments. Thus, by implementing biophysical modeling in the 
data analysis phase, for example the thin films adsorbed onto the sensor surface 
can be analyzed. Consequently, new opportunities are opened as the assays can be 
designed with these new standpoints in mind. The studies (II and IV) highlight some 
of the opportunities found and developed for the analysis of small drug molecules 
and liposomes.
Alzheimer’s disease (AD) is a difficult neurodegenerative disease affecting 
millions of people worldwide. Approximations state that the incidence of AD only 
in the US may triple by 2050 [348]. The disruptions in biochemical pathways 
of amyloid peptide (Aβ) have been recognized as the principal factors in the 
pathophysiology of AD [239]. Although adequate models for the pathophysiology 
of AD have been identified, the complex nature of the pathogenesis hinders the 
development of drug preparations against it [322, 323, 349]. A novel molecule, 
spin-labeled fluorene (SLF), has been previously developed, and its capability to 
block Aβ toxicity and oligomer growth has been demonstrated [350, 351]. However, 
the oligomeric Aβs express highly dynamic nature [352], which encumbers the 
endeavors to obtain fundamental mechanistic insights of small molecule modulators 
of Aβ toxicity and aggregation. In order to address these challenges, a bio-functional 
label-free assay platform was developed to mimic the Aβ self-assembly and 
aggregation at the vicinity of the sensor surface (II). Two distinctive aims were 
set; (i) to measure the SLF binding affinities to different states of the Aβ peptide, 
including a virtually monomeric Aβ peptide scheme and a scenario where further 
oligomerized Aβ peptides were employed. Additionally, the intention was to (ii) 
demonstrate, how the Aβ self-assembly and aggregation can be interfered by the 
SLF. By utilizing the technical advances provided by the MP-SPR instrument and 
molecular layer characterization in the data analysis, we were able to model and 
calculate the interaction kinetics for the SLF in 4 different biomimetic situations 
(II). The calculations suggested for strong Aβ binding of SLF, and existence of 2 
binding sites for SLF in the structures of Aβ peptides. The aggregating Aβ layer 
was demonstrated to build ~ 30 times thinner in the scenario where the SLF was 
present compared with the events where the Aβ peptides were let to interact and 
aggregate freely without the disrupting effect of the SLF. The data analysis and 
conclusions were coherent with the results obtained by the complementary methods; 
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DLS, molecular docking and molecular dynamics simulations. These findings could 
be expanded further to probe for similar diseases manifesting pathogenic behavior 
where protein aggregation plays a role. Such pathogenic phenomena could be 
mimicked accordingly to develop and optimize therapeutic agents against them; a 
descriptive example is the plaque formation in cardiovascular diseases. 
As a continuation to the small drug analytics, DDCs, in particular liposomal 
nanocarriers, were taken under investigation. As of today, liposomal drug delivery 
systems (LDSs) are the only FDA approved nanocarriers for human medication. 
Upon nanocarrier entering the blood circulation, the most essential question is how 
it interacts with the complex biochemical surroundings formed by the proteins, 
peptides and cellular apparatus found in biological fluids. A formation of a layer 
known as the protein corona is of utmost importance when evaluating the ultimate 
properties of the nanocarriers and their pathophysiological effects [329, 353-
357]. The structure of the protein corona can be highly dynamic and complex. 
Furthermore, it can vary between nanoparticles having the same composition but 
different surface chemistries and size in the same solution. An array of technologies 
has been employed to examine the corona, including mass spectrometry [358], DLS 
and differential centrifugal sedimentation [329, 359], circular dichroism [360], and 
fluorescence quenching [361]. Isothermal calorimetry and SPR have been used to 
measure the affinities of protein coronas [362]. Additionally, the zeta potential is 
a frequently used value to characterize the coronas [354, 356]. In general, when 
nanoparticles are introduced to biological fluids such as serum, the protein corona 
is generated in a series of layers called the “soft” and “hard” corona [359, 363]. The 
composition of a protein corona can be defined by 5 distinct components: thickness 
and density, identity and quantity, orientation, conformation and affinities [364]. 
Regardless the rather rigorous approval requisites for LDSs with regard to in vivo 
usage, severe hypersensitivity reactions to existing LDSs have been reported in 
clinical use [332, 365, 366]. The prevailing consensus is to use PEGylation as the 
primary shielding agent for LDSs in order to enhance their bioavailability but it has 
been demonstrated to pose occasional problems as well [143, 144]. The biological 
significance of the liposome-serum interactions and particularly the protein corona 
formation has provoked a need for new and complementing label-free bio-functional 
in vitro assays to probe the interactions and corona characteristics at the early 
stages of LDS development. A deeper motivation for performing such studies is to 
develop generalized methodology for designing safe and effective LDSs.
Physicochemical interactions at the nano-bio interface between LDSs and serum 
components were probed by using 4 different model liposomes immobilized onto the 
SPR sensor surface, one liposome type at a time (IV). The goal was to characterize 
the hypothesized “soft” and “hard” protein corona formation when the serum 
components – particularly immune system – was responding to the presence of 
the model liposomes. Since the interactions in real biological environment take 
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place in dynamic flow conditions, such conditions were established in order to 
accomplish resemblance with the natural biological milieu of administered LDSs. An 
important complement system peptide C3b was chosen for the purpose of collecting 
experimental proof that the observed phenomena could be related to immune 
responses. The “soft” and “hard” protein corona thicknesses (d) and refractive indices 
(n) were calculated on the basis of the acquired MP-SPR data using biophysical 
modeling for each liposome type (IV). The physicochemical characterization of 
liposomes was performed by the NTA, zeta potential measurements, and endotoxin 
detection. Interestingly, clearly distinguishable “soft” protein corona and “hard” 
protein corona phases were observed during the interactions, and the thicknesses 
and refractive indices of the coronas were quantitatively evaluated. The perceived 
differences in the protein corona compositions between various liposome types 
may be in relation to immune system activation induced by the different surface 
chemistries of the used model liposomes. The developed bionanophotonic platform 
is a versatile and sensitive tool to investigate nanocarrier surface chemistries and 
physicochemical events induced by the different nanocarrier compositions. It can 
provide an additional preclinical in vitro method for the purposes of rational and 
efficient design of DDCs.
An ultimate step in developing bionanophotonic methodologies for larger scale 
analytes would be to make a transition to EV analytics. By taking advantage of the 
previously learned lessons from the LTRS studies (II) and LDS investigations (IV), a 
comprehensive sequence of methods for the analysis of EVs could be developed. To 
date, all cells that have been tested, are known to secrete EVs, and their molecular 
compositions reflect their specific functions [367]. The tumor-associated EVs could 
act as biomarkers for cancer diagnostics [104, 337], or they could be harnessed as 
biomimetic DDCs [250, 251]. However, regardless the serious efforts the application 
of tumor-originating EVs as biomarkers is still difficult. The most pertinent problem 
appears the lack of compounds or other means that could provide specific targeting to 
EVs. In order to acquire valid and accurate data on the structures and interactions of 
EVs, a diverse scheme of biophysical measurements is often needed. The introduced 
Raman and MP-SPR techniques are both extremely sensitive, label-free optical 
measurement methods suitable for bionanophotonic studies of EVs. 
As an example, the cancerous SKOV-3 ovarian tumor cells are known to express 
the α3β1 integrin [368]. Thus based on the biogenesis of the EVs [369], it is exceedingly 
likely that the EVs derived from the SKOV-3 cells express the α3β1 integrin on their 
membrane structures. A unique ligand capable of binding specifically to the α3β1 
integrin could be developed with the use of combinatorial chemistry, for example 
the one-bead, one-compound (OBOC) combinatorial library approach [370, 371]. 
By utilizing such targeting ligand a sequence of bulk and single EV measurements 
could be implemented. For instance, flow cytometry and MP-SPR as representatives 
of bulk techniques and LTRS as the single EV measurement method. In essence, a 
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biotinylated targeting ligand could be pre-immobilized onto the SPR sensor surface 
using the well-established biotin-avidin immobilization techniques. In the case of 
LTRS analysis, the ligand could be tagged with a highly Raman-active moiety (e.g. 
alkyne group or groups) in order to produce discernible Raman signal denoting 
of successful α3β1 integrin-ligand binding. Furthermore, this scheme of various 
approaches could be complemented with the time-gated SERS measurements in 
bulk conditions. The time-gated Raman system would allow circumventing the 
conceivably interfering photoluminescence signals. The developed versatile scheme 
of measurements could be later applied to the measurements of EV compositions 
and interactions across a large number of different EV types. The findings could 
be applied for cancer diagnostics or development of biomimetic DDCs. Overall, 
these studies would further elucidate, how the EVs interact at various interfaces 
in their microenvironments, and valuable structural information on distinct EVs 
could be obtained.
15.3 CONCLUSIONS
In these studies, a new Raman technique was employed and its capabilities 
demonstrated (I). Innovative applications exploiting biophotonics were introduced 
(I-IV), and versatile data analysis methods were used to new applications in 
unconventional ways (I-IV). From the standpoint of the aims set for the studies, 
following conclusions can be made:
I The time-gated Raman technology accomplished effective fluorescence 
suppression in solid state small drug studies. An additional benefit in 
comparison with conventional Raman technology is achieved since time-
resolved fluorescence information can be collected simultaneously with the 
Raman emission. The system holds potential for SERS and biopharmaceutical 
applications in general.
II A bio-functional MP-SPR in vitro assay platform was developed to investigate 
prospective small drug candidates against AD. The Aβ peptide aggregation 
and its prevention with a new molecule (SLF) was mimicked; computational 
simulations strengthened the perceptions made. Aβ peptide layer thickness 
and refractive index evaluations provided quantitative information on the 
peptide aggregation which has not been previously available within SPR 
studies.
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III Single extracellular vesicles from 7 different cell lines were measured with 
LTRS technology, and Raman data analyzed by using multivariate data analysis 
methods. Observed variations were in relation to the biochemical compounds 
on the vesicle membranes, in particular cholesterol, phospholipid and protein 
contents. The data analysis revealed the existence of 4 vesicle subpopulations. 
However, the subgrouping was not due to different cell origin but potentially 
due to a particular functional role that is common across certain cell lines.
IV An in vitro bionanophotonic MP-SPR methodology was designed for 
liposomal DDC development. Interactions of 4 model liposomes with serum 
were examined in dynamic flow conditions. For the first time, the composition 
of distinct “soft” and “hard” protein corona onto the immobilized liposomes 
was quantitatively characterized with respect to thickness and refractive index. 
The variations in corona structures between liposomes may implicate that 
different liposomal surface chemistries induce the immune system activation 
divergently. These perceptions can assist in the development of safe and 
effective liposomal DDCs.
Taken together the results represented and discussed here, when complemented with 
conventional techniques and assays, Raman and MP-SPR are effective biophotonic 
tools for a range of applications in the biopharmaceutical research. In the future, 
these results and findings hold potential to be refined further in order to accomplish 
transformation into validated or widely-used methodologies.
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